Chargement

Slzii.com Recherche

Recherche (Nouvelles)

‘Relax and Recharge Mom’ at Taal Vista Hotel this Mother’s Day
THIS Mother’s Day, Taal Vista Hotel invites families to celebrate the most important woman in their lives with a thoughtfully curated experience designed for rest, relaxation, and meaningful moments together. With the “Relax and Recharge Mom” room package, guests can treat Mom to a well-deserved escape surrounded by cool Tagaytay breezes and timeless charm. Rates start at P9,000 for a Superior Room, inclusive of an overnight stay for two adults and two children 12 years old and below, buffet breakfast for two adults and two children five years old and below, and a 60-minute “Awaken the Senses” massage at Rain, The Spa – the perfect indulgence for Mom to unwind and recharge. The package also includes a welcome amenity, use of hotel facilities such as the gym, game room, kids’ club, and swimming pool, along with Wi-Fi access and one parking slot. This special offer is available until May 31, 2026, giving families more time to plan a memorable getaway. On Sunday, May 10, 2026, families can also gather for a delightful Mother’s Day buffet at Veranda restaurant from 12 noon to 3 p.m. Guests can enjoy a spread of well-loved dishes and comforting flavors at P1,980 per adult and P990 for children ages six to 12, while children five years old and below dine for free when accompanied by a paying adult. To make the celebration even more special, guests can enjoy 15 percent off at Ayla Pearls and Jewelry Shoppe, located near Veranda – perfect for finding a thoughtful gift for Mom. A photo booth at the Sampaguita Foyer is also available, offering families a chance to capture and take-home cherished memories of the day. Whether it is a relaxing stay, a hearty family feast, or simple moments spent together, Taal Vista Hotel offers a heartfelt setting to celebrate Mom in the most meaningful way. Visit www.taalvistahotel.com for more information or email reservations@taalvistahotel.com for reservations.
2026-05-10 08:19:02

Grupo Aeroportuario del Pacifico Announces Initiation of the Process to Establish a FIBRA
GUADALAJARA, Mexico, May 09, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the "Company” or "GAP”) announces that it has initiated the process for the potential establishment of an Irrevocable Trust for the Issuance of Energy and Infrastructure Investment Trust Certificates ("FIBRA GAP”), with the objective of subscribing a minority equity interest in the 12 Mexican airport concessionaires operated by GAP. Through the initial issuance of FIBRA GAP, each of the 12 airports intends to obtain funds to complement the execution of the Master Development Program for the 2026-2029 period, which contemplates investments of approximately Ps. 40.0 billion. The Master Development Program will generate significant growth in airport infrastructure, including an approximate increase of 60% in terminals, 35% in inspection points and access areas, 25% in aircraft parking positions, and 10% in airside infrastructure. These investments will contribute to economic development in the areas surrounding the airports through the generation of direct and indirect employment, as well as a multiplier effect on investment. The investment made by FIBRA GAP in the airports will represent an additional source of funds to invest in airport infrastructure, complementing the debt securities issuances under the program that GAP has utilized since 2015. Company Description Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol "PAC” and on the Mexican Stock Exchange under the ticker symbol "GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019. This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words "anticipates”, "believes”, "estimates”, "expects”, "plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations. In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the "Ley del Mercado de Valores”, GAP has implemented a "whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at denuncia@lineadedenunciagap.com. GAP’s Audit Committee will be notified of all complaints for immediate investigation.Alejandra Soto Investor Relations and Social Responsibility Officerasoto@aeropuertosgap.com.mx Gisela Murillo, Investor Relationsgmurillo@aeropuertosgap.com.mx +52 33 3880 1100 ext. 20294
2026-05-09 06:49:54

La Salle guns for ‘Sweet 16’, title-clinching win over NU
Games Saturday (SM Mall of Asia Arena) 11 a.m. - Men's Awarding Ceremony 12 p.m. - NU vs FEU (Men's Finals) 4 p.m. - Women's Awarding Ceremony 5 p.m. - NU vs DLSU (Women's Finals) A dream title win for Angel Canino, a redemption for coach Ramil de Jesus, and a place in history for La Salle. With those as rewards, expect the La Salle Lady Spikers to go for the clincher against the reigning champions National University Lady Bulldogs in Game 2 of their UAAP Season 88 Volleyball Finals Saturday, May 9, at the Mall of Asia Arena in Pasay City, The biggest moment in the lives of Canino and the rest of the Lady Spikers begin at 5 p.m. with the Taft-based squad putting everything on the line in its bid for retribution and a change to exorcise the ghost of 2014 Finals heartbreak that caused too much pain for De Jesus and company. History and momentum is on La Salle’s side since the last four championship series or since 2022 have ended in sweeps. For Canino, their mighty 14-game sweep of the double-round elims would amount to nothing or go down the drain if they allow this golden chance to slip away from the hands. If the Lady Spikers would make it this time, they will become the first in the rich La Salle volleyball history to score a perfect season. They have won three-straight – Seasons 73 to 75 – in their previous 12 championships but nothing beats completing a “Sweet 16” in the Final Four era. And this could be the sweetest of them all as they will achieve it against the very same team that beat them in the Season 84 and 87 Finals. “Sinasabi ko sa kanila ayoko na maulit iyon... sabi ko lang sa kanila eto na ‘yong pagkakataon na makabalik kami at makaharap ang NU, kaya kailangan paghandaan lang namin,” said de Jesus. “Sinasabe ko lang sa kanila ‘di lahat nabibigyan ng opportunity makarating ng Finals.” Also chasing for a piece of history is NU’s men’s team which hopes to extend its reign to six years when it collides with Far Eastern University at 12 noon. Like the Lady Spikers , the Bulldogs also took Game 1 of their own best-of-three title series. And like in the opener, a massive crowd – both from La Salle and NU – is expected to show up and witness either the coronation or extension of the series. But don’t ask Canino about it. Right after winning their first game, Canino had made it known to everyone about their title aspirations – clear as crystal. Apart from Canino, also expected to spew fire for La Salle are Shane Reterta, Amie Provido, Shevana Laput and Eshana Nunag – all played key roles in the team’s 25-23, 25-18, 25-18 win in Game 1. But NU, of course, is not going to raise the white flag without giving a fight. That task rests on the shoulders Vange Alinsug, Lams Lamina, Shaira Jardio, and Arah Panique. Top Rookie of the Year contender Sam Cantada hopes to make amend after a so-so showing the last time after being held to just two points. Out to power the Bulldogs to another championship are Alas Pilipinas stars Buds Buddin, Leo Ordiales, and Jade Disquitado. For the Tamaraws to prevail, Dryx Saavedra and Mikko Espartero should play extraordinarily in hopes of inspiring their teammates to deliver significant numbers as well.
2026-05-08 05:16:00

Protect cops from ashfall health hazards in Mayon, Kanlaon areas, PNP commanders told
Gen. Jose Melencio C. Nartatez, Jr., chief of the Philippine National Police (PNP), ordered the strict implementation of health safety measures for all frontline personnel manning checkpoints and other public safety response to protect them from respiratory risks posed by heavy volcanic ash and sulfur dioxide exposure due to Mayon and Kanlaon volcano activities. Following the May 2 pyroclastic density current of the Mayon Volcano in Albay, Kanlaon Volcano in Negros Island spewed ash plume as high as 800 meters which raised concerns on the health and well-being of frontliners. “We have to look after the welfare of our personnel on the ground, especially those heavily-exposed to volcanic ash, being the frontliners of government response and assistance,” said Nartatez. The Philippine Space Agency (PhilSA) has earlier released a map showing that the May 2 ashfall covered at least 8,544 hectares, or about half the size of Quezon City. For its part. The Philippine Institute of Volcanology and Seismology (Phivolcs) said ashfall is a health hazard as it is composed of fragmented volcanic particles less than two millimeters in diameter. Nartatez ordered regional commanders to provide high-filtration face masks and adequate hydration supplies to all ground units as he emphasized that operational effectiveness depended heavily on the physical well-being of the officers exposed to hazardous volcanic conditions. Policemen are also among those who were tapped to clear roads in affected areas in Albay and while the task has been completed, volcanic ash and particles have not been totally removed. Aside from road-clearing, police personnel were also tapped to secure entry points of danger zones and conduct checkpoints and other response that made them prone to ash inhalation on a daily basis. Meanwhile, Nartatez also instructed police commanders to minimize delays for relief distribution as he explicitly prohibited local police chiefs from conducting unnecessary inspections on humanitarian convoys. “I also directed our local police commanders to refrain from conducting unnecessary inspections and immediately allow the passage of emergency responders as well as vehicles containing relief items,” he said. The Department of Social Welfare and Development previously prepositioned over 300,000 food and non-food items in Bicol Region intended for residents in Guinobatan and Camalig, Albay.
2026-05-07 03:38:00

Bulacan prosecutor junks obstruction rap vs Mollenido
The Office of the City Prosecutor in Malolos, Bulacan has dismissed the obstruction of justice complaint filed against Police Senior Master Sergeant John Mollenido, estranged husband of slain Police Senior Master Sergeant Diane Marie Mollenido, for allegedly allowing the inclusion of his wife's belongings during her cremation. In its resolution dated April 24, the prosecutor's office ruled: “Wherefore, finding no prima facie evidence with reasonable certainty of conviction to charge the respondent in court, undersigned recommends the dismissal of the herein complaint for Obstruction of Justice against respondent PMSg John Mollenido y Ledesma,” the prosecutor ruled. Diane Marie and her son, eight-year-old John Ysmael, both Taguig residents, were found dead after they went missing on Jan. 16. Her body was found in Pulilan, Bulacan on Jan. 24 while John Ysmael's was found on Jan. 29 in Victoria, Tarlac. John Mollenido authorized their cremation. The Pulilan police filed an obstruction of justice complaint against him under Presidential Decree No. 1829, alleging that he authorized Diane Marie’s things to be included during cremation, including a t-shirt, a pair of pants and underwear, even though these were considered evidence. John’s lawyer Cristobal Rimando announced the prosecutor's ruling. “Further, it is highly out of order that the SOCO operatives just left the personal effects of the deceased victim at the morgue right after processing the crime scene and the evidence involved in utter disregard of the procedures and protocol laid down under PNP Memorandum Circular No. 20140-006 dated February 19, 2014,” according to the resolution. In a statement, Rimando said, “The Resolution likewise emphasized that liability under P.D. No. 1829 requires proof that the alleged acts were committed willfully and maliciously—essential elements which were clearly absent in this case.” Rimando said the prosecutor’s resolution will be included in Mollenido’s appeal that will be filed with the National Police Commission (Napolcom). Napolcom dismissed Mollenido from the service for approving the cremation of his wife and son. The agency said despite an ongoing police investigation, Mollenido facilitated the immediate cremation of the remains of his wife and son by signing the authorization and proceeded with the process before the completion of medico-legal procedures that resulted in the destruction of potential evidence in the case. Rimando said they have not received the Napolcom decision.
2026-05-07 03:38:00

Hontiveros pushes for Senate probe into PPI’s ‘sudden, aggressive’ rice importation
Senator Risa Hontiveros has called on the Senate to conduct a thorough and immediate investigation into the “sudden and aggressive” rice importation of Planters Products Inc. (PPI), noting that the agency’s latest questionable moves could further hurt the country’s farmers already reeling from the impact of the Middle East war and the predicted super El Niño. In particular, Hontiveros questioned PPI’s capacity to import over 86,000 metric tons of rice in less than a year, considering that its audited financial statements for Fiscal Year 2023 to 2024—submitted to the Securities and Exchange Commission (SEC) in August 2025—showed an equity of P536-million, with the company also reporting a net loss for the same period. “I call on this chamber to conduct a thorough and immediate investigation into these highly questionable importations so we can determine if these actions are legal. Were public funds used and are now at risk? Were permits hastened and exemptions granted?" Hontiveros said in her privilege speech during plenary session on Wednesday, May 6, 2026. “Our farmers are already burdened by rising input costs, low farmgate prices, and the worsening impacts of climate change. Now, the Middle East war and the predicted super El Nino are driving them to despair,” she pointed out. “Sabi nga ng isang magsasakang nakausap ko sa Bani, Pangasinan, natatamlayan na silang magtanim dahil hindi lamang mababa ang presyo ng palay pero luging-lugi na sila sa taas ng presyo ng gasoline at mga inputs (A farmer I spoke to in Bani, Pangasinan said that they are reluctant to plant because not only are the prices of rice low but they are also suffering losses due to the high prices of gasoline and inputs),” she pointed out. Moreover, she said a Senate inquiry would also help ascertain whether PPI is a private institution or a government owned and controlled corporation (GOCC) to check if it complies with rice procurement laws, because government-to-government (G2G) transactions are tariff-free and if PPI is a private company, it would be required to pay the taxes. “Let us remember that PPI’s status as a corporation remains questionable to this day. Historically, it was rescued from bankruptcy during the first Marcos administration through a fertilizer levy, imposed on Filipino farmers – P10 per every bag of fertilizer sold. In March 2008, the Supreme Court in the case Planters Products, Incorporated vs Fertiphil Corporation GR 166006 stated that PPI, Inc. is a private corporation and declared the Letter of Instruction (LOI 1465, dated June 3, 1985 that imposed the levy unconstitutional as it stood to benefit a private entity. The levies are public funds and therefore should be used for a public purpose,” she explained. “However, and this is what perplexes me and many of our fellow farmers, Mr. President. The majority of PPI’s shares held, 79.24% of them are held by Planters Products FOUNDATION, Inc. chaired by no less than the Secretary of the Department of Agriculture and includes government officials in its Board of Trustees according to LOI 1428, dated September 22,1984,” she said. “In its website, the DA describes PPI as a sequestered company under the administration of the Department. Sequestered because suspected of ill-gotten wealth and crony capitalism,” she further pointed out. “So ano ba talaga ang (So what is the truth about) PPI, Mr. President? (Ist this a) Private ba o government-owned and controlled corporation? Because if it is private, why does it appear to enjoy preferential treatment in getting the necessary phytosanitary permits from the Bureau of Plant Industry (BPI)? And if it is a GOCC, is it using money from the budget, borrowing from GFIs, or getting its imports using trade or supplier credit? Does the government have a guarantee if PPI cannot pay?” asked Hontiveros. The lawmaker said if public funds were indeed used to finance PPI’s rice imports as a private company, it should be able to produce a competitive bidding required under the New Procurement Act. But if it is a GOCC, the DA secretary should clarify if it was designated to import rice from India in compliance with the amended Rice Tariffication Law. However, Hontiveros said a news report from Times of India, dated April 1, 2025 was quoted as saying that the Telangana Civil Supplies Corp. Ltd. was able to sign a memorandum of understanding (MOU) with PPI “representing the Philippine government” to formalize the agreement. “Ito bang surge of rice imports by PPI from other countries such as Vietnam, aside from India, are G2G transactions or private transactions? I am asking these questions because of the financial implications. G2G transactions are tariff-free. If PPI is a GOCC, then it can enjoy this privilege. However, if PPI is a private company, it is required to pay the tariff,” she stressed.
2026-05-07 03:34:00

Micro Credentials Reshaping Learning While Degrees Remain Relevant
SINGAPORE - Media OutReach Newswire - 6 May 2026 - As global education systems evolve to meet rapidly changing workforce demands, micro credentials are gaining traction as a flexible complement to traditional degrees rather than a replacement, according to international policy bodies and education experts. Micro credentials, defined by the European Union as certifications of "learning outcomes of short-term learning experiences," are designed to provide targeted, skills-based learning in a shorter timeframe. Meanwhile, UNESCO notes that micro credentials typically focus on "a specific set of learning outcomes in a narrow field" and are achieved over a shorter period compared to traditional qualifications such as degrees. The Organisation for Economic Cooperation and Development OECD further highlight their growing role in supporting lifelong learning and employability, particularly as individuals seek to upskill and reskill in response to labour market changes. Complementary, Not Competing Pathways While micro credentials are often positioned as an alternative to degrees, global evidence suggests that the two serve different but complementary purposes. Traditional degrees remain the primary pathway for developing broad based knowledge, critical thinking, and foundational expertise, often required for entry into professional fields. In contrast, micro credentials offer targeted, flexible learning that can address specific skills gaps at different career stages. International frameworks increasingly emphasise this complementary role. European policy discussions describe micro credentials as part of flexible learning pathways that can be stacked or combined with larger qualifications, enabling more personalised education journeys. Relevance to Singapore's Lifelong Learning Agenda In Singapore, the emphasis on lifelong learning driven by national initiatives such as SkillsFuture aligns with global developments in modular and flexible education pathways. This approach reflects a growing recognition that learning does not end with a degree, and that individuals increasingly require ongoing access to short form, skills-based education throughout their careers. Institutions such as the Singapore Institute of Management (SIM) illustrate how this shift is being operationalised in practice. With a stated commitment to lifelong learning embedded in its education model, SIM supports learners across different life stages, from pre-employment education to professional and continuing education. SIM offers more than 140 academic programmes in partnership with international universities, alongside a wide range of professional short courses and micro credentials. This enables learners to combine foundational degree education with targeted skills development, reflecting the growing adoption of stackable and modular learning pathways. The institution supports approximately 17,000 students annually and has a network of close to 200,000 graduates, positioning it as a significant player in Singapore's education and lifelong learning ecosystem. Learning is delivered through a mix of in person, online and blended formats, providing flexibility for both full time students and working professionals to upskill and reskill in response to changing industry demands. Implications for Students and Employer For students, micro credentials offer greater flexibility across different stages of learning and career development. Undergraduates can explore areas of interest beyond their primary discipline through short form learning, while fresh graduates can supplement academic knowledge with job relevant skills to improve employability. Mid-career professionals are also able to reskill or pivot into new roles without committing to full time study. For employers, this shift highlights the need to evaluate both foundational and applied capabilities. Degrees continue to signal broad based knowledge, critical thinking and discipline, while micro credentials provide evidence of current, job specific skills. Taken together, these credentials offer a more complete view of an individual's readiness and adaptability in a rapidly changing workforce. A Shift Toward Stackable Learning The future of education is increasingly defined by a stackable and modular approach, where degrees and micro credentials are combined to support continuous learning. Degrees provide the foundational knowledge and academic grounding, while micro credentials enable targeted skills development that can be applied in real time. This approach underscores a broader transition from one time qualification attainment to lifelong capability building, where learning is continuous, adaptable and aligned with changing workforce needs. References: European Commission European Education Area A European approach to micro credentials - https://education.ec.europa.eu/education-levels/higher-education/micro-credentials UNESCO Towards a common definition of micro credentials - https://unesdoc.unesco.org/ark:/48223/pf0000381668 OECD Micro credentials for lifelong learning and employability - https://www.oecd.org/en/publications/micro-credentials-for-lifelong-learning-and-employability_9c4b7b68-en.html Skillsfuture Singapore - https://www.skillsfuture.gov.sg/ Singapore Institute of Management - https://www.sim.edu.sg Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills https://www.sim.edu.sg/The issuer is solely responsible for the content of this announcement. About SIM Global EducationSIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor's and master's degree programmes with some of the world's most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE's cohort is made up of 17,000 full- and part-time students and adult learners, of which approximately 41% are international students hailing from over 50 countries. SIM GE's holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world. For more information on SIM Global Education, visit www.sim.edu.sg
2026-05-06 01:47:19

IF Brand Invests multimillion THB in the only Molecular-Level EA-IRMS Technology in the region to Verify Coconut Water Purity at Source
IF brand introduces EA-IRMS technology, setting a new benchmark in Asia for molecular-level authenticity testing in coconut water. The Multi-million THB investment enables source-level testing, detecting adulteration before production, ensuring what consumers drink is truly from nature. A shift from industry-standard post-production checks to proactive "source verification," reinforcing IF brand's commitment to transparency, quality, and trust. Globally recognised EA-IRMS technology acts as a molecular "truth detector," identifying added sugar and water with precision to safeguard product integrity. SINGAPORE - Media OutReach Newswire - 6 May 2026 - Amid rising global concerns around food fraud, hidden sugars, and ingredient adulteration in the beverage industry, IF brand, the company behind the internationally recognised IF beverage portfolio, has announced the implementation of Elemental Analyzer Isotope Ratio Mass Spectrometry (EA-IRMS) technology - becoming the first coconut water brand in Asia to adopt molecular-level authenticity verification for coconut water purity. Backed by an investment of multi-million THB , this initiative marks a significant shift in how beverage quality is assured. While most industry players rely on post-production testing, IF has taken a proactive approach by implementing EA-IRMS at the raw material receiving stage, enabling the detection of added sugar or water before production even begins. Verifying Purity at the Point of Origin Widely recognised as a global gold standard in food authenticity testing, EA-IRMS technology functions as a molecular "truth detector," analysing isotopic composition to verify whether a product is truly natural or has been altered. By integrating this technology at the earliest stage of production, IF strengthens its end-to-end quality control system, ensuring that only authentic, unaltered ingredients proceed into manufacturing. This pre-emptive approach moves beyond conventional quality checks, delivering assurance that is not only promised, but scientifically validated from the source. What You Drink, Proven by Science At the heart of this initiative is IF brand's commitment to what it calls "molecular integrity" - ensuring that what goes into every bottle is exactly what nature intended, with nothing added or altered. In an industry where concerns around hidden sugars and product tampering continue to surface, EA-IRMS technology acts as a powerful verification tool, allowing IF to confirm the authenticity of its ingredients from the very start. By investing in advanced food technology, IF brand reinforces its belief that what consumers drink should stay true to its natural source, delivering transparency they can trust and quality they can taste. "We believe that trust is built on visible transparency," said the IF brand announcement . "At IF, we are committed to the highest quality standards. The implementation of EA-IRMS is not only a response to market concerns, but also a step toward establishing a new benchmark for the coconut water industry where authenticity is no longer just a claim, but a fact supported by data." With the adoption of EA-IRMS technology, IF brand reinforces its quality assurance framework and supports ongoing efforts to elevate industry standards in Asia. By moving beyond reactive testing to proactive verification, the company is redefining how product integrity can be safeguarded through science, innovation, and transparency. Through this initiative, IF brand continues to lead with purpose, demonstrating that true quality is not just claimed, but proven. Hashtag: #IFBrand The issuer is solely responsible for the content of this announcement. About Innovative Food and Beverage Pte. Ltd.Innovative Food and Beverage Pte. Ltd. (IFB) is a global beverage company headquartered in Singapore, known for its commitment to product quality, innovation, and authenticity. As the company behind the internationally recognised IF brand, IFB has established a strong presence across global markets, offering a diverse portfolio of beverages rooted in natural ingredients and modern lifestyles. Guided by a vision to deliver products that are both high-quality and trustworthy, IFB continues to invest in advanced technologies and sustainable practices across its operations. From ingredient sourcing to production, the company is committed to ensuring transparency, integrity, and consistency at every stage. With a focus on innovation and continuous improvement, IFB aims to set new standards in the beverage industry, bridging science, nature, and consumer trust. Website: https://www.iffamily.com/ Social Media: Linktree
2026-05-06 01:47:06

London police form new unit to boost protection for Jews
LONDON, United Kingdom — London's Metropolitan Police on Wednesday announced the creation of a special unit to protect Jews following a spate of hate attacks amid growing antisemitism. The Met said the new "community protection team" will initially comprise 100 extra officers and combine neighborhood policing with "specialist protection and counter-terrorism capabilities". It will provide "a more visible, intelligence?led and coordinated presence focused on protecting" London's Jewish communities, the force said in a statement. The announcement came the day after police said they were probing the latest arson incident targeting Jews, this time involving a former synagogue in east London. It followed last week's stabbing of two Jewish men in the Golders Green area of north London, which is home to a large Jewish community. A man has been arrested on suspicion of attempted murder after the incident, which injured the pair. In March, an arson attack in the same neighbourhood destroyed four ambulances run by the Hatzola Jewish charity, while bottles suspected of containing petrol have been thrown at two synagogues in other separate incidents. The Met noted in its announcement that it has arrested over 80 people in the past four weeks in response to both antisemitic hate crimes and the string of arson attacks. Met Commissioner Mark Rowley revealed last week he had been discussing with ministers and officials about creating a 300-strong neighbourhood policing team, including specialist armed officers, for the Jewish community. He hailed the creation of the new team, with around a third of that number, as "an important step in strengthening our response to the sustained threats Jewish communities are facing". "It brings together experienced local officers who know their communities, supported by specialist capabilities, to provide more visible, consistent and intelligence?led protection," he added in Wednesday's statement. The Met added the unit would initially be "primarily focused" on protecting the Jewish community but was "also intended to provide a blueprint for how policing responds when tensions rise" in other communities. "This focus does not mean the Metropolitan Police is deprioritising other communities," the force added. "Hate crime in all its forms — including ongoing efforts to tackle racism, anti-Muslim hate crime, homophobia and other forms of hatred in the capital — remains a core policing priority." Meanwhile on Tuesday, the chief prosecutor for England and Wales Stephen Parkinson announced hate crime prosecutions were set to be fast-tracked due to the "deeply troubling rise in antisemitic incidents".
2026-05-06 01:44:15

QCPD files raps vs netizen over fake robbery post
The Quezon City Police District (QCPD) has filed charges against an individual for posting false information online about an alleged robbery along the Quezon Avenue footbridge, an incident authorities confirmed never occurred. Police said the viral post, which claimed a robbery took place on April 24 at around 10 p.m., prompted immediate verification. Ground validation and CCTV backtracking revealed no record of any such incident in Quezon City. QCPD director Police Brig. Gen. Randy Glenn Silvio said Masambong Police Station 2 and Kamuning Police Station 10 were directed to conduct verification and investigation following the circulation of the post. Their efforts led to the identification of the individual responsible, who later appeared before authorities and submitted her statement. A thorough investigation, including review of surveillance footage and coordination with concerned units, confirmed that no robbery incident took place at the reported time and location. QCPD said the post was misleading and warned that spreading unverified information online may cause public alarm and confusion. Silvio reminded the public to exercise responsibility in posting online and to verify information before sharing, stressing that false reports may mislead communities and disrupt public order. Police said charges for violation of Article 154 of the Revised Penal Code, which penalizes the unlawful use of means of publication and the dissemination of false news that may cause public disorder or damage public interest, have been filed against the individual. QCPD also urged the public to report incidents through official channels, including police stations, emergency hotline 911, and the Quezon City Helpline 122, to ensure accurate reporting and immediate response.
2026-05-05 00:14:00

PMET Produces High Recovery (89%) and High Grade Spodumene Concentrate (6.1% Li2O) from Innovative CV5 Sample and DMS Pilot Program
MONTREAL , May 4, 2026 /PRNewswire/ -- May 4, 2026 – Sydney, Australia Highlights The program (termed "ApplePick") utilized multiple large, angular, mineralized boulders situated immediately down-ice of the principal CV5 outcrop (i.e., the source), which were crushed on-site and shipped to SGS (Lakefield) as high head-grade (3.61% Li 2 O) 1 feed for processing in a DMS pilot plant. 4.47 tonnes of high-grade (6.09% Li 2 O) and low-iron (0.58% Fe 2 O 3 ) spodumene concentrate was produced at very high recovery (89.0%) from the CV5 Pegmatite using a Dense Media Separation ("DMS") only pilot plant. The concentrate produced further demonstrates the potential for the Company's proposed DMS only processing pathway for Shaakichiuwaanaan, through; High-grade and consistently large spodumene crystal nature, which contributes to high rates of recovery using just DMS processing; and Reinforces prior test work demonstrating a clean ≥SC5.5 concentrate at high rates of recovery (nominally 70%), per Feasibility development plans and planned average mined heads grades over the life-of-mine. Approach allowed for the rapid and cost-effective generation of spodumene concentrate on a larger scale, without drilling, which further supports the Company's future lithium offtake and midstream product initiatives . DMS tailings streams from the pilot also generated significant quantities of feed material for the Feasibility-level tantalum recovery program, which is now underway. New higher-grade lithia feed samples have generated the data that underpins an improved lithium grade-recovery curve and indicates that stronger recoveries can be achieved at the high-grade end of the curve compared to previous assumptions, which is expected to positively impact the results of the upcoming updated Feasibility Study for the CV5 Pegmatite, as well as a Preliminary Economic Assessment for the broader Project. Given the success of the ApplePick program, the Company intends to launch the 'BerryPick' program, targeting surface pollucite samples for larger scale pilot testwork and concentrate sample preparation, as it engages with strategic caesium players downstream. __________________________________ 1 This head-grade of feed relates to the grade of composited boulders from CV5 selected as part of Project ApplePick and is not representative of expected life-of-mine feed grade as reported in the CV5 Feasibility Study released on October 20, 2025. Darren L. Smith, Executive Vice President Exploration, comments: "The ApplePick program further demonstrates the potential of our DMS only processing pathway and exceeded our expectations in terms of concentrate grade, quality, and tonnes produced. It is an excellent example of the team's innovative thinking, resulting in a practical and cost-effective approach to generate sample product at scale, without significant core drilling being required. "In addition to allowing us to be able to provide substantial quantities of spodumene concentrate from our Shaakichiuwaanaan Project to support our offtake and midstream initiatives, ApplePick has also provided us with significant quantities of tailings material feed to support our Feasibility-level tantalum recovery testwork programs," added Mr. Smith. PMET Resources Inc. (the "Company" or "PMET") (TSX: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce the successful production of approximately 4.47 tonnes of high-grade (6.09% Li 2 O, low iron) spodumene concentrate from the CV5 Pegmatite at the Company's wholly-owned Shaakichiuwaanaan Property (the "Property" or "Project"), located in the Eeyou Istchee James Bay region of Quebec. The pilot-scale program delivered a premium 6.09% Li 2 O spodumene concentrate at low iron levels and very high recovery (89.0%) , providing a high-quality product to advance offtake discussions and downstream processing initiatives. This testwork has also provided a critical data point for assessing lithium recovery from high-grade feed, in the 3% Li 2 O range. The Shaakichiuwaanaan Property hosts one of the largest pegmatite Mineral Resources 2 (Li, Cs, Ta) and Mineral Reserves 3 (Li) in the world, situated approximately 13 km south of the regional and all-weather Trans-Taiga Road (accessible year-round by road) and Hydro Quebec infrastructure corridor. The Company recently announced a robust lithium-only Feasibility Study for the CV5 Pegmatite, which positions the Project as a potential North American critical mineral powerhouse (see news release dated October 20, 2025 ). ___________________________________ 2 The Consolidated MRE (CV5 + CV13 pegmatites), which includes the Rigel and Vega caesium zones, totals 108.0 Mt at 1.40% Li 2 O, 0.11% Cs 2 O, 166 ppm Ta 2 O 5 , and 66 ppm Ga, Indicated, and 33.4 Mt at 1.33% Li 2 O, 0.21% Cs 2 O, 155 ppm Ta 2 O 5 , and 65 ppm Ga, Inferred, and is reported at a cut-off grade of 0.40% Li 2 O (open-pit), 0.60% Li 2 O (underground CV5), and 0.70% Li 2 O (underground CV13). A grade constraint of 0.50% Cs 2 O was used to model the Rigel and Vega caesium zones. The Effective Date is June 20, 2025 (through drill hole CV24-787). Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. Mineral Resources are inclusive of Mineral Reserves. 3 Probable Mineral Reserve of 84.3 Mt at 1.26% Li 2 O at the CV5 Pegmatite with a cut-off grade is 0.40% Li 2 O (open-pit) and 0.70% Li 2 O (underground). Underground development and open-pit marginal tonnage containing material above 0.37% Li 2 O are also included in the statement. The Effective Date is September 11, 2025. See Feasibility Study news release dated October 20, 2025. Spodumene Concentrate Production (Project ApplePick) In the second half of 2025, the Company devised a novel approach to cost-effectively produce further quantities of spodumene concentrate from Shaakichiuwaanaan using a pilot scale DMS processing facility, to satisfy third-party sample requests and support its own midstream lithium processing development initiatives. The program, termed " ApplePick ", utilized the collection of well mineralized spodumene pegmatite boulders situated immediately down-ice of the principal CV5 outcrop that were readily accessible via all-season road and access trails. Based on the boulders' location, size, and angularity, the source was concluded to be from the immediately adjacent CV5 Pegmatite Deposit, and most likely the principal outcrop. Approximately 9.5 tonnes of mineralized boulders were collected at the site via backhoe and transported, via all-season road, to the Company's mobile crusher located adjacent to camp (Figure 1, Figure 2, and Figure 3). The boulders were crushed to roughly fist size (~10 cm) and placed directly into bulk bags via the crusher's conveyor (Figure 4 and Figure 5). The bulk bags were shipped to SGS Canada's Lakefield - Ontario, facility where the samples were further sized and processed through a Dense Media Separation ("DMS") pilot plant (Figure 6 and Figure 7). The DMS pilot produced approximately 4.47 tonnes of high-grade 6.09% Li 2 O spodumene concentrate at a low iron content (0.58% Fe 2 O 3 ) and a high recovery of 89.0%. A portion of the concentrate was then run through a standard magnetic separation circuit which resulted in the production of 1.65 tonnes of 6.32% Li 2 O (0.45% Fe 2 O 3 ) concentrate in the non-magnetic fraction, leaving 2.70 tonnes of 6.09% Li 2 O (0.58% Fe2O3) concentrate without magnetic separation. Shaakichiuwaanaan Project Benefits The program produced significantly more concentrate than expected, in part due to the high head-grade (3.61% Li 2 O) of the composited boulders, but also due to the achievement of a higher-than-expected lithia recovery (89.0%). Importantly, this has further derisked the Company's proposed DMS-only flowsheet and provides a key additional data point on the lithium recovery curve for the Project where, normally, feed grades in the 3% range are either not tested or otherwise typically not available at most projects. Considering the tenor of the high-grade Nova (CV5) and Vega (CV13) zones at Shaakichiuwaanaan, this data point represents a valuable addition to the grade-recovery curve and indicates that stronger recoveries can be achieved at the high-grade end of the curve compared to previous assumptions. At a feed grade of 2% Li 2 O, the results of Project ApplePick indicate an updated recovery curve with an implied global lithium recovery improvement of 2-3% compared to Feasibility Study assumptions 4 . This new lithium recovery data will be incorporated into the updated Feasibility Study for the CV5 Pegmatite, as well as a Preliminary Economic Assessment for the broader Project, scheduled to be announced in Q4-2026. Additionally, the program has provided the Company with significant quantities of spodumene concentrate to facilitate future offtake discussions and midstream initiatives. The availability of concentrate samples (especially for DMS-only processing) for technical evaluation is a valuable component in the development of a spodumene pegmatite project as it provides a tangible basis for engagement with potential partners and offtake counterparties, as well as providing feed for midstream evaluation. Another benefit stemming from the ApplePick program is that the scale of the DMS pilot allowed a significant quantity of tailings material to be generated. As is typically the case with lithium pegmatites, the tailings material normally hosts most of the tantalum and needs to be processed separately to be recovered. The Company is currently completing a feasibility-level tantalum recovery program at SGS (Lakefield) using these tailings as feed, which will then be followed by a variability program on drill core from the CV5 Pegmatite. ___________________________________ 4 See Feasibility Study news release dated October 20, 2025. Pollucite Concentrate Product (Project BerryPick) In light of the success of the ApplePick program, the Company is currently evaluating options for collecting a larger surface sample of pollucite pegmatite (caesium) at the Property. This project, named 'BerryPick' would aim to serve a similar purpose to ApplePick, by enabling the production of a larger volume of pollucite concentrate (i.e., several hundred kilograms to one tonne) samples to support future offtake discussions as well as midstream/downstream caesium product evaluation. The BerryPick Project is in the early stages of planning with locations at CV13 and CV12 (please refer to Figure 1 below) being targeted, where pollucite has been mapped at surface and strong grades have been documented 5 in channel sampling. Pollucite occurrences are very rare and are typically significantly smaller than lithium pegmatite occurrences, making sample collection at scale more challenging but also of high value. In contrast to most projects, at Shaakichiuwaanaan, several surface sample occurrences provide a strong target for a larger surface sampling program, such as that envisaged by BerryPick. Additionally, XRT ore sorting using a different/larger size fraction will aid in the development and final design of the pollucite recovery flowsheet design. ____________________________________ 5 See news releases dated March 2 and April 9, 2025. Figure 1: Location immediately adjacent to outcropping CV5 Pegmatite where the spodumene pegmatite boulders were collected. Figure 2: Backhoe collecting spodumene pegmatite mineralized boulders immediately down-ice of the principal CV5 outcrop (adjacent to the southwest side of the CV5 Pegmatite). Figure 3: Spodumene pegmatite boulders ready for crusher located proximal to Camp Shaakichiuwaanaan. Figure 4: Crushing of spodumene pegmatite boulders into bulk bags. Figure 5: Crushed spodumene pegmatite ready for shipment to the SGS (Lakefield) facility in Ontario for DMS processing with a head-grade assaying 3.61% Li2O Figure 6: Dense Media Separation (“DMS”) pilot operation at SGS (Lakefield) facility in ON, Canada. Figure 7: DMS spodumene concentrate (after magnetic separation) assaying 6.32% Li2O and 0.45% Fe2O3. Qualified/Competent Person The technical and scientific information in this news release that relates to the Mineral Resource Estimate and exploration results for the Company's properties is based on, and fairly represents, information compiled by Mr. Darren L. Smith, M.Sc., P.Geo., who is a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"), and member in good standing with the Ordre des Géologues du Québec (Geologist Permit number 01968), and with the Association of Professional Engineers and Geoscientists of Alberta (member number 87868). Mr. Smith has reviewed and approved the related technical information in this news release. Mr. Smith is an Executive and Vice President of Exploration for PMET Resources Inc. and holds common shares, Restricted Share Units (RSUs), Performance Share Units (PSUs), and options in the Company. The information in this news release that relates to the Mineral Reserve Estimate and Feasibility Study is based on, and fairly represents, information compiled by Mr. Frédéric Mercier-Langevin, Ing. M.Sc., who is a Qualified Person as defined by NI 43-101, and member in good standing with the Ordre des Ingénieurs du Québec. Mr. Mercier-Langevin has reviewed and approved the related technical information in this news release. Mr. Mercier-Langevin is the Chief Operating and Development Officer for PMET Resources Inc. and holds common shares, RSUs, PSUs, and options in the Company. About PMET Resources Inc. PMET Resources Inc. is a pegmatite critical mineral exploration and development company focused on advancing its district-scale 100%-owned Shaakichiuwaanaan Property located in the Eeyou Istchee James Bay region of Quebec, Canada, which is accessible year-round by all-season road and proximal to regional hydro-power infrastructure. In late 2025, the Company announced a positive lithium-only Feasibility Study on the CV5 Pegmatite for the Shaakichiuwaanaan Property and declared a maiden Mineral Reserve of 84.3 Mt at 1.26% Li 2 O (Probable) 6 . The study outlines the potential for a competitive and globally significant high-grade lithium project targeting up to ~800 ktpa spodumene concentrate using a simple Dense Media Separation ("DMS") only process flowsheet. Further, the results highlight Shaakichiuwaanaan as a potential North American critical mineral powerhouse with significant opportunity for tantalum and caesium in addition to lithium. The Project hosts a Consolidated Mineral Resource 7 totalling 108.0 Mt at 1.40% Li 2 O and 166 ppm Ta 2 O 5 (Indicated) and 33.4 Mt at 1.33% Li 2 O and 155 ppm Ta 2 O 5 (Inferred), and ranks as a top ten lithium pegmatite globally in size. Additionally, the Project hosts the world's largest pollucite-hosted caesium pegmatite Mineral Resource at the Rigel and Vega zones with 0.69 Mt at 4.40% Cs 2 O (Indicated), and 1.70 Mt at 2.40% Cs 2 O (Inferred). For further information, please contact us at info@pmet.ca or by calling +1 (604) 279-8709, or visit www.pmet.ca . Please also refer to the Company's continuous disclosure filings, available under its profile at www.sedarplus.ca and www.asx.com.au , for available exploration data. This news release has been approved by " KEN BRINSDEN " Kenneth Brinsden, President, CEO, & Managing Director ___________________________________ 6 See Feasibility Study news release dated October 20, 2025. Probable Mineral Reserve cut-off grade is 0.40% Li 2 O (open-pit) and 0.70% Li 2 O (underground). Underground development and open-pit marginal tonnage containing material above 0.37% Li 2 O are also included in the statement. Effective Date of September 11, 2025. 7 The Consolidated MRE (CV5 + CV13 pegmatites), which includes the Rigel and Vega caesium zones, totals 108.0 Mt at 1.40% Li 2 O, 0.11% Cs 2 O, 166 ppm Ta 2 O 5 , and 66 ppm Ga, Indicated, and 33.4 Mt at 1.33% Li 2 O, 0.21% Cs 2 O, 155 ppm Ta 2 O 5 , and 65 ppm Ga, Inferred, and is reported at a cut-off grade of 0.40% Li 2 O (open-pit), 0.60% Li 2 O (underground CV5), and 0.70% Li 2 O (underground CV13). A grade constraint of 0.50% Cs 2 O was used to model the Rigel and Vega caesium zones. The Effective Date is June 20, 2025 (through drill hole CV24-787). Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. Mineral Resources are inclusive of Mineral Reserves. Disclaimer for Forward-Looking Information This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of present or historical facts, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are typically identified by words such as "potential", "pathway", "plan", "further supports", "future", "can be achieved", "expected", "upcoming", "intends", "targeting", "development", "completing", "aim" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements include, but are not limited to, statements concerning the ability (i) of the ApplePick approach to allow for the rapid and cost-effective generation of spodumene concentrate on a larger scale without drilling to further supports the Company's future lithium offtake and midstream product initiatives, (ii) to complete the Feasibility-level tantalum recovery program, (iii) to achieve stronger recoveries, (iv) to positively impact the results of the upcoming updated Feasibility Study for the CV5 Pegmatite, as well as a Preliminary Economic Assessment for the broader Project. (v) of the BerryPick program to target surface pollucite samples for larger scale pilot testwork, the preparation and release of an updated Feasibility Study for the CV5 Pegmatite with the addition of tantalum as a co-product, as well as a Preliminary Economic Assessment for the broader Project inclusive of lithium, caesium, and tantalum. Forward-looking statements are based upon certain assumptions and other important factors that, if untrue, could cause actual results to be materially different from future results expressed or implied by such statements. There can be no assurance that forward-looking statements will prove to be accurate. Key assumptions upon which the Company's forward-looking information is based include, without limitation, the ability to make discoveries, the potential of each of tantalum, lithium, caesium as a co-product, the ability to complete an updated Feasibility Study for the CV5 Pegmatite with the addition of tantalum as a co-product, as well as a Preliminary Economic Assessment for the broader Project inclusive of lithium, caesium, and tantalum, that proposed exploration work on the Property and the results therefrom will continue as expected, the accuracy of reserve and resource estimates, the classification of resources and the assumptions on which the reserve and resource estimates are based, long-term demand for lithium (spodumene), tantalum (tantalite), and caesium (pollucite) supply, and that exploration and development results continue to support management's current plans for the Property's development. Forward-looking statements are also subject to risks and uncertainties facing the Company's business, any of which could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. Readers should review the detailed risk discussion in the Company's most recent Annual Information Form filed on SEDAR+, for a fuller understanding of the risks and uncertainties that affect the Company's business and operations. Although the Company believes its expectations are based upon reasonable assumptions and has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate. If any of the risks or uncertainties mentioned above, which are not exhaustive, materialize, actual results may vary materially from those anticipated in the forward-looking statements. The forward-looking statements contained herein are made only as of the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law. The Company qualifies all of its forward-looking statements by these cautionary statements. Competent Person Statement (ASX Listing Rules) The information in this news release that relates to the Feasibility Study ("FS") for the Shaakichiuwaanaan Project, which was first reported by the Company in a market announcement titled " PMET Resources Delivers Positive CV5 Lithium-Only Feasibility Study for its Large-Scale Shaakichiuwaanaan Project " dated October 20, 2025 (Montreal time) is available on the Company's website at www.pmet.ca , on SEDAR+ at www.sedarplus.ca and on the ASX website at www.asx.com.au . The production target from the Feasibility Study referred to in this news release was reported by the Company in accordance with ASX Listing Rule 5.16 on the date of the original announcement. The Company confirms that, as of the date of this news release, all material assumptions and technical parameters underpinning the production target in the original announcement continue to apply and have not materially changed. The Mineral Resource and Mineral Reserve Estimates in this release were first reported by the Company in accordance with ASX Listing Rule 5.8 in market announcements titled " World's Largest Pollucite-Hosted Caesium Pegmatite Deposit " dated July 20, 2025 (Montreal time) and " PMET Resources Delivers Positive CV5 Lithium-Only Feasibility Study for its Large-Scale Shaakichiuwaanaan Project " dated October 20, 2025 (Montreal time) and are available on the Company's website at www.pmet.ca , on SEDAR+ at www.sedarplus.ca and on the ASX website at www.asx.com.au . The Company confirms that, as of the date of this news release, it is not aware of any new information or data verified by the competent person that materially affects the information included in the relevant announcement and that all material assumptions and technical parameters underpinning the estimates in the relevant announcement continue to apply and have not materially changed. The Company confirms that, as at the date of this announcement, the form and context in which the competent person's findings are presented have not been materially modified from the original market announcement. Appendix 1 – JORC Code 2012 Table 1 (ASX Listing Rule 5.8.2) Section 1 – Sampling Techniques and Data Criteria JORC Code explanation Commentary Sampling techniques Nature and quality of sampling (eg cut channels, random chips, or specific specialized industry standard measurement tools appropriate to the minerals under investigation, such as down hole gamma sondes, or handheld XRF instruments, etc). These examples should not be taken as limiting the broad meaning of sampling. Include reference to measures taken to ensure sample representivity and the appropriate calibration of any measurement tools or systems used. Aspects of the determination of mineralization that are Material to the Public Report. In cases where 'industry standard' work has been done this would be relatively simple (eg 'reverse circulation drilling was used to obtain 1 m samples from which 3 kg was pulverized to produce a 30 g charge for fire assay'). In other cases more explanation may be required, such as where there is coarse gold that has inherent sampling problems. Unusual commodities or mineralization types (eg submarine nodules) may warrant disclosure of detailed information. Feed samples to the DMS processing were comprised of angular spodumene pegmatite boulders interpreted to be sourced from the CV5 Pegmatite. The boulders were located immediately down-ice to the southwest of the principal outcrop of the CV5 Pegmatite and were of similar size, situated in close proximity to each other, and exposed at surface. Based on location, size, angularity, and mineralogy of the boulders, as well as an understanding of glacial movement in the region, the source is interpreted with high confidence to be the CV5 Pegmatite, and most likely the principal outcrop. Therefore, although not in-situ samples, based on location, size, angularity, and mineralogy, the boulders are considered reasonably representative of the CV5 Pegmatite body as it is – with high confidence – their interpreted source. Boulders were selected based on estimated spodumene percentage as the primary objective was to maximize the amount of spodumene concentrate produced. Drilling techniques Drill type (eg core, reverse circulation, open-hole hammer, rotary air blast, auger, Bangka, sonic, etc) and details (eg core diameter, triple or standard tube, depth of diamond tails, face-sampling bit or other type, whether core is oriented and if so, by what method, etc). N/A. No drill results reported. Drill sample recovery Method of recording and assessing core and chip sample recoveries and results assessed. Measures taken to maximize sample recovery and ensure representative nature of the samples. Whether a relationship exists between sample recovery and grade and whether sample bias may have occurred due to preferential loss/gain of fine/coarse material. N/A. No drill results reported. Logging Whether core and chip samples have been geologically and geotechnically logged to a level of detail to support appropriate Mineral Resource estimation, mining studies and metallurgical studies. Whether logging is qualitative or quantitative in nature. Core (or costean, channel, etc) photography. The total length and percentage of the relevant intersections logged. N/A. No drill results reported. Sub-sampling techniques and sample preparation If core, whether cut or sawn and whether quarter, half or all core taken. If non-core, whether riffled, tube sampled, rotary split, etc and whether sampled wet or dry. For all sample types, the nature, quality and appropriateness of the sample preparation technique. Quality control procedures adopted for all sub-sampling stages to maximize representivity of samples. Measures taken to ensure that the sampling is representative of the in situ material collected, including for instance results for field duplicate/second-half sampling. Whether sample sizes are appropriate to the grain size of the material being sampled. The boulders were crushed at site, using a mechanical crusher, to approximately 10 cm and composited into bulk bags for transport. At the laboratory (SGS Lakefield, ON), the received samples were further crushed and screened to -9.5 mm/+0.8 mm to be used as feed to the DMS circuit. Quality of assay data and laboratory tests The nature, quality and appropriateness of the assaying and laboratory procedures used and whether the technique is considered partial or total. For geophysical tools, spectrometers, handheld XRF instruments, etc, the parameters used in determining the analysis including instrument make and model, reading times, calibrations factors applied and their derivation, etc. Nature of quality control procedures adopted (eg standards, blanks, duplicates, external laboratory checks) and whether acceptable levels of accuracy (ie lack of bias) and precision have been established. DMS concentrate underwent a standard analytical preparation procedure at SGS Canada's Lakefield facility. Samples were then assayed by lithium borate fusion XRF for whole rock / oxides (code GC_XRF72MET), aqua regia ICP-MS (code GC_IMS91AC2) for multi-element, and four-acid ICP-OES for multi-element (code GC_ICP92A50). The Company has relied on the laboratory's internal QAQC. Testwork methods are considered appropriate for the level of evaluation and results targeted. Verification of sampling and assaying The verification of significant intersections by either independent or alternative company personnel. The use of twinned holes. Documentation of primary data, data entry procedures, data verification, data storage (physical and electronic) protocols. Discuss any adjustment to assay data. N/A. No drill results reported. Adjustments to data include reporting lithium, and tantalum in their oxide forms, as it is reported in elemental form in the assay certificates. Formulas used are Li 2 O = Li x 2.153. Location of data points Accuracy and quality of surveys used to locate drill holes (collar and down-hole surveys), trenches, mine workings and other locations used in Mineral Resource estimation. Specification of the grid system used. Quality and adequacy of topographic control. Boulders were collected from a field located at approximately 570039 E, 5930560 N as determined by handheld GPS. The coordinate system used is UTM NAD83 Zone 18. The Company completed a property-wide LiDAR and orthophoto survey in August 2022, which provides high-quality topographic control. The quality and accuracy of the topographic controls are considered adequate for advanced stage exploration and development, including Mineral Resource estimation. Data spacing and distribution Data spacing for reporting of Exploration Results. Whether the data spacing and distribution is sufficient to establish the degree of geological and grade continuity appropriate for the Mineral Resource and Ore Reserve estimation procedure(s) and classifications applied. Whether sample compositing has been applied. Feed samples to the DMS processing were comprised of angular spodumene pegmatite boulders collected from the same boulder field immediately down-ice to the southwest of the principal outcrop of the CV5 Pegmatite. The source of these boulders is interpreted with high confidence to be the CV5 Pegmatite, and most likely the principal outcrop. As the boulders are by definition not in-situ, the data derived from them is not sufficient to inform a Mineral Resource Estimate. Several boulders were composited into a single sample for the DMS pilot run. Orientation of data in relation to geological structure Whether the orientation of sampling achieves unbiased sampling of possible structures and the extent to which this is known, considering the deposit type. If the relationship between the drilling orientation and the orientation of key mineralized structures is considered to have introduced a sampling bias, this should be assessed and reported if material. N/A. No drill results reported. Sample security The measures taken to ensure sample security. The sample for testwork remained under the custody of SGS Canada Inc. as they also completed the testwork and geochemical analysis. Audits or reviews The results of any audits or reviews of sampling techniques and data. A review of the sample procedures for the Company's drill programs has been reviewed by several Qualified/Competent Persons through multiple NI 43-101 technical reports completed for the Company and deemed adequate and acceptable to industry best practices. The most recent Technical Report includes a review of sampling techniques and data through 2024 (drill hole CV24-787) in a technical report titled "CV5 Pegmatite Lithium-Only Feasibility Study NI 43-101 Technical Report, Shaakichiuwaanaan Project" with an Effective Date of October 20, 2025, and Issue Date of November 14, 2025. Additionally, the Company continually reviews and evaluates its procedures in order to optimize and ensure compliance at all levels of sample data collection and handling. Section 2 – Reporting of Exploration Results Criteria JORC Code explanation Commentary Mineral tenement and land tenure status Type, reference name/number, location and ownership including agreements or material issues with third parties such as joint ventures, partnerships, overriding royalties, native title interests, historical sites, wilderness or national park and environmental settings. The security of the tenure held at the time of reporting along with any known impediments to obtaining a licence to operate in the area. The Shaakichiuwaanaan Property (formerly called "Corvette") is comprised of 463 CDC claims located in the James Bay Region of Quebec, with Lithium Innova Inc. (wholly owned subsidiary of PMET Resources Inc.) being the registered title holder for all of the claims. The northern border of the Property's primary claim block is located within approximately 6 km to the south of the Trans-Taiga Road and powerline infrastructure corridor. The CV5 Spodumene Pegmatite is accessible year-round by all-season road is situated approximately 13.5 km south of the regional and all–weather Trans-Taiga Road and powerline infrastructure. The CV13 and CV9 spodumene pegmatites are located approximately 3 km west-southwest and 14 km west of CV5, respectively. The Company holds 100% interest in the Property subject to various royalty obligations depending on original acquisition agreements. DG Resources Management holds a 2% NSR (no buyback) on 76 claims, D.B.A. Canadian Mining House holds a 2% NSR on 50 claims (half buyback for $2M), OR Royalties holds a sliding scale NSR of 1.5-3.5% on precious metals, and 2% on all other products, over 111 claims, and Azimut Exploration holds 2% NSR on 39 claims. The Property does not overlap any atypically sensitive environmental areas or parks, or historical sites to the knowledge of the Company. There are no known hinderances to operating at the Property, apart from the goose harvesting season (typically mid-April to mid-May) where the communities request helicopter flying not be completed, and potentially wildfires depending on the season, scale, and location. Claim expiry dates range from July 2026 to July 2028. Exploration done by other parties Acknowledgment and appraisal of exploration by other parties. No previous exploration targeting LCT pegmatites has been conducted by other parties at the Project. For a summary of previous exploration undertaken by other parties at the Project, please refer to the most recent NI 43-101 Technical Report. Geology Deposit type, geological setting and style of mineralization. The Property overlies a large portion of the Lac Guyer Greenstone Belt, considered part of the larger La Grande River Greenstone Belt and is dominated by volcanic rocks metamorphosed to amphibolite facies. The claim block is dominantly host to rocks of the Guyer Group (amphibolite, iron formation, intermediate to mafic volcanics, peridotite, pyroxenite, komatiite, as well as felsic volcanics). The amphibolite rocks that trend east-west (generally steeply south dipping) through this region are bordered to the north by the Magin Formation (conglomerate and wacke) and to the south by an assemblage of tonalite, granodiorite, and diorite, in addition to metasediments of the Marbot Group (conglomerate, wacke). Several regional-scale Proterozoic gabbroic dykes also cut through portions of the Property (Lac Spirt Dykes, Senneterre Dykes). The geological setting is prospective for multiple commodities over several different deposit styles including orogenic gold (Au), volcanogenic massive sulphide (Cu, Au, Ag), komatiite-ultramafic (Au, Ag, PGE, Ni, Cu, Co), and LCT pegmatite (Li, Cs, Ta, Ga, Rb). Exploration of the Property has outlined three primary mineral exploration trends crossing dominantly east-west over large portions of the Property – Golden Trend (gold), Maven Trend (copper, gold, silver), and CV Trend (lithium, caesium, tantalum). The CV4, CV5, CV8, CV12, and CV13 pegmatites are situated within the CV Trend. The pegmatites at Shaakichiuwaanaan are categorized as Li-Cs-Ta ("LCT") pegmatites. LCT mineralization at the Property is observed to occur within quartz-feldspar pegmatite. The pegmatite is often very coarse-grained and off-white in appearance, with darker sections commonly composed of mica and smoky quartz, and occasional tourmaline. Core assays and ongoing mineralogical studies, coupled with field mineral identification and assays confirm spodumene as the dominant lithium-bearing mineral on the Property, with no significant petalite, lepidolite, lithium-phosphate minerals, or apatite present. The spodumene crystal size of the pegmatites is typically decimeter scale, and therefore, very large. The pegmatites also carry significant tantalum (tantalite) and caesium (pollucite). Gallium is present in spodumene and feldspar via substitution with Al. Drill hole Information A summary of all information material to the understanding of the exploration results including a tabulation of the following information for all Material drill holes: easting and northing of the drill hole collar elevation or RL (Reduced Level – elevation above sea level in metres) of the drill hole collar dip and azimuth of the hole down hole length and interception depth hole length. If the exclusion of this information is justified on the basis that the information is not Material and this exclusion does not detract from the understanding of the report, the Competent Person should clearly explain why this is the case. N/A. No drill results reported. Data aggregation methods In reporting Exploration Results, weighting averaging techniques, maximum and/or minimum grade truncations (eg cutting of high grades) and cut-off grades are usually Material and should be stated. Where aggregate intercepts incorporate short lengths of high grade results and longer lengths of low grade results, the procedure used for such aggregation should be stated and some typical examples of such aggregations should be shown in detail. The assumptions used for any reporting of metal equivalent values should be clearly stated. N/A. No drill results reported. Relationship between mineralization widths and intercept lengths These relationships are particularly important in the reporting of Exploration Results. If the geometry of the mineralization with respect to the drill hole angle is known, its nature should be reported. If it is not known and only the down hole lengths are reported, there should be a clear statement to this effect (eg 'down hole length, true width not known'). N/A. No drill results reported. Diagrams Appropriate maps and sections (with scales) and tabulations of intercepts should be included for any significant discovery being reported. These should include, but not be limited to a plan view of drill hole collar locations and appropriate sectional views. Please refer to the figures included herein as well as those posted on the Company's website. Balanced reporting Where comprehensive reporting of all Exploration Results is not practicable, representative reporting of both low and high grades and/or widths should be practiced to avoid misleading reporting of Exploration Results. Reporting is balanced. Other substantive exploration data Other exploration data, if meaningful and material, should be reported including (but not limited to): geological observations; geophysical survey results; geochemical survey results; bulk samples – size and method of treatment; metallurgical test results; bulk density, groundwater, geotechnical and rock characteristics; potential deleterious or contaminating substances. The Company is currently completing site environmental work over the CV5 and CV13 pegmatite area. No endangered flora or fauna have been documented over the Property to date, and several sites have been identified as potentially suitable for mine infrastructure. The Company has completed a bathymetric survey over the shallow glacial lake which overlies a portion of the CV5 Spodumene Pegmatite. The lake depth ranges from <2 m to approximately 18 m, although the majority of the CV5 Spodumene Pegmatite, as delineated to date, is overlain by typically <2 to 10 m of water. The Company has completed significant metallurgical testing comprised of HLS and magnetic testing, which has produced 6+% Li 2 O spodumene concentrates at >70% recovery on both CV5 and CV13 pegmatite material. A DMS test on CV5 Pegmatite material returned a Subsequent and more expansive DMS pilot programs completed, including with non-pegmatite dilution, produced results in line with prior testwork, confirming a DMS-only flowsheet is applicable. Piloting to date (using both drill core and boulders) has collectively produced over 4.5 tonnes of spodumene concentrate grading over 5.5% Li2O. The Company has also produced a marketable lithium hydroxide concentrate from CV5's spodumene concentrate. The Company has produced marketable tantalite concentrates at bench-scale from the CV5 Pegmatite's DMS (spodumene) tailings fractions. The testwork used gravity or gravity + flotation methods to produce tantalite concentrates grading 8.7% Ta 2 O 5 at 45% global recovery (MC001) and 6.6% Ta 2 O 5 at 49% global recovery (MC002). The Company has produced marketable pollucite concentrates at bench-scale from the CV13 Pegmatite's Vega Caesium Zone. The testwork used XRT ore sorting to produce concentrates of 11.5% Cs 2 O and 20.0% Cs 2 O at an overall 88% recovery. Various mandates required for advancing the Project have been completed or are ongoing, including but not limited to, environmental baseline, metallurgy, geomechanics, hydrogeology, hydrology, stakeholder engagement, geochemical characterization, as well as transportation and logistical studies. A Feasibility Study for lithium-only on the CV5 Pegmatite was announced October 20, 2025. Further work The nature and scale of planned further work (eg tests for lateral extensions or depth extensions or large-scale step-out drilling). Diagrams clearly highlighting the areas of possible extensions, including the main geological interpretations and future drilling areas, provided this information is not commercially sensitive. The Company intends to continue drilling the pegmatites of the Shaakichiuwaanaan Property, primarily targetting lithium, caesium, and tantalum as the primary commodities of interest. This is anticipated to includes step-out and infill drilling. Further drilling is anticipated to support the development of the CV5 and CV13 pegmatites (i.e., resource, geotechnical, geomechanical, and hydrogeological). Metallurgical test programs evaluating the recovery of lithium, caesium, and tantalum are ongoing. Surface prospecting, rock sampling, and mapping is planned to continue across the Property focused on LCT pegmatite. Olivier Caza-Lapointe, Head, Investor Relations, T: +1 (514) 913-5264, E: ocazalapointe@pmet.ca Photo - https://mma.prnasia.com/media2/2971303/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Photo - https://mma.prnasia.com/media2/2971302/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Photo - https://mma.prnasia.com/media2/2971301/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Photo - https://mma.prnasia.com/media2/2971300/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Photo - https://mma.prnasia.com/media2/2971299/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Photo - https://mma.prnasia.com/media2/2971298/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Photo - https://mma.prnasia.com/media2/2971297/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600 Logo - https://mma.prnasia.com/media2/2971314/PMET_Resources_Inc__PMET_Produces_High_Recovery__89___and_High_G.jpg?p=medium600
2026-05-03 22:30:00

US signs deals with 7 tech companies to use AI in classified military systems
WASHINGTON — The Pentagon said Friday that it has reached deals with seven tech companies to use their artificial intelligence in its classified computer networks, allowing the military to tap into AI-powered capabilities to help it fight wars. Google, Microsoft, Amazon Web Services, Nvidia, OpenAI, Reflection and SpaceX will provide their resources to help “augment warfighter decision-making in complex operational environments,” the Defense Department said. The Defense Department has been rapidly accelerating its use of AI in recent years. The technology can help the military reduce the time it takes to identify and strike targets on the battlefield, while aiding in the organization of weapons maintenance and supply lines, according to a report in March from the Brennan Center for Justice. But AI has already raised concerns that its use could invade Americans' privacy or allow machines to choose targets on the battlefield. One of the companies contracting with the Pentagon said its agreement required human oversight in certain situations. Such concerns were raised by a company not on the list, Anthropic, and it is now battling the Pentagon in court. The tech company said it wanted assurances in its contract that the military would not use its technology in fully autonomous weapons and the surveillance of Americans. Defense Secretary Pete Hegseth said the company must allow for any uses the Pentagon deemed lawful. Anthropic sued after President Donald Trump, a Republican, tried to stop all federal agencies from using the company’s chatbot Claude and Hegseth sought to label the company a supply chain risk, a designation meant to protect against sabotage of national security systems by foreign adversaries. OpenAI had announced a deal with the Pentagon in March to effectively replace Anthropic with ChatGPT in classified environments. OpenAI confirmed in a statement Friday that it was the same agreement it announced in early March. “As we said when we first announced our agreement several months ago, we believe the people defending the United States should have the best tools in the world,” the company said. One company's agreement with the Pentagon included language that said there should be human oversight over any missions in which the AI systems act autonomously or semi-autonomously, according to a person familiar with the agreement who was not authorized to speak about it publicly. The language also said the AI tools must be used in ways that are consistent with constitutional rights and civil liberties. Those resemble sticking points for Anthropic, though OpenAI has previously said that it secured similar assurances when it made its own deal with the Pentagon. Emil Michael, the Pentagon's chief technology officer, told CNBC on Friday that it would have been irresponsible to rely on only one company, an acknowledgement of the friction with Anthropic. “And when we learned that that one partner didn’t really want to work with us in the way we wanted to work with them, we went out and made sure that we had multiple different providers," Michael said. Some of the companies, including Amazon and Microsoft, have long worked with the military in classified environments and it was not immediately clear if the new agreements significantly altered their government partnerships. Others, such as chipmaker Nvidia and the startup Reflection, are new to such work. Both companies make open-source AI models, which Michael has described as a priority to provide an “American alternative” to China's rapid development of AI systems in which some key components are publicly accessible for others to build upon. The Pentagon said Friday that military personnel are already using its AI capabilities through its official platform, GenAI.mil. “Warfighters, civilians and contractors are putting these capabilities to practical use right now, cutting many tasks from months to days,” the Pentagon said, adding that the military's growing AI capabilities will “give warfighters the tools they need to act with confidence and safeguard the nation against any threat.”
2026-05-01 19:34:49

Summer DWI Enforcement in Montgomery County: Griffin & Cain Attorneys Urge Residents to Know Their Rights
DWI enforcement in Montgomery Co. Conroe, Texas, April 30, 2026 /MarketersMEDIA/ -- Conroe, Texas - As Montgomery County enters the high-traffic summer months, attorneys at Griffin & Cain Attorneys at Law are urging residents to understand the serious legal consequences and their rights when facing a Driving While Intoxicated (DWI) charge. According to a report by KPRC-TV, nearly 50 DWI arrests were made across Montgomery County during a recent enforcement period-highlighting the area’s increased enforcement efforts and the likelihood of individuals facing charges. In addition to DWI enforcement, law enforcement agencies across the greater Houston area have launched initiatives targeting other forms of dangerous driving. Recent coverage detailed the rollout of "Operation Zero Traction,” an effort aimed at cracking down on illegal street racing and parking lot takeovers. These combined efforts reflect a broader push to reduce high-risk driving behaviors across the region. For many, a DWI arrest happens unexpectedly-often during routine traffic stops or periods of increased enforcement. Local criminal defense attorney Brian Cain says the impact can be immediate and long-lasting. "Montgomery County takes DWI enforcement seriously, especially during high-traffic times of the year,” Cain said. "People can find themselves facing significant consequences very quickly, even if it’s their first offense.” In Texas, DWI charges may carry penalties such as license suspension, fines, mandatory programs, and potential jail time. Beyond the courtroom, individuals may also experience increased insurance rates and limitations on employment opportunities. Based in Conroe, Griffin & Cain Attorneys at Law provides legal representation for individuals navigating DWI charges and other criminal defense matters. The firm emphasizes a proactive and strategic approach, helping clients understand their legal options from the outset. "With enforcement efforts increasing, it’s more important than ever for people to know their rights,” Cain added. "What you do immediately after an arrest can make a difference in how your case moves forward.” Legal professionals note that no two DWI cases are the same, and outcomes often depend on the details surrounding the arrest. Early legal guidance can help individuals better understand the process and make informed decisions. Disclaimer: This press release is for informational purposes only and does not constitute legal advice or create an attorney-client relationship. Contact Info: Name: Ashley Davlin Email: Send Email Organization: Griffin & Cain Attorneys at Law, PC Website: https://griffinandcainattorneys.com/ Release ID: 89190364 Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.
2026-04-30 18:06:21

AdKit Launches MCP Service to Let AI Agents Manage Google and Meta Ad Campaigns
AdKit, a Singapore-based advertising platform, launched a Model Context Protocol service that connects AI agents to Google and Meta ad accounts. Marketers and agencies can research, launch, and analyze campaigns through natural-language prompts, with every agent action staged as a draft for approval going live. Singapore, April 30, 2026 -- Managing paid media has traditionally meant hours inside Google Ads and Meta Ads Manager, clicking through campaign settings, ad sets, creatives, and bid strategies. AdKit, founded by Nico Jeannen, is launching a Model Context Protocol service that hands most of that work to AI agents. Marketers and agency teams describe what they want in plain English to assistants like Claude, ChatGPT, Cursor, or OpenClaw, and the agent drafts the campaign end to end. The launch arrives as more advertisers experiment with autonomous agents but lack a safe way to give them write access to live ad accounts. Existing open-source MCP servers connect agents directly to the Google and Meta APIs, which were built for human operators and validate input accordingly. AdKit’s Google and Meta Ads MCP instead routes every agent action through a draft-first workflow, where campaigns, creatives, budgets, and targeting changes are staged in a review dashboard alongside projections and recommendations until the marketer approves them. Permissions can be set granularly, so teams decide exactly what their agents can touch. Nothing reaches the live account without explicit sign-off. "Ad accounts hold years of pixel data, search history, and trained bidding models, so they are not something you want an agent experimenting on directly," said Nico Jeannen, Founder and CEO of AdKit. "We built AdKit so marketers can hand the busywork to their agents around the clock and still have the final word on what goes live." The service is already in use by more than 500 marketers and agencies, with early users reporting campaign setup time dropping from roughly 45 minutes of manual clicks to a single prompt. AdKit currently supports Google Ads and Meta Ads and works with any MCP-compatible agent. The company reports its protocol uses up to 46 percent fewer tokens than alternative MCP servers by structuring requests around how ad platforms actually validate input. AdKit plans to extend coverage to TikTok, LinkedIn, Reddit, and X, and is preparing a freeAI ad agents playbook with prompt patterns and guardrails drawn from how experienced media buyers structure campaigns. As more advertising work shifts to autonomous agents, the company sees the connection layer between agent and account becoming a core piece of the marketing stack. Boilerplate AdKit was founded by Nico Jeannen, a media buyer who has spent nearly a decade managing performance campaigns and grew two startups through Meta Ads before selling them. After years inside slow advertising dashboards, he built the platform he wished existed. AdKit now serves more than 500 marketers and agencies worldwide. Contact Info: Name: Nico Jeannen Email: Send Email Organization: Adkit Website: https://adkit.so Release ID: 89190450 If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.
2026-04-30 18:06:15

Singapore Fintech Founder Jonathan Low Releases Bestselling Memoir "Cell to CEO,” Debuting as Amazon Bestseller Across Six Categories
From Thai prison to Forbes 40 Under 40 in Technology (2025) - Jonathan Low’s radical transformation blueprint lands on Amazon as an immediate bestseller. SINGAPORE, April 29, 2026 (GLOBE NEWSWIRE) -- Jonathan Low, Founder and CEO of BipTap Group and Founder of Ampyre Group, has released Cell to CEO: A Blueprint for Radical Transformation, which debuted as an Amazon Bestseller across six categories upon publication in March 2026. The book chronicles Low’s transformation from gang member and convicted prisoner - he served time in a Thai prison - to Forbes 40 Under 40 entrepreneur and founder of a financial technology group powering more than 40 licensed partner banks across Asia and the Middle East. Cell to CEO is structured as a five-part system - The Fall, The Transformation, The Resurrection, The Building, The Mission - that maps Low’s personal arc onto a replicable framework for identity-level change. Unlike conventional self-help or business books, the methodology centers on identity transformation rather than behavioral modification, arguing that sustainable reinvention requires a fundamental shift in how individuals understand themselves before strategy, tactics, or execution can take hold. "Most people try to change their behavior while keeping their identity intact. That doesn’t work. I know because I tried it - and prison was the place where trying to hold onto the old version of me finally stopped being an option. The moment I let go of who I was is the moment everything else became possible.” - Jonathan Low, Cell to CEO Low’s story has been documented in Forbes, Dubai Magazine, UAE Stories, and multiple international business publications. He has spoken at dozens of events across four continents - including SiGMA AIBC Dubai, Token2049 Singapore, and TEDx - and is a recognized voice on transformation, leadership under pressure, and financial inclusion. He is currently completing a second book, One to Fifty, focused on scaling. Cell to CEO: A Blueprint for Radical Transformation is available on Amazon About Jonathan Low Jonathan Low is a Forbes 40 Under 40 in Technology (2025) entrepreneur, transformation speaker, and Founder & CEO of BipTap Group - a white-label banking infrastructure company powering 40+ licensed partner banks across Asia and the Middle East. He is the Founder of Ampyre Group, a Singapore-headquartered financial technology group operating across banking infrastructure, AI financial services, and next-generation payment rails. Based in Singapore and Dubai, Low has spoken at dozens of events across four continents and is a recognized voice on transformation, fintech, and financial inclusion. CONTACT: Media Contact Jonathan Low Email: jon@biptap.com
2026-04-29 16:42:51

Thomas Mollick Scholarship for Entrepreneurs Announces 2026 Application Cycle to Support Undergraduate Innovators Nationwide
Thomas Mollick Thomas Mollick TAMPA, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- The Thomas Mollick Scholarship for Entrepreneurs officially opens its 2026 application cycle, offering undergraduate students across the United States an opportunity to gain recognition and financial support for their entrepreneurial ambitions. Established in honor of Thomas Mollick, the scholarship reflects a strong commitment to fostering innovation, integrity, and leadership among the next generation of business founders. The Thomas Mollick Scholarship for Entrepreneurs, founded by Thomas Mollick, serves as a platform to identify and support students who demonstrate a passion for entrepreneurship and a clear vision for solving real-world problems. Drawing inspiration from Thomas Mollick’s own journey-from a business student to a respected entrepreneur and co-founder of Rx Development-the initiative highlights the importance of early-stage encouragement in building successful ventures. At its core, the Thomas Mollick Scholarship for Entrepreneurs aims to reduce financial barriers while recognizing students who are actively working toward launching businesses or developing innovative ideas. Thomas Mollick emphasizes the significance of supporting driven individuals at a formative stage in their academic and professional lives, reinforcing the belief that impactful businesses often begin with a single, well-developed idea. The scholarship is open to undergraduate students currently enrolled at accredited colleges or universities within the United States. Eligible applicants must demonstrate a strong interest in entrepreneurship, whether through an existing business, a startup concept, or a long-term vision for innovation. As part of the application process, students are required to submit an original essay responding to a carefully structured prompt. The essay invites applicants to reflect on their entrepreneurial journey, outlining the ideas they are pursuing, the problems they aim to solve, and the broader impact they intend to create as future founders. Submissions must range between 500 and 1,000 words and be presented in English as a PDF or Word document. All entries are evaluated based on originality, clarity of vision, writing quality, and demonstrated passion for entrepreneurship. Any form of plagiarism or use of AI-generated content results in immediate disqualification, reinforcing the scholarship’s commitment to authenticity and integrity-values closely associated with Thomas Mollick. Each year, the Thomas Mollick Scholarship for Entrepreneurs awards one outstanding student with a one-time grant of $1,000. While the financial support provides meaningful assistance, the recognition associated with the award also serves as a valuable milestone for aspiring entrepreneurs seeking to establish credibility in competitive industries. The application deadline for the 2026 cycle is September 15, 2026, and the selected recipient is scheduled to be announced on October 15, 2026. The scholarship continues to attract applicants who embody creativity, resilience, and a commitment to building solutions that address meaningful challenges. Through this initiative, Thomas Mollick reinforces a long-standing dedication to innovation and community impact. The scholarship reflects the guiding principles that define Thomas Mollick’s professional journey, including strategic thinking, hard work, and a deep belief in the potential of emerging entrepreneurs. By supporting undergraduate students at an early stage, Thomas Mollick continues to contribute to a future where bold ideas are nurtured and transformed into sustainable enterprises. The Thomas Mollick Scholarship for Entrepreneurs stands as a testament to the enduring value of mentorship, opportunity, and vision. As applications open for the 2026 cycle, the program invites aspiring founders to take a decisive step forward in their entrepreneurial journey. Contact Information: Spokesperson: Thomas Mollick Organization: Thomas Mollick Scholarship for Entrepreneurs Website: https://thomasmollickscholarship.com/ Email: apply@thomasmollickscholarship.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/849ddde7-f06d-43b4-b9d3-b61e99aacbc2
2026-04-29 16:42:36

BANG! Salon Chicago Named to 2026 Salon Today 200, Highlighting Philanthropic Impact and Salon Growth
Chicago, Illinois, April 29, 2026 (GLOBE NEWSWIRE) -- BANG! Salon Chicago announced that it has been named to the 2026 Salon Today 200, the annual industry list recognizing salon growth and best business practices. The recognition highlights the salon's philanthropic work, and owner and master stylist Eli Mancha was also featured on the cover of the 29th annual Salon Today 200 digital issue. According to the publication's cover reveal, Mancha was among a select group of salon owners featured on this year's cover as part of the 2026 class. For BANG! Salon Chicago, the recognition centers in part on the salon's long-running community initiative, Cuts for Coats, a November coat drive launched 10 years ago to support unhoused Chicagoans during the city's winter season. Through the program, BANG! Salon Chicago offers free haircuts for anyone who donates a coat. The salon partners with a local nonprofit to help distribute donations throughout the community. To date, the initiative has helped collect and donate more than 1,200 coats. As a salon-based giving program, Cuts for Coats was designed to make participation simple for clients, neighbors, and community members. Each donated coat helps extend the program's reach, while the complimentary haircut creates an accessible way for the salon team to contribute its time and professional skills. The initiative has become a recurring part of BANG! Salon Chicago's November calendar and reflects a service model that connects personal care with impactful local support. "This recognition reflects the kind of business we have worked to build in Chicago," said Eli Mancha, owner and master stylist at BANG! Salon Chicago. "Cuts for Coats started as a direct way to support people in our community, and it has remained important to our team because it connects our work behind the chair with service beyond the salon." BANG! Salon Chicago was included in the Salon Today 200 issue alongside operating details that reflect the salon's scale and consistency, including its 2,500-square-foot location, 14 employees, and a service model supported by professional retail, color, and technology partners. While the business has earned industry recognition, the philanthropic distinction underscores a broader commitment to community impact. The salon's inclusion also reflects the operational discipline required to sustain an independent beauty business in a competitive urban market. In addition to technical hair services, the BANG! Salon Chicago team focuses on client experience, staff development, and consistent service delivery. The salon's Wicker Park location has allowed it to remain closely connected to neighborhood organizations and local community. "The Salon Today 200 honor is meaningful because it recognizes more than business performance alone," Mancha added. "It acknowledges that salons can create a positive local impact, and that matters to our team." The annual Salon Today 200 program is widely followed within the professional beauty industry for spotlighting salon businesses that demonstrate operational strength, leadership, and innovation. For BANG! Salon Chicago, the 2026 recognition provides an opportunity to further elevate the salon's profile in Chicago while also bringing additional attention to a decade of charitable work through Cuts for Coats. The recognition also gives the salon an opportunity to encourage continued participation in future Cuts for Coats drives. Community members who want to support the initiative can look for seasonal announcements from BANG! Salon Chicago each November, when the salon outlines donation timing, participation details, and nonprofit distribution support. For more information about BANG! Salon Chicago, visit www.bangsalonchicago.com. About BANG! Salon Chicago Founded by award-winning stylist Eli Mancha, BANG! Salon Chicago is located in Chicago's vibrant Wicker Park neighborhood. Known for its fresh, trend-driven styles and commitment to quality, BANG! Salon creates a welcoming atmosphere where every client's experience is unique and memorable. The salon prides itself on community engagement and continually seeks ways to support and give back to its local community. ### For more information about BANG! Salon, contact the company here: BANG! Salon Eli Mancha 773-276-9414 bangsalonchicago1@gmail.com 1259 N Milwaukee Ave, Chicago IL, 60622 CONTACT: Eli Mancha
2026-04-29 16:42:27

Three Pressures on Desert Homes Are Driving Home Team Electric’s Expanded Residential Coverage
THOUSAND PALMS, CA, April 29, 2026 (GLOBE NEWSWIRE) -- Three forces are converging on residential electrical systems across the Coachella Valley and Morongo Basin simultaneously: aging housing stock carrying electrical loads it was never designed to handle, accelerating EV charger adoption driven by California's rapidly growing electric vehicle market, and the relentless physical toll that desert conditions impose on every wire, terminal, and connection in a home. Home Team Electric, a family-owned residential electrical contractor with 28 years of residential electrical experience in the Coachella Valley, is expanding its core service coverage in direct response to those pressures, extending reach to additional communities across the valley floor and deeper into the Morongo Basin, including Yucca Valley, Joshua Tree, and Twentynine Palms. The Coachella Valley's residential landscape spans eight decades of construction standards. Mid-century homes in Palm Springs, many built between the 1940s and 1970s, carry original wiring under modern electrical loads their builders never anticipated. A 1958 home designed around a window unit and a kitchen circuit now powers central air conditioning, multiple kitchen appliances, a home office, pool equipment, and increasingly, a Level 2 EV charger pulling 40 to 50 amps overnight in the garage. In the Morongo Basin communities, the challenges shift. Well pump systems draw sustained electrical load across long conduit runs. Properties sit farther apart, with service connections exposed to temperature extremes wider than those on the valley floor. Monsoon season delivers voltage surges that reach panels not designed to absorb them. Across the entire service area, desert conditions are the constant. Temperatures above 120°F fatigue metal connections through daily thermal cycling. Fine alkaline dust works into panel enclosures, coating bus bars and breaker contacts with a resistive film that compounds under load. Air conditioning systems that run six consecutive months place demands on circuits and breakers that residential systems in milder climates never experience. Home Team Electric holds California C-10 Electrical Contractor License #879507. Active and verifiable through the California State License Board (CSLB) at cslb.ca.gov. The company works exclusively in residential service and has completed more than 25,000 residential projects across the region. It maintains a 4.9 out of 5 rating from over 16,000 homeowners. "The homes we work in out here have been through things that homes in other parts of California haven't," said Frank Luersen, Owner of Home Team Electric and California C-10 Electrical Contractor License #879507, with 28 years of residential electrical experience serving the Coachella Valley and Morongo Basin. "Every summer loosens connections that were tight in January. Every monsoon season brings surge damage we don't see in San Diego. When a homeowner calls us, we already know what their house has been through because we've been inside thousands of homes just like it." Luersen's family has lived in the valley for four generations. Home Team Electric operates from Thousand Palms and deploys service teams across Palm Springs, Cathedral City, Rancho Mirage, Palm Desert, La Quinta, Indio, and the Morongo Basin corridor. The expansion covers the company's full residential service line: electrical repairs, panel upgrades, circuit installation, troubleshooting, emergency response, and EV charger installation. Home Team Electric includes a 100% Satisfaction Guarantee and a Lifetime Workmanship Guarantee as part of its service terms. "We'll explain what we find and walk the homeowners through their options. Homeowners decide what fits their home," said Frank Luersen. Home Team Electric is a family-owned residential electrical contractor serving the Coachella Valley and Morongo Basin. Founded in 2006 by Frank Luersen, the company focuses exclusively on residential electrical service and deploys State-Certified Residential Specialists on every call. 28 years of hands-on desert experience. California C-10 Electrical Contractor License #879507. Active and verifiable through the California State License Board (CSLB). ### For more information about Home Team Electric, contact the company here: Home Team Electric Frank Luersen (760) 248-8709 info@hometeamelectric.com 72091 Woburn Court, Suite A, Thousand Palms, CA 92276 CONTACT: Frank Luersen
2026-04-29 16:42:23

復星國際:創造可持續影響 發佈2025年ESG報告及氣候信息披露報告
香港 2026年4月28日 /美通社/ -- 復星國際有限公司(香港聯交所股份代號:00656,簡稱「復星國際」)及其附屬公司(統稱「復星」或「集團」)發佈2025年環境、社會及管治(簡稱ESG)報告。面對愈發嚴峻的全球氣候變化挑戰,復星對標香港聯交所《主板上市規則》附錄C2「環境、社會及管治報告守則」D部分(「新氣候規定」),並參考氣候變化相關財務信息披露工作組(TCFD)建議框架及《國際財務報告準則S2號—氣候相關披露》(「IFRS S2」)發佈了第四份氣候信息披露報告。 作為植根中國、佈局全球的產業集團,復星始終將可持續發展置於戰略核心,以務實行動回應時代與社會的期望。復星的可持續發展戰略為「創造影響力」(Create IMPACT),緊扣六大長期戰略方向,即:I: Innovation-driven 創新驅動、M: Mindful Operation 責任運營、P: People and Partner Oriented 以人為本、A: Advanced Governance精益治理、C: Climate and Planet Positive 綠色發展、T: Transparency透明真實。 積極推動全球可持續發展, ESG 評級屢獲佳績 復星以「創新」與「全球化」為引擎,積極深化ESG與商業融合,加速低碳轉型、拓展責任投資、強化社會實踐,以「全球資源嫁接中國能力」,在超過40個國家和地區負責任運營,為全球可持續發展貢獻復星力量。作為負責任的全球公民,復星於2014年正式加入聯合國全球契約組織,全力支持聯合國全球契約組織在人權、勞工、環境及反腐敗等領域的十項原則,並將這些原則與「創造影響力」的可持續發展戰略及行動準則深度融合。 過去一年,儘管全球環境、社會與經濟充滿不確定性,復星仍堅定履行對可持續發展的長期承諾,並收獲佳績。根據最新MSCI 5.0版標準的ESG評級,復星國際MSCI ESG評級榮升AAA,恒生可持續發展評級保持AA-,入選標普全球《可持續發展年鑑2026》並連續位列中國最佳1%;富時羅素ESG評分升至4.2分,並連續第五次入選FTSE4Good成份股。 積極應對氣候變化,推動低碳轉型 面對氣候變化與低碳轉型的趨勢,復星積極響應國家「雙碳」目標,推動碳中和與節能減排,於2021年向社會做出承諾:「力爭於2028年實現碳達峰、2050年實現碳中和」,通過制訂氣候變化緩解和適應策略,支持《巴黎協定》的1.5°C控溫目標。復星更在2050碳中和承諾的基礎上,提出以2024年為基準年,至2034年範圍1和範圍2的溫室氣體排放強度下降20%的中期目標,這是復星對運營排放的嚴格約束,也彰顯集團推動低碳轉型的決心與行動力。 在綠色金融方面,復星持續運用可持續發展掛鈎融資工具拓展低碳與可持續轉型資金來源。2025年,集團完成到期銀團貸款再融資,並籌組首批規模達6.75億美元等值的三年期可持續發展掛鈎銀團貸款,延續綠鞋機制吸引新增銀行參與,最終於2025年9月簽約時總規模增至9.1億美元等值,創公司近五年離岸銀團貸款規模新高,並刷新2025年以來離岸市場民營企業同類貸款規模紀錄,體現資本市場對復星國際可持續發展與融資結構優化方向的認可。 集團積極推動成員企業開展氣候行動。集團在上海的主要辦公場所—上海地標性建築外灘金融中心(BFC)在規劃初期即引入並遵循被譽為綠色建築界的「奧斯卡」LEED 標準,建造初期獲 LEED 金級認證,並於 2022 年以全球最高分榮獲 LEED 鉑金級認證。2025 年,Club Med旗下97%符合條件的度假村通過審核並獲得全球可持續旅遊權威標準—Green Globe 認證;三亞亞特蘭蒂斯、太倉阿爾卑斯國際度假區及麗江地中海國際度假區獲 LEED 金級認證等,展現復星在綠色建築與可持續旅遊領域的持續努力與成果。 復星葡萄牙保險Fidelidade在COP29宣佈成立氣候變化影響研究中心(ICCC),推動氣候風險管理創新,並在COP30展示階段性成果。成立一年以來,ICCC在森林火災風險建模方面取得突破,並開發洪水災害模型工具和預警系統,助力防災政策與社區韌性提升。同期,公司推出創新投資項目—葡萄牙森林基金(Florestas de Portugal),通過森林管理、碳捕捉和土地治理探索兼顧經濟回報與環境效益的可持續投資模式,成為保險業以金融力量參與生物多樣性保護與氣候行動的典範。 2025年,復星繼續以低碳技術打造豫園燈會,踐行碳中和理念,讓東方生活美學與可持續理念交融。依託復星全球平台,豫園燈會已走出國門,先後落地法國巴黎、越南河內、泰國曼谷,成為中外文化交流的重要載體,持續向世界講述「中國故事」,傳遞可持續生活的美好願景。 創新驅動,為患者帶來治癒希望 復星堅持創新驅動,秉持為更多患者帶來治癒希望的初心。旗下健康產業圍繞未被滿足的臨床需求,深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域,積極拓展慢病及罕見病等領域,打造具有長期競爭力的產品管線與綜合解決方案。同時,持續夯實抗體、ADC、小分子、細胞治療等核心技術平台,並拓展核藥、小核酸等前沿技術。 其中,漢斯狀、HLX43、HLX22等上市及在研創新藥實現多項「全球首個」突破。漢斯狀®成為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗,已在40餘國家和地區上市;HLX43在非小細胞肺癌、婦科腫瘤、食管鱗癌等多個領域展現「高效、低毒」優勢;HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。 此外,復星醫藥持續助力非洲社區健康發展。截至2025年12月底,復星醫藥自主研發的注射用青蒿琥酯累計救治全球超8,800萬重症瘧疾患者,已向全球累計供應超過4.4億支注射用青蒿琥酯。 商業向善,積極回饋社會 「商業向善」是復星不變的承諾。為更好地推動企業社會責任的履行和實施,復星基金會於2012年成立,在全球應急馳援、鄉村振興、健康、教育、文化藝術及青少年發展等領域不懈努力,創造社會價值。復星基金會持續推進鄉村醫生項目,自2017年啓動的鄉村醫生項目,已覆蓋16個省、市、自治區的78個項目縣,累計守護2.5萬名鄉村醫生,惠及300萬戶農村家庭,並將「AI村醫助手」帶入基層,提升醫療服務覆蓋面與效率。 自上而下的 ESG 改進長效機制, ESG 表現與董事會績效掛鈎 復星建立了自上而下的ESG提升長效機制,將ESG管理績效納入執行董事績效評估體系,亦將ESG管理績效考核制度覆蓋範圍延伸至本集團CEO及各業務集團負責人。復星在董事會下設立ESG董事委員會,協助董事會指導及監察集團發展及落實ESG工作。在管理及決策層面,復星在管理層設立ESG決策委員會,對ESG戰略落地提供決策支持。在執行層面,集團亦成立了ESG管理委員會及ESG工作小組,確保設立合適及有效的ESG風險管理及內部監控系統,全面落實復星國際的ESG策略及相關行動。 展望未來,復星將繼續聚焦主業、堅持創新和全球化發展。同時,公司將持續關注全球可持續發展趨勢,不斷完善ESG管理體系,積極響應國家戰略,保障信息安全,落實「雙碳」目標,參與公益慈善,保障員工權益,借助復星全球產業生態的資源與優勢,在可持續發展領域創造更大影響力,持續為世界創造美好。 了解復星ESG的更多詳情,請參閱復星國際2025年ESG報告: 香港聯交所披露易網站( https://www.hkexnews.hk/index_c.htm ) 或本公司ESG網站( https://www.fosun.com/esg/ ) 復星國際2025年氣候信息披露報告電子版本發佈於本公司ESG網站: ( https://www.fosun.com/esg/ ) 關於復星 復星創立於1992年,經過逾30年發展,已成為一家創新驅動的全球家庭消費產業集團。秉持讓全球家庭生活更幸福的使命,復星致力於服務全球家庭客戶,戰略聚焦健康、快樂、富足的幸福生態系統。2007年復星國際在香港聯交所主板上市(股份代號:00656.HK),截至2025年12月31日,公司總資產達人民幣7,162億元,最新MSCI ESG評級為AAA。
2026-04-28 14:38:00

How to Sell a Business Without a Broker: New Course Helps Owners Keep More of Their Money
SellBusinessFaster.com Course Offers Tools and Strategies for Selling Without a Broker https://sellbusinessfaster.com/Orlando, FL, April 25, 2026 (GLOBE NEWSWIRE) -- Bizforsalebyowner.us has launched a new course designed to help business owners sell their companies without a broker and keep more of their money. The course provides a clear process, direct access to buyers, and the tools needed to complete a sale independently. Hans Peter Jeschke Founder of bizforsalebyowner.us The course is delivered through BusinessForSaleByOwner.us, a platform where owners can list businesses for sale directly. It is supported by one of the largest Facebook communities focused on buying and selling businesses, with more than 277,000 members. Most small businesses are already sold by their owners without a broker. The challenge is not whether owners can do it, but how well they do it. Many sales happen without a clear process, without strong buyer exposure, and with inconsistent results. "We are not asking owners to do something new,” said Hans Peter Jeschke, CEO of Idillo Inc. "They are already selling their businesses themselves. We show them how to do it better, reach more buyers, and keep more of their money.” Platform, Buyers, and Execution Most owners struggle with two things when selling a business: finding buyers and knowing what to do next. This system solves both. Owners can list their business on BusinessForSaleByOwner.us and post it in a Facebook community with more than 277,000 members focused on buying and selling businesses. At the same time, the course provides a clear process to handle inquiries, negotiate offers, and move the deal to closing. This combination of listing, built-in buyers, and step-by-step execution gives owners a practical way to sell without relying on a broker. What Business Owners Learn The course focuses on execution and gives owners a clear path to follow: How to estimate the value of a businessHow to prepare information buyers expectHow to create listings that generate interestHow to find and communicate with buyersHow to negotiate price and deal structureHow to handle due diligence and closing Templates and checklists are included so owners can take action immediately. Built for Owners Who Want Control Selling a business is often one of the largest financial events in an owner’s life. Many owners lack access to buyers or a structured process. This course provides both. By combining a listing platform, a large buyer audience, and structured training, the system gives owners a practical way to manage a sale independently. Who This Is For Business owners planning to sellOwners who want to avoid commission feesEntrepreneurs exploring exit optionsSellers who want direct access to buyers Availability The course is available now through SellBusinessFaster.com and delivered through BusinessForSaleByOwner.us About SellBusinessFaster SellBusinessFaster.com is a brand focused on helping business owners sell their companies without relying on brokers. It combines training, listing tools, and access to a large buyer audience. bizforsalebyowner.us Logo About Idillo Inc dBa bizforsalebyowner.us Idillo Inc. operates BusinessForSaleByOwner.us - a marketplace for buying and selling businesses directly between owners and buyers, with no broker commissions. BusinessForSaleByOwner.us grew out of a Facebook community of 270,000+ business buyers and sellers. The group created real connections, but Facebook isn't built for structured search, filtering, or browsing serious opportunities. This platform was built to make discovery easier: better organization, clearer listings, and a marketplace format that supports real due diligence. Our approach Small business deals happen both with and without brokers. We're designed to support direct owner listings while remaining open to broker-represented businesses - with full transparency for buyers. Direct communication. Buyers and sellers connect quickly without unnecessary delays. Owner-first listings. Owners present their opportunity clearly to qualified buyers. Built-in privacy. NDA-gated contact protects sellers before any details are shared. No commission. Sellers keep 100% of their sale price. The company Idillo Inc. is based in Orlando, Florida. BusinessForSaleByOwner.us is our operating brand. Press Inquiries Hans Peter Jeschke hp [at] bfsbo.us https://businessforsalebyowner.us/ A video accompanying this announcement is available here: https://youtube.com/watch?v=sk1ts3PFAbY
2026-04-26 00:38:53

TonicGreens Claims Evaluated: The Truth About the Tonic Greens Benefits Under Investigation
A 2026 informational overview of TonicGreens 6-in-1 immune support formula, Tonic Greens superfood antioxidant and mushroom blend ingredients, proprietary dosing transparency, pricing structure, and what consumers should verify about the phytomix benefits before purchasing Aurora, CO, April 25, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the brand and should be verified directly on the official website before any purchasing decision. The phrasing "claims evaluated" and "under investigation" as used in this article refers to a structured, informational breakdown of how TonicGreens is presented by the brand across its official materials, including product labeling and website descriptions. It does not refer to independent testing, third-party review, or clinical evaluation of the product. The term "benefits" refers strictly to how the brand's marketing language describes potential outcomes, not to clinically verified results. If you've been researching greens supplements and immune support powders online, you've almost certainly come across TonicGreens. The product continues to generate strong consumer interest across wellness blogs, supplement review sites, and social media platforms - particularly among adults who feel their immune resilience has declined despite genuine efforts to eat well and stay active. The brand presents TonicGreens as a dietary supplement formulated with multiple ingredient categories associated with antioxidant and immune-related research. This article provides an informational overview of how these claims are described in official product materials, alongside general ingredient-level research context available in published scientific literature. The product's positioning introduces several areas that consumers may want to understand more clearly. How does the brand describe its immune support positioning? What does published ingredient-level research show under controlled study conditions? And what distinctions exist between ingredient-level research and product-level clinical validation? This overview is designed to clarify these distinctions using publicly available information. Current product details, pricing, and terms can be confirmed by viewing the current TonicGreens offer on the official TonicGreens page. Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen. Understanding the "Truth About" Framing in TonicGreens Marketing Context In this context, "truth about" refers to clarifying how the product's ingredient categories, formulation structure, and benefit positioning are described in official materials, alongside general ingredient-level research context available in scientific literature. It does not indicate that independent clinical testing of the finished product has been conducted for this overview. The term "under investigation" reflects ongoing consumer interest and research into ingredient categories commonly included in greens supplements. It does not indicate regulatory or legal investigation into the product. What Is TonicGreens TonicGreens is presented as a consumer supplement brand built around a comprehensive immune support and antioxidant formula. The product is positioned as a once-daily powder that consumers mix into water, smoothies, or plant-based milk. The label identifies PhytoThrive Labs in Aurora, Colorado as the distributor, and purchasing and order support details are outlined in the official website materials through BuyGoods as the authorized retailer. The brand's official materials state that TonicGreens is manufactured in the United States. The label identifies the product as a dietary supplement with a net weight of 4.69 oz (133g), providing 30 scoops per container. The product is marketed as vegan, dairy-free, soy-free, and gluten-free. Each serving (one scoop, 4.4g) contains a Proprietary Superfood, Antioxidant and Mushroom Blend totaling 3,000 mg, a Proprietary Nutrient Dense Natural Herbs and Extracts Blend totaling 1,000 mg, Apple Fruit Fiber Powder at 350 mg, and a Probiotic Premix 3-Strain Blend at 22.5 mg. The listed other ingredient is Maltodextrin. The 6-in-1 Immune Support Claim: What TonicGreens States vs. What Research Can Confirm The brand's central marketing narrative positions TonicGreens as a "6-in-1 formula enhanced with essential antioxidant sources and a powerful immune-system special phytomix." The official product page describes the supplement as containing over 57 ingredients designed to support immune function, digestion, and overall wellness. The brand's official materials present these benefits using broad wellness language and references to ingredient categories - quercetin sources, resveratrol sources, curcumin, essential antioxidants, an immune-system phytomix, and a probiotic blend - as the six functional pillars. Several of these ingredient categories do have published research behind them. Here is what the peer-reviewed literature shows at the ingredient level: Quercetin is a flavonoid found in vegetables like kale, asparagus, and broccoli. Published research, including a 2016 review in the journal Nutrients, has examined quercetin's antioxidant and immunomodulatory properties in controlled settings. Some studies suggest it may support immune cell function and reduce markers of oxidative stress. Resveratrol, found in berries and grapes, has been studied for its antioxidant properties. Research published in the Annals of the New York Academy of Sciences has examined resveratrol's potential effects on inflammatory pathways and cellular protection. However, bioavailability remains a challenge in oral supplementation, and effective dosages in studies often exceed what a multi-ingredient blend typically delivers. Curcumin, the active compound in turmeric, has extensive published research examining its anti-inflammatory and antioxidant properties. A 2017 review in the journal Foods noted curcumin's potential for modulating immune response. However, curcumin has well-documented bioavailability limitations, and most clinical research uses enhanced-absorption formulations at dosages significantly higher than what a shared blend would contain. Reishi mushroom (Ganoderma lucidum) and Maitake mushroom (Grifola frondosa) have been studied for immunomodulatory properties. Published research has examined beta-glucans from medicinal mushrooms for their potential to support innate immune function. Study dosages for these compounds are typically measured in grams, though - not the milligrams that would be available within a 3,000 mg shared proprietary blend containing over 20 ingredients. Probiotics: The product includes a 3-strain probiotic blend (Lactobacillus reuteri, Bacillus coagulans, Lactobacillus acidophilus) at 22.5 mg total. Published probiotic research generally measures effective dosages in CFU (colony-forming units), not milligrams. The label does not disclose the CFU count per serving, which limits comparison to published research on probiotic immune support. These findings reflect published research on individual compounds - but there are important distinctions worth understanding before connecting that research to this specific product. The studies referenced above tested individual ingredients at known dosages under specific research conditions. TonicGreens uses proprietary blends that list ingredients by weight from highest to lowest without disclosing individual amounts. With over 20 ingredients sharing a 3,000 mg superfood blend and 9 ingredients sharing a 1,000 mg herbs blend, the exact amount of any single compound per serving is not disclosed on the label. Consumers researching terms such as "TonicGreens benefits," "does TonicGreens work," "Tonic Greens immune support results," or "TonicGreens antioxidant effectiveness" should understand that marketing claims referencing ingredient categories describe ingredient-level findings, not product-level clinical outcomes verified through testing of the finished supplement. This overview does not assess product effectiveness or make recommendations. It's designed to help you understand how the brand's benefit-related marketing language connects to published ingredient research, so you can do your own due diligence with better context. How Proprietary Blends Affect Research Comparison Proprietary blends are common across the dietary supplement industry. They allow manufacturers to disclose which ingredients are included without revealing exact amounts for each one. This protects formulation trade secrets but limits a consumer's ability to evaluate whether individual ingredients are present at research-supported dosages. A full-disclosure label, by contrast, lists each ingredient with its specific dosage per serving. That format lets consumers and healthcare providers compare dosages directly against amounts used in published studies and against competing products. Here's the practical math for TonicGreens. The Superfood, Antioxidant and Mushroom Blend totals 3,000 mg across more than 20 listed ingredients. The Herbs and Extracts Blend totals 1,000 mg across 9 ingredients. In both cases, the label shows which ingredients are included and in what order - they appear by weight from highest to lowest per FDA requirements - but doesn't reveal how much of each one is present. For context, published research on turmeric extract (curcumin) commonly uses dosages of 500 to 2,000 mg daily, often with absorption-enhancing compounds like piperine. Ashwagandha studies examining immune or stress-related endpoints typically use 300 to 600 mg of a standardized root extract. Reishi mushroom studies commonly use 1,000 to 3,000 mg of mushroom extract. Those ranges would consume a significant share - or the entirety - of a single proprietary blend. Without disclosed individual amounts, there's no way to confirm or rule out research-level dosing from the label alone. This isn't unique to TonicGreens. Many supplements in this category use proprietary blends. But understanding how they work helps set realistic expectations when marketing materials reference published research conducted at specific, known dosages. TonicGreens Ingredient Profile: What the Label Discloses The TonicGreens Supplement Facts panel lists the following per one-scoop serving (4.4g): Calories: 5 Total Carbohydrate: 1g (Dietary Fiber:Proprietary Superfood, Antioxidant and Mushroom Blend - 3,000 mg: Alfalfa Leaf Powder, Carrot Root Powder, Asparagus Stem Powder, Beet Root Powder, Blackberry Fruit Powder, Blueberry Fruit Powder, Broccoli Whole Plant Powder, Brussels Sprout Whole Plant Powder, Camu Camu Fruit Powder, Cauliflower, Celery Seed Powder, Cranberry Fruit Powder, Cucumber Fruit Powder, Green Bell Pepper Fruit Powder, Kale Sprout Powder, Maitake Mushroom Fruiting Body Powder, Parsley Leaf Powder, Pineapple Fruit Powder, Pomegranate Seed Powder, Raspberry Fruit Powder, Reishi Mushroom Fruiting Body Powder. Proprietary Nutrient Dense Natural Herbs and Extracts Blend - 1,000 mg: Organic Acacia Gum, Turmeric Root Extract (10:1), Eleuthero Root Powder, Green Tea Leaf Powder, Cinnamon Bark Powder, Ginger Root Powder, Mangosteen Fruit Extract (4:1), Stevia Extract (Rebaudioside A), Ashwagandha Root Powder. Apple Fruit Fiber Powder - 350 mg Probiotic Premix 3-Strain Blend - 22.5 mg:Lactobacillus reuteri, Bacillus coagulans, Lactobacillus acidophilus. Other Ingredients: Maltodextrin. The breadth of the ingredient list is notable - over 30 total ingredients across four functional categories. Several of these ingredients have been individually studied in published research for immune-related, antioxidant, or adaptogenic properties. The key consideration here is the same one that applies across the supplement industry: the distinction between what individual ingredient studies demonstrate at specific dosages and what a multi-ingredient proprietary blend may deliver at its total weight. What Would Be Required to Prove Effectiveness This is one of the most useful questions any consumer can ask about a supplement - and it applies broadly, not just to TonicGreens. For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard generally includes a randomized, placebo-controlled trial using the finished product at its actual dosage. The study would need to disclose the exact formulation, specify the duration of use, define measurable endpoints such as changes in immune markers or antioxidant capacity, and enroll a study population representative of the target consumer. Results would typically be published in a peer-reviewed journal and subject to independent scrutiny. Ideally, a second independent study would replicate the findings to strengthen confidence in the conclusions. As of this writing, no published clinical trial appears to have tested TonicGreens as a finished proprietary formula using this standard. The marketing materials on the product website reference ingredient categories with known research - not product-level clinical outcomes verified through testing of the finished supplement. That's common across the supplement industry, but it means the distinction between ingredient-level research and product-level proof remains worth understanding. Understanding this distinction isn't about dismissing the product. It's about knowing exactly what has and hasn't been demonstrated so you can make a purchasing decision based on the actual evidence landscape rather than how marketing materials frame it. TonicGreens Pricing and Purchase Structure The website presents multiple purchasing options at the time of this writing: A 6-bottle option (180-day supply) listed at $49 per bottle ($294 total), which the brand's official materials describe as including free shipping and two bonus digital guides. A 3-bottle option (90-day supply) listed at $59 per bottle ($177 total), with a small shipping fee and two bonus digital guides. A single-bottle option (60-day supply) listed at $79 per bottle ($158 total for 2 bottles), with a small shipping fee. The brand's official materials describe the bonus digital guides included with multi-bottle packages as "Ageless Body Perfect Health" and "Secret Kitchen Cures," positioned as supplementary wellness resources. Pricing and availability may vary and should be confirmed directly on the official website. Current terms can be reviewed by viewing the current TonicGreens offer on the official TonicGreens page. TonicGreens Refund Policy and 60-Day Guarantee The brand's published refund policy describes a 60-day money-back guarantee. Per the published terms, consumers who are unsatisfied within the first 60 days after shipment can request a full refund. The policy indicates that all supplement bottles must be returned to the Aurora, Colorado address listed on the official website: 19655 E 35th Dr #100, Aurora, CO 80011, USA. The brand's official materials note that return shipping costs are the responsibility of the buyer. After processing a refund request, confirmation is sent via email. It's worth reviewing the complete refund policy on the official website and holding on to all purchase confirmation details. Refund requests can also be initiated through BuyGoods' self-service order lookup portal. TonicGreens Testimonials and Marketing Language: What Consumers Should Know The official website includes marketing language describing the product as "rapid, effective, delicious" and uses phrases such as "imagine not having to worry again" and "regain your confidence and take control of your life." The FAQ section states the product "has already worked for almost thousands of people." The brand's published disclaimer, available on the official website, includes important context worth reading carefully. The disclaimer notes that the information is not intended to replace consultation with a qualified medical professional, that statements have not been evaluated by the FDA, that products are not intended to diagnose, treat, cure, or prevent any disease, and that results may vary with no individual result to be seen as typical. The disclaimer also notes that names and personal identifying information on the site may have been changed to protect the privacy of individuals. Readers should factor these disclosures into how they interpret marketing language and implied outcomes on the product website. Consumer Verification Checklist: What to Confirm Before Ordering Verify individual ingredient dosages. Full-disclosure labeling allows you and your healthcare provider to compare dosages against published research. Proprietary blends limit this comparison - if exact amounts matter to you, contact the manufacturer directly. Understand the difference between ingredient research and product research. Many supplements reference published studies on individual compounds or ingredient categories. Fewer have been tested as finished formulations through clinical trials. Knowing the difference helps set realistic expectations. Read the website disclaimers carefully. The fine print often contains information about whether results are typical and whether names or identifying details have been changed. Confirm refund terms independently. Review guarantee terms, return requirements, and processing timelines directly on the official website or through the payment processor before purchasing. Talk to your healthcare provider. This is especially important for adults taking prescription medications, managing chronic health conditions, or navigating immune-related concerns. Professional medical guidance should come before any supplement purchase. Who Might Consider TonicGreens in 2026 Based on the product's published positioning and ingredient profile, TonicGreens may be of interest to adults who prefer plant-based supplement options and who are exploring antioxidant and immune support as one component of a broader wellness approach that includes balanced nutrition and regular physical activity. The product may be less suited for consumers who require transparent individual ingredient dosing for clinical comparison, those seeking targeted immune intervention for specific medical conditions, or individuals expecting measurable clinical outcomes from a single supplement without accompanying lifestyle changes. As with any dietary supplement, individual outcomes depend on a wide range of personal health factors. Supplements are regulated differently than pharmaceutical drugs, and the FDA does not evaluate dietary supplement claims for efficacy before products reach the market. The FDA disclaimer printed on TonicGreens' own label confirms that the product's statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease. Consumer Questions About TonicGreens What is the "6-in-1 immune support phytomix," and how does it relate to TonicGreens? The "6-in-1" designation is a consumer-facing framework used in the brand's marketing. It refers to six ingredient categories - quercetin sources, resveratrol sources, curcumin, essential antioxidants, an immune-system phytomix, and probiotics - combined into a single powder. These categories describe how the brand organizes its ingredient list, not a clinically defined protocol. Individual ingredients within these categories have been studied at the compound level, but the combined formulation has not been clinically tested as a finished product. Is TonicGreens FDA approved? TonicGreens is a dietary supplement. Under current federal regulations, dietary supplements don't require FDA approval before being sold. The FDA does not evaluate supplement efficacy claims. The product label includes the standard DSHEA disclaimer confirming these statements have not been evaluated by the FDA. Does TonicGreens contain caffeine? The formula includes Green Tea Leaf Powder in the Herbs and Extracts Blend, which naturally contains caffeine. The specific caffeine content per serving isn't disclosed on the label. If you have caffeine sensitivity, it's worth confirming this detail with the manufacturer before use. Can I verify the ingredient research TonicGreens references? The product website references ingredient categories with known research - quercetin, resveratrol, curcumin, medicinal mushrooms, and probiotics. You can look up published research on these individual compounds through PubMed or relevant journal archives. Keep in mind that these studies examined individual compounds at specific dosages - not TonicGreens' proprietary formula as a finished product. Why does TonicGreens use proprietary blends? Proprietary blends allow manufacturers to disclose which ingredients are included without revealing exact amounts for each one. This protects formulation trade secrets but limits your ability to compare individual ingredient dosages against published research ranges. How long does TonicGreens take to show results? The brand's FAQ section suggests results may vary and that consistent daily use is important. The website disclaimer clarifies that results are not guaranteed and no individual result should be seen as typical. Individual timelines depend on factors including baseline health, dietary habits, and overall lifestyle. What does "FDA-registered facility" mean? The brand's official materials reference GMP-certified manufacturing. An FDA-registered facility is a manufacturing location that has registered with the FDA as required by federal law. Registration means the facility is subject to FDA inspection. It doesn't mean the FDA has reviewed, approved, or endorsed any specific product manufactured at that location. Where is TonicGreens sold? The brand's official materials describe TonicGreens as available exclusively through the official website. Purchases are processed through BuyGoods. The brand advises consumers to purchase directly to ensure product authenticity and refund eligibility. Additional Consumer Research Consumers conducting additional research may choose to review other publicly available informational content related to TonicGreens and greens supplement ingredient categories. The following resources cover related topics from different angles: A detailed breakdown of Tonic Greens ingredients and supplement facts provides a closer look at what the label discloses across each proprietary blend category. A separate overview of how TonicGreens fits within the immune support supplement category covers broader consumer interest in plant-based wellness formulations and daily immune resilience. Evaluating multiple sources and reviewing official product materials directly can help provide broader context. Reviewing the FDA's general guidance on dietary supplement labeling and claims is also recommended before making any purchasing decision. Summary of Key Considerations TonicGreens is a dietary supplement that positions itself as a 6-in-1 immune support and antioxidant superfood blend. The product contains ingredients with published research at the individual compound level, including quercetin sources, resveratrol, curcumin, medicinal mushrooms, and probiotics. However, the proprietary blend structure limits visibility into individual dosing, and no published clinical trial has evaluated the finished product as formulated. The brand's official materials describe a 60-day refund guarantee, one-time purchase pricing, and state that the product is manufactured under GMP standards. The website disclaimer notes that statements have not been evaluated by the FDA, that the product is not intended to diagnose, treat, cure, or prevent any disease, and that individual results should not be seen as typical. Consumers who have completed their own research and want to review the full product details can do so. Complete product details, current pricing, and published terms are available by viewing the current TonicGreens offer on the official TonicGreens page. Consumers are encouraged to review the official product page and consult a qualified healthcare professional before making decisions related to dietary supplements. Contact Information Brand Label Distributor: PhytoThrive Labs Return Address: 19655 E 35th Dr #100, Aurora, CO 80011, USA Product Support Email: support@phytogreens.net BuyGoods Order Support:https://www.buygoods.com/orderlookup BuyGoods Phone: 302-404-2568 Disclaimers Content and Consumer Information Disclaimer: This article is for informational purposes only and summarizes product details as presented in official materials. It does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the brand on its publicly available website and product labeling. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement. Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Immune health concerns should be discussed with a qualified healthcare provider who is familiar with the individual's personal medical history. Results, Pricing, and Product Variability: All pricing, bonus offers, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website or the authorized payment processor before completing any purchase. FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. BuyGoods serves as the authorized payment processor for this product. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes. CONTACT: Product Support Email: support@phytogreens.net BuyGoods Order Support: https://www.buygoods.com/orderlookup BuyGoods Phone: 302-404-2568
2026-04-26 00:38:46

SK hynix receives 2026 IEEE Corporate Innovation Award for Driving AI Computing Expansion with HBM
SK hynix honored at the 2026 IEEE Awards for leading AI technology innovation with HBM Contributed to the global AI computing ecosystem via stable mass production across all HBM generationsCompany committed to becoming a premier leader in AI innovation through collaboration with global customers and partnersSEOUL, South Korea, April 26, 2026 /PRNewswire/ -- SK hynix Inc. (or "the company", www.skhynix.com) announced today that it received the Corporate Innovation Award at the '2026 IEEE1 Honors Ceremony' held in New York on the 24th (local time). IEEE is the world's largest technical professional organization dedicated to advancing technology for the benefit of humanity. Established more than a century ago, the IEEE Awards Program recognizes individuals and teams whose innovations have advanced technology and improved the human condition. The IEEE Corporation Innovation Award, part of the Recognitions category, has been presented since 1986 to companies that have significantly contributed to the advancement of industry and society through innovative technology. This marks the first time SK hynix has received this honor. SK hynix attributed the honor to its contribution to the global AI computing ecosystem by ensuring the stable mass production of all High Bandwidth Memory (HBM) generations. Looking ahead, the company aims to solidify its position as a trusted partner in the global AI market by providing memory solutions that are critical to overcoming the performance limitations of AI platforms. The recognition highlights SK hynix's achievements in driving the expansion of AI computing through HBM innovation and application. Central to this success was the company's ability to preemptively offer innovative HBM solutions and respond timely to customer demands in the global AI market. Industry observers also credit this achievement to the strategic direction of SK Group Chairman Chey Tae-won, who has long emphasized securing long-term technological competitiveness. Under his leadership, the company has consistently expanded its AI infrastructure partnerships with global Big Tech firms in the United States. Ahn Hyun, President and Chief Development Officer (CDO), attended the ceremony as the company representative to accept the award. "It is an honor to receive this award on behalf of our employees, who have tirelessly challenged the limits of technology," said Ahn. "By collaborating closely with our global customers and partners, we will stay ahead in creating the value the market demands and continue to be a premier company leading AI innovation." About SK hynix Inc. SK hynix Inc., headquartered in Korea, is the world's top-tier semiconductor supplier offering Dynamic Random Access Memory chips ("DRAM") and flash memory chips ("NAND flash") for a wide range of distinguished customers globally. The Company's shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com. About IEEE IEEE is the world's largest technical professional organization and a public charity dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org.
2026-04-26 00:38:44

Oxford Royale学院与MIT合作,为暑期学校的学生提供AI教育
欧洲发展最快的教育机构之一(在FT 1000榜单中排名第156位)宣布与MIT的RAISE计划达成课程合作,将于今年夏天在牛津为青少年提供AI素养认证课程。 英格兰牛津 2026年4月24日 /美通社/ -- Oxford Royale学院是欧洲营收增长最快的教育机构之一,近日宣布与麻省理工学院(MIT)达成合作,将在今年为国际暑期学校的学生提供AI素养教育。 参加Oxford Royale学院牛津暑期课程的学生,将有机会完成MIT RAISE FutureBuilders的AI学习路径。 通过此次合作,参加Oxford Royale牛津暑期课程的学生将完成MIT RAISE FutureBuilders学习路径。这是一套结构化的AI教育课程,由MIT的“负责任的AI社会赋能与教育”(RAISE)计划与Pharos Education合作开发。 完成该课程的学生将获得正式的MIT RAISE证书。 Oxford Royale每年夏季接待来自超过175个国家和地区3,000多名学生,在牛津的各个学院内提供大学风格的学术课程。 此次合作首次在现有学术项目中引入了正式的AI课程板块。 这一消息发布之前,Oxford Royale刚刚入选“《金融时报》FT 1000:2026年欧洲增长最快的1,000家企业”榜单,在全欧洲排名第156位。 各方声音 “未来的领导者,必将是那些既懂技术、又懂如何负责任地驾驭技术的人。 我们与MIT的RAISE计划及Pharos Education的合作,让学生有机会在早期阶段就接触和探索AI——不仅作为一种工具,更作为一股将塑造职业生涯、未来行业格局乃至整个社会的力量。” ——Oxford Royale学院首席执行官Andy Palmer “MIT RAISE FutureBuilders课程有一个明确的目标:将下一代从技术的消费者转变为AI的构建者。 Oxford Royale的学生群体来自超过175个国家和地区,因而成为我们合作过的国际化程度最高的学生群体之一。” ——Pharos Education首席执行官Felipe Arango 大背景 近年来,随着大语言模型及其他AI系统的快速商业部署,AI在中小学校、大学及政策制定者的议程中占据了越来越重要的位置。 多国政府已出台AI教育的国家战略,而面向雇主的调查也一致显示,AI素养已成为新员工进入职场时最受重视的技能之一。 尽管如此,多数国家中学阶段的结构化AI教育仍然十分有限。 Oxford Royale引入MIT RAISE学习路径,旨在弥合这一差距,使13至18岁学生在进入大学前即可接触人工智能的技术原理与伦理维度。 MIT RAISE将其使命定义为在全球年轻学习者中推广AI素养与伦理理解。 该计划开发的课程旨在帮助学生以更审慎的方式理解并参与AI,同时重点关注公平性、问责机制以及自动化系统的社会影响等议题。 Oxford Royale由牛津大学毕业生William Humphreys于2004年创立。 自成立以来,已有来自超过175个国家和地区的50,000多名学生在此学习。 编辑注意事项 课程日期与报名信息 该暑期课程将分两期进行:2026年7月5日至18日,以及7月19日至8月1日。 两期课程共计60个名额。 关于Oxford Royale学院 Oxford Royale学院是一家领先的国际教育机构,在英国牛津的各个学院以及全球多个校区提供学术型暑期学校课程。 自2004年成立以来,已接待来自超过175个国家和地区的50,000多名学生。 该机构在“《金融时报》FT 1000:2026年欧洲增长最快的1,000家企业”榜单中排名第156位。 如需了解更多信息,请访问oxfordroyale.com。 关于MIT RAISE MIT RAISE(全称“负责任的AI社会赋能与教育”)是一项由麻省理工学院发起的全球性计划,致力于让更多人接受AI素养教育。 其FutureBuilders项目为年轻学习者提供了发展AI技能的结构化学习路径,重点关注注重伦理且负责任使用这项技术。 关于Pharos Education Pharos Education是一家教育科技公司,与顶尖学术机构合作开发和交付AI学习项目。 Pharos是MIT RAISE FutureBuilders课程的交付合作伙伴。
2026-04-24 14:30:00

OMODA&JAECOO VPD Smart Parking Tech Set for Global Debut: Tackling Parking Anxiety in High-Demand Scenarios
Wuhu, Anhui, China, April 24, 2026 -- Is the parking problem really about to become none of your business? Still circling to the third floor of a mall garage without finding a spot? Staring blankly at a sea of white cars after a music festival? Dashing through the scorching sun or pouring rain to reach your car hundreds of meters away? These scenes will soon be a thing of the past. On April 26, the world's first "parking hack" for young people - OMODA&JAECOO's Valet Parking Driver - will make its global public debut in a real-world test. This is not only a powerful display of technological prowess, but also a key move in the brand's "New million mission”. Unlike traditional APA (Auto Parking Assist) systems that heavily rely on clearly marked parking lines, the core breakthrough of OMODA&JAECOO's Valet Parking Driver technology lies in achieving a complete closed-loop process of "cruising for an available spot + parking into the spot". Throughout the process, no driver needs to be near the vehicle, truly solving the parking headache for users. It is reported that this technology test will be conducted on three SHS hybrid models - JAECOO 5 SHS-H, JAECOO 7 SHS-P, and OMODA 7 SHS-P - in the presence of nearly 100 global dealer representatives, key media, and KOLs. Three highly challenging scenarios will be publicly tested. The big question: Can it handle these challenges more smoothly than an experienced driver? First challeng: "Comes When Called". Within remote summoning distance, users can control the vehicle via a mobile app to exit its parking spot and autonomously drive to a designated pickup point. Obstacles such as traffic cones, pedestrians, or other vehicles blocking the way? The system will identify risks in real time based on environmental perception and autonomously adjust its path - saying goodbye to the misery of searching for your car in heavy rain or scorching sun. Second challenge: "Leaves When Waved". After arriving at their destination, users simply get out of the car and activate the valet parking function via the mobile app. The vehicle will automatically cruise to find an available parking spot, precisely park itself, power off, and lock. Whether at a mall entrance or office building, "get out and go" will become an everyday reality. Third challenge: Human vs. Machine comparison test. In extreme scenarios such as extremely tight parking spaces and dead-end parking spots, an experienced driver will compete directly against the VPD system. The face-off will be judged on three dimensions: parking efficiency, number of steering corrections, and parking quality. Can Valet Parking Driver "clear the level with one tap" and turn a novice into a parking pro? The answer will be revealed at the test site. From solving frequent parking anxiety to reshaping the future mobility ecosystem, the global debut of Valet Parking Driver technology is not only a technological statement by OMODA&JAECOO in the intelligent parking arena, but also another substantial step forward in the brand's vision of "co-creating a better life with young people around the world." Going forward, the brand will continue to deepen intelligent technology innovation, focusing on hybrid powertrains, smart driving, and cutting-edge directions such as smart robots, bringing more imaginative and intelligent mobility experiences to global users. As the global debut of Valet Parking Driver officially kicks off, this black tech that makes parking no longer a burden may well become the new starting point for young users worldwide to move toward "parking freedom." *Note: Valet Parking Driver is a driver-assist feature. It is intended for use only in enclosed parking lots and is strictly prohibited on public roads. While using this feature, please remain continuously aware of your surroundings and be ready to take over control of the vehicle when necessary. About OMODA&JAECOO In 2025, Chery Group, the parent company of OMODA&JAECOO, ranked 233rd in the Fortune Global 500, achieving the fastest ascent among global automakers, and maintained its position as China's top passenger vehicle exporter for 23 consecutive years.OMODA & JAECOO takes "Co-Create A Beautiful Life With Young People" as its brand vision, while OMODA focuses on building"The World's Leading Crossover Brand”, JAECOO adheres to the philosophy of "From Classic Beyond Classic" and is committed to building"Global Elegant Off-Road Brand”, and building differentiated competitiveness through dual routes. By 2025, the OMODA & JAECOO brand has expanded into 64 markets worldwide, covering Europe, Asia, Australia, Africa, Latin America, the Middle East, and more,demonstrating strong global growth momentum,especially in the European market, becoming the fastest growing car brand in Europe and even the world. In the field of new energy vehicles,OMODA&JAECOO relies on the world's leading SHS technology, with Super High Power,Super Low Efficiency,Super Long Combined Range,while providing efficient new energy solutions for global users, but also steadily advancing towards the objective of becoming the "The World's Number One Hybrid Brand". Notably, beyond its continuous breakthroughs in the core automotive sector, OMODA & JAECOO has extended its technological innovation into the field of intelligent technologies. The robot, jointly developed with the AiMOGA team, has entered real public service scenarios and made its official debut at the Asian Youth Para Games,representing a landmark practice in automakers’ intelligent transformation and further expanding the brand’s value boundaries. Contact Info: Name: Sherry Cheng Email: Send Email Organization: OMODA&JAECOO Website: https://www.omodajaecoo.com/ Release ID: 89189786 In the event of any inaccuracies, problems, or queries arising from the content shared in this press release, we encourage you to notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our diligent team will be readily available to respond and take swift action within 8 hours to rectify any identified issues or assist with removal requests. Ensuring the provision of high-quality and precise information is paramount to us.
2026-04-24 14:29:40

From Next-Generation Mobility to Global Expansion: iCAUR Demonstrated Its Vision at Beijing Auto Show 2026
Wuhu, Anhui, China, April 24, 2026 -- Beijing, China - [April 24th, 2026] - The Beijing Auto Show 2026, which opened on April 24, marked a key moment for iCAUR as the brand presented two major highlights: the ROBOX concept car and the right-hand-drive (RHD) version of the V27. Both were presented by Dr. Su Jun, CEO of iCAUR. The ROBOX concept car represents iCAUR’s exploration of future mobility. Named from a combination of "ROBOT” and "BOX,” it adopts a future-classic design philosophy, combining timeless proportions with forward-looking design elements. It introduces a new design language that merges a streamlined OneBox silhouette with a high-clearance structure, balancing aerodynamic efficiency with off-road capability. Distinctive features such as split round and rectangular lighting, clean modular surfaces, and a reimagined cabin space create a clear technological identity. Alongside it, the right-hand-drive V27 reflects iCAUR’s ongoing global expansion. The left-hand-drive version of the V27, positioned as a new energy boxy vehicle with classic design, has already gained strong market response in China and the Middle East. Its combination of distinctive styling and practical capability has contributed to its growing recognition among users in these markets. Developed as a global model, the V27 meets five-star safety standards in both China and Europe while adapting to the requirements of right-hand-drive markets. Its introduction supports the brand’s expansion across Southeast Asia and Oceania, where diverse driving environments and user needs require localized solutions. The model reflects iCAUR’s ability to translate global standards into practical, market-relevant products. Beyond its product lineup, iCAUR continues to build a global user ecosystem. In partnership with China National Geographic, the brand is launching "The Grand Tour,” a global exploration program designed to connect users with diverse landscapes and cultural experiences. At the same time, reflecting the idea that each iCAUR is unique, the second season of the iCAUR Player Carnival invites users worldwide to participate in co-creation through vehicle customization projects, with selected works to be showcased at the SEMA Show. A wide range of customized versions of the V23 and V27 will also be displayed at the booth, highlighting the brand’s approach to personalization and user-driven design. At the exhibition booth, the AiMOGA Robotics was featured as an interactive element, demonstrating iCAUR’s exploration of intelligent technologies beyond the vehicle. Through real-time interaction and scenario-based applications, it reflects the integration of mobility, AI, and user experience. As iCAUR expands its presence across more than 40 countries and regions, supported by a growing network of global partners, the Beijing Auto Show marks another step in the brand’s global development. About iCAUR iCAUR is a new-energy vehicle brand created for global users, rooted in the philosophy that "Classic Never Fades.” By integrating timeless design with advanced technology and global standards, iCAUR aims to become the first choice for users seeking a new-energy SUV with enduring character and versatile capability. Contact Info: Name: Xu Yong Email: Send Email Organization: iCAUR Global Website: https://www.icaurglobal.com/ Release ID: 89189785 Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.
2026-04-24 14:29:29

Correction: Notice on Convocation of Annual General Meeting of Shareholders of AB "KN Energies”
Correction: Amended profit (loss) distribution proposal (technical error has been corrected) Taking into account the technical error identified in the profit (loss) distribution proposal, the following documents submitted to the Annual General Meeting of Shareholders have been amended: Annex No. 1 - Draft Resolutions - GSM of AB KN Energies; Annex No. 2 - Voting Ballot - GSM of AB KN Energies; Annex No. 3 - Profit (Loss) Distribution Proposal - GSM of AB KN Energies. AB "KN Energies” notes that the technical correction made will have no impact on the dividends proposed to be paid by the company. AB "KN Energies” informs about the amendments in accordance with the procedure established by the Law on Companies of the Republic of Lithuania. Notice is hereby given that on the initiative and by the resolution of the Board of AB "KN Energies”, legal entity code 110648893, with the registered office at Burių str. 19, Klaipėda (hereinafter - the Company), Annual General Meeting of Shareholders of the Company will be held on 30 April 2026 at 1:00 p.m. The meeting will be held in the Company’s administrative office, J. Janonio str. 6B, Klaipėda (in the hall of the meeting on the 3rd floor). Agenda of the meeting: 1. Announcement of the Auditor’s Report regarding the Financial Statements and Management Report of AB "KN Energies” for the year 2025 to the shareholders. 2. Announcement of the Management Report of AB "KN Energies” for the year 2025 to the shareholders. 3. Approval of the audited Financial Statements of AB "KN Energies” for the year 2025. 4. Approval of the appropriation of profit (loss) of AB "KN Energies” for the year 2025; 5. Agreement on the Report on the remuneration of AB "KN Energies”. 6. Abolition of the Supervisory Council of AB "KN Energies”. 7. Increase in the number of members of the Board of AB "KN Energies”. 8. Approval of the amended Articles of Association of AB "KN Energies”. 9. Approval of the amended Remuneration Policy of AB "KN Energies”. 10. Approval of the amended Corporate Governance Policy of AB "KN Energies”. 11. Election of the members of the Board of AB "KN Energies” and determination of their remuneration. 12. Approval of the standard form of the activity agreement for a member of the Board and a committee of AB "KN Energies”. The shareholders will be registered from 12:00 p.m. to 12:55 p.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization issued in a foreign state shall be translated into the Lithuanian language and legalized under the procedure prescribed by the laws). A shareholder or his proxy shall have the right to vote in writing in advance by filling in a general ballot paper. At the request of the shareholder, the Company shall send a general ballot paper to the shareholder by registered mail free of charge at least 10 days before the meeting. The filled-in general ballot paper and the document attesting the voting right shall be submitted to the Company no later than until the meeting, sending by registered mail or providing them at the address of the registered office of the Company indicated in the notice. The shareholders who hold shares carrying at least 1/20 of all the votes may propose additions to the agenda of the general meeting of shareholders by submitting with every proposed additional item of the agenda a draft resolution of the general meeting of shareholders or, when no resolution is required, an explanation. Proposals on addition to the agenda shall be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: info@kn.lt and i.sungailaite@kn.lt. The agenda shall be supplemented if the proposal is received no later than 14 days before the Ordinary General Meeting of Shareholders. If the agenda of the general meeting of shareholders is supplemented, the Company shall notify on the additions no later than 10 days before the meeting in the same ways as in the case of convocation of the meeting. The shareholders, who hold shares carrying at least 1/20 of all the votes, at any time before the general meeting of shareholders or during the meeting, may propose new draft resolutions on items which are or will be included in the agenda of the meeting. The proposals may be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: info@kn.lt and i.sungailaite@kn.lt. The shareholders shall have the right to submit to the Company in advance questions relating to the items on the agenda of the meeting. The shareholders may submit their written questions to the Company on business days or send by registered mail at the address of the registered office of the Company indicated in the notice no later than 3 business days before the meeting. The Company will reply to the questions by e-mail or in writing before the meeting, except the questions which are related to the Company’s commercial (industrial) secret, confidential information or which have been submitted later than 3 business days before the meeting. The Company provides the possibility of voting at the meeting by submitting to the Company a general ballot paper signed with a qualified electronic signature no later than 1:00 p.m. on the day of the meeting. The shareholder shall have the right to authorize through electronic communications means another person (natural or legal) to participate and vote in the meeting on behalf of the shareholder. No notarization of such authorization is required. The shareholder must confirm the proxy issued through electronic communications means by an electronic signature developed by a secure signature-creation device and approved by a qualified certificate effective in the Republic of Lithuania. The shareholder shall inform the Company on the proxy issued through electronic communications means to the following e-mails: info@kn.lt and i.sungailaite@kn.lt no later than until the last business day before the meeting at 1:00 p.m. The proxy and the notice must be issued in writing. The proxy and the notice to the Company shall be signed with the electronic signature but not the letter sent by e-mail. By submitting the notice to the Company, the shareholder shall include the internet address from which it would be possible to download software free of charge to verify the shareholder’s electronic signature. The record date of the meeting shall be 23 April 2025 (only those persons who will be shareholders of the Company at the close of the record date of the general meeting of shareholders or their authorized persons, or persons with whom an agreement on assignment of the voting right has been executed, may participate and vote at the general meeting of shareholders). The record date which entitles shareholders to receive a portion of the Company’s profit (dividend) - 15 May 2026. The shareholders of the Company may familiarise with the draft resolution of the meeting and the form of the general ballot paper under the procedure prescribed by the laws in the administrative office of the Company at J. Janonis str. 6B, Klaipėda (tel.: 8 46 391 772), or on the Company’s website at http://www.kn.lt/. Tomas Tumėnas, Chief Financial Officer, +370 682 36616 Attachments Annex No 1_Draft decisions_GMS of AB KN Energies (1) Annex No 2_Ballot paper_GMS of AB KN Energies (1) Annex No 3_Appropriation of profit (loss)_GMS of AB KN Energies (1) Annex No 4_KN Consolidated Annual Report 2025 Annex No 5_KN Report on remuneration 2025 Annex No 6_Change of the Corporate Governance Model of KN Annex No 7_Articles of Association of KN Annex No 8_Corporate Governance Policy of KN Annex No 9_Remuneration Policy Annex No 10_Activities agreement_Board member_FORM Annex No 11_AB KN Energies - Auditor's report_2025
2026-04-24 14:27:46

Resolutions of the Annual General Meeting
April 24, 2026 Announcement no. 10 Resolutions of the Annual General Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 24, 2026, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today held its Annual General Meeting with the following results: Item 1 - The Board's report on the Company’s activities during the past year was noted by the Annual General Meeting. Item 2 - The Annual Report was approved by the Annual General Meeting and the result for the financial year 2025 was approved to be carried forward to the next financial year. Item 3 - Discharge of liability was granted to the Board of Directors and Executive Management. Item 4 - The Company’s Remuneration Report for the financial year 2025 was approved by an advisory vote. Item 5 - The Annual General Meeting approved the following remuneration for the members of the Board of Directors for the financial year 2026: The cash remuneration is as follows (unchanged compared to 2025): Members of the Board of Directors - DKK 300,000 Vice Chair of the Board of Directors - DKK 450,000 Chair of the Board of Directors - DKK 900,000 Remuneration for participation in committees: Board Members receive DKK 25,000 per committee, and the Chair of the committee receives DKK 50,000. The Chair and Vice Chair of the Board of Directors are not entitled to receive additional remuneration for participation on committees. The committees and their current members are described on the Company’s website. Board members may elect to receive all or part of their cash remuneration (excluding committee fees) in the form of warrants. The number of warrants will be determined based on the Black-Scholes value of the warrants at the time of grant. The warrants shall otherwise be subject to the following terms: The election to convert shall be rendered no later than 29 April 2026. 25% of warrants will be vested upon grant, the remainder will vest in three equal tranches at the end of each subsequent calendar quarter. In the event the service as Board member ceases (irrespective of cause), unvested warrants shall lapse without compensation. Vested warrants may be exercised, to the extent vested, during applicable trading windows and shall expire five (5) years after the date of grant.The warrants shall otherwise be governed by the terms and conditions of the Company’s Incentive Warrant Program, as set out in Appendix 1 of the Company’s Articles of Association, with appropriate adjustments reflecting the board members' role. The implementation of the above grants shall be carried out by the Board of Directors in accordance with the authorization set out in the Company’s Articles of Association and the Company’s Remuneration Policy. In case board members also hold officer positions or directorships in subsidiaries of the Company, the above-mentioned remuneration constitutes the aggregate maximum amounts payable for all officer or directorships held in the group. Item 6 - The Annual General Meeting re-elected the following board members: Jens Due Olsen, Henrik Juuel and Mats Thorén and Donna Haire. After the Annual General Meeting, the Board of Directors constituted itself by electing Jens Due Olsen as Chair and Henrik Juuel as Vice Chair of the Board of Directors. Item 7 - The Annual General Meeting re-elected Deloitte Statsautoriseret Revisionspartnerselskab, company registration number 33963556, as the Company’s auditor. Item 8.a(i)-(ii) - The Annual General Meeting approved new authorizations to increase the share capital with and without pre-emptive rights in the Company’s Articles of Association § 17a-c. The aggregate share capital increases with pre-emptive rights shall be subject to a limit of nominally DKK 50,000,000. For share issues without pre-emptive rights, the aggregate share capital increase shall be subject to a limit of nominally DKK 50,000,000. The two authorizations expire on 30 April 2030 and are subject to an aggregate limit of nominally DKK 75,000,000. Items 8.b - The Annual General Meeting renewed the authorization to the Board of Directors to issue warrants to employees and members of the executive management and the Board of Directors in Article 18a of the Articles of Association. The authorization is set out limited so that (i) the aggregate number of warrants outstanding issued to employees and members of management shall not exceed the equivalent of 10% of the Company’s share capital from time to time; and further that (ii) the maximum share capital increase pursuant to the authorization shall be nominally DKK 6,000,000 (corresponding to approximately 1.21% of the Company’s share capital). The authorization has a duration of one year expiring on 30 April 2027. Item 8.c -The Annual General Meeting approved the following provision be added to Article 12 of the Articles of Association: "Resolutions by the board of directors shall be passed by a simple majority of votes unless otherwise stipulated in these Articles of Association.In the event of a tie, the chair shall have the casting vote.” Item 8.d - The Chair of the General Meeting, with a right of substitution, was approved to file the resolutions adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require in order to register or approve the resolutions adopted. To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/. Investor Relations Contacts Klaus Juhl Wulff, Investor Relations, BioPorto A/S, investor@bioporto.com, C: +45 25633990 About BioPorto BioPorto is an in vitro diagnostics company focused on saving patients’ lives and improving their quality of life with actionable kidney biomarkers - tools designed to help clinicians make changes in patient management. The Company leverages its expertise in assay development to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide and FDA cleared ProNephro AKITM (NGAL) for pediatric use in the US. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. Attachment 2026 04 24 - Announcement no. 10 - UK
2026-04-24 14:27:42

Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment
High adoption rates for obesity treatment are noted across both LillyDirect and NovoCare platforms, but key workflow differences drive a split in preferences Exton, PA, April 24, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape evolves, new access channels are reshaping how patients receive care. Since the launch of Eli Lilly’s LillyDirect in January 2024 and Novo Nordisk’s NovoCare pharmacy in March 2025, physicians are increasingly incorporating manufacturer direct-to-patient platforms and telehealth partnerships into their treatment workflows, expanding pathways to GLP-1 therapies and streamlining patient access. New findings from Spherix Global Insights, based on an April 2026 pulse survey of 102 physicians (51 primary care physicians and 51 endocrinologists), highlight both the rapid uptake of these platforms and emerging differences in how they are experienced across specialties. Utilization of manufacturer direct-to-patient platforms is now nearly universal. LillyDirect has been used by 90% of PCPs and 92% of endocrinologists, while NovoCare has been used by 59% of PCPs and 75% of endocrinologists, underscoring the growing importance of these platforms in facilitating access to obesity therapies. At the same time, physicians are expanding their participation in telehealth-driven care models that complement these access pathways. In the past 12 months, 22% of PCPs and 12% of endocrinologists report working as independent contractors for telehealth companies, most commonly partnering with organizations such as Weight Watchers, Noom, Hims/Hers, and Ro. Physicians cite increased patient reach as a primary driver of participation, alongside greater flexibility, ease of collaboration, and improved medication access. As one endocrinologist noted, telehealth enables them to "reach more patients to help in their weight loss journey.” Despite broad adoption across both telehealth and direct-to-patient platforms, physician experience diverges sharply when comparing Eli Lilly and Novo Nordisk’s platforms. Among endocrinologists, LillyDirect leads across nearly all evaluated attributes, outperforming NovoCare on seven of eight measures. The largest gap is in visibility into the prescription process, where 80% of endocrinologists report high satisfaction with LillyDirect compared to 58% for NovoCare. LillyDirect also outperforms NovoCare in prior authorization support, insurance documentation submission, and reducing administrative burden in cash-pay workflows. PCPs show a clear preference for NovoCare, which leads on six of eight attributes. The biggest difference is again in visibility into the process, with 67% of PCPs reporting high satisfaction with NovoCare, compared to 53% for LillyDirect. NovoCare also leads in EHR prescription submission, hub services and support, and overall ease of platform use among PCPs. Overall satisfaction among PCPs is lower across both platforms than among endocrinologists, pointing to broader workflow and usability challenges in the primary care setting. Across both specialties, insurance-related administrative burden remains a persistent weakness. Both platforms receive relatively low ratings in this area, indicating a category-wide pain point rather than a platform-specific limitation and highlighting an opportunity for innovation in simplifying reimbursement and access workflows. These findings underscore a rapidly evolving landscape in obesity care, where telehealth and manufacturer-driven access platforms are expanding patient reach while reshaping physician workflows and treatment pathways. The divergence in platform preferences between endocrinologists and primary care physicians highlights the importance of aligning solutions with specialty-specific needs, particularly around transparency and administrative efficiency. Spherix Global Insights provides comprehensive coverage of these themes and more through its Market DynamixTM: Obesity 2026 and Launch DynamixTM services. Contact Spherix to subscribe and access tailored insights on the evolving obesity market. About Launch DynamixTM Launch DynamixTM is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Market DynamixTM Market DynamixTM is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. Spherix Global Insights Contact Jim Hickey, Gastroenterology Franchise Head james.hickey@spherixglobalinsights.com NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insights’ analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Jim Hickey Spherix Global Insights 484-879-4284 james.hickey@spherixglobalinights.com
2026-04-24 14:27:38

A.D.A.M. Innovations Unveils GeneLockTM: The World’s First Genetic Data Protection Platform
Pioneering Biosecurity for Genomic Data TOKYO, April 24, 2026 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare Co.) today announced GeneLockTM, a new genomic security platform designed to help secure and control one of the world’s most sensitive assets: genetic data. Genomic data is becoming critical infrastructure. Protecting it demands more than encryption. It demands a new protection model. GeneLock is introduced as the world’s first genetic data protection platform, combining de-sequencing, decentralized protection and authorized reconstruction controls. By fragmenting and distributing genomic information across independent secure environments, GeneLock helps prevent meaningful exposure and enables reconstruction only under authorized conditions. Protecting the World’s Most Personal Data Genomic data is becoming a strategic asset. Most systems weren’t built to protect it. Built for genomic data sovereignty, GeneLock helps protect genomic assets across human, animal, plant and pathogen applications, with an architecture designed to be: Fragmented for protectionDistributed for resilienceReassembled only with authorizationGoverned through data sovereigntyScaled across genomic assetsA New Category: Biosecurity for Genomic Data Genomic information introduces a new class of risk. GeneLock helps establish a new category - Biosecurity for Genomic Data - treating DNA as a strategic biological asset requiring dedicated protection. "Genomic data is becoming foundational infrastructure for health, research and the emerging bioeconomy,” said Michel Mommejat, President of A.D.A.M. Innovations. "With GeneLock, we aim to pioneer a new category in biosecurity for genomic assets.” GeneLock is designed for users ranging from government genomic programs and large-scale databases to research institutions, life sciences organizations and consumer applications, including selected GeneLife test kits. It extends advanced genetic data protection from institutions to individuals. GeneLock reflects A.D.A.M. Innovations’ commitment to trusted platforms for a new era of genomic biosecurity. For additional information, visit www.adam-innovations.com About A.D.A.M. Innovations Co. Founded in 2004 in Tokyo, A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.) is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning clinical diagnostics, AI-driven R&D data platforms, and consumer genomics. To date, A.D.A.M. Innovations has conducted more than 2.9 million genetic tests and maintains the largest R&D genomic database of the Japanese population. About GeneLockTM GeneLockTM is a secure, sovereign platform for genomic data at scale. Through encryption, fragmentation and distributed architecture, it enables controlled access, resilient protection and governed use of high-value datasets across clinical, research and consumer environments. Designed for data sovereignty, GeneLock supports deployment across on-premises and hybrid cloud infrastructures. GeneLock (pending) and DNA DAY are registered trademarks of A.D.A.M. Innovations Co. Corporate contact: Email: press@adam-innnovations.com Media Relations: Crocker Coulson Email: Crocker.Coulson@aumadvisors.com +1 (646) 652-7185
2026-04-24 14:27:35

The Genius Song & The Brain Song Official 2026: 7-Second Brain Trick’ Genius Brainwave Music to Improve Focus and memory By Genius wave?
The Genius Song Claims Evaluated Latest 2026 "7-Second Brain Trick" Read Report on Gamma Wave Audio Marketing, Consumer Report, Pricing, and What Consumers Should Verify New York City, April 24, 2026 (GLOBE NEWSWIRE) -- IN 2026, The Brain Song & The Genius Song introduce a simple audio-based approach to support focus, mental clarity, and relaxation. Designed for daily listening, these programs fit easily into modern routines, offering a convenient way to encourage better concentration, calm thinking, and overall cognitive wellness in today’s fast-paced lifestyle. Visit The Brain Song Official Website. Click Here to Read more In the digital age, where pursuing financial success and abundance is a prevalent aspiration, a new wave of online programs has emerged, promising to unlock the secrets of wealth manifestation. These programs capitalise on the intersection of technology and personal development, offering individuals the tools and insights to transform their financial realities. One such program that has gained attention is The Brain Song & The Genius Song. Visit The Genius Song Official Website Click Here to Read more Online wealth manifestation programs are designed to harness the power of the mind to attract abundance, prosperity, and success. Rooted in positive psychology, neuroscience, and metaphysics principles, these programs leverage digital platforms to deliver transformative experiences to participants seeking financial elevation. The allure of online wealth manifestation programs lies in their accessibility, allowing individuals to embark on self-improvement and financial empowerment from the comfort of their homes. These programs often incorporate educational content, guided exercises, and interactive tools to rewire thought patterns and cultivate a mindset conducive to wealth creation. The The Brain Song & The Genius Song and similar programs represent a digital frontier where technology converges with personal development to offer a pathway to abundance. However, participants are encouraged to approach such programs with discernment, understanding that individual results may vary and success often involves a combination of mindset, action, and external factors. Get The Brain Song from the official website What is the The Brain Song & The Genius Song Program? The The Brain Song & The Genius Song program has garnered attention as a unique approach to harnessing the power of brain waves to manifest wealth. In a world where various programs promise fast wealth and success, this program stands out by focusing on the two primary brain waves of wealth: Beta and Theta. The program asserts that most people operate in a state of Beta, linked to stress, bad luck, and a lack of abundance. On the other hand, Theta is associated with wealth, creativity, and relaxation. The The Brain Song & The Genius Song program centres around a 7-minute audio track designed to shift the listener's brain waves from Beta to Theta, aiming to stimulate the growth of a specific brain region called the hippocampus. According to the program, a larger hippocampus correlates with a more vital ability to attract wealth. The program claims to initiate a "wealth attraction mode" by rewiring the brain for success through the influence of Theta brainwaves. This, in turn, leads to increased motivation, a more positive mindset, and, ultimately, financial success. Is The Genius Song Actually Legit? Visit the official website to read more.. How does it work? The program is structured into three main stages, each with a specific timeframe and expected outcomes. In the initial 1 to 4 weeks, users may notice subtle changes in their lives, such as increased motivation and positivity. The subsequent stage, spanning 1 to 3 months, is claimed to significantly impact users' financial situations, including higher income and improved opportunities. During the first stage of the The Brain Song & The Genius Song program, which spans 1 to 4 weeks, users will likely experience subtle yet noticeable changes in various aspects of their lives. During this period, the primary focus is inducing a shift from the Beta state to the Theta state through the 7-minute audio track. The Beta state, associated with stress and bad luck, is intended to transform into the Theta state, linked to wealth, creativity, and relaxation. Expected Outcomes in the Initial Stage (1 to 4 weeks): Increased Motivation: Users will likely experience heightened motivation, potentially influencing their approach to tasks, challenges, and opportunities. The program aims to instil a positive mindset, fostering a proactive and determined approach to various aspects of life.Positive Mindset: The audio track's influence on brain waves is designed to promote a more positive mindset. This shift in mindset can contribute to improved mental well-being, resilience in the face of challenges, and an overall optimistic outlook.Introduction to Wealth Attraction Mode: As users listen to the audio track consistently, the program stimulates the hippocampus, encouraging its growth. The program suggests a larger hippocampus is associated with a more vital ability to attract wealth. Users may notice subtle changes aligning with a "wealth attraction mode." Moving beyond the initial stage, the program extends into the second stage, covering a period of 1 to 3 months. This stage is marked by more significant impacts on users' financial situations and opportunities for personal growth.Expected Outcomes in the Subsequent Stage (1 to 3 months):Significant Financial Impact: Users are promised substantial changes in their financial circumstances, including higher income and improved financial opportunities. The program suggests consistently listening to the audio tracks contributes to these positive shifts.Optimised Financial Opportunities: Theta brainwave stimulation is purported to positively influence users' financial outcomes. Tangible improvements in income and access to better financial prospects characterise this stage.Reinforcement of Positive Changes: The longer duration of the second stage allows for the reinforcement of positive changes initiated in the initial weeks. Users are encouraged to continue the daily practice for optimal results. Users must approach the program with a commitment to consistent practice and an open mind, recognising that individual experiences may vary. While the program outlines specific timeframes and expected outcomes, the effectiveness of brain wave modulation for wealth attraction is a subjective experience influenced by various factors. Benefits of the Program The The Brain Song & The Genius Song program promises several potential benefits for individuals seeking to enhance their wealth manifestation and overall well-being. While individual experiences may vary, the program outlines several advantages users may derive from consistent practice. Here are the potential benefits associated with the The Brain Song & The Genius Song program: Wealth Attraction: The program's core objective is to shift users from the Beta brainwave state associated with stress and bad luck to the Theta state linked to wealth, creativity, and relaxation. The program suggests that this transition can create a "wealth attraction mode," potentially influencing financial outcomes.Increased Motivation: Users in the initial stage (1 to 4 weeks) are expected to experience heightened motivation. The program aims to instil a proactive and determined approach to various aspects of life, contributing to increased productivity and goal achievement.Positive Mindset: The audio tracks induce a positive mindset, fostering mental well-being and resilience. A more optimistic outlook can positively impact daily experiences, relationships, and overall life satisfaction.Financial Impact: The second stage (1 to 3 months) promises significant impacts on users' financial situations. This includes higher income and improved financial opportunities. The program suggests that consistent use of the audio tracks contributes to tangible improvements in financial outcomes.Better Financial Opportunities: Theta brainwave stimulation is intended to influence users' access to financial opportunities positively. This may involve improved job prospects, business opportunities, or investment success.Optimised Decision-Making: The program suggests that the influence on brain waves positively affects decision-making processes. Users may experience enhanced clarity, focus, and discernment, leading to more informed and effective choices.Positive Lifestyle Changes: Beyond financial aspects, users may witness positive changes in their lifestyle, relationships, and overall well-being. The program aims to create a holistic transformation that extends beyond monetary gains.Cultivation of Discipline: Consistent practice of listening to the audio tracks requires discipline. Engaging in this routine can foster a sense of commitment and discipline, which may extend to other areas of life.Critical Components of the The Brain Song & The Genius Song Program Educational Content This program typically offers educational modules covering various aspects of wealth manifestation, positive thinking, and financial strategies. Participants gain insights into the principles that underlie the program's approach. Guided Exercises Interactive exercises like visualisation, affirmation practices, and meditation are integral to these programs. These exercises aim to reprogram subconscious beliefs and align thought patterns with abundance. Digital Tools Many programs leverage digital tools, including audio tracks, videos, and mobile applications, to deliver content and guide participants through daily practices. These tools enhance accessibility and convenience. Community Support Online forums, discussion groups, or live sessions foster community among participants. Sharing experiences, challenges, and successes creates a supportive environment for personal growth. Price and Bonuses The The Brain Song & The Genius Song program is available for purchase at the discounted price,Visit The Brain Song Official Website Click Here to order reduced from its regular price of $49. This affordable investment grants users access to a unique audio track designed to shift brainwave states from Beta to Theta to stimulate wealth attraction. The company offers the following bonus for user feasibility; Visit The Genius Song Official Website Click Here to order Usage guide for The Brain Song & The Genius Song The Brain Song & The Genius Song is designed to be user-friendly, ensuring that individuals of all backgrounds can easily incorporate it into their daily routines. The program's compatibility with various devices allows users to seamlessly integrate it into their preferred platforms, promoting convenience and accessibility. For optimal results, it is recommended to use The Brain Song & The Genius Song once daily, listening to the entire music set without any interruptions. Using headphones is advised to enhance focus and minimise distractions. In the event of an interruption, restarting the program from the beginning is suggested to maintain the continuity of the experience. The program's benefits extend beyond the auditory experience. The Brain Song & The Genius Song aims to enhance cognitive thinking skills and problem-solving abilities. By working on the brain's theta waves, the program intends to stimulate a mindset focused on seeking opportunities for personal growth. This dual approach - combining auditory stimulation with cognitive enhancements - underscores the program's holistic approach to mindset transformation. In essence, The Brain Song & The Genius Song is crafted to be a versatile and accessible tool for individuals seeking to harness the potential of brainwave states for personal development. The simplicity of its usage and the flexibility of device compatibility makes it feasible for users to seamlessly integrate the program into their daily lives, potentially unlocking pathways to cognitive improvement and enhanced problem-solving abilities. Why should one use the Billionaire Brainwave Program? The The Brain Song & The Genius Song program is a compelling solution for individuals seeking to transform their mindset and manifest success. Here are key reasons why one might consider using the The Brain Song & The Genius Song Program: 1. Fast Results with Manifesting Success The program claims to offer fast results in manifesting success. By targeting brainwave states associated with wealth, the 7-minute audio track is designed to induce a shift from Beta to Theta, fostering a mindset conducive to attracting prosperity. For individuals looking for a relatively quick and efficient method to enhance their financial outlook, the program suggests that positive changes can be experienced quickly. 2. Very Little Investment, Huge Returns One of the appealing aspects of the The Brain Song & The Genius Song program is its affordability. Priced at $39, with a discounted rate from the regular $49, the program positions itself as a low-cost investment with the potential for significant returns. This affordability makes it accessible to a broad audience, removing financial barriers that may hinder individuals from exploring wealth manifestation programs. 3. Proven Results The program claims to have proven results, particularly in the second stage, spanning 1 to 3 months. During this period, users are purported to experience significant impacts on their financial situations, including higher income and better opportunities. While individual experiences may vary, the program suggests consistent use of the 7-minute audio track can lead to tangible and positive outcomes. 4. No Side Effects Unlike some interventions or programs that may have potential side effects, the The Brain Song & The Genius Song program emphasises that it is side-effect-free. The methodology revolves around audio tracks and brainwave stimulation, posing minimal user risk. This feature adds to the program's appeal, especially for those prioritising natural and non-invasive personal development approaches. 5. All one needs is 7 Minutes a Day The convenience of the The Brain Song & The Genius Song program is underscored by its requirement for just 7 minutes a day. In our fast-paced lives, where time is often a precious commodity, the program's brevity makes it manageable for individuals with busy schedules. This daily commitment is a small investment of time for potential significant gains in mindset transformation. Final Verdict The affordability of the The Brain Song & The Genius Song program, coupled with its supplementary resources, positions it as an accessible option for those interested in exploring the potential intersection of neuroscience and wealth manifestation. As with any personal development program, an open mind and dedication to the recommended practices are crucial for users to derive the maximum benefit. Ultimately, the The Brain Song & The Genius Song program provides a unique avenue for individuals to explore the impact of brainwave states on mindset and financial outcomes. As users embark on this journey, they are encouraged to approach it with a sense of curiosity, recognizing that individual factors and a commitment to the prescribed practices can influence the effectiveness of such programs. Ancient "song” helps 18,000+ find money effortlessly References: https://finance.yahoo.com/sectors/healthcare/articles/purisaki-berberine-patches-2026-effective-143400167.html https://finance.yahoo.com/news/best-creatine-supplements-women-men-223200002.html https://finance.yahoo.com/news/advanced-fat-burners-men-women-140800557.html https://finance.yahoo.com/sectors/healthcare/articles/strongest-phentermine-alternatives-weight-loss-115400071.html Company: Genius Wave Jurisdiction: Puerto Rico Product Support Email: support@geniussongofficial.com Payment Processor: Click Sales Inc., 1444 S. Entertainment Ave., Suite 410, Boise, ID 83709 Contact Us for Advertising: Info@allprsolution.com
2026-04-24 14:27:15

Ayala Land cools expansion, boosts leasing push amid uncertainty
Real estate giant Ayala Land Inc. (ALI) is choosing to hunker down and easing its aggression in the face of additional challenges posed by the conflict in Iran, even as it has yet to recover from the adverse impact of a middle-income condominium oversupply after the loss of the Philippine offshore gaming operators (POGO) market. “There’s no doubt that the Middle East crisis is a significant disruptor, especially for the property development industry. In times like these, our top priority is stability over aggressive growth. We’re focused on ensuring ample liquidity and maintaining the flexibility to act swiftly when the environment improves,” said ALI Chairman Jaime Augusto Zobel de Ayala. In this light, ALI will manage its residential launches, reduce inventory, and lower its capital expenditure (capex) plans as part of balance sheet management. “We want to preserve our flexibility so that we have the resources available when this crisis ends or when new opportunities arise. ALI’s track record shows resilience through multiple cycles, and that’s thanks to our prudent management of both our balance sheet and our diverse portfolio,” Mr. Zobel said. ALI’s strategy now pivots toward leasing, with the company noting that expanding its leasing footprint and reinventing its malls and hotels has become even more relevant under these circumstances. “Our focus on building a stronger recurring income business is precisely to help us weather disruptions and cycles with more dependable revenue streams,” Mr. Zobel said. ALI President and Chief Executive Officer (CEO) Anna Ma. Margarita Bautista-Dy noted that, “Visibility as to what lies ahead is admittedly limited. However, we’re preparing for the lingering effects of this crisis. We will face these challenges with direction.” Despite the difficult environment, she said, “Our leasing business is expected to remain on a growth trajectory and will be the primary driver of our company’s expansion once there is greater clarity in the operating environment.” Meanwhile, Bautista-Dy said they believe certain segments of property development will recover and grow and, when that happens, ALI will be ready with its offerings. The property giant’s estates will continue to serve as the cornerstone for both its leasing and property development activities, and 100 percent of the leasing footprint planned over the next three years will be located within these estates. “We foresee that in this period, the share of leasing in our earnings portfolio will increase, making our business more predictable,” Bautista-Dy said. ALI Senior Vice President and Leasing and Hospitality Group Head Mariana Beatriz Zobel de Ayala said that, “Across both malls and hotels, reinvestments are expected to deliver a 15- to 20-percent uplift in rents and room rates upon stabilization. Our office portfolio remained resilient with an 87-percent lease upgrade.” “Looking ahead to 2026, we will open over 200,000 square meters (sqm) of new retail space, our largest annual addition in history, and deliver more than 70,000 sqm of new office capacity,” she noted. The Mandarin Oriental will also reopen in the fourth quarter, returning five-star hospitality to Makati City after more than a decade. ALI is also scaling its industrial real estate, particularly cold storage facilities, which are steadily gaining strategic importance within its leasing portfolio. “Together, these efforts are repositioning leasing to play a much larger role in our earnings mix over time,” Ms. Zobel said.
2026-04-23 04:20:00

Ayala Land cools expansion, boosts leasing push amid Middle East uncertainty
Real estate giant Ayala Land Inc. (ALI) is choosing to hunker down and easing its aggression in the face of additional challenges posed by the conflict in Iran, even as it has yet to recover from the adverse impact of a middle-income condominium oversupply after the loss of the Philippine offshore gaming operators (POGO) market. “There’s no doubt that the Middle East crisis is a significant disruptor, especially for the property development industry. In times like these, our top priority is stability over aggressive growth. We’re focused on ensuring ample liquidity and maintaining the flexibility to act swiftly when the environment improves,” said ALI Chairman Jaime Augusto Zobel de Ayala. In this light, ALI will manage its residential launches, reduce inventory, and lower its capital expenditure (capex) plans as part of balance sheet management. “We want to preserve our flexibility so that we have the resources available when this crisis ends or when new opportunities arise. ALI’s track record shows resilience through multiple cycles, and that’s thanks to our prudent management of both our balance sheet and our diverse portfolio,” Mr. Zobel said. ALI’s strategy now pivots toward leasing, with the company noting that expanding its leasing footprint and reinventing its malls and hotels has become even more relevant under these circumstances. “Our focus on building a stronger recurring income business is precisely to help us weather disruptions and cycles with more dependable revenue streams,” Mr. Zobel said. ALI President and Chief Executive Officer (CEO) Anna Ma. Margarita Bautista-Dy noted that, “Visibility as to what lies ahead is admittedly limited. However, we’re preparing for the lingering effects of this crisis. We will face these challenges with direction.” Despite the difficult environment, she said, “Our leasing business is expected to remain on a growth trajectory and will be the primary driver of our company’s expansion once there is greater clarity in the operating environment.” Meanwhile, Bautista-Dy said they believe certain segments of property development will recover and grow and, when that happens, ALI will be ready with its offerings. The property giant’s estates will continue to serve as the cornerstone for both its leasing and property development activities, and 100 percent of the leasing footprint planned over the next three years will be located within these estates. “We foresee that in this period, the share of leasing in our earnings portfolio will increase, making our business more predictable,” Bautista-Dy said. ALI Senior Vice President and Leasing and Hospitality Group Head Mariana Beatriz Zobel de Ayala said that, “Across both malls and hotels, reinvestments are expected to deliver a 15- to 20-percent uplift in rents and room rates upon stabilization. Our office portfolio remained resilient with an 87-percent lease upgrade.” “Looking ahead to 2026, we will open over 200,000 square meters (sqm) of new retail space, our largest annual addition in history, and deliver more than 70,000 sqm of new office capacity,” she noted. The Mandarin Oriental will also reopen in the fourth quarter, returning five-star hospitality to Makati City after more than a decade. ALI is also scaling its industrial real estate, particularly cold storage facilities, which are steadily gaining strategic importance within its leasing portfolio. “Together, these efforts are repositioning leasing to play a much larger role in our earnings mix over time,” Ms. Zobel said.
2026-04-23 04:20:00

TCL Solar Highlights Groundbreaking Solar Products at Korea Green Energy Expo 2026
Booth No: K-450 DAEGU, South Korea, April 23, 2026 /PRNewswire/ -- TCL Solar is currently exhibiting its latest photovoltaic solutions at the Korea Green Energy Expo, reinforcing its commitment to advancing South Korea's renewable energy market. As South Korea is poised to become a key global player in the solar energy sector, the country is on track to achieve a cumulative installed solar capacity of 55.7GW by 2030, with over 5GW set to be installed annually. Among the growing demand, distributed and floating photovoltaic systems are driving significant market expansion. The TCL Solar booth was bustling with visitors throughout the event. TCL Solar is actively supporting South Korea's renewable energy goals by offering high-efficiency, reliable solar modules and localized services that are integral to helping the country meet its solar installation targets and accelerate its transition to sustainable energy. TCL Solar is showcasing its T5 Pro TOPCon Multi-Cut Product, which utilizes advanced TOPCon technology with overlapping cell architecture, offering a maximum power output of up to 670W、755W. This cutting-edge solution represents the pinnacle of high-efficiency solar energy. Additionally, the C2 BC Module, powered by Back Contact technology, delivers significantly higher energy yields, making it perfect for complex applications with high BOS costs, low ground reflectivity, limited land availability, partial shadow scenarios, or aesthetic requirements. The BC module with its no busbar design and no front metal lines present a more visually appealing aesthetic, meeting Korean architectural requirements. Offering a power output 20W higher than TOPCon modules, it also maintains significantly better hot spot resistance and a degradation rate of just 0.35%. Additionally, the company introduced the lightweight modules (5.4kg/m2, reducing weight by 49%) that are particularly suitable for low-load rooftops of aging factories in Korea. Besides, the company proudly congratulate Prana Solution Co., Ltd. on winning the 2025 TCL Solar Top Sales Award on site. This remarkable achievement highlights the strong partnership between Prana Solution and TCL Solar, built on a shared commitment to innovation and sustainable energy. Backed by TCL Zhonghuan's (TCL Solar parent company) advanced manufacturing capabilities including the launch of the industry's first 4.0 silicon wafer factory in 2020, TCL Solar guarantees excellent quality and technical support. TCL Solar will continue to collaborate with local partners to help South Korea achieve its renewable energy goals, while advancing its global expansion through partnership with the Korean market for mutual growth.
2026-04-23 04:19:58

Wondershare Demonstrates AI-Powered Document Workflows with PDFelement at Microsoft AI Tour Hong Kong
HONG KONG, April 23, 2026 /PRNewswire/ -- Wondershare, a global leader in digital productivity and creativity software, showcased its latest AI-powered solutions at the Microsoft AI Tour Hong Kong, highlighting how its flagship product, Wondershare PDFelement, integrates with Microsoft technologies to enable smarter, more secure, and more efficient document workflows for enterprises. Wondershare showcased its latest AI-powered solutions at the Microsoft AI Tour Hong Kong, highlighting how its flagship product, Wondershare PDFelement, integrates with Microsoft technologies to enable smarter, more secure, and more efficient document workflows for enterprises. As Microsoft's flagship global AI event, the Microsoft AI Tour brings together partners and industry leaders to explore how AI is transforming business operations. At the Hong Kong stop, Wondershare demonstrated its deep collaboration with Microsoft across key solution areas, showcasing how its product ecosystem aligns with Microsoft technologies to deliver integrated, end-to-end AI workflows. At the center of the showcase was Wondershare PDFelement, an AI-powered, all-in-one PDF solution designed to streamline document-centric processes in enterprise environments. Through deep integration with the Microsoft ecosystem, PDFelement enables seamless interoperability with widely used applications such as Word, Excel, and PowerPoint, allowing users to convert PDFs into fully editable formats while preserving original layout and structure. With built-in Office plugins, users can also generate standardized PDFs directly within Microsoft applications. PDFelement further supports deployment in Microsoft Azure environments, enabling Single Sign-On (SSO) for streamlined access management, while maintaining compatibility with Microsoft Rights Management Services (RMS) to securely manage protected documents. Beyond its ecosystem integration, PDFelement also introduces a suite of AI-powered capabilities to enhance productivity across document workflows. Smart Redact enables automatic detection and masking of over 70 types of sensitive data to support compliance requirements, while Professional AI Translation delivers accurate, industry-specific language output for cross-border collaboration. The Admin Console provides enterprise-grade centralized access and permission control, allowing IT teams to manage AI, cloud, and eSign features with real-time visibility into license usage. At the event, attendees can also experience a range of enhanced AI features, including AI Summarize, Chat with PDF, AI Translate, AI Detect and Rewrite, as well as AI Proofread, Voice, Explain, Grammar Check, and Mind Map Generation. In addition to PDFelement, Wondershare also showcased how its broader product portfolio integrates with Microsoft technologies. EdrawMax offers full compatibility with Microsoft Visio through bidirectional .vsdx import and export, along with Office add-ins, OLE embedding, and data-driven diagram generation from Excel, while also featuring AI-powered capabilities such as the Edraw Agent, natural language-driven diagram generation, and text-to-diagram conversion across platforms. EdrawMind enables one-click conversion of mind maps into PowerPoint and supports intelligent analysis of Office documents to generate structured knowledge frameworks, alongside AI features including webpage summarization, node-based note generation, and AI-powered search. Filmora is optimized for the Windows AI PC ecosystem, leveraging on-device NPU acceleration for AI-powered video processing, supporting Windows on Arm, and enabling natural language interaction with RAG-based asset matching, while also incorporating AI Extend, AI Portrait, and Smart Cutout. Reelmate provides an AI-powered, agent-driven platform covering the full content production pipeline from generation to post-production for creating premium comic series. Through live demonstrations, attendees were able to experience how Wondershare's AI-powered solutions can be applied across real-world enterprise scenarios, from document processing and knowledge management to visual communication and content creation. The showcase attracted strong interest from professionals across industries such as finance, education, information technology, and telecommunications, particularly around capabilities related to document security, automation, and cross-language collaboration. Wondershare's participation in the Microsoft AI Tour Hong Kong highlights its continued commitment to advancing practical AI adoption through deep ecosystem integration. By combining AI capabilities with seamless compatibility across Microsoft technologies, Wondershare is helping enterprises build more secure, connected, and efficient workflows for the future. About Wondershare: Wondershare is a globally recognized software company founded in 2003, known for its innovative solutions in creativity and productivity. Driven by the mission "Creativity Simplified", Wondershare offers a range of tools, including PDFelement for document management; EdrawMax, EdrawMind for diagraming, Filmora and SelfyzAI for video editing. With over 2 billion cumulative active users across all products and a presence in over 200 countries and regions, Wondershare empowers the next generation of creators with intuitive software and trendy creative resources, continually expanding the possibilities of creativity worldwide.
2026-04-23 04:19:39

Romualdez in the Philippines; 'flee country' narrative slammed
Former House Speaker Leyte 1st district Rep. Martin Romualdez remains in the Philippines, his counsel-spokesperson confirmed on Thursday morning, April 23. This, as the Romualdez camp slammed the apparent narrative that he planned on fleeing the country amid alleged links to anomalous flood control projects. "We acknowledge reports that the Sandiganbayan has issued a precautionary hold departure order (PHDO) against Leyte Rep. Ferdinand Martin G. Romualdez upon request of the Office of the Ombudsman," lawyer Ade Fajardo said in a statement sent to House reporters. "At the outset, we categorically clarify: Rep. Romualdez is in the Philippines and has not left the country. Any report or insinuation that he has fled is false and irresponsible," he said. Earlier, the Lakas-Christian Muslim Democrats (Lakas-CMD) president secured a travel authority from the House of Representatives leadership. He was supposed to be in Singapore from April 20 to May 4, 2026 for "a long overdue follow-up" on his angioplasty surgery. The lawyer assured the public that Romualdez, "followed the proper process". "He sought and secured the necessary travel authority, and coordinated in good faith with the Department of Justice (DOJ) and the Bureau of Immigration (BI) for a brief, long-overdue four-day medical check-up with his attending physician in Singapore," Fajardo said. "This is fully consistent with his conduct from the very beginning—one of cooperation, transparency, and respect for legal processes. Unfortunately, this legitimate act has been twisted to create a prejudicial narrative that he intended to flee," noted Fajardo. The lawyer further said: "We will avail of all appropriate legal remedies to question the issuance of this order before the proper forum." "Rep. Romualdez remains committed to facing these allegations squarely," Fajardo said. There is as yet no formal filed case against Romualdez, a former two-time House Speaker.
2026-04-23 04:18:00

UP student leader's death in military 'encounter' with NPA rebels in Negros condemned
MANILA, Philippines — Students from the University of the Philippines (UP) in Diliman, Quezon City are in mourning after one of their own was killed in what the military described as an encounter with rebels of the New People’s Army (NPA) in Toboso, Negros Occidental last April 19, 2026. The UP Diliman University Student Council confirmed late on Wednesday that the victim was identified as Alyssa Alano, an Education and Research Councilor. “In connection with this, the UP Diliman University Student Council reports that one of those killed was our fellow Iskolar ng Bayan, USC Councilor Alyssa Alano, due to the fascist attack and military repression in Negros,” the council said in a statement in Filipino. The council condemned Alano’s killing by the Philippine Army’s 79th Infantry Battalion against an innocent civilian. “Alyssa lived and studied among our farmer brothers and sisters in Negros to understand their true conditions in the face of land grabbing, exploitation, and militarization,” the council said. “As long as the root causes of poverty remain unresolved, there will be more like Alyssa who are willing to study society and fight for a society free from exploitation. The spirit of Alano will never fade among the ranks of Iskolar ng Bayan, who will further strengthen unity to ultimately defeat an oppressive and exploitative social system,” they added. Meanwhile, the UP Office of the Student Regent also condemned the death of Alano, who also served as chairman of the UP Diliman division of the League of Filipino Students and led a walkout that was participated by 8,000 students. “Even before this, Alyssa had already made significant contributions in amplifying campaigns against corruption, against the militarization of the university, and for increasing the UP budget. Her commitment to immersing herself in the conditions of farmers reflects the spirit of public service and compassion expected of an Iskolar ng Bayan,” the office said.
2026-04-23 04:17:01

CCIB CEO Tabatha Bull Appointed to Government Advisory Committee on Canada-U.S. Economic Relations
TORONTO, ON, April 21, 2026 (GLOBE NEWSWIRE) -- Today, Prime Minister Mark Carney announced that Canadian Council for Indigenous Business President and CEO Tabatha Bull, as well as 23 other leaders in business, investment, trade, and labour, will join the newly formed Advisory Committee on Canada-U.S. Economic Relations. The committee, which replaces the former Council on Canada-U.S. Relations, will be chaired by the Honourable Dominic LeBlanc, Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs, Internal Trade and One Canadian Economy. With negotiations for the Canada-U.S.-Mexico Agreement (CUSMA) set to resume, the advisory committee will serve as a strategic forum to strengthen Canada’s position within its most critical economic partnership with the United States. "Our participation on this committee will allow CCIB to leverage our research efforts and national engagement with Indigenous businesses, to ensure that Indigenous voices and economic interests are fully represented and integrated into trade solutions,” says Tabatha Bull, President and CEO of CCIB. "Indigenous businesses play a vital role in Canada's economy, and cross-border relations significantly influence their success. I look forward to collaborating with the committee and participating in this important dialogue.” According to CCIB research, Indigenous export value increased steadily between 2005 and 2022, mirroring national trends of rising productivity. While CCIB’s Adàwe and Atāmitowin reports indicate that direct exporting currently sits at approximately seven per cent, compared to the national average of 12.1 per cent, this export gap represents a significant opportunity for growth. As Canada’s youngest and fastest-growing population, Indigenous entrepreneurs are foundational to export-adjacent industries. Trade policy shifts impact the entire Indigenous economy, from direct shippers to the service providers and suppliers powering the national supply chain. The committee is set to hold its first meeting on April 27, 2026, as Canada prepares for the critical Joint Review of the Canada-United States-Mexico Agreement (CUSMA) on July 1. Visit CCIB’s website to learn more about its public policy advocacy and its latest research on the Indigenous economy. -30- About Canadian Council for Indigenous Business CCIB is committed to the full participation of Indigenous Peoples in Canada’s economy. As a national, non-partisan association, its mission is to promote, strengthen and enhance a prosperous Indigenous economy through the fostering of business relationships, opportunities, and awareness. CCIB offers knowledge, resources, and programs to its members to cultivate economic opportunities for Indigenous peoples and businesses across Canada. For more information, visit www.ccib.ca. CONTACT: Shannon Sutherland Canadian Council for Indigenous Business 1.403.462.9363 x822 ssutherland@ccib.ca Chris Overton Canadian Council for Indigenous Business 1.403.462.9363 x828 coverton@ccib.ca
2026-04-21 17:56:51

Aleta Named Winner of Best Consolidated Reporting at the WealthBriefing Awards 2026
Recognition confirms Aleta's position as the leading purpose-built family office software platform for consolidated wealth reporting NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Aleta, the purpose-built family office software platform has won Best Consolidated Reporting at the WealthBriefing Awards 2026. The award recognizes Aleta for delivering the aggregation, design, and analytics that give family offices a complete, trusted wealth overview. In announcing the win, the judges highlighted Aleta for "demonstrating the best data aggregation, intuitive design, and flexible, real-time analytics that empower family offices to own and understand their entire wealth structure, transforming complex portfolios into actionable insights and strategic decisions.” The WealthBriefing Awards are among the most rigorous recognition programs in the wealth management industry. Judged by an independent panel of practitioners and trusted advisors (none of whom hold commercial relationships with the entrants) the awards recognize organizations that demonstrate measurable excellence rather than self-reported claims. The win marks Aleta’s second major industry award in 2026. In January, Aleta was named Best Data Provider at the Family Wealth Report Awards, where an independent panel recognized the platform’s ability to verify data before reporting it. The two awards underscore Aleta’s leadership across both the data foundation and the reporting layer - the full stack of consolidated wealth intelligence. "Consolidated reporting is the heart of what we do at Aleta. We built the platform to give the principal an intuitive, verified picture of total wealth, the investment team the depth they need to oversee it, and the ecosystem around them an open data layer made for the age of AI. To be recognized by an independent panel in this specific category means a great deal to us,” says Ken Gamskjaer, CEO & Co-founder of Aleta. Aleta serves single and multi-family offices managing wealth across public portfolios, private equity, real estate, and alternative investments. The platform consolidates holdings across custodians, entities, and currencies into a single verified picture of total wealth, combining automated data collection, AI-driven document processing, and a built-in investment General Ledger to deliver institutional-grade consolidated reporting with a zero-learning-curve interface for principals and power users alike. The Best Consolidated Reporting award specifically recognizes platforms that turn fragmented custodian feeds, private holdings, and alternative investments into a single source of truth for the family office. A category that sits at the core of Aleta’s platform design. Aleta’s architecture verifies every position, valuation, and transaction before it reaches the dashboard. "Winning Best Data Provider in January validated our data foundation. Winning Best Consolidated Reporting now validates the full picture: that the reporting, the interface, and the analytics we build on top of that data are also best in class. These are two independent panels telling us the same thing: that the bet we made on radical simplicity on the surface and serious power underneath is paying off,” says Ken Gamskjaer. About Aleta Aleta is a purpose-built family office software platform for consolidated wealth reporting and wealth intelligence. The platform serves offices managing complex wealth across public portfolios, private equity, real estate, and alternative investments. Aleta consolidates holdings across custodians, entities, and currencies into a single verified picture of total wealth with a built-in investment General Ledger, open API architecture, and an award-winning interface. Aleta is SOC 2 Type II certified and is available from $1,000/month with a go-live timeline of 4-8 weeks. About the WealthBriefing Awards WealthBriefing is the leading subscriber-based newswire covering the global wealth management sector. The WealthBriefing Awards recognize excellence across the sector, judged by independent panels of practitioners who have no commercial relationship with entrants. Isabella S. Rasmussen Head of Marketing & Communications isabella@aleta.io
2026-04-21 17:56:42

Home EMF Protection Searches Hit Post-5G Highs, Reports EMF Protection Pros
Site traffic has surged 110% since mid-2024, mirroring broader search trends as connected device counts in U.S. homes continue to climb. Home EMF Protection Searches Hit Post-5G Highs, Reports EMF Protection Pros Site traffic has surged 110% since mid-2024, mirroring broader search trends as connected device counts in U.S. homes continue to climb. Grand Rapids, MI , April 21, 2026 (GLOBE NEWSWIRE) -- A growing body of consumer data suggests that interest in home EMF protection is no longer a niche concern. EMF Protection Pros, an online resource for EMF education and product reviews, reports that daily visitor traffic to its website has increased by more than 110% since the summer of 2024, reaching its highest sustained levels on record in early 2026. EMF Protection Pros Google Trends data for the U.S. search term "emf protection" shows interest rising gradually since late 2023, now approaching levels not seen since the 2020 5G rollout. Unlike that earlier spike, which was sharp and short-lived, the current increase has built slowly over more than two years without a single triggering news event and is part of a longer-term rise that began around 2017. That distinction matters. The last major spike in EMF search interest came around 2019 and 2020, tied directly to the rollout of 5G networks and the uncertainty surrounding it. The current growth is different in character: slower, steadier, and driven by everyday questions about wireless routers, smart appliances, baby monitors, and bedroom environments rather than a single technology controversy. "The questions I'm getting now are much more practical than they were a few years ago," said Greg Davis, EMF protection advocate and founder of EMF Protection Pros. "People aren't asking whether EMF is dangerous in the abstract. They're asking which devices in their bedroom are most worth addressing, or what they can do without rewiring their house. That shift tells me this has moved from a fringe concern to a mainstream home health question." Commercial data supports the pattern. The EMF personal protection market was estimated at $500 million in 2025 and is projected to reach approximately $1.8 billion by 2033, expanding at a compound annual growth rate of 15%, according to Data Insights Market. The broader EMF protection tools market is growing even faster, at 20% annually through the same period. The WHO notes that EMFs represent one of the most common and fastest-growing environmental influences, with exposure levels expected to increase as technology advances. Several factors appear to be converging. The average American household now contains significantly more wireless devices than five years ago, from smart speakers and video doorbells to fitness trackers and wireless charging pads. The appointment of Robert F. Kennedy Jr. as U.S. Secretary of Health and Human Services has also brought environmental health topics, including EMF exposure, into broader public conversation. And with the WHO having recently completed a landmark series of systematic reviews on radiofrequency EMF exposure, the science itself remains active and evolving. Davis first identified the awareness gap in a 2024 poll of more than 2,000 newsletter subscribers and social media followers, which found that while the typical home contains more than 15 devices producing EMF, most people could name only three when asked. Robot vacuums, wireless security cameras, smart thermostats, and Bluetooth speakers consistently went unrecognized as sources. That poll, and the traffic growth since its release, suggest the appetite for practical, non-alarmist guidance is larger than the market had previously assumed. "The goal has never been to scare people or suggest they give up modern technology," Davis added. "It's about helping them understand what's actually in their environment so they can make informed choices. Once people realize how many sources they're working with, the first thing most of them want to know is how to actually measure what's in their home. We've become one of the more referenced sources for best EMF meters simply because people want somewhere practical to start." Free room-by-room reduction guides, device identification checklists, and EMF meter reviews are available at emfprotectionpros.com. New subscribers receive a Quick Start Guide covering ten steps anyone can take without technical expertise or home modifications. ### About EMF Protection Pros EMF Protection Pros offers trusted guidance on reducing electromagnetic field exposure through practical tips, product reviews, and effective protection solutions. Founded by EMF protection advocate Greg Davis, the website serves thousands of subscribers seeking balanced, science-aware information about electromagnetic fields. Media Contact Greg Davis EMF Protection Pros Address: 330 E Beltline Ave NE Suite 399, Grand Rapids, MI 49506 Phone: 616 214 6368 Website: https://www.emfprotectionpros.com/ Attachment Home EMF Protection Searches Hit Post-5G Highs, Reports EMF Protection Pros
2026-04-21 17:56:33

Aquatics Safety Experts Address the ‘National Distraction Epidemic’ This Summer
Quick moments of inattention can have serious consequences, and caregivers play a key role in keeping children safe. CHICAGO, April 21, 2026 (GLOBE NEWSWIRE) -- Summer brings long days of swimming, outdoor play, and family fun - but also hidden dangers. Even brief distractions, like checking a phone, can lead to injuries or drowning incidents among children. In fact, 88% of children drown with at least one adult present. Aquatics safety experts like those at the YMCA of the USA are raising awareness with calls to action like Phones Down, Eyes UpTM, a campaign designed to help parents and caregivers stay fully present and attentive during summer activities. "Even a few seconds of inattention around water can be dangerous,” said Lindsay Mondick, Director of Aquatics Strategy at YMCA of the USA. "We want to empower adults to enjoy summer with their kids while maintaining the focus that keeps children safe.” National statistics highlight the stakes: drowning is a leading cause of accidental death among children, with research showing that lack of supervision is a key factor in most incidents. YMCA locations nationwide have implemented Phones Down, Eyes UpTM, sharing stories of staff, volunteers, and parents successfully keeping kids safe while enjoying pools, splash pads, and family vacations. "This is not about shaming parents,” added Mondick. "It’s about creating awareness and habits that protect children while allowing families to make the most of summer.” For more information on the Phones Down, Eyes Up campaign, visit phonesdowneyesup.org. About the Y Driven by its founding mission, the Y has served as a leading nonprofit committed to strengthening community for more than 175 years. The Y empowers everyone, no matter who they are or where they’re from, by ensuring access to resources, relationships, and opportunities for all to learn, grow and thrive. By bringing together people from different backgrounds, perspectives and generations, the Y’s goal is to improve overall health and well-being, ignite youth empowerment and demonstrate the importance of connections in and across 10,000 communities nationwide. Learn more at ymca.org. Contact: Ashley Rubenstein YMCA of the USA media@ymca.net
2026-04-21 17:56:28

Greenstone Announces Sale of Shares of Gunnison Copper Corp.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. GUERNSEY, Channel Islands, April 21, 2026 (GLOBE NEWSWIRE) -- Greenstone Resources II LP ("Greenstone”) announces that further to its news releases of 4 February 2026 and 18 February 2026, on 21 April 2026 it, together with its affiliates Greenstone Excelsior Holdings LP, Greenstone Co-Investment No 1 (Excelsior) LP and Greenstone Co-Investment No 2 (Excelsior) LP (together, the "Greenstone Group”), sold (the "Sale”) 29,601,737 common shares (the "Shares”) of Gunnison Copper Corp. ("Gunnison”). The Sale followed the appointment by the Greenstone Group of Paradigm Capital Inc. ("Paradigm”) to act as agent on a commercially reasonable "best efforts” basis, to sell the Shares. The Shares were sold at a price per Share of C$0.40, for gross proceeds to the Greenstone Group of C$11,840,694.80, excluding commissions and expenses payable to Paradigm. The Shares were sold through a block trade over the facilities of an exchange in Canada. Prior to the Sale, the Gunnison Group owned 7.0% of the issued and outstanding common shares of Gunnison (excluding the conversion and exercise of convertible debentures and options of Gunnison owned by the Greenstone Group). Following the Sale, the Greenstone Group no longer holds any common shares of Gunnison, representing a decrease of 7.0% of the issued and outstanding common shares of Gunnison. Assuming the conversion of debentures and vested options of Gunnison owned by the Greenstone Group, the Greenstone Group would own 33,241,275 common shares of Gunnison, representing an aggregate interest of 7.3% of the issued and outstanding shares of Gunnison (on an as-converted and as-exercised basis). Depending on market conditions and other factors, the Greenstone Group may from time to time acquire and/or dispose of securities of Gunnison or continue to hold its current position. Following completion of the Sale, a copy of the early warning report required to be filed with the applicable securities commission in connection with the transactions will be available on SEDAR+ at www.sedarplus.ca and can be obtained by contacting Gary Mauger at GreenstoneGSY@aztecgroup.co.uk or at +44 1481 749 700. Greenstone’s address is set out below. Greenstone Resources II L.P. PO Box 656 East Wing, Trafalgar Court, Les Banques St Peter Port, Guernsey, GY1 3PP Gunnison Copper Corp. Concord Place 300 - 2999 North 44th Street Phoenix, AZ 85018 This announcement is not for publication or distribution in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.
2026-04-21 17:56:25

Docupilot Unifies Document Generation and eSignature Into One Seamless Workflow
New features support complete document automation from generation to delivery in a single platform, reducing tool switching Template preview for Docupilot Seamlessly setup eSignature automation using drag and drop template editor eSignature for Docupilot Create and send documents for eSignature using Docupilot DOVER, Del., April 21, 2026 (GLOBE NEWSWIRE) -- Docupilot, a document automation software that helps businesses eliminate manual document creation, today announced key product enhancements, including automation-first, API-ready eSignature support, and improved workflow capabilities. The enhancements make it easier for companies to generate, customize, deliver, and sign documents without switching between tools. Docupilot helps businesses automate repetitive document tasks using intelligent templates and data. The platform allows users to create dynamic templates with placeholders and conditional logic, pull data from sources such as CRMs, HR systems, forms, and generate documents in multiple formats, including PDF and DOCX. With automation-first, API-ready eSignature functionality, users can now send documents for signature directly within the Docupilot interface as part of a complete automated workflow. The eSignature support is part of the document delivery process, enabling secure, trackable signing without exporting documents to a separate application. Improving Document Workflows End-to-End With Docupilot, a sales contract can move through a complete automated workflow-from CRM data to document generation, eSignature, automated reminders, and syncing the signed copy back to the CRM record. Docupilot also allows: -Template creation using a visual, no-code builder that works with Word or in-platform tools. -Dynamic document generation that automatically fills templates with data from integrated systems. -Secure document delivery with options to email attachments, upload to storage systems, or route for signature as part of workflow. -Built-in eSignatures that eliminate the need to switch to external signing systems. -Integration with other apps, enabling data to flow from CRM, Cloud Database Solutions, Work/Process Management Platforms, Forms and other tools, into the document process. Customer-Centric Workflow Automation Companies across industries use Docupilot to generate a wide range of business documents, including contracts, proposals, invoices, HR paperwork, reports and legal forms. Since workflows automatically pull in data and apply logic embedded in templates, teams spend less time on manual entry and repetitive tasks. Docupilot customers report meaningful time savings on document-heavy processes-sometimes cutting prep/signing time by 500%. Hear it directly from a customer: https://youtu.be/CwIuUphV1ak?t=107 "Our goal is to make document workflows smoother from start to finish,” said Rohit Reddy Abbadi, CEO of Docupilot. "Customers no longer have to generate a document in one place and send it for signature in another; now the entire process lives in a unified workflow that saves time and reduces friction.” About Docupilot Docupilot is a document automation software platform that replaces manual document creation with automated workflows. Users build templates with dynamic fields and logic, connect data sources, and generate documents that can be delivered, stored or routed for signature. The platform supports integrations with a wide range of business tools and is used by companies managing high-volume document processes. For more information, visit https://www.docupilot.com Media Contact Vamsi Vutukuru press@docupilot.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/509b3e7c-cdf7-4224-8b41-0023d1e4443d https://www.globenewswire.com/NewsRoom/AttachmentNg/ae6fe7c3-32ca-4e3c-ba8d-e8cd03d14a56
2026-04-21 17:56:10

HIKMICRO, World Leader in Smart Thermal Imaging, Marks 10th Anniversary with Launch of Trailblazing AI-Powered SuperSceneTM Mode
10 Years of Expert Knowledge. Now AI-Enabled. HANGZHOU, China , April 20, 2026 /PRNewswire/ -- HIKMICRO is celebrating 10 years of global leadership in smart thermal imaging by introducing SuperSceneTM Mode . This AI-powered breakthrough facilitates faster, simpler, and more accessible thermal inspections for trade professionals and DIY enthusiasts of any skill level. HIKMICRO 10th Anniversary Far more than just a new feature, SuperSceneTM Mode represents a transition from simple image capture to instant actionable insight. By embedding a decade of field expertise into AI-driven analysis, HIKMICRO is removing the complexity that has traditionally limited thermal imaging while setting a new benchmark in usability and performance. "Our vision from day one was to take thermal imaging solutions from niche applications to the mass market, adding more intelligence and accessibility," says Stefan Li, Overseas General Manager at HIKMICRO. "SuperSceneTM Mode marks a new chapter in that vision. This advanced technology embeds the knowledge of experienced trade professionals directly into our products, enabling any user to work like an expert." From Detection to Decision Thermal imaging can reveal hidden issues, but correct device configuration and image interpretation have long-proved barriers. Adjusting parameters, understanding thermal patterns, and making accurate diagnoses typically require training and experience. SuperSceneTM Mode eliminates these obstacles through its two-layer architecture. First, Expert Presets, See like an Expert, automatically optimize camera settings for common inspection scenes that include Water Leak, Insulation, Floor Heating, Electrical, Macro, Solar Panel, and more. This saves time and eliminates guesswork, so every inspection starts with the right settings. For professionals, advanced scenes like Insulation Pro and Condensation deliver enhanced visual alerts and environmental data integration for deeper diagnostic insights. Second, Smart SuperSceneTM, Think like an Expert, applies AI to analyze thermal images. In key scenes like Water leak, Insulation, and Floor Heating, the system detects and flags anomalies on screen, turning raw data into clear, actionable information. The result is an instant step change in ease of use. What once depended on specialist expertise can now be completed with greater speed, consistency, and confidence. HIKMICRO Smart SuperScene Positive Feedback Using the technology to see and think like an expert is already delivering gains in the real world. "The visual indicators, such as anomaly markers, are clear and highly effective," states Aleksandar Stojanović, a Level 2 certified thermographer. "They streamline the inspection process and make it much easier to communicate findings, as issues are immediately visible and easy to explain." Get an AI-Enabled Advantage Since its foundation in 2016, HIKMICRO has engaged closely with trade professionals that include electricians, plumbers, HVAC service personnel, and energy auditors to understand thermal imaging in practice. SuperSceneTM Mode reflects this collaboration. HIKMICRO AI learns from thousands of real-world examples, adapting to different environments without rigid rules. By combining thermal imaging with visible light, the camera understands what it sees: a wall, a floor, or a pipe. A leak is only flagged when both temperature and scene context make sense. The result? A reduction in false alarms from 90% to near zero, with detection accuracy up by 61%. Everything runs on-device. There is no cloud, no delay, and no privacy worries, providing real-time answers right in the hand of the user. Looking ahead, HIKMICRO will continue to extend its product AI capabilities, further reduce false positives, and expand into applications such as solar inspection and automotive diagnostics. Update to v5.5.112 and unlock SuperScene Mode. With this upgrade, HIKMICRO is setting a new industry benchmark by making smart thermal imaging accessible to all, a fitting way to celebrate a decade of industry-leading innovation. SuperScene Mode is available now on Eco Series , B Series , and Pocket Series (select models only - contact HIKMICRO for specific compatibility) thermal camera devices. For more information visit www.hikmicrotech.com or the official Amazon Store .
2026-04-20 08:00:00

Gatchalian pushes for suspension of excise tax on diesel
Senator Sherwin Gatchalian is pushing for suspension of excise tax on diesel, arguing that it is the "fuel for the masses." While President Marcos already suspended excise tax on liquefied petroleum gas (LPG) and kerosene, Gatchalian wanted to expand scope of such suspension on oil products to include diesel. "Ito ang ginagamit ng marami sa ating mga public utility drivers, public utility vehicles, pang-deliver ng gulay at prutas. Logistics, yan talaga ang pinakamalawak na fuel o malawak na ginagamit sa mga sasakyan at transportasyon (This is what many of our PUV drivers use, as well as those delivering vegetables and fruits. Logistics—that is the widely-used fuel for vehicles and transportation)," Gatchalian said in a radio interview over the weekend. "Kaya ako ang aking panawagan ay isuspend pa rin. Dahil kung titignan natin, nag-umpisa tayo sa P60 per liter. Ngayon, nasa P110, P115 pa rin tayo per liter. Halos doble pa rin (That’s why my call is still to suspend it. Because if we look at it, we started at P60 per liter. Now, we are still at P110, P115 per liter. It's still almost double,)," he added. Gatchalian also does not believe suspending excise tax on oil products that are being used by cars would only benefit the rich, as the Department of Finance (DOF) said, because most luxury cars still use gasoline. "Pero ang diesel, gamit yan ng mga jeep, gamit ng mga bus, gamit ng mga truck, gamit rin nga yan ng mga generator sa mga isla (Jeeps, buses, trucks, and even generators on the islands still use diesel)," he said. "Kaya mas malawak yung paggamit ng diesel. Kaya ako nakikita ko na meron pa rin, at this point, meron pa rin dahilan na pwedeng suspindihan ng excise tax sa diesel (The use of diesel is still widespread. That’s why I see that there is, at this point, a reason to be able to suspend the excise tax on diesel)," he added. Gatchalian also proposed a "targeted approach" if the government could not entirely suspend tax on diesel. "Ako pabor ako sa targeted approach dahil ang targeted, una-una, diretso yan sa mga nangangailangan talaga. At pangalawa, yung mga totoong nangangailangan na nabibigyan ng tulong (I am in favor of a targeted approach because, first of all, it goes directly to those who truly need it. And secondly, those who actually need it are the ones given help)," he said. However, Gatchalian noted that the problem with a targeted approach is it being implemented very "slowly," like what's being done with a targeted fuel subsidy. "Kung titignan yung pagbibigay ng fuel subsidy 45 percent pa lang ang nabibigyan. Eh, ano na, isang buwan at kalahati na ngayon. So, yun ang problema natin, ang bagal ng pagbibigay ng targeted subsidy (If you look at the distribution of the fuel subsidy, only 45 percent have been given their share. And yet, it’s already been a month and a half. So, that is our problem—the distribution of the targeted subsidy is too slow)," he said.
2026-04-20 07:59:00

Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation
A 2026 informational overview of Vigor Boost Gummies ingredient disclosures, proprietary blend structure, label-vs-marketing discrepancies, ForceVital male enhancement positioning, and what men should verify before purchasing Largo, FL, April 18, 2026 (GLOBE NEWSWIRE) -- This release provides an informational summary of Vigor Boost Gummies based on company product materials and brand-presented descriptions. The purpose of this report is to outline how the product is described, including its ingredient profile, formulation structure, and purchasing framework as currently presented. This content does not represent a third-party product review, independent clinical evaluation, or investigative assessment, but rather a structured informational overview intended for general consumer awareness. All product details referenced in this report reflect information presented within the brand's own materials at the time of writing. Readers are encouraged to verify current ingredient composition, pricing, and usage guidance directly through the official Vigor Boost website before making any purchasing decisions. Within the context of this report, the phrase "under investigation" refers to a structured review of publicly available product information for consumer understanding, rather than any regulatory, legal, or clinical investigation. This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. Supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any new supplement. If you've been looking into male vitality supplements and Vigor Boost Gummies has come up in your search, you're probably trying to figure out whether the product lines up with what you actually need. That's a fair question - and it's one worth spending a few minutes on before making a decision. The product is positioned as a gummy-format dietary supplement built around traditional botanicals associated with men's health. It's marketed toward men over 40 who are navigating age-related changes in energy, stamina, and overall wellness. The brand describes the formula as a combination of natural vitality-supporting ingredients designed for daily use. This overview walks through how the product is presented, what the ingredient label actually discloses, how the formulation structure compares to what published research has examined at the ingredient level, and what details you may want to confirm before ordering. Current product details, pricing, and terms can be confirmed by viewing the current Vigor Boost offer (official Vigor Boost page). Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen. Understanding How Vigor Boost Is Positioned Vigor Boost is presented as a dietary supplement sold in gummy form, described as a male vitality support formula. According to the company's website, the product is designed to support men's virility, energy, and vitality through a combination of botanical extracts and amino acids. The product is distributed by LOJA EXPERIENCE LTDA, with a listed business address at 11870 62nd St N, Largo, FL 33773. According to the label, the supplement is produced in a GMP facility. Each bottle contains 30 gummies, representing a 30-day supply at the suggested use of one gummy daily. The Supplement Facts panel lists a proprietary blend totaling 82 mg per serving, which the label states is equivalent to approximately 567 mg of dry powders. The formulation includes eight ingredients: Muira Puama Extract, Ashwagandha Maca Extract, Catuaba Extract, Green Tea Extract, Caffeine (10 mg), L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract. Each serving also provides 10 calories, 2 g of total carbohydrate, and 2 g of sugar (including 2 g added sugar). Other ingredients include Corn Syrup, Cane Sugar, Water, Apple Pectin, Sorbitol Powder, Natural Flavors, Citric Acid, and Sodium Citrate Dihydrate. Ingredient Presentation Across Product Materials: What Consumers Should Know Product materials reviewed for this report present differing ingredient descriptions across various sections of the Vigor Boost ecosystem. The sales page highlights five featured ingredients - Curcumin-7, L-Citrulline, Tongkat Ali Root, L-Theanine, and Saw Palmetto Extract - accompanied by specific descriptions of what each is intended to support. However, the actual Supplement Facts panel associated with the product lists a different set of ingredients: Muira Puama Extract, Ashwagandha Maca Extract, Catuaba Extract, Green Tea Extract, Caffeine, L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract. Certain ingredients highlighted in promotional content may not directly align with those listed in the Supplement Facts panel associated with the product. The Supplement Facts panel represents the standardized on-label ingredient disclosure typically used by consumers when comparing a supplement's listed contents with its promotional materials. Consumers seeking clarity on formulation details are encouraged to confirm the most current ingredient composition directly with the manufacturer prior to purchase. This overview proceeds based on the ingredients listed on the actual Supplement Facts label. Vigor Boost Formulation Profile: What the Label Discloses The Vigor Boost Gummies Supplement Facts panel lists the following per one-gummy serving: Proprietary Blend: 82 mg (equivalent to approximately 567 mg of dry powders), containing Muira Puama Extract, Ashwagandha Maca Extract, Catuaba Extract, Green Tea Extract, Caffeine (10 mg), L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract. Several of these ingredients have been individually discussed in published research for properties related to energy, libido, or general wellness. Here is what available research has examined for each one included on the label. Ashwagandha (Withania somnifera) is one of the more widely studied adaptogens in the supplement space. Published research in the Journal of the International Society of Sports Nutrition has examined ashwagandha root extract at dosages typically ranging from 300 to 600 mg daily for effects on stress response, testosterone levels, and physical performance. The Vigor Boost label lists "Ashwagandha Maca Extract" as a combined ingredient, and the individual amount is not disclosed. Tribulus Terrestris has a long history in traditional medicine systems for male vitality. Published research on tribulus and testosterone levels has produced mixed findings - some studies have noted modest effects on libido and sexual satisfaction, while systematic reviews have generally not found consistent evidence that tribulus significantly raises testosterone levels in healthy men. Dosages in published studies typically range from 250 to 750 mg daily. L-Arginine is an amino acid involved in the body's production of nitric oxide, which plays a role in vascular function and blood flow. Published research has examined L-Arginine supplementation at dosages typically between 1,500 and 5,000 mg daily for vascular health applications. The amount of L-Arginine within Vigor Boost's 82 mg total proprietary blend is not disclosed. Horny Goat Weed (Epimedium) contains icariin, a compound that has been discussed in preclinical research for potential effects on phosphodiesterase-5 (PDE5) activity. While traditional use is well-documented, human clinical evidence for standardized dosing and measurable outcomes remains limited compared to pharmaceutical alternatives studied for similar applications. Muira Puama and Catuaba are traditional South American botanicals historically used as tonics for male vitality. Published clinical evidence for these ingredients remains limited, with most available information consisting of traditional use documentation and preliminary studies rather than large-scale randomized controlled trials. Green Tea Extract and Caffeine (10 mg) provide mild stimulant and antioxidant properties. The caffeine content is relatively low - approximately one-tenth of a standard cup of coffee - which is worth noting if caffeine sensitivity is a factor for you. How the Proprietary Blend Structure Affects What You Can Compare This is where a practical consideration comes in - one that applies to Vigor Boost and to many supplements in this category. The total proprietary blend is listed at 82 mg across eight ingredients. Even accounting for the company's notation that 82 mg of extract is equivalent to approximately 567 mg of dry powders, the individual amounts per ingredient remain undisclosed. This matters because published research on these ingredients typically involves significantly higher individual dosages. For context, ashwagandha studies commonly use 300 to 600 mg daily of standardized root extract. L-Arginine research for vascular support typically uses 1,500 mg or more. Tribulus studies use 250 to 750 mg. Because the total blend is distributed across multiple ingredients, the individual amounts per ingredient are not disclosed. As a result, direct comparisons to dosages discussed in published research are not possible based on the label alone. This is a common structural limitation of multi-ingredient proprietary blend supplements - not unique to Vigor Boost, but relevant to how you interpret the product's positioning. A full-disclosure label listing each ingredient with its specific dosage per serving would allow you and your healthcare provider to compare dosages directly against amounts discussed in published studies. Without that transparency, there's no way to confirm or rule out research-level dosing from the label alone. General Considerations When Evaluating Vigor Boost Gummies Vigor Boost may align well with people who: Prefer a gummy-format supplement: Some men find gummies more convenient than capsules or tablets, particularly those who have difficulty swallowing pills or prefer a more approachable daily supplement format. Are exploring natural botanical options for general wellness: The formulation includes several traditionally used botanicals. Men interested in trying traditional herbal ingredients as part of a broader wellness approach may find the ingredient profile worth looking into further. Want a low-caffeine option: With only 10 mg of caffeine per serving, Vigor Boost is positioned as a relatively mild stimulant profile compared to many energy-oriented supplements on the market. Other options may be preferable for people who: Require transparent individual ingredient dosing: The proprietary blend structure limits the ability to compare ingredient amounts against published research. Men who want to verify research-level dosing for specific ingredients may prefer supplements with full-disclosure labeling. Are seeking clinically studied finished products: No published clinical study evaluating the finished Vigor Boost Gummies formulation was identified within the materials reviewed for this report. Men who prioritize product-level clinical evidence may want to explore alternatives with published study data. Need pharmaceutical-level interventions for specific health concerns: Dietary supplements are not intended to replace medical evaluation or prescription treatments. Men experiencing significant health concerns should consult a qualified healthcare provider for appropriate clinical guidance. Questions to Ask Yourself Before choosing any male vitality supplement, consider: Have you discussed your specific concerns with a healthcare provider? Do you understand the difference between ingredient-level research and product-level clinical evidence? Are you comfortable with a proprietary blend where individual dosages are not disclosed? Have you confirmed the product's ingredient list against its marketing materials? Your answers help determine which supplement characteristics matter most for your specific situation. Product Usage Expectations Based on Brand Materials The company's website describes Vigor Boost as a daily supplement taken as one gummy per day. Product materials indicate that the formula is designed for consistent daily use and note that users may notice changes over time, though no specific timeline is provided in the Supplement Facts documentation. Individual timelines depend on factors including age, baseline health, dietary habits, and physical activity level. As with all dietary supplements, this product is not a medication, and individual experiences vary. Consult a healthcare provider before starting any new supplement, particularly if you take prescription medications or manage existing health conditions. Key Product Considerations: Pricing and Purchase Structure The product is currently presented in multiple purchasing options, including single and multi-bottle packages. According to the company's website at the time of this report: A single bottle (30-day supply) is described at $89, plus shipping. A 3-bottle package (90-day supply) is described at $59 per bottle ($177 total) with free U.S. shipping. A 6-bottle package (180-day supply) is described at $49 per bottle ($294 total) with free U.S. shipping. Multi-bottle purchases are described as including two digital bonus guides. All purchases are presented as one-time payments. Pricing structures and promotional offers may vary over time, and readers are encouraged to confirm the latest availability and terms directly through the official Vigor Boost page by viewing the current Vigor Boost offer (official Vigor Boost page). Vigor Boost Refund Policy and 60-Day Guarantee According to the company's published terms, Vigor Boost orders are described as protected by a 60-day money-back guarantee from the date of purchase. The published policy indicates that consumers who have used the product for at least 30 days and are not satisfied can contact the support team at contact@customercs.com to initiate a refund. The company's return process is described as requiring all bottles to be sent back (whether empty or not) to the company's Largo, Florida address with a note including full name, email, and order ID. According to the published terms, the company does not cover return shipping costs. Refund processing is described as taking between 5 and 10 business days after the company receives the returned package. It's worth reviewing the complete refund policy on the official website and holding on to all purchase confirmation details before ordering. Verify current guarantee terms, timeframes, and conditions directly with the company, as these details are subject to change. Contact Information For questions before or during the ordering process, according to the company's website, Vigor Boost offers customer support through the following channels: Phone: +1 323-372-9581 Email: contact@customercs.com Address: 11870 62nd St N, Largo, FL 33773 View the current Vigor Boost offer (official Vigor Boost page) Consumer Verification: What to Confirm Before Ordering Confirm the ingredient list against marketing materials. Compare the Supplement Facts panel against any ingredient descriptions presented in the company's promotional content. If you notice differences, contacting the company directly for clarification before purchasing is a reasonable step. Understand proprietary blend structure. The blend format means individual ingredient amounts are not disclosed. If specific dosages matter to your evaluation, asking the manufacturer directly is the most reliable path to clarity. Separate ingredient-level research from product-level evidence. Individual ingredients may have published research behind them, but those studies examined specific compounds at specific dosages - not Vigor Boost's proprietary formula as a finished product. Confirm refund terms and process. Verify the 60-day guarantee window, the requirement to use the product for at least 30 days before requesting a refund, and the requirement to return all bottles at your own shipping expense. Consult your healthcare provider. This is especially important for men taking prescription medications, managing chronic conditions, or concerned about specific health issues. Professional medical guidance should come before any supplement purchase. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval. For those who have consulted their healthcare provider and completed their own due diligence, current product details are available by viewing the current Vigor Boost offer (official Vigor Boost page). Consumer Questions About Vigor Boost Gummies Is Vigor Boost FDA approved? Vigor Boost is presented as a dietary supplement. Under current federal regulations, dietary supplements do not require FDA approval before being sold. The FDA does not evaluate supplement efficacy claims. The product label states it is produced in a GMP facility, which relates to manufacturing standards rather than product approval. What ingredients are listed on the Vigor Boost label? According to the Supplement Facts panel, the proprietary blend includes Muira Puama Extract, Ashwagandha Maca Extract, Catuaba Extract, Green Tea Extract, Caffeine (10 mg), L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract within an 82 mg total blend. Consumers may wish to compare this against ingredient descriptions presented in the company's promotional materials. Does Vigor Boost contain stimulants? The formulation includes Green Tea Extract and 10 mg of Caffeine per serving. This is a relatively small amount of caffeine - approximately equivalent to one-tenth of a standard 8 oz cup of coffee. If you have caffeine sensitivity, this is worth factoring into your decision. What is the Vigor Boost refund process? According to the published terms, consumers have 60 days from purchase to request a refund after using the product for at least 30 days. All bottles must be sent back to the Largo, Florida address at the consumer's own shipping expense. Processing is described as taking 5 to 10 business days after the company receives the return. Where is Vigor Boost available? According to the company's website, the product is available through the official Vigor Boost website. Summary Vigor Boost Gummies is presented as a natural male vitality support formula in a gummy format. The formulation includes a proprietary blend of eight botanical extracts and amino acids at a total of 82 mg per serving. Several of these ingredients have been discussed in published research at the individual compound level, though published research on these ingredients often involves specific dosage ranges that are not directly disclosed within the proprietary blend structure. Product materials present differing ingredient descriptions across the sales page and the Supplement Facts panel. Consumers seeking clarity on formulation details are encouraged to confirm the most current ingredient composition directly with the manufacturer. The company describes a 60-day refund guarantee (with a 30-day minimum use requirement), one-time purchase pricing starting at $49 per bottle for the 6-bottle package, and states that the product is manufactured under GMP standards. This article is for informational purposes and does not constitute medical advice. Vigor Boost is presented as a dietary supplement, not a medication. If you are currently taking medications, have existing health conditions, or are considering any major changes to your health regimen, consult your physician before starting Vigor Boost or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval. Complete product details, current pricing, and published terms are available by viewing the current Vigor Boost offer (official Vigor Boost page). Disclaimers FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing. Professional Medical Disclaimer: This article is for informational purposes and does not constitute medical advice. Vigor Boost is presented as a dietary supplement, not a medication. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting Vigor Boost or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval. Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. Results are not guaranteed. FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from the company's official website and general research context. Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were accurate at the time of publication (April 2026) but are subject to change without notice. Always verify current pricing and terms on the official Vigor Boost website before making your purchase. Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. Responsibility is not accepted for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with Vigor Boost and their healthcare provider before making decisions. Product Claims Disclaimer: All product features, specifications, ingredient descriptions, and formulation details referenced in this report are sourced from the company's publicly available product materials and have not been independently verified by the publisher. CONTACT: Phone: +1 323-372-9581 Email: contact@customercs.com
2026-04-18 21:49:46

Tencent Music Entertainment Group Filed 2025 Annual Report on Form 20-F
SHENZHEN, China , April 17, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it has filed its annual report on Form 20-F that includes its audited financial statements for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission (the "SEC") on April 17, 2026, U. S. Eastern Time. The annual report can be accessed on TME's investor relations website at ir.tencentmusic.com and on the SEC's website at www.sec.gov . The Company will also provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and American Depositary Share holders upon request. About Tencent Music Entertainment Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com. Investor Relations Contact Tencent Music Entertainment Group ir@tencentmusic.com +86 (755) 8601-3388 ext. 885034
2026-04-17 11:30:00

ZTO Files Annual Report on Form 20-F for Fiscal Year 2025
SHANGHAI , April 17, 2026 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and HKEX: 2057), a leading and fast-growing express delivery company in China ("ZTO" or the "Company"), today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on April 17, 2026. The annual report on Form 20-F can be accessed on the Company's investor relations website at http://zto.investorroom.com as well as the SEC's website at http://www.sec.gov . The Company will provide a hard copy of its annual report on Form 20-F containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company's IR Department at ir@zto.com . The Company has also today published its annual report for the fiscal year ended December 31, 2025 pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("HKEX"), which can be accessed on the Company's investor relations website at http://zto.investorroom.com as well as the HKEX's website at http://www.hkexnews.hk . About ZTO Express (Cayman) Inc. ZTO is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China. ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain. For more information, please visit http://zto.investorroom.com . For investor and media inquiries, please contact: ZTO Express (Cayman) Inc. Investor Relations E-mail: ir@zto.com Phone: +86 21 5980 4508
2026-04-17 11:28:00

Startek® 與 CCI Global 完成合併,成為人類增強人工智能領域的環球領導企業
合併後的機構擁有遍及全球 55 個交付中心的 50,000 多名員工,為世界頂尖企業大規模提供以人工智能為主導、以人為本的客戶體驗方案。 丹佛 2026年4月17日 /美通社/ -- 全球數碼主導的客戶體驗 (CX) 解決方案供應商 Startek ® 今日宣佈,與 CCI Global 的合併已圓滿完成。 是次合併締造出新行業領導先鋒,當中建基於明確願景:大規模提供以人為本、以人工智能 (AI) 為主導的客戶體驗。 合併後的機構匯聚 50,000 多名員工,服務對象包括銀行及金融服務、保險、零售、醫療護理、電子商務和電訊等行業的環球頂尖企業。 憑藉遍及 22 個國家的 55 個交付中心,集團版圖得以擴展,從而在橫跨美洲、亞太、歐洲及非洲的多元網絡中,提供無縫且優質的客戶體驗。 Startek 的數碼傳承與 CCI Global 的營運架構融為一體,為人類增強人工智能築起強大根基。 透過融合代理型人工智能能力與高情商 (EQ) 的全球員工隊伍,合併後的機構提供精密的自動化技術,旨在深化人際連繫,而非取而代之。 此方針透過更智能且更具成本效益的解決方案滿足客戶的複雜需求,在推動業務增長的同時,亦能兼顧人情味。 Startek 環球行政總裁 Bharat Rao 表示:「透過融合 Startek 的數碼傳承與 CCI 的營運優勢,我們所做的遠不止於規模擴張, 我們正在重新定義客戶體驗這個領域。 我們正跨越傳統的業務流程外判 (BPO) 模式,開創人類增強人工智能的新紀元。科技讓員工得以專注於情商,而情商正能吸引客戶真正忠實支持。」 新機構正著手融合 Startek 的專有數據分析平台與 CCI 首屈一指的營運框架。 此整合發展藍圖確保客戶能即時改善預測分析、減少數碼流程阻礙,並透過實時人工智能指導,實質明確地提升代理的生產力。 CCI Global 行政總裁 Martin Roe 表示:「我們的成功向來源於公司員工。 透過與 Startek 合作,我們為 50,000 名員工提供行內先進無比的人工智能工具,確保不論是在非洲、歐洲、亞洲還是美洲,每次客戶互動都同時體現出精準技術和人類智慧。」 關於 Startek Startek ® 是客戶體驗管理方面的環球先驅,為企業提供全面的數碼轉型及客戶體驗方案。 憑著超過 35 年的專業經驗,Startek 協助各行各業的企業創造令人難忘的個人專屬客戶互動。 Startek 在全球 14 個國家設有據點,團隊人數逾 38,000 名,矢志以創新、關懷及卓越營運,為品牌與客戶建立緊密聯繫。 如欲了解更多資訊,請瀏覽 www.startek.com ,並於 LinkedIn @Startek 關注我們。 關於 CCI Global CCI 是非洲最大的業務流程外判公司,也是業界先驅,為全球頂尖品牌提供由數碼技術驅動的創新客戶體驗解決方案。 憑藉 20 年的行業經驗以及超過 17,000 名員工的團隊,CCI 支援英國、美國、澳洲、加拿大、紐西蘭及其他地區的客戶。 CCI 透過創造就業,已為超過 350,000 人的生活帶來正面影響,並持續在卓越營運、具影響力的增長及世界級客戶體驗方面樹立典範。 如欲了解更多資訊,請瀏覽 www.cciglobal.com 。
2026-04-17 11:28:00

LG ELECTRONICS TO SHOWCASE NEW DISHWASHER LINEUP AT EUROCUCINA 2026
Company's New Line of Energy Efficient Dishwashers Delivers Improved Speed, Convenience and Modern European Style News Summary LG Electronics will unveil its new dishwasher lineup at EuroCucina 2026, introducing a one-hour wash and dry cycle designed to maximize daily kitchen efficiency without compromising performance.LG's core technologies, including QuadWash Pro, Dynamic Heat Dry+ and TrueSteam, work together to improve cleaning and drying performance.The new dishwasher features the AI SenseClean, which detects soiling levels and adjusts wash conditions for more tailored operation and efficient performance.Designed for the European market, the lineup provides A-grade energy efficiency across key models spanning both premium and volume segments.SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- LG Electronics (LG) will showcase its new dishwasher lineup at EuroCucina - the international kitchen exhibition held as part of Milan Design Week - taking place at Fiera Milano in Milan, Italy, from April 21-26. The lineup represents the first full platform redesign of LG's built-in dishwashers in nine years. New models have been engineered specifically for the European market, delivering the speed, performance and energy efficiency that local consumers demand. LG Electronics will showcase its new 'LG Built-in' Dishwasher lineup designed specifically for the European market to deliver speed, performance and energy efficiency at EuroCucina 2026. Faster, More Effective Cleaning and Drying The new LG Dishwasher completes a full wash and dry cycle in just one hour, applying LG's latest dishwashing technologies to improve overall performance. QuadWashTM Pro generates micro-bubbles that allow detergent to penetrate food residue more effectively, improving cleaning across a wider range of dishware and soiling levels while reducing the need for pre-rinsing. Dynamic Heat Dry+ uses a material that generates heat as it absorbs humidity inside the dishwasher. This improves air circulation, shortens drying time and lowers energy consumption. These functions are complemented by TrueSteam, which minimizes water marks for a spotless finish.* Intelligent Operation With Advanced AI With the AI SenseCleanTM cycle, the new dishwasher uses a digital turbidity sensor to detect soiling levels during the pre-wash, main wash and rinse stages. Based on this data, the system automatically adjusts water temperature, rinse count and detergent amount, with up to 32 possible combinations, to tailor cleaning performance and enhance user convenience. Machine learning further enhances operation by enabling faster and more energy-efficient cleaning for lighter loads while facilitating a thorough and effective wash for heavily soiled items. Designed for the Modern European Household The new model integrates seamlessly with built-in cabinetry commonly found in modern European kitchens. Its flat design aligns with surrounding cupboards and drawers for a clean and consistent aesthetic. Inside, the adjustable EasyRackTM Plus system elevates usability and convenience, providing the flexibility to accommodate a variety of different dishware. The Bottle Wash function delivers precise, targeted cleaning for bottles and deep cups using dedicated upper nozzles, while a hidden LED display shows remaining cycle time and an interior light improves visibility when loading and unloading. The lineup also caters to two priorities often associated with the European market: low noise and energy efficiency. A select model operates at noise levels as low as 37dB, helping maintain a pleasantly quiet home environment, while A-grade energy efficiency is available across key models in both premium and volume segments. "The new dishwasher lineup reflects our focus on improving core washing and drying performance, and on delivering features and design tailored to the preferences and lifestyles of European customers," said Baek Seung-tae, president of the LG Home Appliance Solution Company. LG welcomes EuroCucina 2026 attendees to experience its innovative home solutions firsthand at Milan Design Week (Stand C24 and C31, Hall 4, EuroCucina/FTK: Fiera Milano, Milan, Italy). * TrueSteam is an optional wash-cycle feature that must be selected by the user.About LG Electronics Home Appliance Solution Company The LG Home Appliance Solution Company (HS) is a global leader in home appliances and AI home solutions. By leveraging industry-leading core technologies, the HS Company is committed to enhancing consumers' quality of life and promoting sustainability. The company develops thoughtfully designed kitchen and living appliance solutions and has recently integrated LG's Robot Business Division to incorporate advanced robot technologies into its home solutions. Together, these products offer enhanced convenience, exceptional performance, efficient operation and sustainable lifestyle solutions. For more news on LG, visit www.LG.com/global/newsroom/. LG Built-in Dishwasher is designed to integrate seamlessly with built-in cabinetry commonly found in European kitchens, featuring a flat design that creates a clean and consistent aesthetic. LG Built-in Dishwasher features QuadWashTM Pro with micro bubbles and powerful water spray, delivering fast and consistent cleaning performance. LG Built-in Dishwasher features an adjustable EasyRackTM Plus system, allowing flexible loading to accommodate a wide range of dishware. LG Built-in Dishwasher features the AI SenseCleanTM, delivering more tailored operation and efficient performance, while a hidden LED display and interior light enhance usability.
2026-04-16 01:28:04

资源聚合,精准对接----易享平台重塑生物医药采购新体验
上海 2026年4月15日 /美通社/ -- 在生物医药行业,采购决策往往关乎企业的生产进度与产品质量。面对日益复杂的供应链环境,如何在确保质量的同时提升采购效率,成为众多药企与生物公司关注的焦点。易享平台( https://mall.morebio.cn/ )依托 周均50条以上生物药企采购需求 的丰富资源,通过主动服务模式为采购方争取权益,以"资源+服务"双轮驱动,构建起从需求对接、试用验证到下单合作的闭环生态,助力行业采购效率与质量双提升。 资源聚合+主动服务,打造采购"强磁场" 易享平台深耕生物医药领域,已汇聚超15万行业用户及数千家优质供应商资源,形成强大的供需网络。易享平台会关注外部环境和行业采购趋势,向采购出具专业性的资讯文章,提醒他们要提高对某类产品的关注 度。 面对海量需求,易享团队并非被动等待匹配,而是主动介入,深度解析客户需求,精准定位潜在合 作方。 四大核心价值,赋能采购全链路 易享平台目前已累积多宗成功案例 ,它们折射出易享平台在生物医药采购领域的独特价值。作为易贸医疗旗下的生物产业线上平台,易享致力于打通上游供应商与下游采购方的信息壁垒: 信息先导,抢占先机: 依托行业资讯与价格预警,帮助采购方提前洞察市场波动,掌握决策主动权。 精准覆盖,高效触达: 平台服务覆盖15万+生物医药行业人员,直接触达药企采购与研发技术人员,实现精准营销与高效传播。 高效沟通,缩短链路: 内嵌一键联系功能,采购方可直接对接厂家,大幅降低沟通成本。 主动服务,全程赋能: 从需求解析、资源协调到试用申请、商务谈判,平台团队全程跟进,为采购方争取最优条件(如试用权益、价格优惠),降低决策成本。
2026-04-16 01:28:00

Premiere at Food & Hospitality Asia 2026: Convotherm expands its range for professional kitchens, The Convotherm flexx pro - the premium class multifunction cooking system at Food & Hospitality Asia 2026
SINGAPORE, April 16, 2026 /PRNewswire/ -- Convotherm flexx pro, a brand of Welbilt Asia Private Limited, makes its debut at Food & Hospitality Asia 2026 from 21-24 April 2026 at Welbilt's innovative showcase in Singapore, located at Hall 1, booth 1K3-01. Professional kitchens are looking for products that provide a boost and help to meet the various challenges the industry faces. Therefore, intelligent kitchen appliances that are easy to use, multifunctional, and also help save resources are in high demand. Convotherm introduces the new flexx pro, a multifunction cooking system that sets new standards in efficiency, space and energy savings, versatility, and user-friendliness. "We are pleased to expand our product portfolio once again in the field of professional cooking technology with the new flexx pro. With the multifunction cooking system, workflows in every professional kitchen are optimised and can lead to increased efficiency and energy savings," explains Claus Pedersen, Managing Director at Convotherm. "It offers savings, versatility, flexibility, and user-friendliness all-in-one and can thus meet all the requirements of modern gastronomy businesses when combined with our mini, maxx, and maxx pro combi ovens." Smart multifunctional solution for the challenges of the gastronomy industry The flexx pro is not just a cooking appliance but an indispensable partner in the kitchen that counteracts both rising energy costs and staff shortages in the gastronomy industry. It is easy to use, as it offers a control and user interface that is common to those of Convotherm combi ovens. It is available in various languages. This puts in perfect harmony with Convotherm's combi ovens. Thanks to its wide variety of cooking methods and model ranges, as well as its ability to create and edit custom recipes, the flexx pro offers chefs the maximum amount of flexibility. This allows multiple dishes to be prepared simultaneously, optimising the deployment of staff and saving valuable time. With the Press&Go function, the right cooking programs are always activated, ensuring standardized cooking results with consistently high quality. Overall, the multifunction cooking system enables even faster mise en place preparations. Innovative features for increased efficiency and safety The outstanding features of the flexx pro include an intuitive 12" color touchscreen control panel with quick response and an operating concept that is common to that of Convotherm combi ovens, as well as the display of cooking processes and error messages. Consumption data is also displayed on the screen. The proven design ensures easy maintenance and operation with central connections for water, drainage, and power as well as integrated steam extraction. The accident-proof lid operation of the flexx pro with safety control also provides added value around work safety. Unrivalled performance and versatility Clever features make the flexx pro the ideal multifunction appliance for kitchens that want to cook, fry, and grill simultaneously: Operating concept that is common to that of Convotherm combi ovensAutomatic lifting of the baskets with separate motors, which also function with the lid closedThe insulated pan ensures minimal power consumptionTwo-stage electromechanical tilting of the panAutomatic system for water fillingUnique pressure release system without direct water consumptionJPX 17 - Surface heating with thick-film radiators that ensure even temperature distribution over the entire surface.The scratch-resistant stainless steel pan bottom guarantees cooking, without burning or boiling over and easy cleaning as well as precise temperature controlPreheating to 180 degrees in three minutesAccessories for optimal efficiency The flexx pro comes with a variety of useful accessories, including electric battery lifting trolleys, oil frying trolleys, and transport rack trolleys for baskets, to further facilitate everyday work. For more information about Convotherm: https://www.convotherm.com/ More about Convotherm flexx pro: https://www.welbiltde.com/Products/multifunction-cooking-system/flexx-pro-series
2026-04-16 01:27:50

Efficiently Managing Hundreds of Billions of Quality Inspection Dataram IDM Empowers PCB Enterprises to Build World-Class Quality Systems
TAIPEI, April 16, 2026 /PRNewswire/ -- As Smart Manufacturing becomes the core driver of industrial transformation, the electronic assembly industry—led by PCB (Printed Circuit Boards)—is undergoing a profound digital revolution. In high-precision production environments, the widespread adoption of machine vision equipment such as AOI (Automated Optical Inspection), X-ray, SPI (Solder Paste Inspection), and CCD cameras has significantly improved yields. However, it has also generated massive volumes of inspection images, system logs, and process parameters. Industry Background & Core Challenges Taking world-leading PCB manufacturers as an example, large-scale AI vision inspection systems are deployed across the entire FPC (Flexible Printed Circuit) manufacturing process—from Incoming Quality Control (IQC) and SMT mounting to electrical testing (ICT/FCT) and reliability lab experiments. These devices identify defects in real-time with 0.01mm precision, generating data assets totaling hundreds of billions of records and dozens of PBs (Petabytes) in volume. To meet the quality compliance requirements of Tier-1 global clients such as Apple and Tesla, relevant data must be retained for periods ranging from 6 months to 15 years to ensure end-to-end Traceability. However, enterprises face severe challenges in managing these "data behemoths": Data Silos: Inspection data is scattered across different factories and machines. The lack of a unified aggregation platform forces manual, cross-departmental searches during quality audits.Uncontrolled Storage Costs: Massive high-resolution image files drive hardware costs to unsustainable levels. Traditional storage architectures fail to balance performance with cost-efficiency.Compliance Risks: High-end sectors like automotive electronics (e.g., IATF 16949) require long-term, immutable data preservation. Manual management struggles to meet these stringent regulatory standards. Dataram IDM: A Unified Inspection Data Management Platform for the PCB Industry To address these pain points, Dataram IDM (Inspection Data Management) reconstructs the entire data lifecycle—from collection and storage to management and application—providing a one-stop quality data ecosystem: Centralized Governance & Eliminating Silos IDM aggregates scattered inspection data from various production lines and equipment brands into a unified platform. This enables group-level data asset management and eliminates information asymmetry at its source. Second-Level Precision Search Engine Built on a high-performance distributed architecture, IDM supports multi-dimensional queries via custom tags such as date, machine ID, and Serial Number (SN). Quality tracing processes that once took days can now be completed in seconds. High-Efficiency Lossless Image Compression Utilizing proprietary AI Intelligent Compression Algorithms specifically developed for industrial inspection, IDM optimizes AOI and X-ray images through intelligent block-segmentation. It achieves compression ratios of up to 90% while ensuring 100% detail retention, significantly reducing storage pressure. Automated Hot/Cold Data Tiering Based on Access Frequency, IDM automatically migrates data between "Hot," "Warm," and "Cold" storage tiers. By integrating Tape Library archiving technology for lifecycle management, the total cost of ownership (TCO) can be reduced by over 65%. High-Standard Compliance & Information Security A robust backup and Disaster Recovery (DR) framework ensures secure data preservation for over 15 years, fully satisfying IATF 16949 and the most rigorous client-side audit standards. Conclusion: From Data Management to Quality Prediction Dataram IDM does more than solve the problem of "storing and finding" data; it builds the foundation for Big Data Analytics. By leveraging unified data, enterprises can drive process improvements and Predictive Maintenance. This transforms the operation from passive "issue tracing" to proactive "quality forecasting," ensuring a dominant position in the global supply chain competition. About Dataram.ai Dataram is a trusted global leader in enterprise-grade memory, storage, and networking hardware. For half a century, Dataram has driven global computing with high-performance storage. Today, with the launch of Dataram.ai, we are officially expanding from hardware to intelligent storage and the cloud, building a global platform, serving AI, cloud computing, and next-generation data infrastructure. Dataram.ai accelerates the transformation of factory floor data into actionable business intelligence. We provide the unified software layer necessary to tackle the complexity of massive detection data in intelligent manufacturing. This platform ensures the seamless, high-speed data ingestion and classification essential for operational efficiency. With built-in analytical capabilities and visual business dashboards, Dataram.ai converts complex data into simple, traceable insights, providing the hierarchical control needed to optimize equipment management and secure quality assurance.
2026-04-16 01:27:49

Southeast Asia Blockchain Week Returns to Bangkok for Its Third Edition
SEABW 2026 convenes May 20-21 at True ICON Hall, ICON SIAM, as Southeast Asia enters a defining phase in digital asset development. BANGKOK, April 16, 2026 /PRNewswire/ -- Southeast Asia Blockchain Week (SEABW) officially returns to Bangkok from May 18 to 24, 2026. Organized by global Web3 venture capital Hashed and its innovation lab ShardLab-operating under a strategic partnership with SCBX, Thailand's leading financial technology group-SEABW is the premier blockchain conference in the region. The third edition gathers global Web3 leaders, institutional investors, and policymakers to shift the industry narrative from speculation to real-world integration. Southeast Asia Blockchain Week (SEABW) 2026 convenes May 20-21 at True ICON Hall, ICON SIAM, as Southeast Asia enters a defining phase in digital asset development. SEABW 2026 will center around five core themes: The Regulatory Frontier, Institutional Verticalization, RWA 2.0, The Agentic Economy, and The Base Layer Imperative. Hojin Kim, CEO of ShardLab, emphasized the strategic importance of this year's agenda: "By 2026, Southeast Asia has evolved into a global 'Powerhouse of Value,' where the boundaries between institutional finance and everyday consumer applications are disappearing. At ShardLab, we see the region leading a massive shift where Agentic AI and on-chain infrastructure are no longer invisible technologies, but the very tools empowering millions of users in their daily lives. SEABW 2026 is designed to be the ultimate meeting ground for the visionaries bringing Web3 to the masses, bridging cutting-edge protocols with the real-world experiences of the world's most vibrant digital population." Why Bangkok? Why Now? Southeast Asia has transitioned from a retail interest hub to a global leader in institutional infrastructure. Thailand is currently setting the regional standard; the Thai SEC's approval of crypto ETFs, regulated futures trading on TFEX, and capital gains tax exemptions signal a market in active integration. With the Bank of Thailand's programmable payment sandbox and formal approval of major stablecoins, the market is anchored by leading institutions like SCBX. Highlighting this milestone, SCBX has joined SEABW 2026 as the Main Sponsor. This partnership underscores the deep integration of digital assets into Thailand's financial core and reinforces SCBX's commitment to leading the convergence of traditional finance and the on-chain economy. What's New at SEABW 2026? The 2026 program focuses on high-quality engagement. While the Main Stage addresses industry-defining questions, the Exhibition and Spotlight Stage gives builders direct access to an institutional audience. The "Play to Build" hackathon will take developers from concept to product, culminating in a Demo Day for investors. A defining feature is the Exclusive Institutional Roundtables, connecting funds, infrastructure players, and regulators in closed-door sessions to build cross-border partnerships. Furthermore, to broaden ecosystem access, General Admission is free for the 2026 edition, while curated private programs remain reserved for senior participants and partners. SEABW 2026 returns at a moment when Southeast Asia's role in global digital finance is more central than ever. Join us this May in Bangkok to define the future of value. Mark Your Calendars: Dates: May 20-21, 2026Location: TRUE ICON HALL, Bangkok, ThailandVisit www.seablockchainweek.org to secure your tickets today. For press inquiries: media@seablockchainweek.org
2026-04-16 01:27:44

imin Surpasses $2 Billion in Cumulative Transaction Volume, Accelerating Expansion as a Lifestyle Social Platform
Rebranding drives broader user adoption as personalized fund management structure pushes cumulative transaction volume beyond KRW 3 trillion (USD 2.03 billion) SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- Twave, the company behind the social platform imin, announced today that imin has surpassed KRW 3 trillion (approximately USD 2.03 billion) in cumulative transaction volume. The company said the milestone reflects the combined impact of a growing user base and continued service advancement. imin Surpasses $2 Billion in Cumulative Transaction Volume, Accelerating Expansion as a Lifestyle Social Platform Following its recent rebranding, Twave has strengthened imin's brand identity while expanding its user base on the foundation of stable service operations. Building on this momentum, the company aims to further evolve imin into a social platform that extends across a broader range of lifestyle needs. At the core of imin is its "Stage" model - a group-based structure in which users can participate in collective funding arrangements designed around shared financial goals. Through this system, users can choose how to manage and deploy funds based on their individual objectives and circumstances, whether for targeted savings, planned spending, or yield-oriented participation. According to the company, this flexible structure addresses a broad spectrum of user needs, serving both those seeking timely access to funds and those focused on disciplined and stable financial management. Twave said this user-centric experience has been a key driver behind imin's transaction growth. Leveraging the purpose-driven funds and user behavior data generated on the platform, Twave is also expanding B2B partnerships across a range of sectors, including finance, travel, and commerce. The company added that conversion rates into partner services have reached as high as 96%. Service reliability remains another core strength. Twave said it has maintained a low delinquency rate of 0.22% through its advanced alternative credit assessment system and user protection mechanisms, which have helped build long-term user trust. "Surpassing KRW 3 trillion in cumulative transaction volume is the result of the trust our users have placed in us," said Jaejun Seo, CEO of Twave. "We will continue to expand B2B partnerships across industries such as travel and commerce, and grow imin into a platform that delivers meaningful value to both users and partners." About Twave(https://www.twave.co.kr/) Twave is the operator of imin, a social platform built around user-driven financial participation and lifestyle-linked services. Through its flexible Stage-based structure, imin enables users to engage in funding experiences tailored to their goals while creating new opportunities for partnership across multiple industries.
2026-04-16 01:27:38

Aarush Garg Announces Aarion Capital LP as a Next-Generation Investment Platform Built for Volatility, Market Complexity, and Institutional Growth
The multi-strategy hedge fund highlights its focus on volatility-driven opportunity capture, AI-assisted risk intelligence, and disciplined capital deployment across global markets NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Aarush Garg, Founder and Chief Investment Officer of Aarion Capital LP, today announced the continued development and positioning of the firm as a multi-strategy investment platform designed to operate across volatile, stagnant, and rapidly changing global market environments. Officially launched in January 2026, Aarion Capital LP trades across equities, cryptocurrency, macroeconomic markets, options, bonds, and fixed income instruments. The firm states that its operating framework is built around selective capital deployment, disciplined exposure during high-conviction market environments, and active strategy development informed by volatility, liquidity conditions, and macroeconomic catalysts. The announcement comes as investors and institutions continue to adapt to a financial environment increasingly shaped by geopolitical instability, abrupt policy changes, liquidity fragmentation, and cross-asset volatility. In that setting, Aarion Capital says its objective is not simply to maintain broad market exposure, but to identify dislocation-driven opportunities while preserving strategic flexibility across asset classes. Rather than positioning itself around generic diversification alone, the firm says it is focused on volatility-driven opportunity capture supported by active management, disciplined risk controls, and a research framework built for modern market complexity. A Platform Built Around Selective Capital Deployment According to the firm, Aarion Capital’s investment philosophy is centered on the idea that increasingly unstable markets require more than static portfolio construction. The firm says it has developed its strategy around identifying periods of asymmetric opportunity, deploying capital selectively, and maintaining disciplined exposure when conviction, liquidity, and market structure align. This approach is intended to allow the firm to operate across a range of environments, including elevated volatility, prolonged sideways markets, sudden liquidity contractions, and macro-driven dislocations that can materially reshape cross-asset pricing. Aarion Capital states that this framework is designed for sophisticated investors seeking actively managed strategies that are responsive to changing financial conditions rather than dependent on a single market regime. VAL Positioned as a Proprietary Risk and Volatility Intelligence System Supporting that framework is VAL, Aarion Capital’s proprietary AI-assisted market intelligence system. According to the firm, VAL was developed to analyze real trading data and historical market scenarios in order to support strategy development, market analysis, and risk management. The system is described by the company as a proprietary risk and volatility intelligence layer built to help interpret financial conditions across multiple environments. Aarion Capital says VAL has been trained on extensive market data and subjected to hundreds of stress tests simulating volatility spikes, liquidity contractions, and prolonged sideways trading environments. Those simulations were designed to help the firm evaluate how different strategies may behave under pressure and to support ongoing refinements in risk management, capital allocation, and portfolio construction. Rather than being presented as a standalone automated trading claim, VAL is positioned by the firm as a support system intended to assist research, volatility assessment, market interpretation, and decision support across a complex global investment landscape. Founder Background Shaped by Derivatives, Market Structure, and Macro Catalysts Aarion Capital also points to the background of founder Aarush Garg as a defining part of the firm’s development. According to company materials, Garg developed the core trading models behind the fund through years of studying market cycles, derivatives strategies, market microstructure, and macroeconomic catalysts. The firm says this background contributed to its emphasis on volatility-resilient strategy design, selective capital deployment, and identifying non-correlated opportunities across global markets. Company materials further state that Garg has received recognition connected to entrepreneurship and finance, including being recognized as Entrepreneur of the Year in Times Square by New York City Mayor Eric Adams. The company also describes him as having been identified among Long Island’s notable young entrepreneurs and as having experience managing and scaling high-liquidity portfolios exceeding $70 million. Differentiation Through Active Risk Management and Opportunity Capture A central theme in Aarion Capital’s positioning is differentiation through active risk management rather than passive market participation. The firm says it aims to distinguish itself by focusing on volatility-driven opportunity capture instead of relying on broad diversification as its primary value proposition. In company materials, this includes an emphasis on disciplined exposure in high-conviction environments, ongoing market analysis, and a willingness to stay selective when conditions do not support efficient capital deployment. Aarion Capital states that its internal development has therefore focused not only on where to deploy capital, but also on when not to deploy it, how to size exposure under changing volatility conditions, and how to maintain adaptability across multiple market structures. Positioning for Sophisticated Investors and Institutional Expansion Looking ahead, Aarion Capital says it intends to scale its platform globally while expanding institutional relationships and continuing to develop its proprietary technology infrastructure. The firm’s longer-term strategy includes deepening research capabilities, strengthening market intelligence systems, and operating as a next-generation investment platform built for the demands of modern financial markets. According to the firm, that includes continued investment in infrastructure supporting strategy development, decision support, and institutional-grade oversight. Aarion Capital says its objective is to serve sophisticated investors seeking actively managed exposure, non-correlated strategy development, and an investment platform designed with institutional ambition. About Aarion Capital LP Aarion Capital LP is a multi-strategy hedge fund officially launched in January 2026 and focused on navigating volatile and stagnant market environments through active exposure across equities, cryptocurrency, macroeconomic markets, options, bonds, and fixed income. The firm combines disciplined risk management with AI-assisted market analysis through its proprietary VAL system to support strategy development, market intelligence, and portfolio decision support. Media Contact Contact Person - Aarush Garg Company - Aarion Capital LO Email - Aarushgarg.ceo@gmail.com Website - https://aarioncapital.com/ Country - United States Disclaimer: This content is provided by Aarion Capital LO. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3344b275-4c4b-41b0-ab1a-df8709e5db0f https://www.globenewswire.com/NewsRoom/AttachmentNg/5b15cc10-c071-44fc-bcbc-b0694aee1bd6
2026-04-14 15:30:00

Fresh Start, Fresh Planet: 5 Steps to Reduce Waste During Spring Cleaning
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- (Feature Impact) As the days get longer and the weather improves, many people often find the motivation to refresh their homes - and their habits. A Media Snippet accompanying this announcement is available by clicking on this link. Spring cleaning is a perfect opportunity to reset, reorganize and make small changes that can help the planet. What’s more, these changes are simple to implement and can even earn you some extra cash. Consider these five easy waste-reduction tips from the experts at CalRecycle to help you jump into the season feeling organized and eco-friendly. 1. Recycle Kitchen Waste As you clear out expired or forgotten food, sort items for maximum impact: Remove plastic and non-compostable packaging and put spoiled or freezer-burned food into your green bin. These scraps can be turned into compost and clean energy, helping cut methane emissions from landfills.Toss empty, dry recyclables, including condiment bottles, glass jars, metal cans and plastic food containers, into your blue bin.2. Cash in Empty Beverage ContainersCleaning out your home may uncover some empty or forgotten beverage containers. Empty out leftover liquids and take eligible beverage containers for soda, water, juice, wine and distilled spirits to your nearest recycling site for cash back. Every California Redemption Value (CRV) beverage container you recycle saves resources and puts money back in your pocket.If you’re short on time, donate your empty CRV beverage containers to your favorite nonprofit organization. Set up a separate bin just for eligible beverage containers and drop them off for donation when it’s full.3. Give Clothes and Household Items a Second LifeDig into your closets and shelves to see what you can repair, repurpose or donate. Fix a missing button, turn old fabric into cleaning rags or give gently used items to a local free-exchange group or thrift store to reduce textile waste. Simple steps like these can keep usable items out of the landfill and help someone else put them to good use.4. Declutter Paper and ElectronicsRecycle junk mail, magazines and newspapers in your blue bin. Remove any plastic windows, wrap or stickers first. If you shred documents, place the shredded paper inside a paper bag before recycling. Bonus tip: Switching to digital statements and bills can help prevent paper clutter in the first place.Old electronics and used batteries don’t belong in the trash. Gather them from drawers and cabinets then take them to an e-waste drop-off site or local household hazardous waste collection center for safe handling.5. Refresh the BathroomWhen restocking soaps or cleaners, look for products that offer refillable containers (especially reusable glass and aluminum ones). It’s a simple way to cut down on plastic waste.When you finish bottles of shampoo, conditioner, soap or cleaning sprays, make sure they land in your recycling bin after you empty them out.Swap out single-use paper towels for washable cloths or rags. They’re reusable, durable and kinder to the environment. For more details, CRV redemption locations and food scrap recycling tips, visit RecyclingReimaginedCA.com. Photos courtesy of Shutterstock Michael French michael.french@featureimpact.com https://editors.featureimpact.com/ About Feature Impact Feature Impact is 4media group’s earned-first content solution for audience-ready storytelling at scale. Formerly Family Features, the editorial service delivers measurable earned media results and authentic consumer engagement through high-quality, topical and seasonally relevant multimedia content. Publicly-facing content is available at culinary.net and eLivingToday.com, with additional ready-to-publish resources for editors and journalists at editors.featureimpact.com. Learn more at featureimpact.com.
2026-04-14 15:29:51

Qosina to Showcase New Booth Experience and Interactive Sampling at INTERPHEX 2026
Ronkonkoma, April 14, 2026 (GLOBE NEWSWIRE) -- Qosina, a global leader in single-use components for the medical and pharmaceutical industries, will exhibit at INTERPHEX, April 21-23, at the Jacob Javits Center in New York City. At this year’s event, Qosina will debut an all-new booth design featuring a fresh, modern look and an open layout. The redesigned space reflects Qosina’s continued investment in enhancing customer experience and showcasing its expanding product portfolio. "INTERPHEX 2026 is an important opportunity for us to connect directly with the innovators shaping the future of pharmaceutical and bioprocessing technologies,” said Lee Pochter, CEO of Qosina. "We’re excited to showcase not only our latest booth experience and interactive sampling solutions, but also our ongoing commitment to helping customers overcome supply chain challenges with reliable, flexible and forward-thinking component solutions.” A key highlight of the booth is the cube sample wall, an interactive display that allows visitors to touch, turn and take sample components home. This hands-on experience offers a closer look at Qosina’s high-quality products, giving attendees the opportunity to evaluate components before incorporating them into their designs. Qosina’s team will be on site throughout the event to connect with engineers, designers and sourcing professionals, discuss customization capabilities and provide solutions for projects at every stage-from concept through production. To learn more about Qosina at INTERPHEX 2026, visit https://bit.ly/Qosina-Interphex2026. About Qosina Qosina is a leading global supplier of OEM single-use components to the medical and biopharmaceutical industries. With over 45 years of experience, Qosina offers one of the world’s largest selections of stock components-including connectors, fittings, valves, tubing and other critical parts-to help companies accelerate innovation and reduce time to market. In addition to its extensive catalog, Qosina provides custom sourcing, molding and assembly solutions. Headquartered in Ronkonkoma, New York, with a European office in Milan, Italy, Qosina serves customers worldwide with a commitment to quality, compliance and innovation. Contact Info Rachelle Morrow rmorrow@qosina.com +1 631-242-3000
2026-04-14 15:29:50

Only Two Days Away - Don’t Miss it! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy’s 2026 New York Summit. Be a Part of It. Register Now.
FAIRFIELD, Conn., April 14, 2026 (GLOBE NEWSWIRE) -- HMG Strategy, the world’s leading platform for inspiring technology executives to lead boldly and shape the future of business, will bring Big Apple C-level leaders together in April 2026 to explore how technology, AI, and leadership excellence are redefining the enterprise of 2030. This is no cost to qualified attendees - Register Now. The highly anticipated 19th Annual New York CIO Summit of America will be held this Thursday, on April 16, 2026. This year’s programming will include a new emphasis on Iconic Leadership - How to Lead Like a CEO and Why the Future Demands Authentic and Visionary Leaders, reflecting the emerging leadership capabilities required in today’s fast-moving environment. In an era defined by exponential innovation, AI disruption, and rising stakeholder scrutiny, the role of the technology executive is undergoing a profound transformation. The expectations placed on CIOs, CTOs, CISOs, and digital leaders have never been higher-or more multidimensional. "The pace of innovation today demands technology leaders who are not only strategic thinkers but also confident, authentic voices in the C-suite,” said Hunter Muller, Founder and CEO of HMG Strategy. "At the 19th Annual New York CIO Summit of America, we’re especially excited to feature two outstanding leadership sessions led by women at the forefront of the industry: Dr. Janet Sherlock of Org.Works on leading technology with clarity and authority, and Cindy Hoots, Chief Digital Officer and CIO of AstraZeneca, on leading as the CEO of technology with a technology-first mindset. Their perspectives will highlight how visionary leadership and collaboration across the CIO community can shape the future of enterprise innovation.” Topics to be explored at the 19th Annual New York CIO Summit of America are scheduled to include: How to Lead Like a CEOHarnessing Data, AI and Strategic Technologies to Drive Long-Term Business PerformanceSecurity Innovation as a Strategic DifferentiatorVisionary Tech Leaders on Innovation and Inner Balance In addition, the 19th Annual New York CIO Summit of America includes an exclusive session on Leading Technology with Clarity and Authority, featuring Dr. Janet Sherlock, Founder and CEO of Org.Works, and Leading as the CEO of Technology With a Technology-First Mindset, featuring Cindy Hoots, Chief Digital Officer & CIO of AstraZeneca. Speakers are selected from each Summit’s region so content reflects local dynamics and market-specific challenges. Here are some of the speakers for the 19th Annual New York CIO Summit of America: Adam Alfi, General Partner, ICONIQ Capital Judy Arteche-Carr, CEO & Managing Director, Arteche Global Group Mahesh Babu, CMO, Kodem Security Shawn Banerji, Managing Partner, Technology, Digital and Data Leaders, The Caldwell Partners Craig Cuyar, Global CIO, Omnicom Group Keith Donnelly, Vice President, Global Head of Risk & Compliance, Broadridge Financial Michael Frankel, Founder and Managing Partner, Trajectory Capital Rocco Grillo, Managing Director - Global Cyber Risk Services & Incident Response Investigation, Alvarez & Marsal Douglas Hegley, Chief Digital Officer, Metropolitan Museum of Art Eric Helmer, Global CTO, Rimini Street Chris Holden, Senior Vice President & CISO, Crum & Forster Cindy Hoots, Chief Digital Officer & CIO, AstraZeneca Mike Kempe, CIO, Grant Thornton Lars Kielhorn, President, NY Metro SIM Tony Leng, Managing Partner, H.I.E.C Sal Marraccino, Divisional Chief Data Officer & Managing Director, BNY Mellon Vipul Nagrath, Distinguished Fellow, Avasant Jim Panos, CIO, Central National Gottesman Inc. Frank Price, Senior Vice President & Chief Information Risk Officer, Labcorp Salwa Rafee, Managing Partner, Cybersecurity Practice Lead Public Markets, IBM Jesse Reich, Technology Officers Practice Lead, Russell Reynolds Peter Rosario, CISO, USI Insurance Services Denise Russell Fleming, CIO & Executive Vice President, Technology and Global Services, Becton Dickinson Janet Sherlock, Founder and CEO, Org.Works Marina Spyrou, CIO, multinational healthcare organization Vaidy Subramanian, Senior Vice President Digital & Information Technology, Daikin Comfort (Speaker list subject to change.) The 19th Annual New York CIO Summit of America is scheduled to be held at the Harvard Club, 35 W. 44th St., New York, New York, 10036. Events are underway across North America, with Summits scheduled from Atlanta to Silicon Valley and several major cities in between. Each HMG Strategy C-Level Technology Leadership Summit is designed as an invitation for technology leaders to step into the next evolution of leadership, gaining insight, perspective, and peer connection as they navigate unprecedented change. Hunter Muller is a trusted voice on the global IT landscape, spanning cybersecurity threats, geopolitical dynamics, and the leadership expectations placed on today’s C-level technology executives. With 30+ years of experience guiding Fortune 2000 leaders through strategic planning and career advancement, Muller brings deep perspective to the challenges and opportunities ahead. He founded HMG Strategy in 2008 to champion innovative, bold, and forward-looking leadership across the technology community. About HMG Strategy HMG Strategy is the world’s leading digital platform for CIO leadership, CISO leadership, and CEO leadership, empowering executives to reimagine the enterprise, drive career ascent, and shape the future of business technology. With a global network of more than 500,000 CIOs, CISOs, CTOs, CDOs, technology leaders, consultants, and C-Suite executives, HMG delivers unmatched opportunities to connect CIO peers, share insight, and accelerate professional development. Founded in 2008 by Hunter Muller, a trusted leadership expert with over 30 years of experience guiding Fortune 2000 executives, HMG Strategy is built on its 7 Pillars of Trust & Inspire. Its unique business-to-business media model generates more than one million weekly digital impressions, delivering powerful visibility for executives and sponsor partners to strengthen their branding and expand their influence. Through its CIO & CISO Executive Leadership Series, CIO events, publications, and Digital Resource Center, HMG Strategy provides world-class coverage of AI, cyber security, IT leadership, digital transformation, SASE, and consulting trends. The Global CIO & CISO Executive Leadership Alliance (CELA) convenes elite leaders to solve today’s toughest challenges, while HMG’s Global Advisory Services deliver peer-driven research, insights, and intelligence to help executives lead with vision. At HMG, we believe in Trust & Inspire leadership - helping executives inspire innovation, expand their network, and create legendary careers. HMG Strategy: Iconic Leadership - Where Legends Are Built Contact: Peggy Pedwano, Chief Operations Officer, HMG Strategy 203-221-2702 | peggyp@hmgstrategy.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a30dd1bb-d52c-4c5b-8133-af09b52cfa13
2026-04-14 15:29:35

Joint Commission’s Dr. Perlin honored with American Hospital Association’s Distinguished Service Award
Prestigious award recognizes significant lifetime contributions to healthcare industry OAKBROOK TERRACE, Illinois, April 14, 2026 (GLOBE NEWSWIRE) -- Joint Commission is honored to announce that its President and Chief Executive Officer Jonathan B. Perlin, MD, PhD, has received one of healthcare’s highest honors: the American Hospital Association’s (AHA) Distinguished Service Award. The prestigious award recognizes a leader whose lifetime achievements have provided national leadership in healthcare delivery and service, especially regarding the welfare of patients and the community, healthcare delivery practices and structure, and organizations in the healthcare field. Dr. Perlin’s esteemed career has spanned decades of service across the public, private and non-profit domains of healthcare. He has spent the last four years at Joint Commission, where he has led the nation’s oldest and largest standards-setting and accrediting organization through its most significant transformation since 1965 - modernizing the mission and building an agile, innovative enterprise to meet the needs of the United States’ complex healthcare system. Under his guidance, Joint Commission has eliminated more than 1,000 accreditation requirements for hospitals that no longer added value, radically increased the transparency of the standards and survey process, and driven the organization to pursue improvements in patient outcomes over processes. He’s also moving the quality needle forward through Joint Commission’s affiliate organizations: Joint Commission International introduced its Patient Safety Pathways program in 2025, bringing healthcare quality and safety frameworks to more than 20 lower- and middle-income countries to ensure that community engagement is at the heart of patient care.National Quality Forum (NQF) and Joint Commission are modernizing the measurement landscape through new Outcomes-Driven Certifications for perinatal and cardiac care, two high-priority clinical areas where improved outcomes can have a profound impact on patients, families, and communities. The organizations are also streamlining patient safety event reporting through one aligned safety event framework - reducing measurement burden for healthcare organizations to help them focus on what matters most: patients. "I’m deeply honored and humbled by this recognition from the American Hospital Association,” said Dr. Perlin. "Throughout my career, my passion has been grounded in a simple purpose: helping ensure every patient receives the safest, highest-quality care possible. That work is never done alone - it is driven by the clinicians, caregivers and healthcare teams who show up every day with skill, compassion and resolve. I share this honor with them, with those carrying forward Joint Commission’s mission to ensure all patient receive safe, high-quality care, and with all those committed to strengthening care for the communities we serve.” Dr. Perlin had the distinction of service as the AHA’s Board Chair for the 2015 term, where he helped hospitals and health systems navigate rapid shifts in payment and care delivery while facing intensifying regulatory scrutiny and financial strain. In this role, he consistently pushed to connect quality improvement with affordability and access, underscoring hospitals’ roles as community anchors and partners in population health - while keeping patient care at the center of the work. "A steady and trusted voice throughout his distinguished career as a leader on quality at the Department of Veterans Affairs, at a large health system, and now at Joint Commission, Jon has worked collaboratively with providers, policymakers, and stakeholders to drive improvements in care,” said AHA President and CEO Rick Pollack. "His work has been especially influential in advancing patient quality, clinical effectiveness and community health.” Prior to Joint Commission, Dr. Perlin was President, Clinical Operations, and Chief Medical Officer, HCA Healthcare, where he led clinicians, data scientists and researchers in developing a learning health system model for improving care at the system’s 189 hospitals and 2,200 other locations. As Under Secretary for Health at the U.S. Department of Veterans Affairs, Dr. Perlin led the Veterans Health Administration to national prominence for full implementation of a national electronic health record and benchmark clinical performance. Dr. Perlin continues to pass his experience on to the next generation of healthcare professionals and leaders through faculty positions at Vanderbilt University and Virginia Commonwealth University, as well as through board service at several universities. "Over the last decade, I have seen how Jon has devoted his career to strengthening healthcare for patients, caregivers and communities. This well-deserved recognition is a testament to the impact of his service on our industry,” said Michael Suk, MD, JD, MPH, MBA, FACS, chair of Joint Commission’s Board of Commissioners, a practicing board-certified orthopedic surgeon, and Immediate Past Chair, Board of Trustees, American Medical Association. "Under his guidance, Joint Commission has a clear vision for how our work is helping transform the healthcare industry - pushing for better patient outcomes, spotlighting innovation and reducing burden for the healthcare teams delivering care under extraordinary pressure.” "Jon’s career reflects the kind of leadership healthcare needs now: relentlessly focused on patient safety and outcomes, and flexible in the face of challenges and change,” said Eric Langshur, vice chair of Joint Commission’s Board of Commissioners and founder and managing director of Abundant Venture Partners. "We are grateful for his vision and commitment to improving healthcare for patients, caregivers, and communities everywhere. His example inspires leaders at all levels to pursue excellence, embrace change, and always keep the well-being of those we serve at the forefront of our mission.” Dr. Perlin will receive the award at the AHA’s Annual Membership Meeting on April 20. ### About Joint Commission Joint Commission enables and affirms the highest standards of healthcare quality and patient safety for all. Founded in 1951, it is the nation’s oldest and largest standards-setting and accrediting body in healthcare, evaluating more than 23,000 healthcare organizations and programs across the United States. As an independent, nonprofit organization, Joint Commission inspires healthcare organizations across all settings to excel in providing safe and effective care of the highest quality and value. Learn more at www.jointcommission.org. CONTACT: Hannah Miller Joint Commission 630-792-5174 press@jointcommission.org
2026-04-14 15:29:29

Vanguard and Pratt Miller Partner To Deliver High-Performance Integrated Electrification Systems
New Vanguard Battery Technology Partner The collaboration unites Vanguard high-performance battery technology with Pratt Miller’s deep expertise in advanced system integration. Milwaukee, WI, April 14, 2026 (GLOBE NEWSWIRE) -- Vanguard, a leading provider of commercial power solutions, announced Pratt Miller as the newest member of its Battery Technology Partner program. A wholly owned subsidiary of the Oshkosh Corporation, Pratt Miller is a technology and product development firm specializing in solving complex technical challenges for the defense, mobility and commercial sectors. The collaboration unites Vanguard high-performance battery technology with Pratt Miller’s deep expertise in advanced system integration. This partnership focuses on delivering integrated, engineered solutions that improve productivity and enhance performance in demanding environments. By integrating Vanguard’s modular battery technology into its engineered systems, Pratt Miller can provide customers with compact, high-energy-density solutions specifically designed with the rugged reliability required in real-world, high-demand duty cycles. "What excites us most is partnering with a provider that brings production-ready, field-proven solutions to a maturing electrification market," said Bob Prohaska, Director of Mobility & Innovation at Pratt Miller. "Our shared vision is to accelerate the deployment of systems that deliver a measurable return on investment. By integrating Vanguard’s robust battery platform, we can offer our customers compact solutions that lower operating costs, reduce maintenance complexity and expand use cases, especially in environments where emissions and noise constraints limit traditional equipment.” This collaboration relies on Pratt Miller’s systems engineering discipline to ensure that the battery, power electronics and controls function together as a cohesive system. Rather than simply combining components, the team builds and validates complete architectures to support performance and manufacturability. This technical approach is particularly effective for equipment in warehouses, industrial facilities and construction interiors, where Vanguard’s compact battery footprint helps address packaging constraints while delivering zero local emissions. "Welcoming Pratt Miller into our Battery Technology Partner program allows us to push system-level innovation further by combining electrification with advanced controls and performance optimization,” said David Frank, Senior Vice President and President of Electrification at Briggs & Stratton. "The transition to electrification requires more than just a battery; it requires a cohesive, engineered system that performs in the most demanding environments. Pratt Miller’s ability to optimize the entire architecture - from power electronics to mechanical systems - leverages Vanguard technology to its full potential.” Vanguard battery products are assembled in the United States and supported by the global Briggs & Stratton service network. The commitment to quality is further backed by an industry-leading eight-year* commercial limited warranty on all battery packs. *See vanguardpower.com/na/en_us/support/warranty.html for warranty details. ### About Briggs & Stratton Briggs & Stratton, headquartered in Milwaukee, Wisconsin, provides innovative products and diverse power solutions to help people get work done. Briggs & Stratton is the world’s largest producer of engines for lawn and garden, turf care and job site power equipment and is a leading designer, manufacturer and marketer of lithium-ion batteries, standby generators and energy storage systems through its Briggs & Stratton®, Vanguard®, Ferris®, Simplicity®, Snapper®, Billy Goat® and Branco® brands. Briggs & Stratton products are designed, manufactured, marketed and serviced in over 100 countries on six continents. Learn more at BriggsandStratton.com. About Pratt Miller Founded in 1989, Pratt Miller, a wholly owned subsidiary of the Oshkosh Corporation (NYSE: OSK), is a groundbreaking engineering and product development company. Our winning roots in motorsports enable us to deliver ingenious solutions to our clients' most challenging problems - and wildest ideas. That history enables our team of highly adaptive innovators to apply speed, agility and engineering expertise to every project, swiftly transforming what's possible in our clients' industries - taking what they do to the next level and changing their world for the better. Attachment New Vanguard Battery Technology Partner CONTACT: Elianna Novitch Two Rivers Marketing eliannan@2rm.com
2026-04-14 15:29:13

CORRECTION - Israel Tech Week Moves Forward in Miami Amid Ongoing War in Israel
The conference is one of the year’s few in-person platforms for Israeli innovation to connect directly with global investors and partners MIAMI, April 13, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 9, 2026, by Israel Tech Week, please note that updates have been made to the speaker names and titles. The corrected release follows: Amid the ongoing war in Israel, Israel Tech Week (ISRTW) will move forward with its 2026 Miami conference, positioning itself as one of the few major international platforms taking place outside of the country this year, as many other conferences have been postponed or canceled. Despite the circumstances, Israeli founders, investors and industry leaders are making the journey to Miami, reflecting a clear commitment to staying connected to global markets and advancing innovation beyond borders. The event, taking place April 27-30, is expected to draw more than 1,500 attendees, including hundreds of participants traveling from Israel and dozens of startups presenting on stage in the startup showcase. For many, the event represents one of the few opportunities this year to meet face-to-face with investors and partners outside of Israel. "Israel Tech Week has always been about creating opportunities for innovation to extend beyond borders,” said Lior Halabi, co-founder of ISRTW. "This year, bringing the event to life carries added significance. It creates a space for Israeli founders and investors to stay visible, continue building and engage directly with global partners at a time when that access is more important than ever.” The conference will open with remarks from Miami-Dade County Mayor Daniella Levine Cava and feature panel discussions across nine technology verticals. Sessions will take place across Miami, with the main conference hub anchored at The LAB Miami, and will include private executive breakfasts, investor roundtables and startup showcases designed to facilitate meaningful business connections. ISRTW 2026 will also feature a high-caliber lineup of speakers across technology, investment and government, bringing together leaders actively shaping their respective industries. Below are some of the remarkable keynote speakers who will be featured at the event: David Blumberg, founder and managing partner, Blumberg CapitalEd Sim, founder and general partner, Boldstart VenturesMichael Barbero, former lieutenant general of the U.S. Army and president of MDB PartnersPeter Yared, founder and CEO, InCountryArmando Codina, founder and executive chairman, Codina PartnersArnaud Karsenti, managing principal, 13th Floor InvestmentsMichael Coates, general partner of Seven Hill Ventures, former chief information security officer of Twitter and MozillaScott Srebnick, CEO, Goldman PropertiesAndrew Parker, founder and CEO, PapaNatti Ginor, head of Israel Investment Banking, Jefferies "The strength of Israel Tech Week comes from the caliber of voices we bring together,” said Ayal Stern, co-founder of ISRTW. "This year’s speakers are not just thought leaders; they are the people actively building, investing in and shaping the future of their industries, creating opportunities for those in the room.” New sponsors include Jefferies, joining as a premier partner, alongside Holland & Knight and Stratos Ventures, further reinforcing the conference’s reach across finance, legal and defense technology sectors. Conference passes are now available, with options ranging from general admission to VIP access, offering entry to panels, networking events and exclusive programming throughout the week. Founded by Lior Halabi and Ayal Stern, Israel Tech Week is a global platform connecting Israeli innovation with the U.S. and international markets. The event has welcomed more than 1,500 attendees, featured over 150 speakers and engaged more than 50 partners from Israel, the U.S. and global markets. For more information about Israel Tech Week, including programming, speakers and registration, visitwww.israeltechweek.com and follow along on Instagram and LinkedIn. For press inquiries, please contact media@israeltechweek.com or anayansy@yansymedia.com. About Israel Tech Week Israel Tech Week is a global innovation conference designed to connect Israel’s technology ecosystem with the United States and international markets. Through conferences, curated networking and strategic partnerships, Israel Tech Week brings together startups, investors, enterprises and industry leaders to showcase Israeli innovation and foster cross-border collaboration. The platform focuses on facilitating meaningful partnerships, knowledge exchange and market expansion opportunities across sectors. Media Contact: Israel Tech Week media@israeltechweek.com Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/cb33a0a8-8062-4a98-bcaf-4ec1690a2593 https://www.globenewswire.com/NewsRoom/AttachmentNg/c0bb4916-15bc-4f54-9c59-dc1ee56569fe
2026-04-13 05:09:19

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults The latest approval expands Dupixent’s indication for CSU in the EU to children as young as 2 years; Dupixent is now approved for children less than 12 years of age across four chronic diseases driven in part by type 2 inflammation TARRYTOWN, N.Y. and PARIS, April 13, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU. This expands the previous approval in the EU for adults and adolescents aged 12 years and older with CSU, a chronic, inflammatory skin disease that causes sudden and debilitating hives and recurring itch. "Young children suffering from chronic spontaneous urticaria often experience an unpredictable barrage of unrelenting itch and visible hives during the critical years of their growth and development. As the first and only targeted medicine for young children in the EU with CSU, Dupixent has the potential to become the new standard of care for those who remain symptomatic despite other available treatments,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. "Dupixent is the most widely used innovative branded antibody medicine in the world, and this fourth approval for young children with chronic diseases driven in part by type 2 inflammation brings its proven efficacy and long-term safety profile to yet another vulnerable population in need.” The approval in the EU is based on data from the LIBERTY-CUPID clinical trial program. This includes an extrapolation of efficacy data in adults from two Phase 3 trials (Study A and Study C) complemented by pharmacokinetic, safety and efficacy data from the single-arm CUPIDKids Phase 3 trial in children aged 2 to 11 years with CSU. Study A and Study C demonstrated Dupixent significantly reduced urticaria activity (a composite of itch and hives) and individual measures of itch and hive severity compared with placebo at week 24. Dupixent also increased the percentage of patients with well-controlled disease and complete response at week 24 compared with placebo. Safety results from Study A, Study C and CUPIDKids were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. The most common adverse reactions for Dupixent overall are injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes and eosinophilia. Additional adverse reactions of injection site induration, injection site dermatitis and injection site bruising or hematoma were reported in the CSU adult and adolescent trials.* The adverse event more commonly observed with Dupixent (≥5%) than placebo in Study A and Study C in adults and adolescents with CSU was COVID-19. Safety data for children aged 2 to 11 years with CSU were generally consistent with the safety profile for adult and adolescent patients with CSU treated with Dupixent. "Previous treatment options for young children with chronic spontaneous urticaria left many patients with uncontrolled disease where the unpredictable appearance of itch and hives continued to disrupt their daily lives,” said Alyssa Johnsen, M.D., Ph.D., Global Therapeutic Area Head, Immunology Development at Sanofi. "Dupixent, which inhibits signaling of IL-4 and IL-13, two of the key and central drivers of type 2 inflammation, provides a first-of-its-kind approach to addressing chronic spontaneous urticaria in young children. This approval demonstrates our commitment to extending the value of Dupixent to all who may benefit, including young children.” In the U.S., the supplemental Biologics License Application (sBLA) for Dupixent has been accepted for review in certain children aged 2 to 11 years with CSU. Dupixent is currently approved for CSU in certain adults and adolescents in many jurisdictions, including the U.S. and Japan. *Adverse reactions in adults and adolescents were pooled from Study A, Study B and Study C. Study B evaluated Dupixent in patients aged 12 years and older who were inadequate responders or intolerant to anti-IgE therapy and symptomatic despite H1AH use. About CSU CSU is a chronic, inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. CSU is typically treated with H1AH, medicines that target H1 receptors on cells to control symptoms of itch and urticaria. However, the disease remains uncontrolled despite H1AH treatment in many patients, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and significantly impact their quality of life. About the Dupixent CSU Phase 3 Trial Program The LIBERTY-CUPID Phase 3 program evaluating Dupixent for CSU in children aged 2 to 11 years includes Study A, Study C and CUPIDKids. CUPIDKids was a single arm clinical trial that assessed the safety, efficacy and pharmacokinetics of Dupixent in children aged 2 to 11 years with CSU who remained symptomatic despite the use of antihistamines. During the 24-week treatment period, Dupixent was administered at 200 mg every two or four weeks or 300 mg every four weeks, with or without an initial loading dose, based on age and weight. The primary endpoint measured the serum concentration of Dupixent over time, including Ctrough (lowest concentration before the next dose) at week 12 and week 24. Study A and Study C were replicate, double-blind, placebo-controlled clinical trials that assessed Dupixent as an add-on therapy to standard-of-care antihistamines compared to antihistamines alone in patients aged 6 years and older who remained symptomatic despite the use of antihistamines and were naïve to anti-IgE therapy. During the 24-week treatment period in both trials, all patients received an initial loading dose followed by either 300 mg Dupixent every two weeks, or for pediatric patients weighing 30 kg to Change from baseline in itch and hives (weekly urticaria activity score [UAS7], 0-42 scale) the primary endpoint.Change from baseline in itch (measured by the weekly itch severity score [ISS7], 0-21 scale), the key secondary endpoint.Change from baseline in hives (measured by the weekly hive severity score [HSS7], 0-21 scale), secondary endpoint.Proportion of patients achieving well-controlled disease status (UAS7 ≤6).Proportion of patients with complete response (UAS7=0).About Dupixent Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites. In children aged 2 to 11 years with CSU who remain symptomatic despite H1AH treatment, Dupixent is administered based on age and weight. In children aged 2 to 5 years, Dupixent is administered at 200 mg every four weeks for patients weighing ≥5 kg to Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, CSU, chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP) and allergic fungal rhinosinusitis (AFRS) in different age populations. More than 1,400,000 patients are being treated with Dupixent globally.1 **For children and adolescents aged 6 to 17 years weighing 15 kg to About Regeneron's VelocImmune Technology Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, Board co-Chair, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. Dupilumab Development Program Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 12,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. U.S. INDICATIONS DUPIXENT is a prescription medicine used: to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with AD under 6 months of age.with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with EoE under 1 year of age, or who weigh less than 33 pounds (15 kg).to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with COPD under 18 years of age.to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with CSU under 12 years of age, or who weigh less than 66 pounds (30 kg).to treat adults with bullous pemphigoid (BP). It is not known if DUPIXENT is safe and effective in children with BP under 18 years of age.to treat adults and children 6 years of age and older with allergic fungal rhinosinusitis (AFRS), who have had surgery on their nose or sinuses in the past. It is not known if DUPIXENT is safe and effective in children with AFRS under 6 years of age.DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine or to treat any other forms of hives (urticaria). IMPORTANTSAFETYINFORMATION Donotuse if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®. Before usingDUPIXENT,tellyourhealthcareprovideraboutall yourmedicalconditions,includingif you: have eye problems.have a parasitic (helminth) infection.are scheduled to receive any vaccinations. You should not receive a "live vaccine” right before and during treatment with DUPIXENT.are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby.are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, BP, or AFRS and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back. DUPIXENTcancauseserious sideeffects,including: Allergicreactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye, painful red or blue bumps under the skin, or red pus-filled spots on the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.Eyeproblems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.Inflammationof yourbloodvessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.Themostcommon sideeffectsinclude:Eczema: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.ChronicRhinosinusitiswithNasalPolyps: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache.Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).Prurigo Nodularis: eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, stomach problems (gastritis), joint pain (arthralgia), toothache, headache, and urinary tract infection.Chronic Spontaneous Urticaria: injection site reactions.Bullous Pemphigoid: joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections.Allergic Fungal Rhinosinusitis: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver. PleaseseeaccompanyingfullPrescribingInformationincludingPatientInformation. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron” or the "Company”), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate,” "expect,” "intend,” "plan,” "believe,” "seek,” "estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria in children aged 2 years and above; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals). Sanofi Disclaimers or Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as "expect,” "anticipate,” "believe,” "intend,” "estimate,” "plan,” "can,” "contemplate,” "could,” "is designed to,” "may,” "might,” "potential,” "objective,” "attempt," "target,” "project,” "strategy," "strive," "desire," "predict,” "forecast,” "ambition,” "guideline,” "seek," "should,” "will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including "most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under "Risk Factors” and "Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. Regeneron Contacts: Media RelationsInvestor RelationsKailey Kilmartin Tel: +1 914-652-0679 Kailey.Kilmartin@regeneron.com Mark Hudson Tel: +1 914-847-3482 Mark.Hudson@regeneron.com Sanofi Contacts: Media RelationsInvestor RelationsSandrine Guendoul Tel: +33 6 25 09 14 25 Sandrine.Guendoul@sanofi.com Thomas Kudsk Larsen Tel: +44 7545 513 693 Thomas.Larsen@sanofi.com Evan Berland Tel: +1 215-432-0234 Evan.Berland@sanofi.com Alizé Kaisserian Tel: +33 6 47 04 12 11 Alize.Kaisserian@sanofi.com Léo Le Bourhis Tel: + 33 6 75 06 43 81 leo.lebourhis@sanofi.com Keita Browne Tel: +1 781-249-1766 Keita.Browne@sanofi.com Victor Rouault Tel: +1 617-356-4751 Victor.Rouault@sanofi.com Nathalie Pham Tel: +33 7 85 93 30 17 Nathalie.Pham@sanofi.com Timothy Gilbert Tel: +1 516-521-2929 Timothy.Gilbert@sanofi.com Nina Goworek Tel: +1 908 569 7086 Nina.Goworek@sanofi.com Léa Ubaldi Tel: + 33 6 30 19 66 46 lea.ubaldi@sanofi.com Thibaud ChâteletTel: +33 6 80 80 89 90 Thibaud.Chatelet@sanofi.com Ekaterina Pesheva Tel:+1 410 926 6780 ekaterina.pesheva@sanofi.com Yun LiTel: +33 6 84 00 90 72 Yun.Li3@sanofi.com 1 Data on File
2026-04-13 05:09:16

Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes drug-resistance to Mycobacterium tuberculosis (Mtb).Alpibectir is a potential first-in-class molecule for treating drug-resistant tuberculosis (TB) by targeting new bioactivation pathways exploited by ethionamide in Mtb.Pre-clinical data show that alpibectir potentiates ethionamide (Eto) bioactivation, resulting inrapid killing of the bacteria and restoring Eto susceptibility in resistant Mtb strains. AlpE, is currently being studied by BioVersys’ partner GSK in a pulmonary tuberculosis Phase 2b trial, expected to finalize recruitment by end of 2027, and by BioVersys in a tuberculosis meningitis Phase 2 trial that was recently initiated.BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today, the publication of pre-clinical data in the prestigious journal of Nature Communications, for its innovative anti-tuberculosis combination AlpE.1 Alpibectir, a small molecule acting through a novel mode of action, represents a new concept of overcoming drug-resistance in M. tuberculosis, by potentiating the activity of an existing antibiotic, ethionamide, and was identified in a research collaboration with GSK and the academic groups of Dr. Alain Baulard, Prof. Benoit Deprez and Prof. Nicolas Willand. Tuberculosis is one of the leading causes of death by infectious diseases globally, as existing standard of care treatments diminish in efficacy due to growing drug resistance. Following the recently published clinical proof-of-concept for AlpE in pulmonary TB2, BioVersys and collaborators now publish pre-clinical evidence supporting the potential of AlpE to provide a new therapeutic option to treat tuberculosis: In in vitro studies, AlpE showed potent activity against a diverse set of M. tuberculosis clinical strains, including those resistant to standard of care treatments. AlpE was also active against intracellular M. tuberculosis.In in vivo studies, AlpE rapidly reduced bacterial load levels and improved survival, demonstrating clear translation from in vitro to in vivo proof of concept. Through the BioVersys and GSK partnership, alpibectir has completed Phase 1 and two Phase 2a pulmonary TB trials and is considered to be generally safe and well tolerated. Currently, AlpE is being studied in a pulmonary TB Phase 2b trial in combination with first-line TB drugs (NCT05807399), within IMI2 UNITE4TB project and BioVersys recently initiated a Phase 2 trial in meningeal TB (NCT07350174). Dr. Michel Pieren, Clinical Project Team Leader at BioVersys: "The data provide a compelling scientific foundation in understanding the potential positioning of AlpE in future drug regimens to treat TB and thus for the next stages of clinical development. Alpibectir is the product of a successful public private partnership between BioVersys an academic consortium from Lille, France and large pharma, GSK. We are grateful to all our partners and funders for their support in the development of AlpE.” Dr. Alain Baulard, Director of Research Inserm at CIIL, Institut Pasteur de Lille: "Alpibectir reprograms the transcriptional landscape of M. tuberculosis, increasing the activity of ethionamide. Elucidating the precise mechanism of action of a novel drug is not only a scientifically rewarding process, it is also instrumental in anticipating potential resistance escape routes, rationalizing the design of synergistic therapeutic regimens, and ultimately paving the way for next-generation treatment strategies. This has been a truly exciting and passionate journey, one that has brought together biologists and chemists and bridged the public and private sectors. I am firmly convinced that alpibectir will soon expand the therapeutic arsenal available to clinicians and their patients.” Prof. Nicolas Willand, of M2SV, University of Lille: "This scientific work is the culmination of a decade of intensive research into an innovative concept based on enhancing existing anti-tuberculosis drugs to make them effective again against resistant strains. It also represents a breakthrough in the detailed understanding of the mechanisms of action of alpibectir at the molecular level. Finally, it is the result of a fruitful collaboration between leading academic research units in the field of anti-infectives, private and public pharmaceutical companies seeking new alternatives to existing treatments.” Dr. David Barros-Aguirre, Head of Global Health Medicines R&D, GSK: "The publication of these pre-clinical data for AlpE supports the continued progress of this potential treatment in clinical development and shows the value of collaborative research. GSK, alongside our partners, remains deeply committed to changing the trajectory of tuberculosis.” The pre-clinical and clinical development of alpibectir has been strongly supported by the European Union’s Innovative Medicines Initiative 2 (IMI2) through the TRIC-TB project (grant agreement No 853800), under which some studies described in the Nature Communications publication were funded. About tuberculosis (TB) Tuberculosis (TB) remains one of the leading causes of death worldwide. It is caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb). According to the WHO Global Tuberculosis Report 2025, an estimated 10.7 million people developed TB in 2024, and approximately 1.23 million died from TB. Drug resistance continues to pose a major challenge. There were about 390,000 people who developed rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB) in 2024. MDR-TB remains a public health crisis and a health security threat, with global treatment success rates at only 71%. The major burden of TB is concentrated within 30 high TB burden countries, accounting for 87% of the global total in 2024. Of those, the top eight countries for TB cases worldwide were, India (25%), Indonesia (10%), the Philippines (6.8%), China (6.5%), Pakistan (6.3%), Nigeria (4.8%), the Democratic Republic of the Congo (3.9%) and Bangladesh (3.6%). Globally, 8.3 million people were reported as newly diagnosed with TB in 2024, Significantly, it remains that 3.2% of new TB cases and 16% of previously treated cases are MDR/RR-TB. About Alpibectir Alpibectir (previously known as BVL-GSK098) is a small molecule developed from BioVersys’ award winning Transcriptional Regulatory Inhibitory Compounds (TRIC) platform in a successful collaboration with GSK, the Institut Pasteur de Lille and the University of Lille. Alpibectir acts through a novel mode of action, potentiating the activity of the anti-TB drug ethionamide (Eto). Alpibectir is being studied for its potential to lower the efficacious human dose of Eto, minimizing of dose-dependent side effects, and overcome Eto resistance. The combination alpibectir/Eto (AlpE) is being developed for the treatment of pulmonary TB and TB meningitis. In 2023 AlpE was granted orphan-drug designation (ODD) for the treatment of tuberculosis, by the U.S. Food and Drug Administration (U.S. FDA) providing for certain incentives including seven years US market exclusivity. Similarly in 2025, AlpE was granted Orphan Designation from the European Medicines Agency (EMA), providing for certain incentives including 10-year EU market exclusivity. About TRIC-TB Project (grant agreement No 853800) Ethionamide (Eto) and prothionamide (Pto) are recommended by the World Health Organization (WHO) for use as second-line agents in the treatment of drug-resistant pulmonary TB and TB meningitis. Despite their usefulness as TB drugs, Eto/Pto cause dose-dependent adverse events that negatively impact treatment adherence. Eto/Pto are prodrugs and their antibacterial activity can be linked to the level of bioactivation inside Mycobacterium tuberculosis (Mtb). The clinical candidate alpibectir (formerly BVL-GSK098) acts on transcriptional regulators of Mtb, stimulating novel bioactivation pathways for Eto, that has resulted in an observed increase of Eto efficacy, while simultaneously overcoming Eto resistance and keeping potent activity on MDR strains, including to a vast majority of isoniazid-resistant strains. BVL-GSK098 renders Eto rapidly bactericidal and reduces the emergence of Eto resistance development in vitro and in vivo. Based on pre-clinical data, the TRIC-TB project started to explore whether BVL-GSK098 could ultimately, lower the efficacious human oral dose of Eto by at least 3-fold, minimize dose-dependent side effects, and support patient compliance. With the completion of Phase 1 a major milestone of the TRIC-TB Project was achieved and a novel, fast acting TB agent with the potential to replace isoniazid in TB therapy has been brought into clinical development. About the Innovative Medicines Initiative The Innovative Medicines Initiative (IMI) IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It was set up to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas. IMI projects are now managed by the Innovative Health Initiative (IHI), which builds on the successes of IMI and is a cross-sectoral public-private partnership involving a wider range of health industries. More info on IHI: https://www.ihi.europa.eu/Twitter: @IHIEuropeMore info on IMI AMR accelerator: https://amr-accelerator.eu/project/tric-tb/About Lille Center for Infection and Immunity (CIIL) The CIIL (University of Lille, CNRS UMR9017, Inserm U1019, Institut Pasteur of Lille, and Lille University Hospital) brings together 11 research teams and more than 220 members. CIIL develops a research program spanning from fundamental knowledge of the molecular and cellular mechanisms of infectious and chronic inflammatory respiratory diseases to the development and improvement of diagnostics, as well as vaccines and treatments. This vision requires the deployment of an interdisciplinary approach by bringing together complementary expertise covering a wide range of fields, from epidemiology, molecular and cellular virology, bacteriology, and parasitology, to the immunological bases of infectious and non-infectious diseases and clinical applications. CIIL members study, in particular, host-pathogen interactions in bacterial, viral, and parasitic diseases, the immune response to these infections, and immune dysfunctions associated with non-infectious respiratory diseases. About the Research Unit M2SV-Drugs and Molecules for Living Systems U1177 "Drugs & Molecules for Living Systems” is a multidisciplinary research team operated by Université de Lille, INSERM and Institut Pasteur de Lille. The team aims at inventing drug candidates to fulfil unmet medical needs through innovative modes of action. Areas currently explored are infectious diseases, immunity, metabolism and CNS diseases. Two IND designations have been obtained in the last four years as well compassionate use for repurposed medicines. The team benefits from state of the art discovery platforms including a 200k compound library, automated screening platforms in BSL2 and BSL3 as well as a dedicated pharmacokinetics laboratory. It is founded by Université de Lille, INSERM and Institut Pasteur de Lille. It receives funds from Europe, French Ministry of Research, Region Hauts de France, and Métropole Européenne de Lille. Advanced projects are supported by two technology transfer offices: Inserm Transfert and SATT Nord. About BioVersys BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. BioVersys contact Anca Cighi, Head of IR and Communication, Tel. +41 79 949 33 09; E-Mail: anca.cighi@bioversys.com For IR: IR@bioversys.comWebsite: www.bioversys.com X: https://x.com/Bioversys LinkedIn: https://www.linkedin.com/company/bioversys-ag Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. 1Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis | Nature Communications 2Revival of Ethionamide by Alpibectir | New England Journal of Medicine
2026-04-13 05:09:11

Aktsiaselts Infortar own share acquisition transactions
Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 6 April - 10 April 2026 as follows: DateAggregated volume (pcs)Weighted average price per day (EUR)06.04.2026--07.04.202621046,000008.04.202620046,000009.04.202619546,000010.04.202619646,0000 Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 October 2025. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar. Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar ́s investor website. Further detailed information on the transactions is attached. A consolidated overview of the transactions is attached to this notice. Infortar operates in seven countries. the company's main fields of activity are maritime transport. energy and real estate. Infortar owns a 68.47% share in Tallink Grupp. a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141.000 m2. In addition to the three main areas of activity. Infortar also operates in agriculture, engineering, construction minerals, printing sector, services and other areas. A total of 109 companies belong to the Infortar group: 100 subsidiaries 4 affiliated companies and 4 subsidiaries of affiliated companies. Excluding affiliates Infortar employs 6466 people. Additional information: Kadri Laanvee Investor Relations Manager Phone: +372 5156662 e-mail: kadri.laanvee@infortar.ee www.infortar.ee/en/investor Attachment Transaction information_ENG 10.04.26
2026-04-13 05:09:07

WISeSat and Swiss Space Command of the Swiss Armed Forces Complete Pilot Phase and Prepare Next-Generation WISeSat 6U Mission Planned for November 2026
WISeSat and Swiss Space Command of the Swiss Armed Forces Complete Pilot Phase and Prepare Next-Generation WISeSat 6U Mission Planned for November 2026 Pilot phase validates key technical and operational foundations for a sovereign, secure Swiss space communication architecture. Next-generation 6U platform intends to form the first building blocks, fully funded, of WISeSat’s Quantum Space Orbital Cloud (QSOC) roadmap. Geneva and Bern, Switzerland - April 13, 2026 - WISeKey International Holding Ltd ("WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, through its space technology subsidiary WISeSat.Space ("WISeSat”), and semiconductors, PKI, and post-quantum technology subsidiary SEALSQ Corp ("SEALSQ”) (NASDAQ: LAES), today announced the completion of a pilot phase in their strategic partnership with the Space Command of the Swiss Armed Forces. The collaboration, initiated in 2022 and further strengthened in 2024, has focused on evaluating technical and operational building blocks relevant to a future Swiss sovereign and quantum-resilient space communications infrastructure. https://uk.finance.yahoo.com/news/wisekey-swiss-armed-forces-sign-050000648.html During this pilot phase, WISeSat, SEALSQ and their partners conducted satellite missions, payload integration work and secure communications testing designed to assess architecture options, operational concepts and future government and defense use cases. The program has provided technical validation and practical lessons for the next stage of development. WIseSat 6U - The Next Phase towards QSOC Building on these results, WISeSat and the Swiss Space Command continue their partnership. WISeSat is now preparing a next-generation 6U mission, planned to launch in Q4 2026. The new platform is intended to offer greater payload flexibility, longer mission endurance and broader application potential for secure communications and other sovereign space infrastructure uses. The first 15 next-generation 6U satellites planned by 2027 are intended to form the initial elements of WISeSat’s Quantum Space Orbital Cloud ("QSOC”). WISeSat is expected to own and operate these satellites and the associated space and ground segment in cooperation with the Swiss Space Command as part of its program architecture, while SEALSQ is expected to contribute its quantum and cybersecurity technology stack across selected constellation resources and capabilities. A Platform for the Swiss New Space Ecosystem The new 6U generation is also intended to serve as a modular in-orbit platform that will allow Swiss space companies to test and validate selected products, subsystems and applications in a real mission environment, and therefore contribute to the Swiss innovation ecosystem. WISeSat’s objective is to provide a practical framework through which emerging Swiss New Space players may gain access to flight heritage, accelerate development cycles and demonstrate technologies relevant to sovereign and secure space infrastructure. QSOC Roadmap to 2033 The 6U mission and the first 15 satellites planned by 2027 are intended to constitute the first building blocks of WISeSat’s QSOC roadmap, with full operational capability currently envisioned for 2033. As the programme develops, future platform generations could support a broader set of payloads and services, depending on technical validation, mission priorities, financing and customer demand. These may include secure communications payloads, advanced post-quantum cryptographic functions, sovereign identity and trust infrastructure, direct-to-device connectivity, optical communications, selected sensing capabilities, onboard processing, secure data storage and other digital infrastructure services. This roadmap reflects WISeSat’s ambition to help establish a Swiss-led, secure and scalable orbital infrastructure serving both sovereign and commercial applications. Col GS Ludovic Monnerat, Commander, Space Command, Swiss Armed Forces / Air Force, noted, "The completion of this pilot phase has helped clarify technical possibilities and operational considerations for the next stage of development, including, for our command, regarding highly secure space-based communications. The planned 6U mission represents an important next step in assessing how sovereign and secure space capabilities could evolve for Switzerland, while giving unique opportunities for our ecosystem to test and mature new technologies.” Carlos Moreira, Founder and CEO, WISeKey, added, "Completing the pilot phase with these satellites in orbit is a milestone that few partnerships at this level of technical complexity achieve in two years. It reflects the depth of trust, shared vision, and engineering excellence of both teams. With the WISeSat 6U launch on the horizon, we are entering a new chapter in Switzerland’s quantum-secure space program.” About WISeSat.Space WISeSat.Space AG is pioneering a transformative approach to IoT connectivity and climate change monitoring through its innovative satellite constellation. By providing cost-effective, secure, and global D2D connectivity, WISeSat is enabling a wide range of applications that support environmental monitoring, disaster management, and sustainable practices. The integration of satellite data with advanced climate models holds great promise for enhancing our understanding of climate change and developing effective strategies to combat its impacts. As the world continues to grapple with the challenges of climate change, initiatives like WISeSat’s IoT satellite constellation are essential for creating a more resilient and sustainable future. About SEALSQ: SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable. SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries. For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com. About WISeKey WISeKey International Holding Ltd ("WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ("FinSA”), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Press and Investor Contacts WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com WISeKey Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lcati@theequitygroup.com
2026-04-13 05:09:04

GAM Holding AG announces proposed Board of Directors for election at 2026 Annual General Meeting
PRESS RELEASE: Ad hoc announcement pursuant to Art. 53 LR GAM Holding AG announces proposed Board of Directors for election at 2026 Annual General Meeting Planned Board renewal as part of succession and continuity planningAnthony Maarek proposed as new Chairman of the Board of DirectorsAlbert Saporta, Group CEO, and John Niel proposed as new Board membersBoard to comprise six members with equal gender balanceZurich, 13 April 2026 - GAM Holding AG ("GAM") (SIX: GAM) today announces the proposed composition of its Board of Directors to be submitted for election at the Annual General Meeting on 12 May 2026. The proposals reflect a planned succession and the continued commitment of GAM’s principal shareholder to the Company’s long-term strategic development. Proposed Board composition The Board of Directors proposes the re-election of Anthony Maarek as a member and his election as Chairman of the Board of Directors, and the re-election of Inès de Dinechin, Anne Empain and Donatella Ceccarelli, as well as the election of Albert Saporta and John Niel as members of the Board of Directors, each for a term of office until the end of the Annual General Meeting 2027. Albert Saporta, who was appointed Group Chief Executive Officer in July 2025, is proposed for election as a new executive member of the Board of Directors. John Niel, an investment professional with a background in technology, telecommunications and digital platforms, is proposed for election as a new non-executive member of the Board of Directors. Antoine Spillmann, Carlos Esteve and Jeremy Smouha have decided not to stand for re-election. The Board of Directors extends its sincere thanks to all three for their significant contributions to GAM during a period of strategic transformation and renewal. These nominations form part of the Board’s existing succession and continuity planning and are intended to ensure the proper functioning and continued strategic development of the Board of Directors. Albert Saporta and John Niel’s profiles complement the existing competencies of the Board and support the continued development of GAM’s strategic direction. The Board of Directors and the Governance and Nomination Committee are confident that Albert Saporta and John Niel will make a valuable contribution to the long-term development of GAM. With the election and re-election of all candidates nominated by the Board of Directors, the Board considers itself to be balanced and appropriate in terms of size, expertise, experience and independence. The resulting composition will comprise three female and three male directors. Shareholder proposal A shareholder proposal has been made for the election of Benedetta Arese Lucini as a new member of the Board of Directors, in place of Anne Empain. The Board of Directors and the Governance and Nomination Committee have reviewed this proposal and recommend that shareholders reject the election of Benedetta Arese Lucini. Full details of this proposal will be set out in the AGM invitation. Comment Antoine Spillmann, Chairman of the Board of Directors, said: "The proposed Board composition reflects the natural evolution of GAM’s governance as the Company enters its next phase of development. I am confident that, under Anthony Maarek’s chairmanship and with the addition of Albert Saporta and John Niel, the Board will be well positioned to continue delivering on GAM’s strategic priorities. I would like to thank Carlos Esteve and Jeremy Smouha for their dedicated service and commitment to GAM.” Annual General Meeting Full details of all proposals, including the biographies of all candidates, will be provided to shareholders in the AGM invitation to be published on 20 April 2026. The Annual General Meeting will be held on 12 May 2026 in Zurich. All supporting materials will be made available at www.gam.com/agm2026. Investor Relations Magdalena Czyzowska T +44 (0) 207 917 2508 Media Relations Colin Bennett T +44 (0) 207 393 8544 Visit us: www.gam.com | Follow us: X and LinkedInAbout GAM Investments GAM is an independent investment manager that is listed in Switzerland. It is an active, independent global asset manager that delivers distinctive and differentiated investment solutions for its clients across its Investment and Wealth Management Businesses. Its purpose is to protect and enhance its clients’ financial future. It attracts and empowers the brightest minds to provide investment leadership, innovation and a positive impact on society and the environment. Total assets under management were CHF 12.5 billion as of 31 December 2025. GAM has global distribution with offices in 15 countries and is geographically diverse with clients in almost every continent. Headquartered in Zurich, GAM Investments was founded in 1983 and its registered office is at Hardstrasse 201, Zurich 8005, Switzerland. For more information about GAM Investments, please visit www.gam.com Other Important Information This release contains or may contain statements that constitute forward-looking statements. Words such as "anticipate”, "believe”, "expect”, "estimate”, "aim”, "project”, "forecast”, "risk”, "likely”, "intend”, "outlook”, "should”, "could”, "would”, "may”, "might”, "will”, "continue”, "plan”, "probability”, "indicative”, "seek”, "target”, "plan” and other similar expressions are intended to or may identify forward-looking statements. Any such statements in this release speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance, and estimates. Any forward-looking statements in this release are not indications, guarantees, assurances or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the person making such statements, its affiliates and its and their directors, officers, employees, agents and advisors and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct and may cause actual results to differ materially from those expressed or implied in any such statements. You are strongly cautioned not to place undue reliance on forward-looking statements and no person accepts or assumes any liability in connection therewith. This release is not a financial product or investment advice, a recommendation to acquire, exchange or dispose of securities or accounting, legal or tax advice. It has been prepared without taking into account the objectives, legal, financial or tax situation and needs of individuals. Before making an investment decision, individuals should consider the appropriateness of the information having regard to their own objectives, legal, financial and tax situation and needs and seek legal, tax and other advice as appropriate for their individual needs and jurisdiction. Attachments Adhoc_Press_Release_GAM_Board_AGM2026_EN Adhoc_Medienmitteilung_GAM_Verwaltungsrat_AGM2026_DE
2026-04-13 05:08:59

Netic and OVHcloud Forge Strategic Partnership to Bolster Digital Sovereignty for Danish Enterprises, Public & Highly Regulated Sectors
Press Release Netic and OVHcloud Forge Strategic Partnership to Bolster Digital Sovereignty for Danish Enterprises, Public & Highly Regulated Sectors Aalborg Denmark, 13 April 2026 Danish managed service provider Netic A/S and European cloud leader OVHcloud have entered into a strategic partnership aimed at delivering sovereign cloud solutions to Danish companies and public sector organizations. The collaboration ensures that critical data remains under European jurisdiction, providing a robust alternative to non-European cloud providers. Supporting Digital Sovereignty In an era of increasing geopolitical instability, Danish organizations are seeking cloud environments that offer more than just storage. This partnership is built on three core principles designed to address the modern threat landscape: Data Control: Ensuring all business-critical information is stored, managed, and processed strictly according to local European laws. This guarantees that data is never disclosed to third parties or subject to extra-territorial surveillance.Technological Independence: Reducing dependency on foreign technology providers to mitigate the risks of international sanctions, espionage, or sudden service shutdowns. By utilizing a European stack, Danish companies secure their long-term operational freedom.Operational Security: Managing cloud infrastructure to maintain the highest levels of confidentiality and integrity. Through secure, localized cloud services, Netic and OVHcloud ensure that critical systems remain resilient against external interference.A Powerful European Alternative Against this backdrop, Netic and OVHcloud are joining forces to integrate OVHcloud’s sovereign infrastructure into Netic’s service portfolio. By combining OVHcloud’s transparent and open cloud technology with Netic’s deep expertise in managed services, Danish customers can now access high-performance cloud solutions that adhere to the strictest European standards. "We are witnessing a definitive shift in the market. Customers are no longer willing to accept vendor lock-in, they want transparency and technological independence," says Steen Jensen, CEO of Netic. "By partnering with OVHcloud, we are offering a genuine European alternative. We combine this infrastructure with our local advisory and operations, ensuring that our customers maintain absolute data control without compromising on performance." Expertise and Implementation To ensure a seamless transition, Netic is launching a comprehensive internal enablement program. This initiative focuses on adding the OVHcloud platform to Netic's portfolio, with a particular emphasis on operational security and Public and Private Cloud features. With these enhanced capabilities, Netic will provide: Strategic Advisory: Navigating the complexities of digital sovereignty and GDPR.Data Migration: Securely moving mission-critical workloads to sovereign infrastructure.Managed Operations: 24/7 support and integration as part of a comprehensive multicloud offering.Future Outlook Netic and OVHcloud see significant potential in the Danish market, particularly within sectors such as healthcare, Public Security, and government, where data integrity is paramount. The commercial collaboration has already begun, with expectations to onboard the first customers to the sovereign platform during the year. About Netic A/S Netic A/S is a leading Danish Managed IT Service Provider with over 20 years of experience in operating complex and critical IT infrastructure. The company is a specialist in business-critical IT operations and operates as a subsidiary of the Trifork Group. With an uncompromising focus on security, stability, and compliance, Netic delivers hosting and operations solutions from its own Danish data centers. With national residency requirements and employees eligible for security clearance, Netic ensures stable operations for customers in complex sectors with stringent security and compliance requirements. Contact Malthe Kringelbach Iversen, CMO mki@trifork.com +45 31 53 65 79 Attachment PR april 13042026
2026-04-13 05:08:56

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods.By providing deeper insight into underlying neuroinflammatory activity, Elecsys NfL has the potential to enable effective MS monitoring and earlier clinical intervention. 2, 3 Basel, 13 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients diagnosed with relapsing remitting multiple sclerosis (RRMS).1 The test brings meaningful innovation to MS disease management, offering clinicians a minimally invasive way to monitor the biological damage caused by multiple sclerosis. Using a simple blood test to measure NfL - a protein released during nerve cell injury - Elecsys NfL provides a picture of the neuroinflammation associated with multiple sclerosis, and could help to make more regular monitoring a reality for more people living with the disease. Multiple sclerosis is a chronic disease that affects more than 2.9 million people worldwide.8 Early and regular monitoring of disease activity is critical to optimising treatment, yet some patients can find it difficult to access routine assessments such as MRI scanning that would allow timely detection of changes in their condition. The Elecsys NfL test provides a different type of insight by measuring biological markers of neuroaxonal damage that reflect neuroinflammation. These insights complement routine clinical assessments and MRI, potentially aiding in earlier and better-informed clinical management. "This approval marks a transformative step forward in how we support adults with relapsing-remitting multiple sclerosis (RRMS),” said Matt Sause, CEO of Roche Diagnostics. "The availability of a simple blood-based test has the potential to complement resource-intensive MRI scans and improve access for patients with RRMS. The Elecsys NfL test will help healthcare providers support timely clinical reassessment, enabling better disease management and more personalised care for patients.” Performed on Roche’s widely available cobas instruments, the Elecsys NfL test provides standardised and consistent results,1 ensuring reliable insights regardless of where the test is carried out. Requiring only a simple blood sample, collections can be done locally, reducing the need for patients to travel to specialist centres. With traditional testing for multiple sclerosis often limited by geographic, financial, or logistical barriers, Elecsys NfL makes frequent monitoring more practical and accessible. About NfL Neurofilament Light Chain (NfL) is an abundant cytoskeletal protein4 found almost exclusively in neurons5 and is a sensitive indicator of neuroaxonal damage2,6. Under normal conditions, NfL is released at low levels from axons4; however, release increases with age7 and following neuroaxonal damage.4 Consequently, abnormally elevated NfL concentrations can be measured in cerebrospinal fluid and blood in a range of acute and chronic neurological disorders.2, 4, 6 About Elecsys® NfL Roche’s Elecsys NfL is an in vitro quantitative immunoassay for the measurement of NfL protein in human serum and plasma. Elecsys NfL is intended to be used to reflect neuroinflammation in adult subjects diagnosed with relapsing-remitting multiple sclerosis.2 The test was granted Breakthrough Device Designation by the US FDA in November 2023. Following CE Mark approval, broad access to testing will exist through the large number of instruments currently available in countries accepting CE mark. About Roche in neurology Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally. Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and Cerebrospinal Fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Roche Diagnostics GmbH. Elecsys NfL. Method Sheet 09880488500 V1.0. Roche Diagnostics GmbH; 2025. [2] Khalil M, et al. Nat Rev Neurol 2018;14:577-89. https://doi.org/10.1038/s41582-018-0058-z [3] Bar-Or A, et al. EBioMedicine 2023;93:104662. https://doi.org/10.1016/j.ebiom.2023.104662 [4] Gaetani L, et al. J Neurol Neurosurg Psychiatry 2019;90:870-81. https://doi.org/10.1136/jnnp-2018-320106 [5] Gafson AR, et al. Brain 2020;143:1975-98. https://doi.org/10.1093/brain/awaa098 [6] Freedman MS, et al. EBioMedicine 2024;101:104970. https://doi.org/10.1016/j.ebiom.2024.104970 [7] Itorralba J, Schneider R. Pract Neurol (US) 2024;23(2):18-21. https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/the-prognostic-utility-of-neurofilament-light-chain-in-multiple-sclerosis-a-narrative-review/32098/ [8] MS International Federation. Atlas of MS: Number of people with MS. Accessed 1 April 2026. https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhD Phone: +41 79 407 72 58 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Irène Stephan Phone: +41 79 377 83 75 Roche Investor RelationsDr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com Investor Relations North AmericaLoren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment Roche Media Investor Release CE mark for new Elecsys NfL English
2026-04-13 05:08:52

Cebu Landmasters expands beyond VisMin, buys 70-hectare Cavite property for flagship Luzon township
Visayas and Mindanao (VisMin) developer Cebu Landmasters Inc. (CLI) has firmed up its plan to venture into the more competitive Luzon real estate market with the acquisition of a 70-hectare (ha) property in Dasmariñas City, Cavite province. In a disclosure to the Philippine Stock Exchange (PSE) on Friday, April 10, the firm said the move strengthens its foothold beyond its core markets and sets the stage for a landmark township development in southern Luzon. “This milestone represents a key step in widening CLI’s reach and entering new growth markets,” said CLI Chairman and Chief Executive Officer (CEO) Jose R. Soberano III. “As we expand beyond our Visayas and Mindanao stronghold, we aim to bring CLI’s brand of service, quality, and thoughtfully planned communities to Luzon, unlocking new economic opportunities, creating jobs, and contributing to sustained regional growth while responding to the evolving needs of Filipino homebuyers.” Strategically located near Governor’s Drive and proximate to major thoroughfares, including Cavite-Laguna Expressway (CALAX), the Dasmariñas site sits within a vibrant economic corridor in Calabarzon region. The area benefits from strong residential demand, improving infrastructure, and accessibility to key transport routes, as well as proximity to notable schools, hospitals, and established residential communities, positioning it well for a large-scale, master-planned township development. CLI said it intends to develop the property into its flagship township project in Luzon, with a predominantly residential offering across economic and mid-market segments, targeting the development of 6,000 homes over multiple phases. The master plan will allocate dedicated spaces for commercial, institutional, and estate facilities, designed to support a self-sustaining, integrated, and sustainable community aligned with CLI’s township development expertise. The initial phases of the township are targeted for near-term launch, with first-phase developments expected between 2027 and 2028, allowing for immediate utilization of the site and timely response to housing demand in the area. The Dasmariñas property forms part of CLI’s broader Luzon expansion strategy, as the company continues to prudently grow its land bank to support future project launches while maintaining discipline in capital deployment and execution. Relative to the company’s overall scale and current development pipeline, the transaction is not expected to materially affect CLI’s operations or financial condition in the near term.
2026-04-10 07:20:00

Quimbo: Philippine credit rating could take a hit from fuel VAT removal
Marikina City 2nd district Rep. Miro Quimbo has expressed reservations on the proposed scrapping of value-added tax (VAT) on fuel amid the House of Representatives\' efforts to come up with a legislative response to the persisting fuel price crisis. Quimbo, an economist, is mainly worried about the impact of such move on the Philippines\' credit rating. Credit ratings are crucial for developing countries because they directly affect access to international financing, borrowing costs, and investor confidence. A strong rating lowers interest rates and attracts investment, while a weak rating raises borrowing costs and can trigger economic instability. “Ang epekto niyan (fuel VAT removal), hindi lang ang kawalan ng government revenue but more significant na hindi nakikita ng marami nakakaapekto sa credit rating natin (The effect of that is not only the loss of government revenue, but more significantly and something many do not see is it impacts our credit rating),” said Quimbo, chairman of the House Committee on Ways and Means. “Kapag ang ating credit rating ay mababa ang number one na nakakaapekto is your ability to repay (When our credit rating is low, the number one factor affected is your ability to repay)," he noted. Quimbo--presiding officer of the 13-committee Legislative Energy Action Development (LEAD) Council--is concerned of the possibility that banks might impose higher interest rates on housing loans, car loans, and other personal or business loans. The LEAD Council held its first hearing at the House of Representatives last Wednesday, April 8. The marathon hearing was attended by the economic managers of the Marcos administration. During the hearing, Department of Finance (DOF) Undersecretary Karlo Fermin Adriano said the government could forego P210 billion in revenues if the excise tax and VAT on fuel products were to be suspended for the rest of the year. "If we include like a VAT suspension on top of the suspension of excise tax, if we suspend VAT on petroleum products, it would be around P210 billion for eight months,” Adriano told the energy crisis council. According to Adriano, diesel prices could be reducec by P6.70 per liter and gasoline prices by P11 per liter if the excise tax and VAT are suspended. Local pump prices of fuel have practically doubled the past month because of the spillover tensions in the Middle East caused by the United States-Israel-Iran conflict.
2026-04-10 07:19:00

Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
CHANGZHOU, China , April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL ) (" Jin Medical" , and together with all its subsidiaries and consolidated entities, the " Company "), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has received written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. The Company regained compliance after its Class A ordinary shares maintained a closing bid price of at least $1.00 per share for more than ten (10) consecutive business days. The Company will continue to focus on its core business operations and ongoing strategic initiatives. About Jin Medical International Ltd. Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com . Forward-Looking Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (" SEC "). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: ir@jinmed.com
2026-04-07 11:00:00

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study . The fixed dose combination had excellent oral bioavailability, drug exposure and a half -life of up to 12 hours. These data support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for obesity. -ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39 when combined together, with room temperature stability and a small pill size. -ASC30 is a Phase III-ready o ral s mall m olecule GLP-1R a gonist that had a favorable gastrointestinal ( GI ) profile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration. -ASC39, an o ral s mall m olecule a mylin- s elective a mylin r eceptor a gonist, demonstrated e loralintide-like a mylin s electivity and e fficacy in p reclinical m odels . -Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets is expected in the third quarter of 2026. HONG KONG , April 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30, once-daily oral small molecule GLP-1R agonist and ASC39, once-daily oral small molecule amylin-selective amylin receptor agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets for the treatment of obesity in the third quarter of 2026. ASC30_39 FDC tablets, dosed orally in dogs, demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours. These key parameters of ASC30_39 FDC tablets are consistent with those observed in their respective monotherapies in a head-to-head dog study. Furthermore, ASC30_39 FDC tablets, developed utilizing Ascletis' proprietary formulation technology, demonstrated a good compatibility between ASC30 and ASC39 with room temperature stability and a small pill size. The combination of the excellent pharmacokinetic profile of ASC30_39 FDC, the potential best- in-class efficacy and gastrointestinal (GI) tolerability of ASC30 and the first eloralintide-like small molecule amylin support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for the treatment of obesity. ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinal (GI) profile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration in non-head-to-head studies ( Press release ). As a clinical development candidate, ASC39 is a potent and amylin-selective oral small molecule amylin receptor agonist and demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. "Selection of this fixed dose combination, which we believe is the first publicly announced co-formulation of an oral GLP-1 and an oral amylin, is an important step in the development of a new oral, potentially synergistic combination of ASC30 and ASC39 for the treatment of obesity," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "We believe this fixed dose combination, which combines the key features of high bioavailability, high drug exposure, a long half-life, and the convenience of a small pill, has the opportunity to improve patient outcomes for the treatment of obesity." About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit www.ascletis.com . Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Peter.vozzo@icrhealthcare.com Ascletis Pharma Inc. PR and IR Teams +86-181-0650-9129 (China) pr@ascletis.com ir@ascletis.com
2026-04-07 11:00:00

PAL set to fly Chicago as Delta backs off
Flag carrier Philippine Airlines (PAL) will soon mount direct flights to Chicago after Delta Air Lines Inc., the lone opposition to its proposed service, withdrew its appeal before the United States (US) government. Delta said in an April 3 regulatory filing, seen by Manila Bulletin, that it is dropping its objection to PAL’s planned Chicago service following the Philippine government’s assurance that it will support the US carrier’s plans to mount direct flights to Manila by 2027. Delta, one of America’s largest carriers, earlier asked the US Department of Transportation (DOT) to defer its decision on PAL’s request, raising concerns about barriers to obtaining the necessary slots at main gateway Ninoy Aquino International Airport (NAIA). The airline argued that it would be unfair if the US DOT authorizes PAL to operate flights to Chicago while it has yet to secure adequate access to Manila, as this would further limit choices for passengers traveling directly between the Philippines and the US. As reported by Manila Bulletin, the Civil Aeronautics Board (CAB) assured Delta last month that it is ready to “give due course to and act favorably” on the carrier’s request. There is currently no pending application from Delta for any flight schedule or slot allocation at NAIA. “In light of subsequent developments... Delta does not oppose a limited, time-bound exemption that allows the [US DOT] to assess market conditions and competitive effects on an interim basis,” the airline said. As such, Delta said the US DOT should grant an exemption to PAL’s proposed service only on the condition that it be limited to a one-year term. This is consistent with the agency’s approach to exemption authority “in similar circumstances where market conditions and reciprocal access are evolving.” For one, PAL’s service between Manila and Seattle currently operates under a one-year exemption. “A one-year exemption would allow the [US DOT] to revisit this matter in the future if Delta is ultimately denied commercially viable access sufficient to launch its own contemplated Manila service,” said Delta. Delta stressed that its appeal is not intended to delay PAL’s efforts to mount flights to Chicago, noting that it aligns with precedent and public interest. Once the US DOT grants PAL’s request, the Lucio Tan-led airline said it is ready to launch flights between Manila and Chicago “as soon as authorized by the department to do so.” Based on its application, PAL plans to launch the transpacific route during the summer schedule of the International Air Transport Association (IATA), which runs from March to October. The new route will widen PAL’s reach in North America, particularly in the Midwest, which is home to a large Filipino diaspora. PAL currently operates flights to nine destinations in the region, including San Francisco, Los Angeles, Vancouver, New York, and Toronto, as well as Honolulu, Guam, and Saipan in the Pacific.
2026-04-07 11:00:00

歌禮宣佈每日一次口服小分子GLP-1R激動劑ASC30與每日一次口服小分子胰澱素選擇性胰澱素受體激動劑ASC39的固定劑量復方制劑進行臨床開發
- 在一項頭對頭研究中, ASC30 與 ASC39 固定劑量復方制劑( ASC30_39 FDC )片在犬中口服給藥後,其藥代動力學特徵與 ASC30 和 ASC39 在各自單藥療法中觀察到的相當。該固定劑量復方制劑表現出良好的口服生物利用度、藥物暴露量以及長達 12 小時的半衰期。這些數據支持 ASC30_39 FDC 片有望成為每日一片的新型肥胖症療法。 -ASC30_39 FDC 顯示出 ASC30 與 ASC39 聯合制備時具有良好的兼容性,以及室溫穩定性和小片劑規格的特點。 -ASC30 是一款已準備進入 III 期臨床的口服小分子 GLP-1R 激動劑,具有良好的胃腸道耐受性特徵,每週滴定( weekly titration )的 ASC30 的嘔吐發生率僅為每週滴定的 orforglipron 的一半。 - 對胰澱素具有選擇性的口服小分子胰澱素受體激動劑 ASC39 在臨床前模型中顯示出類似 eloralintide 的胰澱素選擇性與療效。 - 預計將於 2026 年第三季度向美國食品藥品監督管理局( FDA )遞交 ASC30_39 FDC 口服片的新藥臨床試驗申請( IND )。 香港 2026年4月7日 /美通社/ -- 歌禮製藥有限公司(香港聯交所代碼:1672,簡稱「歌禮」)宣佈已選定ASC30_39 FDC,即每日一次口服小分子GLP-1R激動劑ASC30與每日一次口服小分子胰澱素選擇性胰澱素受體激動劑ASC39的固定劑量復方制劑(FDC),進行臨床開發。歌禮預計將於2026年第三季度向美國食品藥品監督管理局(FDA)遞交ASC30_39 FDC口服片治療肥胖症的新藥臨床試驗申請(IND)。 ASC30_39 FDC片在犬中口服給藥後,表現出優越的口服生物利用度、藥物暴露量以及長達12小時的半衰期。在一項頭對頭的犬研究中,ASC30_39 FDC片的關鍵參數與ASC30和ASC39在各自單藥療法中觀察到的一致。此外,採用歌禮專有制劑技術開發的ASC30_39 FDC片顯示出ASC30與ASC39之間良好的兼容性,以及室溫穩定性和小片劑規格的特點。ASC30_39 FDC擁有優越的藥代動力學特徵,ASC30有望擁有同類最佳療效和胃腸道耐受性,以及ASC39是首款類似eloralintide的小分子胰澱素,上述優勢支持ASC30_39 FDC片有望成為每日一片的新型肥胖症療法。 ASC30是一款已準備進入III期臨床的口服小分子GLP-1R激動劑,具有良好的胃腸道耐受性特徵,在非頭對頭研究中,每週滴定(weekly titration)的ASC30的嘔吐發生率僅為每週滴定的orforglipron的一半( 新聞發佈 )。 ASC39是一種對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑,在臨床前模型中顯示出類似eloralintide的胰澱素選擇性與療效,已作為臨床開發候選藥物。 「據我們所知,這是首個公開宣佈的口服GLP-1與口服胰澱素復方制劑,選定這一固定劑量復方制劑是開發ASC30與ASC39新型潛在協同口服復方制劑治療肥胖的重要一步。」歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示,「我們相信,該固定劑量復方制劑兼具了生物利用度高、藥物暴露量高、半衰期長以及小藥片便利性等關鍵特點,有望改善肥胖症患者的治療效果。」 關於歌禮製藥有限公司 歌禮製藥有限公司是一家全價值鏈整合型生物技術公司,聚焦有望成為治療代謝疾病同類最佳(best-in-class)和同類首創(first-in-class)藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現(Artificial Intelligence-assisted Structure-Based Drug Discovery,AISBDD)、超長效藥物開發平台(Ultra-Long-Acting Platform,ULAP)技術以及口服多肽遞送增強技術(Peptide Oral Transport ENhancement Technology,POTENT),歌禮已自主研發多款小分子和多肽候選藥物,包括其核心項目ASC30,一款在研小分子GLP-1R激動劑,既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法,用於長期體重管理;ASC36,一款胰澱素受體激動劑多肽,ASC35,一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽,ASC37,一款GLP-1R/GIPR/GCGR三靶點激動劑多肽,ASC39,一款對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑,用於長期體重管理。歌禮已在香港聯交所上市(1672.HK)。 欲瞭解更多信息,敬請登錄網站: www.ascletis.com 。 詳情垂詢: Peter Vozzo ICR Healthcare 443-231-0505 (美國) Peter.vozzo@icrhealthcare.com 歌禮製藥有限公司PR和IR團隊 +86-181-0650-9129 (中國) pr@ascletis.com ir@ascletis.com
2026-04-07 11:00:00

歌礼宣布每日一次口服小分子GLP-1R激动剂ASC30与每日一次口服小分子胰淀素选择性胰淀素受体激动剂ASC39的固定剂量复方制剂进行临床开发
- 在一项头对头研究中, ASC30 与 ASC39 固定剂量复方制剂( ASC30_39 FDC )片在犬中口服给药后,其药代动力学特征与 ASC30 和 ASC39 在各自单药疗法中观察到的相当。该固定剂量复方制剂表现出良好的口服生物利用度、药物暴露量以及长达 12 小时的半衰期。这些数据支持 ASC30_39 FDC 片有望成为每日一片的新型肥胖症疗法。 -ASC30_39 FDC 显示出 ASC30 与 ASC39 联合制备时具有良好的兼容性,以及室温稳定性和小片剂规格的特点。 -ASC30 是一款已准备进入 III 期临床的口服小分子 GLP-1R 激动剂,具有良好的胃肠道耐受性特征,每周滴定( weekly titration )的 ASC30 的呕吐发生率仅为每周滴定的 orforglipron 的一半。 - 对胰淀素具有选择性的口服小分子胰淀素受体激动剂 ASC39 在临床前模型中显示出类似 eloralintide 的胰淀素选择性与疗效。 - 预计将于 2026 年第三季度向美国食品药品监督管理局( FDA )递交 ASC30_39 FDC 口服片的新药临床试验申请( IND )。 香港 2026年4月7日 /美通社/ -- 歌礼制药有限公司(香港联交所代码:1672,简称"歌礼")宣布已选定ASC30_39 FDC,即每日一次口服小分子GLP-1R激动剂ASC30与每日一次口服小分子胰淀素选择性胰淀素受体激动剂ASC39的固定剂量复方制剂(FDC),进行临床开发。歌礼预计将于2026年第三季度向美国食品药品监督管理局(FDA)递交ASC30_39 FDC口服片治疗肥胖症的新药临床试验申请(IND)。 ASC30_39 FDC片在犬中口服给药后,表现出优越的口服生物利用度、药物暴露量以及长达12小时的半衰期。在一项头对头的犬研究中,ASC30_39 FDC片的关键参数与ASC30和ASC39在各自单药疗法中观察到的一致。此外,采用歌礼专有制剂技术开发的ASC30_39 FDC片显示出ASC30与ASC39之间良好的兼容性,以及室温稳定性和小片剂规格的特点。ASC30_39 FDC拥有优越的药代动力学特征,ASC30有望拥有同类最佳疗效和胃肠道耐受性,以及ASC39是首款类似eloralintide的小分子胰淀素,上述优势支持ASC30_39 FDC片有望成为每日一片的新型肥胖症疗法。 ASC30是一款已准备进入III期临床的口服小分子GLP-1R激动剂,具有良好的胃肠道耐受性特征,在非头对头研究中,每周滴定(weekly titration)的ASC30的呕吐发生率仅为每周滴定的orforglipron的一半( 新闻发布 )。 ASC39是一种对胰淀素具有选择性的强效口服小分子胰淀素受体激动剂,在临床前模型中显示出类似eloralintide的胰淀素选择性与疗效,已作为临床开发候选药物。 "据我们所知,这是首个公开宣布的口服GLP-1与口服胰淀素复方制剂,选定这一固定剂量复方制剂是开发ASC30与ASC39新型潜在协同口服复方制剂治疗肥胖的重要一步。"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示,"我们相信,该固定剂量复方制剂兼具了生物利用度高、药物暴露量高、半衰期长以及小药片便利性等关键特点,有望改善肥胖症患者的治疗效果。" 关于歌礼制药有限公司 歌礼制药有限公司是一家全价值链整合型生物技术公司,聚焦有望成为治疗代谢疾病同类最佳(best-in-class)和同类首创(first-in-class)药物的开发和商业化。利用公司专有的基于结构的AI辅助药物发现(Artificial Intelligence-assisted Structure-Based Drug Discovery,AISBDD)、超长效药物开发平台(Ultra-Long-Acting Platform,ULAP)技术以及口服多肽递送增强技术(Peptide Oral Transport ENhancement Technology,POTENT),歌礼已自主研发多款小分子和多肽候选药物,包括其核心项目ASC30,一款在研小分子GLP-1R激动剂,既可每日一次口服也可每月一次至每季度一次皮下注射作为减重治疗疗法和减重维持疗法,用于长期体重管理;ASC36,一款胰淀素受体激动剂多肽,ASC35,一款每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽,ASC37,一款GLP-1R/GIPR/GCGR三靶点激动剂多肽,ASC39,一款对胰淀素具有选择性的强效口服小分子胰淀素受体激动剂,用于长期体重管理。歌礼已在香港联交所上市(1672.HK)。 欲了解更多信息,敬请登录网站: www.ascletis.com 。 详情垂询: Peter Vozzo ICR Healthcare 443-231-0505 (美国) Peter.vozzo@icrhealthcare.com 歌礼制药有限公司PR和IR团队 +86-181-0650-9129 (中国) pr@ascletis.com ir@ascletis.com
2026-04-07 11:00:00

Lenovo partners with David Beckham ahead of FIFA World Cup 2026
Lenovo has announced a global partnership with football icon David Beckham, uniting one of the world\'s most recognized cultural figures with a leading technology company as the FIFA World Cup 2026 draws closer. Partnership rooted in football and AI The collaboration builds on Lenovo\'s expanding footprint in global football. The company currently serves as the Official Technology Partner of FIFA World Cup 2026 and the FIFA Women\'s World Cup 2027. Under the partnership, Beckham will participate in Lenovo\'s development of sports-focused, AI-driven solutions designed to transform the game across multiple dimensions: improving team performance, enhancing fan experiences, enabling more efficient club operations, and driving new revenue streams through AI-powered innovation. Beyond the pitch: A business and technology vision Lenovo says the partnership is about more than football. As an entrepreneur who runs multiple businesses, Beckham brings a perspective that resonates across professional and commercial audiences from individual professionals managing their workday on a single device, to small business owners seeking greater efficiency, to enterprises rethinking how entire teams operate. The central idea behind the collaboration, according to Lenovo, is that the right technology powered by AI can help anyone perform at their best. Beckham said: "Lenovo is a global leader with a proven track record on the world\'s biggest stages. I am proud to partner with Lenovo for the FIFA World Cup and beyond. Football will always be defined by talent, instinct, hard work and the unforgettable moments that make the game special. Now AI and data are helping us to understand the sport more deeply - shaping how players and coaches prepare and how fans connect with the game. I look forward to learning more about Lenovo\'s cutting-edge work which is opening up new ideas and expanding access to the game." Global campaign launching in May Beckham will also front Lenovo\'s upcoming global marketing campaign, set to launch in May 2026, one month before the start of FIFA World Cup 2026. Lenovo CEO and Chairman Yuanqing Yang said: "David is not only a global figure across football, business, and culture, but is someone who understands the power of innovation to transform the world. That makes him the perfect partner to help us demonstrate how Smarter AI can drive better life and more efficient work for all."
2026-04-06 00:20:00

Brown, Tatum propel Celtics in win over Raptors
LOS ANGELES, United States — Jaylen Brown scored 26 points and Jayson Tatum added 23 as the Boston Celtics beat the Toronto Raptors 115-101 on Sunday. Tatum added 13 rebounds, seven assists and three steals for the Celtics, who notched their third straight win to tighten their grip on second place in the NBA Eastern Conference. After hot starts in their past two victories, the Celtics looked sluggish in the early going. They were bedeviled by 18 turnovers, leading to 24 Raptors points, and connected on just eight of their 28 three-point attempts. Up 80-77 going into the fourth quarter, the Celtics were buoyed by 11 points from Payton Pritchard in the final frame, pushing their lead to as many as 18. Ja'Kobe Walter scored 16 points and RJ Barrett and Brandon Ingram added 15 points each for the Raptors, who are seventh in the East but neck and neck with Philadelphia in the fight for sixth and a chance to escape the play-in tournament. Later Sunday LeBron James leads a depleted Lakers team against the Mavericks in Dallas. The Lakers, clinging to third place in the Western Conference, have confirmed they will be without NBA leading scorer Luka Doncic and offensive sparkplug Austin Reaves for at least the last five games of the regular season. Doncic suffered a hamstring strain in a loss to Oklahoma City Thursday and Reaves has an oblique muscle injury. The fourth-placed Denver Nuggets are hot on the Lakers' heels with the Houston Rockets just two games behind them in fifth place. Golden State superstar Stephen Curry is expected to return from a 27-game injury absence when the Warriors host the Rockets. Curry, who last played on January 30, was diagnosed with a bone bruise and patella-femoral pain syndrome in his right knee. The 38-year-old said this week that he'd been frustrated at the slow pace of recovery from an injury he expected to sideline him "a week, 10 days max". "The patience then was tough just because it's one of those injuries you really have to let rest," he said. Curry said there is "nothing structurally wrong" with his knee but acknowledged he's dealing with "a new normal" in terms of managing the issue. Warriors coach Steve Kerr said Curry will be on a minutes restriction as the team, currently 10th in the West, builds toward the play-in tournament.
2026-04-06 00:15:36

Israel renews Lebanon strikes, forces Syria border crossing closed
BEIRUT, Lebanon — Israeli strikes in Lebanon on Sunday killed at least 15 people, a day after Israel threatened to hit Lebanon's main border crossing with Syria, forcing it to close. Israel has launched airstrikes across Lebanon as well as a ground invasion in the south since March 2, when armed group Hezbollah entered the Middle East war on the side of its backer Iran. Israeli military chief Lieutenant General Eyal Zamir visited troops in southern Lebanon on Sunday and pledged to intensify strikes against Hezbollah. One of Israel's strikes in Beirut Sunday killed at least five people and wounded 52 in the Jnah neighbourhood, the Lebanese health ministry said. A strike targeting an apartment building in Ain Saadeh town east of Beirut killed three people and injured three others, while a strike in the southern town of Kfar Hatta, far from the border with Israel, killed seven people including a four-year-old girl, the ministry said. Hezbollah on Sunday claimed to have fired a cruise missile at an Israeli warship off the coast, but the Israeli military told AFP it was "not aware" of such an incident. Israeli attacks on Lebanon since the start of the war have killed more than 1,400 people, including 126 children, and displaced over a million, according to Lebanese authorities. Panic attacks The strike in Beirut's Jnah neighbourhood landed about 100 metres away from the Rafik Hariri University Hospital, the largest public medical facility in Lebanon, a medical source told AFP. Zakaria Tawbeh, deputy head of the hospital, said they received "four killed, three Sudanese and a 15-year old girl, and 31 wounded". "Lots of glass was broken, and some of our patients had panic attacks." After the first attack, 53-year-old Jnah resident Nancy Hassan thought she was safe at home. "Shortly after, the planes were flying overhead, and we heard a huge bang, then stones rained down on us," she told AFP. Hassan lost her daughter in an Israeli strike on the same area during the 2024 war between Hezbollah and Israel. "My daughter was killed, she was 23 years old. Today, her friends were killed. Every time, they bomb us in the neighbourhood without warning," she added. Israel also launched several strikes on the southern suburbs of Beirut, an area now largely evacuated but where Hezbollah holds sway. The United Nations Interim Force in Lebanon warned that attacks by Israel and Hezbollah near its positions "could potentially draw return fire". Vital crossing On Saturday, Israel had said it would target the Masnaa border crossing between Lebanon and Syria, the main gateway between the two countries. "Due to Hezbollah's use of the Masnaa crossing for military purposes and smuggling of combat equipment, the (Israeli army) intends to carry out strikes on the crossing in the near future," said the military's Arabic-language spokesman Avichay Adraee, urging people to leave the area. The border post was quickly evacuated on the Lebanese side. In Syria, borders and customs public relations director Mazen Aloush insisted the crossing was exclusively used by civilians but said it would close temporarily due to the threats. Masnaa is a vital trade route for both countries and a key gateway to the rest of the region for Lebanese people. Military expert Hassan Jouni told AFP that Israel's threat to strike the crossing "is not based on sound security considerations but rather aims to pressure the Lebanese government... to disarm Hezbollah". At another border crossing further north known as Qaa, an AFP correspondent on Sunday saw a long line of cars and vans waiting to enter Syria as people sought an alternative route. As Israeli troops push into border areas in southern Lebanon, destroying villages, Lebanese President Joseph Aoun reiterated his call for talks with Israel, saying he wanted to spare his country's south from destruction on the scale seen in the Palestinian territory of Gaza. "Why don't we negotiate... until we can at least save the homes that have not yet been destroyed?" he said in a televised address.
2026-04-06 00:12:14

TÜV南德发布全新白皮书,探讨如何建立AI治理
慕尼黑 2026年4月3日 /美通社/ -- 人工智能早已成为众多企业日常运营的一部分。然而,客户、商业伙伴、投资者以及监管机构不仅期待创新的 AI 应用,还希望获得可验证的证明,以证实这些系统是以负责任、透明且受控的方式使用的。这正是首个 AI 管理体系国际标准 ISO/IEC 42001:2023 的用武之地。 TÜV 南德意志集团(以下简称" TÜV 南德")最新发布的白皮书展示了如何运用该标准建立 AI 治理体系,并将 " 信任源于设计 " 原则付诸实践。 TÜV南德全球AI产品组合经理兼业务顾问Ali Behbahani表示:"即使仅仅发生一次AI事故,也足以永久性地损害客户或投资者的信任。因此,企业需要一种治理方法,能够从源头识别AI风险,并在整个AI生命周期内可靠地管理这些风险。ISO/IEC 42001标准正是为了解决这一问题制定的。" 贯穿整个 AI 生命周期的信任 "信任源于设计"原则遵循一种清晰的管理逻辑:对AI的信任不能依赖于偶然因素或单个项目,而必须从一开始就在企业结构上予以锚定。这一原则包含了公平性、透明度、可问责性和合乎道德的行为等要素。因此,值得信赖的AI必须从技术层面和社会组织层面共同落实。 从合规遵循到经济安全 ISO/IEC 42001标准将这一原则转化为具体、可验证的管理要求。它不针对单个AI系统或应用,而是着眼于组织整体的治理能力,涵盖从管理职责、风险管理和有效控制机制,到持续改进的全过程。其结果是:降低责任和声誉风险,加快市场准入,并向客户和合作伙伴发出强烈的信任信号。 企业如何务实地践行 " 信任源于设计 " 这份全新的TÜV南德白皮书明确指出,推行ISO/IEC 42001并非单纯的技术项目,而是一项涉及人员、流程和技术的管理实践。采用结构化方法有助于其落地实施: 明确界定责任: AI治理必须作为一项战略任务来确立。 建立 AI 应用的透明度 清晰界定哪些AI系统属于治理范围,有助于提升透明度。需明确哪些因素属于技术、伦理及监管层面的考量范畴。 评估与业务相关的 AI 风险 在风险分析环节,对公平性、透明度、潜在偏见以及对利益相关方影响等标准进行评估。 贯穿 AI 生命周期的治理措施 制定相关措施,并使其与现有管理框架保持一致。同时,在整个AI生命周期内实施监控和验证机制。 构建负责任的 AI 文化 通过有针对性的培训,让员工和相关合作伙伴参与其中。 定期评审与改进 将AI治理纳入管理周期,通过定期审核和可能的认证确保持续改进。 Behbahani表示:"许多企业从对业务关键型应用开始着手开展AI治理。然而,系统性、长期性地建立信任至关重要。尤其是在这个信任决定市场机会、责任风险和企业价值的时代,遵循ISO/IEC 42001标准开展的AI治理正成为现代企业管理的核心要素。" 这份《信任源于设计:基于ISO/IEC 42001:2023构建AI治理》白皮书汇集了诸多最佳实践,可在此下载: https://www.tuvsud.cn/zh-cn/resource-centre/white-papers/trust-by-design-building-ai-governance-with-iso-iec-42001
2026-04-03 03:49:00

Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
SINGAPORE, April 3, 2026 /PRNewswire/ -- The Sustainable Tourism Impact Fund, a partnership between Agoda, World Wide Fund for Nature (WWF) Singapore, and the UnTours Foundation, has announced its second round of investments alongside early impact results from the Fund's inaugural cohort. Livingseas foundation Designed to provide affordable, flexible financing to small and medium-sized tourism enterprises, the Fund supports businesses that integrate environmental restoration, climate resilience, and inclusive economic development into their core operations. Indonesia-based Livingseas Asia and Bambike Ecotours in the Philippines are the beneficiaries of the new investments. Each new investee receives USD 25,000 in loan capital to expand impact-driven initiatives across the region. In Indonesia, Livingseas Asia combines dive tourism with coral reef restoration in Padangbai, Bali. Its nonprofit arm, the Livingseas Foundation, has restored more than 7,300 square meters of degraded reef, deploying artificial reef structures and planting over 320,000 coral fragments, with measurable biodiversity recovery. The Fund's investment will support the construction of modular housing for staff and trainees near the restoration site. This will expand Livingseas Asia's hosting capacity and strengthen the Foundation's ability to deliver marine education, conservation training, and reef restoration activities. Bambike Ecotours in the Philippines connects bamboo agroforestry, fair trade bicycle manufacturing in rural communities, and regenerative tourism experiences. The loan will support the development of Ligtasin Cove in Batangas, a bamboo-built tourism destination that will include coastal ecotours and a bamboo nursery for reforestation and erosion control. The initiative aims to create local jobs while expanding lower-carbon tourism experiences that connect travelers with community-led environmental restoration. Bambike Ecotours "At Agoda, we believe the future of travel depends on the resilience of the destinations we serve," said Timothy Hughes, Vice President of Corporate Development at Agoda. "These investments support local pioneers integrating environmental restoration and community well-being into their operations, demonstrating the potential of impact-driven travel." Six months after the Fund's initial investments, early results across Thailand, Indonesia, and the Philippines demonstrate encouraging environmental and community impact. Across Southeast Asia, three organizations advanced community-led tourism in meaningful ways. In Thailand, Local Alike expanded its Travel With Care initiative to 10 destinations, launching 16 regenerative tourism activities and securing partnerships with national parks and tourism authorities to develop a white paper on regenerative tourism. In the Philippines, Ecohotels grew its Bahay Farms initiative by onboarding 22 farmers, planting 500 mango trees, increasing plant-based menu offerings from 35% to 50%, and launching its Green Warriors workforce program, with 5 of 15 trainees already placed in hospitality roles. In Indonesia, Sejiva introduced heritage walking tours and coral restoration experiences across West Java and Jakarta, while scaling its #travelpositive campaign to reach broader audiences. "We are incredibly encouraged by the impact created so far by our inaugural cohort," said Sarah Payne, Senior Director of Impact at the UnTours Foundation. "These businesses are expanding regenerative tourism models, strengthening local livelihoods, and embedding measurable environmental outcomes into their growth. Their progress shows how flexible financing can translate into tangible impact on the ground." The Fund is part of Agoda's broader sustainability strategy and builds on its partnership with WWF-Singapore through Agoda's Eco Deals program. Through Eco Deals, Agoda works with hotel partners across Asia to offer travelers discounted stays while directing a portion of proceeds to WWF's conservation initiatives. Those funds also support the Sustainable Tourism Impact Fund, extending conservation impact to small tourism enterprises, strengthening ecosystem health and community resilience at the destination level. Tourism enterprises across the region advancing conservation, climate resilience, sustainable mobility, and community-led economic development are encouraged to apply for the next round of funding at: https://untoursfoundation.org/sustainable-tourism-impact-fund.
2026-04-03 03:46:19

'ArcheoBot' introduced to speed up archaeological study
MANILA, Philippines - An archeaeology professor of the Ateneo de Manila University (ADMU) has introduced a robot that would help excavate archaeological sites with "greater consistency, precision, and care than via manual methods," Called "ArchaeoBot", the robot was created in collaboration with the Ateneo Laboratory for Intelligent Visual Environments (ALIVE) and was introduced by Dr. Alfred Pawlik, a professor of the ADMU's Department of Sociology and Anthropology, as well as the research coordinator of the Dr. Rosita G. Leong School of Social Sciences and director of the Anthropological and Sociology Institute of the university. Pawlik's work is focused on Southeast Asian archaeology, hunter-gatherer societies, and past human behavior The robot was introduced on March 27 at the Escaler Hall during the Ateneo Breakthroughs lecture featuring Pawlik. By integrating robotics and machine learning into archaeological excavation, the project enhances precision, minimizes human error, and reveals details that further deepen the understanding of early human life in the Southeast Asian region. Pawlik said that the idea grew out of a long standing ambition to build a machine that could take on the physically demanding parts of excavation while also reducing the kind of human error that could happen in the field—especially when teams are tired, inexperienced, or working across multiple trenches at once. The robot is imagined not only as a digging machine, but as a "smart, multipurpose system that can detect finds, recognize archaeological features and contexts, and carefully retrieve objects without damaging them," Using the robot, Pawlik presented evidence that by around 40,000 years ago, humans were already venturing across island chains such as Palawan and Mindoro. By using the ArchaeoBot, the Ateneo said that these experimental and interdisciplinary efforts aim to reconstruct not only artifacts but entire systems of knowledge, making visible the invisible technologies that rarely survive in the archaeological record.
2026-04-03 03:43:34

LTFRB summons taxi franchise after viral overcharging of South Korean pop star
The Land Transportation Franchising and Regulatory Board (LTFRB) on Good Friday, April 3, summoned a taxi operator linked to the alleged overcharging of South Korean pop star Soobin, who is in Cebu for a vacation this Holy Week. LTFRB chairperson Vigor D. Mendoza II said the operator must surrender the taxi’s license plate while the driver was also ordered to turn over his license. “This is a serious offense especially that this incident puts the name of our country in a bad light in the international community. The viral video itself is already strong evidence,” said Mendoza. Soobin, leader of K-pop group Tomorrow X Together (TXT), shared in a vlog that a taxi driver in Cebu tried to overcharge him. He said the fare from Mactan Cebu International Airport to their hotel should have been around P300 but the driver initially asked for P500, citing high gas prices, then tried to raise it to P1,000. Soobin and his friend insisted on paying P500, and the driver ultimately charged that amount. The LTFRB said this violates basic rules and the terms of a Certificate of Public Conveyance (CPC), which require drivers to use meters and charge approved fares. The taxi unit involved has body number 4351 and the LTFRB Region 7 found violations for overcharging and deliberate non-use of the meter in its initial probe. The unit has been suspended for 30 days and a hearing has been set on April 21. The operator was asked to explain why its franchise should not be revoked. “We are with the taxi drivers who follow the rules and regulations but we will make sure that we will send a strong message on what will happen if they ignore and defy the rules and regulations at the expense of the passengers,” Mendoza said. The LTFRB said it is studying stricter measures, including automatic filing of criminal cases and impounding of units involved in overcharging. “Hindi ito ugali ng Pilipino, ugali ito ng mga walang hiya. At huwag ninyong idadahilan ang kahirapan dito dahil napakaraming kababayan natin na lumalaban ng patas at hindi nanggugulang ng kapwa (This is not the behavior of Filipinos, this is the behavior of shameless people. And do not use poverty as an excuse because there are so many of our fellow countrymen who fight fairly and do not take advantage of others),” Mendoza stressed.
2026-04-03 03:38:00

Arclin Completes Acquisition of the DuPontTM Aramids Business, Including Iconic Kevlar® and Nomex® Brands
ALPHARETTA, Ga. , April 2, 2026 /PRNewswire/ -- Arclin, a global materials science company, today announced that it has completed the acquisition of DuPont's Aramids business, including the renowned Kevlar® and Nomex® brands, for approximately $1.8 billion. The transaction marks a transformational milestone for Arclin, significantly expanding its scale, capabilities, and presence across life-critical industries. Arclin is a portfolio company of an affiliate of TJC, L.P. Acquisition Fast Facts "Kevlar® and Nomex® are the gold standard in their respective industries, and we are very excited to incorporate the Aramids platform into Arclin's broader material science portfolio. This acquisition strategically strengthens Arclin's operational and geographic footprint," said Mark Glaspey, Arclin's President. "With established manufacturing operations in Europe and Asia and ~1,800 new team members around the world, we are focused on operational continuity from day one while investing in manufacturing capabilities and innovation to support long-term growth." With the addition of the Aramids brands, Arclin's portfolio now spans aerospace, electrical infrastructure, electric vehicles, and personal protection and defense. The acquisition further strengthens Arclin's leadership across construction, infrastructure, transportation, and weather and fire protection as demand for advanced protective materials continues to grow. Arclin's proprietary materials and technologies are mission-critical, supporting products that protect people, communities, and essential infrastructure worldwide. "We're excited to join the Arclin family and continue advancing the renowned performance that customers have relied on from Kevlar® and Nomex® for decades," said Matt Reinhardt, Business Unit President for Aramids. "Our team's deep expertise in aramid fiber technology, combined with Arclin's commitment to investing in innovation and growth, positions us to better serve our customers and accelerate the development of next-generation protective solutions across industries." "Looking ahead, our mission is to build on the superior strength of the Aramids brands," said Bradley Bolduc, Arclin's Chief Executive Officer. "We're focused on accelerating what these materials can do, putting meaningful investment behind technological innovation and deploying Kevlar® and Nomex® strategically across the world's most performance-critical applications." Piper Sandler & Company served as financial advisor and Kirkland & Ellis LLP served as legal counsel to Arclin and TJC. Centerview Partners and Goldman Sachs & Co. LLC served as DuPont's financial advisors and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. About Arclin Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products, and specialized materials for the construction, agriculture, transportation infrastructure, weather & fire protection, pharmaceutical, nutrition, electronics, design, and other industries. Headquartered in Alpharetta, Georgia, Arclin has offices and manufacturing facilities across North & South America, Europe, and Asia and serves customers worldwide. For more information, visit www.arclin.com . About TJC TJC, L.P., formerly known as The Jordan Company, has worked for more than 40 years with CEOs, founders and entrepreneurs across a range of industries including Consumer, Diversified Industrials, Healthcare, Industrial Technology, Logistics & Business Services and Digital & Power Infrastructure. With $30.9 billion of assets under management as of September 30, 2025, TJC is managed by a senior leadership team that has invested together for over 24 years on over 90 investments. TJC has offices in New York, Chicago, Miami and Stamford. For more information, please visit www.tjclp.com . About DuPont DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com . Investors can access information included on the Investor Relations section of the website at investors.dupont.com. Arclin Media Contact Jana Wright Chief Marketing & Communications Officer inquiries@arclin.com Kevlar® and Nomex® are registered trademarks of Arclin. DuPontTM is a trademark of affiliates of DuPont de Nemours, Inc.
2026-04-01 17:36:00

Zeus Expands Access to Catheter Components Through Chamfr Marketplace
Over 100 Zeus liner and heat shrink components will now be available to engineers through Chamfr's online marketplace to accelerate medical device development. ORANGEBURG, S.C. , April 2, 2026 /PRNewswire/ -- Zeus, a global leader in advanced polymer solutions and catheter manufacturing, announced a partnership with Chamfr to make more than 100 liner and heat shrink products readily available through Chamfr's online marketplace. The collaboration gives device engineers faster, on-demand access to critical components used in catheter development and prototyping. "We understand that speed-to-market can make all the difference in the success of an end device," said Jim O'Connell, Chief Commercial Officer at Zeus. "By making Zeus components available through Chamfr, we're giving engineers easier access to the materials they need to prototype, test, and advance their designs." Chamfr is the leading digital marketplace for medical device components, equipment, tools, and service providers, connecting manufacturers with engineers searching for high-performance materials to solve complex design challenges and speed up product development. By bringing Zeus products to the platform, engineers can more quickly discover, evaluate, and source the materials needed to develop next-generation medical technologies. "Chamfr has built a powerful platform that connects engineers with the components they need to innovate faster – all in one place," said Mike Evers, Director of Commercial Marketing at Zeus. "By partnering with Chamfr, we're expanding access to the high-performance materials engineers rely on during early-stage development." Products available through the marketplace include FEP heat shrink, FluoroPEELZTM peelable heat shrink, PTFE Sub-Lite-WallTM liners, and PTFE StreamLinerTM catheter liners, with additional Zeus products expected to be added over time. QUICK FACTS Zeus is partnering with Chamfr to add 100+ liner and heat shrink products to Chamfr's online marketplace. The new partnership is designed to help medical device engineers expedite the prototyping and development of next-generation medical technologies. Zeus products added to the platform include a range of PTFE liners, FEP heat shrink, and FluoroPEELZTM peelable heat shrink products. For more information, visit: www.zeusinc.com/Chamfr ABOUT ZEUS Zeus, headquartered in Orangeburg, South Carolina, is the world's leading polymer extrusion and catheter design manufacturer. More than 60 years of experience in medical, aerospace, energy, automotive, fiber optics, and more allows Zeus to achieve its mission to provide solutions, enable innovation, and enhance lives. The company employs over 2,200 people worldwide with facilities in Aiken, Columbia, Gaston, Orangeburg, St. Matthews, South Carolina; Branchburg, New Jersey; Chattanooga, Tennessee; San Jose, California; Arden Hills, Minnesota; Guangzhou, China; and Letterkenny, Ireland. For more information, visit www.zeusinc.com
2026-04-01 17:35:00

强链共赢,协同共进:中国移动供应链管理中心赴记忆科技总部参观考察
深圳 2026年3月31日 /美通社/ -- 近日,中国移动通信集团供应链管理中心总经理朱国弟、副总经理吴江,广东移动副总经理商亮一行赴记忆科技总部考察调研。记忆科技董事长胡道鑫、总经理Mike,忆联总经理寇朋韬、忆芯总经理甘金涛等公司高层予以热情接待,并全程陪同参观交流。 在记忆科技展示中心,朱国弟一行详细了解了记忆科技的发展历程、产品线布局、研发实力及未来战略规划。作为国内领先的IT硬件品牌部件提供商,记忆科技深耕存储领域多年,形成了扎实的技术积累与产业化优势。考察团队对其在存储核心技术自主研发、产业链整合等方面取得的成果,给予高度关注与充分肯定。 在随后的座谈交流中,忆联总经理寇朋韬代表记忆科技热烈欢迎朱国弟一行,并系统分享了存储市场前景及公司在闪存、内存两大核心业务领域的发展情况。寇朋韬表示,记忆科技将持续加大研发投入,不断提升产品竞争力,全力为中国移动等战略合作伙伴提供高品质、高可靠性的存储产品与解决方案。 当下,AI技术正以前所未有的速度重塑千行百业,面对AI浪潮带来的海量数据存储与高速存取需求,记忆科技充分发挥自身在存储领域的全链条整合能力,依托自主研发的主控芯片、固件算法、硬件设计及生产测试等关键环节,构建起从芯片到模组的完整技术闭环。公司通过灵活的商业模式与高效的供应链协同,为客户提供定制化、高适配的存储方案,全面赋能AI服务器、边缘计算、智能终端等多元化场景,助力AI应用高效落地。 目前,在闪存领域,记忆科技旗下多款企业级固态硬盘已在中国移动完成测试入围,其中包含PCIe Gen4 UH811a/UH831a系列,PCIe Gen5 UH812a/UH832a系列以及SATA UM311d,凭借高可靠、高性能、低时延等多重优势,这一系列产品为双方在AI算力基础设施领域的深度协同奠定了坚实的产品基础。 此次考察交流,进一步深化了记忆科技与中国移动的相互认知,也为双方在存储产业链上下游的深度协同打开了更广阔的空间。记忆科技将秉持开放合作、创新驱动的理念,持续提升产品竞争力和供应链韧性,与中国移动携手并进,共同推动存储产业高质量发展,为数字经济建设贡献更大力量。
2026-03-31 07:40:00

網龍董事會主席兼控股股東擬增持股份 彰顯長期發展信心
香港 2026年3月31日 /美通社/ -- 全球領先的互聯網社區創建者—網龍網絡控股有限公司(「網龍」或「本公司」;香港交易所股份代號:777)欣然宣布,本公司董事會主席兼控股股東 擬 自 2026 年 3 月 30 日起計 12 個月內,透過公開市場交易方式增持本公司股份。 在引領網龍向全球領先的 AIGC 創作型企業進發的關鍵階段,本公司董事會主席兼控股股東作出增持股份的決定,顯示了其對公司全新戰略方向和長期股權價值的認可。展望未來,網龍將繼續圍繞「AI+」核心戰略,深化業務布局,提升運營效率,並在實現可持續增長的同時,為股東創造長期、穩健的回報,與全體股東攜手共進,共享公司發展成果。 –完– 關於網龍網絡控股有限公司 網龍網絡控股有限公司(香港交易所股份代號:777)是全球領先的互聯網社區創建者,在開發和擴展多個互聯網及移動平台方面擁有優良往績,曾先後在桌面互聯網和移動互聯網時代建立中國領先的網絡遊戲門戶-17173.com和中國極具影響力的智能手機應用分發平台-91無線,覆蓋用戶數以億計。 網龍成立於 1999 年,成功自主研發多個著名的旗艦遊戲,包括《魔域》、《征服》、《英魂之刃》和《終焉誓約》,是中國最具聲譽及知名度的網絡遊戲開發商之一。在過去的十年中,網龍成功地在國內外市場拓展教育科技業務。網龍採取全面擁抱AI新時代的戰略,以「AI+遊戲」和「AI+教育」兩大策略踐行「無限成長」的企業理念。通過打造AI生產中心賦能於業務全局,並與合作夥伴一道打造面向全球學習者的教育元宇宙,網龍致力於在AI新時代再次打造超大型的用戶社區。 網龍的海外教育科技業務子公司 Mynd.ai已在美國獨立上市,是全球互動課堂科技領域的領導者。Mynd.ai 的互動平板和軟件產品屢獲殊榮,已在全球 126 個國家為超過 200 萬間教室提供產品和服務。 如有投資者垂詢,敬請聯絡: 網龍網絡控股有限公司 電郵: ir@netdragon.com
2026-03-31 07:38:00

网龙董事会主席兼控股股东拟增持股份 彰显长期发展信心
香港 2026年3月31日 /美通社/ -- 全球领先的互联网社区创建者 - 网龙网络控股有限公司 ("网龙"或"本公司",香港交易所股票代码:777)欣然宣布,本公司董事会主席兼控股股东 拟 自2026年3月30日起计12个月内,通过公开市场交易方式增持本公司股份。 在引领网龙向全球领先的AIGC 创作型企业进发的关键阶段,本公司董事会主席兼控股股东作出增持股份的决定,显示了其对公司全新战略方向和长期股权价值的认可。展望未来,网龙将继续围绕"AI+"核心战略,深化业务布局,提升运营效率,并在实现可持续增长的同时,为股东创造长期、稳健的回报,与全体股东携手共进,共享公司发展成果。 –完– 关于网龙网络控股有限公司 网龙网络控股有限公司(香港交易所股份代号:777)是全球领先的互联网社区创建者,在开发和扩展多个互联网及移动平台方面拥有优良往绩,曾先后在桌面互联网和移动互联网时代建立中国领先的网络游戏门户-17173.com和中国极具影响力的智能手机应用分发平台-91无线,覆盖用户数以亿计。 网龙成立于 1999 年,成功自主研发多个著名的旗舰游戏,包括《魔域》、《征服》、《英魂之刃》和《终焉誓约》,是中国最具声誉及知名度的网络游戏开发商之一。在过去的十年中,网龙成功地在国内外市场拓展教育科技业务。网龙采取全面拥抱AI新时代的战略,以"AI+游戏"和"AI+教育"两大策略践行"无限成长"的企业理念。通过打造AI生产中心赋能于业务全局,并与合作伙伴一道打造面向全球学习者的教育元宇宙,网龙致力于在AI新时代再次打造超大型的用户社区。 网龙的海外教育科技业务子公司 Mynd.ai已在美国独立上市,是全球互动课堂科技领域的领导者。Mynd.ai 的互动平板和软件产品屡获殊荣,已在全球 126 个国家为超过 200 万间教室提供产品和服务。 如有投资者垂询,敬请联络: 网龙网络控股有限公司 电邮: ir@netdragon.com
2026-03-31 07:37:00

Kapuso Stream: March 30, 2026 | LIVE
It's time to binge-watch all your favorite Kapuso programs LIVE on Kapuso Stream! Catch our Kapuso shows here by subscribing to the GMA Network's official YouTube channel! Here's the list of programs with their PHT timeslots: 05:30 AM - Unang Hirit 08:00 AM - Kapuso Mo, Jessica Soho (Jessica Soho) 09:00 AM - Pinas Sarap (Kara David) 09:39 AM - Biyahe ni Drew (Drew Arellano) 10:10 AM - Good News (Vicky Morales) 11:00 AM - Tiktoclock (Kuya Kim Atienza, Pokwang, Faith Da Silva, Herlene Budol) 12:00 PM - It's Showtime! (Vice Ganda, Vhong Navarro, Anne Curtis, Jhong Hilario) 02:30 PM - Born To Shine (Zephanie, Michael Sager, Olive May, Vina Morales, Manilyn Reynes, Smokey Manaloto) 03:20 PM - House of Lies (Beauty Gonzalez, Kris Bernal, Mike Tan, Martin Del Rosario) 04:05 PM - Apoy sa Dugo (Elle Villanueva, Ashley Ortega, Derrick Monasterio) 04:45 PM - Fast Talk With Boy Abunda (Boy Abunda) 05:10 PM - Encantadia 2016 (Kylie Padilla, Glaiza De Castro, Gabbi Garcia, Sanya Lopez) 05:40 PM - Family Feud Philippines (Dingdong Dantes) 06:30 PM - 24 Oras (Mel Tiangco, Vicky Morales, Emil Sumangil) 08:00 PM - Encantadia Chronicles: Sang'gre (Rhian Ramos, Bianca Umali, Faith Da Silva, Kelvin Miranda, Angel Guardian) 08:50 PM - Never Say Die (Jillian Ward, David Licauco, Kim Ji Soo, Raheel Bhyria) 09:35 PM - The Secrets of Hotel 88 (Mika Salamanca, Brent Manalo, Will Ashley, Ralph De Leon, Esnyr, River Joseph, AZ Martinez, Bianca De Vera, Josh Ford, Dustin Yu) 10:20 PM - Saksi 11:05 PM - State of the Nation (Atom Araullo) Watch your favorite GMA Network shows at https://www.youtube.com/@gmanetwork/live and subscribe to get notified. #GMANetwork #KapusoStream GMA Live, GMA Livestream today, GMA Live Today
2026-03-29 21:20:00

Nxled beats Galeries to set up clash with Farm Fresh in PVL Play-In
MANILA, Philippines — The well-rested Nxled Chameleons defeated the Galeries Tower Highrisers via sweep, 25-23, 25-18, 25-23, to stay alive in the 2026 Premier Volleyball League (PVL) All-Filipino Conference on Saturday at the Ninoy Aquino Stadium in Malate. The Chameleons will next face the Farm Fresh Foxies in the last phase of the play-in round. The winner of the match will advance in the semifinals. Galeries held a 23-21 cushion in the third set with Erika Deloria showing heart to extend the match. However, the Chameleons rallied with a 4-0 run to turn things around as Ranya Musa and Brooke Van Sickle deflected the Highrisers' attempts to lead, 24-23. Van Sickle quickly fended off Aiza Maizo-Pontillas’ hit to swiftly finish the match, 25-23. “This is a conference with a lot of alchemy—and it’s a strange one. Playing against Galeries is difficult because they serve really well, and they have a good block. It was very difficult since every time we gained a point, they showed toughness,” Nxled Italian coach Ettore Guidetti said after the match. “We already lost one time, today was a tough match. Maybe not the second set, but the other sets they gave it really tough. At the end of the day we won 3-0, and we’re stepping to the next part of the conference,” he added. Nxled was led by Phillips’ 17-point output on 13 attacks, three blocks, and an ace, while Van Sickle added 14 markers along with nine excellent digs. Chiara Permentilla also chipped in 10 points to allow the Chameleons move on to the next round. The Highrisers failed to replicate their four-set win against Nxled in the preliminary round, making them to exit the conference early. Galeries was led by Deloria’s 13-point effort and Jean Asis 11-point scoring.
2026-03-28 11:14:28

Inside Batangas’ first CBD: Lima Estate's Biz Hub makes the case for industry-anchored decentralization
AS congestion in the nation’s capital deepens, the real estate solutions platform of the Aboitiz Group positions Biz Hub at Lima Estate as an industry-driven central business district, integrating commerce, offices, mobility, and community within an operating ecosystem designed for productivity and sustainable growth. Over the past few days, a familiar frustration has returned to the center of public discourse: traffic, congestion and the daily cost of simply getting to and from work. For many professionals in Metro Manila, the workday begins well before the first meeting, it begins on the road. The scale of the problem is now hard to ignore: the Philippines ranked as the most congested country in Asia based on the 2025 TomTom Traffic Index, which analyzes GPS data. The lost time is not just an inconvenience, it is an economic drag. A 2021 study by AltMobility and the Friedrich Naumann Foundation estimates that Metro Manila commuters spend 188 hours a year in traffic, roughly seven days, translating to P27.221 billion in economic losses based on average hourly salary in the capital region. Over time, congestion has assumed a more structural character, shaping patterns of mobility, access and economic activity across the country’s primary business center. Its effects are felt in daily operations, influencing productivity, talent mobility, and supply chain performance. As these pressures deepen, companies are re-evaluating where to locate and expand, while investors are placing greater attention on emerging growth corridors that can better support long-term competitiveness. Within this context, integrated, industry-anchored estates are taking on a more central role in enabling a more distributed and resilient pattern of development. Situated along the Luzon Growth Corridor in Lipa-Malvar, Batangas, Lima Estate, the flagship development of Aboitiz Economic Estates, offers a working model of what purposeful decentralization can look like at scale. Spanning over 1,100 hectares, Lima Estate is not simply an industrial park. It is a fully master-planned, industry-anchored ecosystem that brings together industrial factories, office towers, commercial centers, and residential communities within a single, well-connected development. Instead of dispersing these functions across congested urban centers – where employees navigate separate zones for work, services and daily living – Lima integrates them into a single, connected environment. The result is a system where operations run more efficiently, and where time lost to movement is significantly reduced for the 75,000 individuals working within the estate. Accessibility is a key part of this design. Lima is currently accessible via the STAR Tollway and will soon be further enhanced by the Lima Gateway and new STAR Tollway Interchange along the Lipa–Malvar corridor, which is expected to improve mobility into and within the estate, including access to Biz Hub. Multiple ingress and egress points along J.P. Laurel Highway also supports more efficient movement throughout the township. As Lima’s industrial ecosystem grows, commercial and professional activity naturally grows with it. Biz Hub at Lima Estate serves as the township’s commercial and business core, supporting the estate’s workforce and community through retail, dining, services, offices, and complementary district components that enable everyday life and business continuity. More importantly, Biz Hub at Lima Estate is positioned to be employment-anchored, not lifestyle-led. Its differentiation is structural: it is built on a real economic engine and the daily activity of an operating township. “Biz Hub at Lima Estate is not competing on lifestyle alone. It is a central business district built on an operating economy, anchored by jobs and designed for productivity,” said Rafael Fernandez de Mesa, CEO and President of Aboitiz Land and Aboitiz Economic Estates. “When commerce, mobility, offices, and education are planned together inside an industry-anchored ecosystem, you reduce friction across daily life and create a stronger platform for long-term value,” he added. The growth of Lima Estate and the development of Biz Hub reflect a larger structural trend unfolding across the Philippines: the gradual but deliberate redistribution of economic activity away from Metro Manila and toward growth corridors that are better positioned to absorb it. This shift is not driven by proximity alone. It is driven by the recognition that efficiency, livability, and competitiveness are interconnected, and that the environments where businesses operate directly shape their ability to perform. When infrastructure, industry, commerce and community are planned together from the beginning, the entire system becomes more functional, more resilient, and more capable of sustaining long-term growth. Aboitiz Economic Estates is engaging investors and business operators through curated briefings and site visits to share Biz Hub’s role within the Lima ecosystem and the broader case for decentralization.
2026-03-28 11:14:05

A "Love for Sports" Fosters Non-Cognitive Skills: Latest Statistical Analysis Reveals Correlation Between Affinity for Sports and Non-Cognitive Skills
Milabo Data Analysis Highlights Scalable Insights Supporting Leifras' Education Philosophy TOKYO, March 27, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social business company dedicated to youth sports and community engagement, announced today that it has released the results of a survey and analysis conducted using its proprietary non-cognitive skill measurement system "Milabo." The results demonstrate a link between affinity for sports and non-cognitive skill development, supporting Leifras' education philosophy of "acknowledge, praise, encourage, and motivate." The Company analyzed factors influencing the growth of non-cognitive skills using Milabo data from students at Hachioji City Takane Elementary School and the results of New Physical Fitness Test of 126 children. The results statistically demonstrate that a child's level of non-cognitive skills and key character strengths is more closely linked to a positive "love for sports" mindset than to actual physical athletic ability. The study reveals that "liking sports (affinity for sports)" is an important factor in improving non-cognitive skills, with a significant correlation coefficient. In the Milabo measurement system, non-cognitive skills are measured by five factors defined by the Company: Courtesy and Etiquette, Leadership, Cooperativeness, Self-Management, and Problem-Solving. Survey Results: Correlation Between Affinity for Sports and Non-Cognitive Skills 1. Children Who "Like Sports" Exhibit Higher Non-Cognitive Skills Correlation analysis between the total score of non-cognitive skills and the item "Do you like playing sports?" produced a correlation coefficient of r = 0.34. By comparison, the correlation coefficient between the total score of the physical fitness test and non-cognitive skills was r = 0.21, indicating that, compared to athletic performance, a positive attitude toward sports is more strongly linked to non-cognitive skill development. 2. Five Non-Cognitive Skills Fostered by a Positive Attitude Toward Sports This study showed that a positive attitude toward sports has a positive effect on all five factors of non-cognitive skills defined by the Company (Courtesy and Etiquette, Leadership, Cooperativeness, Self-Management, and Problem-Solving). 3. Strongest Effects on Self-Regulation and Problem-Solving Among the five factors of non-cognitive skills, correlations were highest in "Self-Management" at r = 0.39 and "Problem-Solving" at r = 0.29. These results suggest that a positive attitude toward sports is closely related to the development of the ability to regulate oneself and the strength to face difficulties. These results support that a strong motivation for sports activities plays a more important role in sustaining high levels of non-cognitive skills than athletic performance alone. Relevance to Leifras' Education Philosophy The results of this analysis have once again validated how Leifras' education philosophy contributes to the growth of children. Wide Scope and Applicability: This survey and analysis were conducted in a general school education setting with children who are not members of a specific sports school, supporting the broader applicability of the Company's methodology.Education Philosophy to Foster a "Love for Sports": Since its founding, the Company has held the philosophy of " acknowledge, praise, encourage, and motivate," and has been developing an education methodology that emphasizes the growth of non-cognitive skills rather than a victory-first mentality.Continuous Implementation of Philosophy: In light of the findings, the Company plans to continue implementing its education philosophy that cultivates intrinsic motivation and passion for sports in each individual student.About the Non-Cognitive Skill Measurement System "Milabo" "Milabo" is Leifras' proprietary assessment tool designed to quantify non-cognitive skills, developed based on the Company's accumulated know-how and joint research with experts in sports psychology. The system focuses on evaluating non-cognitive skills using five factors: "Courtesy and Etiquette," "Leadership," "Cooperativeness," "Self-Management," and "Problem-Solving". Milabo helps the Company to visualize the developmental progress of students' non-cognitive skills, establish learning goals, and create instructional strategies, enhancing Leifras' service differentiation. Future Development Plans The Company intends to further visualize data through "Milabo" to enhance educational outcomes and strengthen its data-driven service model. Specifically, to build on this survey, which has supported the link between sports affinity and non-cognitive skill development, Leifras plans to conduct longitudinal studies to explore other factors and further clarify causal pathways influencing non-cognitive skill development. About LEIFRAS Co., Ltd. Headquartered in Tokyo, Leifras is a sports and social business company dedicated to youth sports and community engagement. The Company primarily provides services related to the organization and operations of sports schools and sports events for children. As of December 31, 2024, Leifras was recognized as one of Japan's largest operators of children's sports schools in terms of both membership and facilities by Tokyo Shoko Research. The Company's approach to sports education emphasizes the development of non-cognitive skills, following the teaching principle "acknowledge, praise, encourage, and motivate." The holistic approach that integrates physical and mental development sets Leifras apart in the industry. Building upon deep experience and know-how in sports education, Leifras also operates a robust social business sector, dispatching sports coaches to meet various community needs with the aim to promote physical health, social inclusion, and community well-being across different demographics. For more information, please visit the Company's website: https://ir.leifras.co.jp/. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may," or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the U.S. Securities and Exchange Commission (the "SEC"). Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. For more information, please contact: LEIFRAS Co., Ltd. Investor Relations Department Email: IR@leifras.co.jp Ascent Investor Relations LLC Tina Xiao Phone: +1-646-932-7242 Email: investors@ascent-ir.com
2026-03-27 01:19:59

Kickapoo Lucky Eagle Casino & Hotel Advances Digital Transformation with QCI Enterprise Platform
SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI), a leader in data-driven solutions for the gaming and hospitality industries, today announced that Kickapoo Lucky Eagle Casino & Hotel has taken a significant step forward in its digital transformation journey by implementing the QCI Enterprise Platform. As the gaming industry continues to evolve, leading operators are investing in unified, real-time intelligence to stay competitive and deliver elevated guest experiences. Kickapoo Lucky Eagle Casino & Hotel’s move to QCI reflects a strategic initiative to modernize its analytics infrastructure and unlock new levels of operational agility. By adopting the QCI Enterprise Platform, the property is transitioning to a fully integrated environment where player development, marketing, and operations are powered by real-time data and advanced analytics. This shift enables teams across the organization to act faster, align more effectively, and deliver more personalized guest engagement. "Our transition to the QCI Enterprise Platform reflects our commitment to operational excellence and delivering outstanding service to our guests. The real-time insights and comprehensive analytics offered by QCI enable us to make data-driven decisions that will enrich the overall customer experience and enhance our internal processes,” said Benito Fernandez, Director of Marketing, Kickapoo Lucky Eagle Casino & Hotel. QCI CEO Dr. Ralph Thomas emphasized the importance of modernization across the gaming industry. "Today’s most successful operators are those who can unify their data and act on it in real time,” said Thomas. "Kickapoo Lucky Eagle Casino & Hotel is embracing a more modern, agile approach to operations, and we’re proud to support their transformation as they leverage data to drive performance and elevate the guest experience.” Melissa Chiaurro, former President of VizExplorer and current VP of Business Development at QCI, highlighted the impact of the transition. "The team has successfully transitioned Kickapoo Lucky Eagle to the QCI Platform, expanding their analytical capabilities while maintaining continuity across operations,” said Chiaurro. "This next step will deliver a more intuitive user experience and deeper visibility into player behavior, and we’re excited to support their continued evolution with QCI.” ABOUT KICKAPOO LUCKY EAGLE CASINO & HOTEL Kickapoo Lucky Eagle Casino & Hotel, located in Eagle Pass, Texas, is a premier gaming destination offering a wide array of casino games, dining options, and luxurious accommodations. With a commitment to providing an unparalleled entertainment experience, Kickapoo Lucky Eagle Casino • Hotel is dedicated to creating moments of excitement and joy for its guests. You can learn more about the Kickapoo Lucky Eagle Casino & Hotel by visiting the website at www.luckyeagletexas.com. For media inquiries, please contact the Casino Marketing Department at 830.773.2255. ABOUT QCI Quick Custom Intelligence (QCI) has pioneered the revolutionary QCI AGI Platform, an artificial intelligence platform that seamlessly integrates player development, marketing, and gaming operations with powerful, real-time tools designed specifically for the gaming and hospitality industries. Our advanced, highly configurable software is deployed in over 300 casino resorts across North America, Australia, New Zealand, Canada, Latin America, and The Bahamas. The QCI AGI Platform, which manages more than $42 billion in annual gross gaming revenue, stands as a best-in-class solution, whether on-premises, hybrid, or cloud-based, enabling fully coordinated activities across all aspects of gaming or hospitality operations. QCI’s data-driven, AI-powered software propels swift, informed decision-making vital in the ever-changing casino industry, assisting casinos in optimizing resources and profits, crafting effective marketing campaigns, and enhancing customer loyalty. QCI was co-founded by Dr. Ralph Thomas and Mr. Andrew Cardno and is based in San Diego, with additional offices in Las Vegas, St. Louis, Denver, Seattle, and Phoenix. Main phone number: (858) 299.5715. Visit us at www.quickcustomintelligence.com. ABOUT DR. RALPH THOMAS Dr. Ralph Thomas is the Co-Founder and Chief Executive Officer of Quick Custom Intelligence. Ralph is a product visionary in applied analytics and the founder of two companies that deliver solutions in casino gaming, education, and adult learning. As a gaming industry veteran, Dr. Thomas has substantial experience implementing analytics into single and multi-property gaming companies to drive tangible and measurable gains to the bottom line and has built business intelligence tools for multibillion-dollar casinos. Dr. Thomas is co-author of fifteen books and over 80 articles on applied analytics and data science in gaming, an inventor on dozens of patents, and understands gaming from raw data up through casino operations, giving him a unique, 360-degree view of the industry.
2026-03-25 15:19:45

CNL Employees and NLPC Team Up to Raise $160,000 for United Way
Nuclear Laboratories Partners of Canada (NLPC) matches Canadian Nuclear Laboratories (CNL) employee donations during annual United Way campaign CNL EMPLOYEES AND NLPC TEAM UP FOR UNITED WAY Nuclear Laboratories Partners of Canada (NLPC) matches Canadian Nuclear Laboratories (CNL) employee donations during annual United Way campaign CNL EMPLOYEES AND NLPC TEAM UP FOR UNITED WAY Nuclear Laboratories Partners of Canada (NLPC) matches Canadian Nuclear Laboratories (CNL) employee donations during annual United Way campaign CHALK RIVER, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that its employees have teamed up with Nuclear Laboratory Partners of Canada (NLPC) to raise $160,000 for this year’s United Way campaign. Thanks to a matching contribution from NLPC, CNL’s parent company, the $80,000 raised by CNL employees was doubled in size, making this year’s annual campaign a resounding success, while delivering much-needed funds to improve the lives of those in need throughout CNL’s local communities. CNL employees have been participating in fundraising activities for the United Way dating all the way back to the early 1960s, with annual campaigns held at the company’s Chalk River Laboratories campus, and more recently at the Port Hope locations in Ontario and at the Pinawa site in Manitoba. Collectively this year, employees raised $50,000 for the United Way Eastern Ontario chapter, over $10,000 for the United Way Winnipeg chapter, and $20,000 for the Northumberland United Way. Each of these three locations will receive a matching contribution from NLPC, doubling the fundraising total. "CNL and NLPC recognize the role that local businesses can play as a community partner in supporting those who are less fortunate, and we are incredibly proud of the way our employees dug deep into their pockets this year to do so through CNL’s annual United Way campaign,” commented Dennis Carr, CNL’s President and CEO. "NLPC has only recently assumed ownership of CNL, but the United Way campaign is aligned with our values and part of a larger community involvement plan that is only getting started. Working together, we intend to offer meaningful support to our local communities in areas that include education, social services and economic development. We’re off to a great start, and I want to personally thank everyone who donated this year through their time and financially, to make this year’s campaign so successful.” In addition to cash and ongoing payroll donations, CNL staff participated in various fundraising activities during the campaign at the Chalk River Laboratories. This included the always popular pancake breakfast, the human resources team’s annual bake sale, the successful ‘Pet Photo Contest,’ online BINGO, and parking spot raffles. At Whiteshell, the famous Chili Cook Off returned, while employees participated in the Ultimate Burger Battle showdown in Port Hope. Overall, it was a month of fun and fundraising, all for a good cause. To learn more about CNL and its annual United Way campaign, please visit www.cnl.ca. About CNL As Canada’s premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance - restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector, and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions. To learn more about CNL, please visit www.cnl.ca. CNL Contact: Philip Kompass Director, Corporate Communications 1-866-886-2325 media@cnl.ca Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/df03d0a5-ac5f-4f75-bd2d-554ae6952fdc https://www.globenewswire.com/NewsRoom/AttachmentNg/96b2f67a-b2c3-4041-a1e8-238e00e5a4e2
2026-03-25 15:19:26

Orange Door Music Video Inc. Signals Shift in Hospitality as Venue Screens Emerge as Revenue Drivers
LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- Orange Door Music Video Inc. is highlighting a major shift in how hospitality venues are using their TV screens, following new industry data from OptiSigns that shows rapid growth in digital out-of-home (DOOH) advertising across entertainment environments. According to OptiSigns, U.S. out-of-home advertising revenue surpassed $9 billion, with digital formats now accounting for approximately 42% of total spend. Programmatic DOOH grew 34% over the same period, with entertainment venues emerging as one of the fastest-growing segments, increasing their share of spend from 8% to 11% recent data shows. For Orange Door, the data reflects what is already playing out inside venues. "What used to be background TV is quickly becoming one of the most valuable assets in the venue,” said Ross, Managing Director at Orange Door Music Video Inc. "Operators are starting to treat their screens as something they can actively manage, not just something that fills space.” The OptiSigns report highlights why entertainment venues are attracting increased advertising investment. Patrons typically spend between 40 and 60 minutes in these environments, compared to just a few minutes in traditional out-of-home settings. That extended dwell time, combined with a strong concentration of Gen Z and Millennial audiences, is driving higher engagement and premium advertising rates. There is also a clear link to purchasing behaviour. Campaign data referenced by OptiSigns shows alcohol brands achieving sales lifts of up to 26%, while quick-service restaurant campaigns have driven foot traffic increases of more than 30% when advertised within venue environments. For hospitality operators, the implications are immediate. Venues that actively manage their screens, rather than defaulting to news broadcasts or replayed sports, are beginning to treat them as part of their overall revenue strategy. This includes promoting in-house offers, upcoming events, and tapping into increasing demand for in-venue advertising. "There’s a clear gap opening up,” said Ross. "Venues that take control of their screens are creating a better customer experience while also opening up new revenue opportunities. Those that don’t are leaving value on the table.” As competition across hospitality continues to intensify, the role of in-venue screens is shifting from passive entertainment to a core part of both the customer experience and the commercial model. For more information, visit www.orangedoormusic.com --------------------------------- About Orange Door Orange Door is a provider of music video, digital signage, and in-venue entertainment systems for hospitality venues. With head offices in the United States and abroad, the company supports bars, restaurants, and entertainment venues across North America and beyond, helping operators take control of their on-screen content and unlock new revenue opportunities through advertising and engagement. Media Contact: Andrew Vickers andrew@orangedoormusic.com 888-679-7422 www.orangedoormusic.com
2026-03-25 15:19:24

Resolutions of Annual General Meeting of LHV Group
The Annual General Meeting of Shareholders of AS LHV Group (LHV Group) was held on 25 March 2026 at Swissôtel Tallinn Hotel. It was possible to participate in the meeting both physically and electronically. A total of 1,449 shareholders participated in the meeting, representing a total of 197,011,133 votes, which corresponds to 60.09% of all votes entitled to participate in the meeting. Of the participants 1,302 shareholders, representing a total of 182,546,136 votes, voted before the meeting according to the procedure for pre-voting and electronic participation published with the notice on calling the meeting. The notice on calling the Annual General Meeting was published in the stock exchange information system and on the Group’s website on 3 March 2026. On the same date, the notice was printed in Postimees daily newspaper. The Annual General Meeting of the Shareholders of LHV Group adopted the following resolutions: 1. Annual Report 2025 Approve the Annual Report of LHV Group for the financial year 2025 as submitted to the General Meeting. In favour: 186,725,976 votes (94.78% of the represented votes) Opposed: 182,116 votes (0.09% of the represented votes) Neutral: 20,151 votes (0.01% of the represented votes) Withheld: 10,082,890 votes (5.12% of the represented votes) 2. Profit Distribution for Financial Year 2025 The consolidated net profit attributable to LHV Group as the parent company of the consolidation group in the financial year 2025 amounts to EUR 114,265 thousand. Transfer EUR 0 to the legal reserve. Approve the profit allocation proposal made by the Management Board and pay dividends in the net amount of 17 euro cents per share. The list of shareholders entitled to receive dividends will be established as at on 10 April 2026 EOD of Nasdaq CSD settlement system. Consequently, the day of change of the rights related to the shares (ex-dividend date) is set to 9 April 2026. From this day onwards, the person acquiring the shares will not have the right to receive dividends for the financial year 2025. Dividends shall be disbursed to the shareholders on 15 April 2026. In favour: 194,594,507 votes (98.77% of the represented votes) Opposed: 18,729 votes (0.01% of the represented votes) Neutral: 30,754 votes (0.02% of the represented votes) Withheld: 2,367,143 votes (1.2% of the represented votes) 3. Financial Results of First Two Months of 2026 An overview of the economic results of LHV Group for the first two months of 2026 was given by the CEO of LHV Group. 4. Five-Year Financial Forecast An overview of the five-year financial forecast of LHV Group was given by the CEO of LHV Group. 5.Dividend Policy An overview of the amendment to the Dividend Policy of LHV Group was given by the CEO of LHV Group. 6. Remuneration Principles To approve the Remuneration Principles of the Management Board of LHV Group as presented to the General Meeting. In favour: 192,288,724 votes (97.60% of the represented votes) Opposed: 877,138 votes (0.45% of the represented votes) Neutral: 557,509 votes (0.28% of the represented votes) Withheld: 3,287,762 votes (1.67% of the represented votes) 7. Recall of Supervisory Board Members To recall Raivo Hein (personal identification code: 36611230293) and Tiina Mõis (personal identification code: 45702240324) from the Supervisory Board of LHV Group, effective immediately upon the adoption of this resolution. In favour: 182,098,664 votes (92.43% of the represented votes) Opposed: 31,299 votes (0.02% of the represented votes) Neutral: 219,937 votes (0.11% of the represented votes) Withheld: 14,661,233 votes (7.44% of the represented votes) 8.Election and Extension of Term of Office of Supervisory Board Members To elect Kairi Pauskar (personal identification code: 48201312725) and Christian Schröder (birth date: 18.01.1971) as new members of the Supervisory Board of LHV Group, with the term commencing immediately upon the adoption of this resolution and continuing for three years, i.e., from 25 March 2026 until 24 March 2029 (inclusive). To extend the term of office of Rain Lõhmus (personal identification code: 36612300228), Andres Viisemann (personal identification code: 36810020231), and Tauno Tats (personal identification code: 37205160226), members of the Supervisory Board of LHV Group, for a period of 3 (three) years from the expiry of their current term of office, i.e., from 29 March 2026 until 28 March 2029 (inclusive). In favour: 192,149,465 votes (97.53% of the represented votes) Opposed: 1,219,036 votes (0.62% of the represented votes) Neutral: 329,735 votes (0.17% of the represented votes) Withheld: 3,312,897 votes (1.68% of the represented votes) All relevant documents associated with the Group’s General have been presented in more detail on the Group’s website https://investor.lhv.ee/en/general-meetings/ where the minutes of the meeting shall also be made available at the latest 7 days after the General Meeting. LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus, and LHV Bank Limited. The Group employs approximately 1,200 people. The services of LHV Pank are being used by 497,000 customers, the II pillar pension funds managed by LHV have 105,000 active customers and LHV Kindlustus protects a total of 235,000 customers. LHV Bank Limited, a subsidiary of the Group, holds a banking licence in the United Kingdom and provides banking services to international financial technology companies, as well as loans to small and medium-sized enterprises. Investor relations Sten Hans Jakobsoo Head of Investor Relations and Corporate Development Email: stenhans.jakobsoo@lhv.ee Media and communications Paul Pihlak Head of Communications Email: paul.pihlak@lhv.ee
2026-03-25 15:19:22

Cumulus Media’s Westwood One Presents Exclusive Multiplatform Audio Coverage of the 2026 NCAA® Women’s Basketball Tournament
NCAA March Madness Logo NCAA March Madness March Madness® Broadcasts Connect College Hoops Fans across Multiple Platforms - 200+ Radio Stations, SiriusXM, NCAA March Madness LiveTM, WestwoodOneSports.com, the Westwood One Sports App, The Varsity Network App, Alexa-Enabled Devices, and TuneIn Premium ATLANTA, March 25, 2026 (GLOBE NEWSWIRE) -- Cumulus Media’s (OTCQB: CMLS) Westwood One, one of America’s largest audio networks and the official NCAA audio broadcast partner, will once again deliver comprehensive coverage of the NCAA Division I Women’s Basketball Championship. Fans can follow every play-from the Sweet Sixteen and Elite Eight through the Final Four and National Championship. Coverage tips off Friday, March 27 with Sweet Sixteen matchups featuring two doubleheaders. The first begins at 2:00 p.m. ET from Dickies Arena in Fort Worth, TX, followed by a second doubleheader at 7:15 p.m. ET from Golden 1 Center in Sacramento, CA. Action continues Saturday, March 28 with two additional Sweet Sixteen doubleheaders-starting at 12:00 p.m. ET from Fort Worth and 4:45 p.m. ET from Sacramento. Elite Eight coverage begins Sunday, March 29 with Fort Worth tipping off at 12:30 p.m. Eastern time, followed by Sacramento tipping off at 3 p.m. ET. Monday March 30 has Fort Worth 3’s Elite Eight beginning at 6:30 p.m. followed by Sacramento 4’s Elite Eight at 9 p.m. Westwood One’s championship coverage concludes with the Final Four from Phoenix, AZ. The national semifinals tip off Friday, April 3, at 6:30 p.m. ET, leading into the NCAA Division I Women’s Basketball National Championship game on Sunday, April 5, at 3:00 p.m. ET. Where to Listen Westwood One’s NCAA men's tournament coverage can be heard on terrestrial radio stations nationwide and via SiriusXM. The Division I Women’s games will also be streamed for free at NCAA.com/MarchMadness and on westwoodonesports.com and on the Westwood One Sports app available in the iTunes and Google Play stores. Additionally, the broadcasts will be available for free via the NCAA March Madness Live app or The Varsity Network app. Fans can also access live audio via Alexa-enabled devices by asking to "Open Westwood One Sports”. TuneIn premium subscribers can also hear all the action live. All-Star Broadcast Team Ryan Radtke and Debbie Antonelli will announce all the action for the Final Four and the National Championship. Ros Gold-Onwude will serve as courtside reporter and J.B. Long and Kim Adams will host the pregame, halftime and postgame shows from the Final Four and National Championship in Phoenix, Arizona. In addition, Westwood One's coverage of NCAA March Madness® will also feature a wealth of renowned commentators and analysts including Nate Gatter, Lance Medow, Mary Murphy, Danny Reed, Isis Young, and Sam Neidermann. Westwood One’s schedule of 2026 NCAA Women’s Basketball Tournament broadcasts: Sweet Sixteen Doubleheaders:Friday, March 27, 2:00 p.m. ET and 7:15 p.m. ETSaturday, March 28, 12:00 p.m. ET and 4:45 p.m. ETElite Eight Doubleheaders:Sunday, March 29, 12:30 p.m. ETMonday, March 30, 6:30 p.m. ETWomen’s Final Four:Friday, April 3, 6:00 p.m. ETWomen’s National Championship:Sunday, April 5, 3:00 p.m. ET A complete schedule of games, announcer bios, exclusive audio content, and a list of radio stations airing Westwood One’s broadcast of the NCAA Women’s Division I Basketball Championship can be found on westwoodonesports.com or the Westwood One Sports app. NCAA, First Four, Final Four, and March Madness are trademarks of the National Collegiate Athletic Association. About Westwood One Sports Westwood One Sports is home to some of the most exciting sports broadcasts on radio. In addition to being the exclusive national audio broadcaster of the NFL since 1987 - featuring regular and post-season NFL football, including the playoffs and the Super Bowl - its other extensive properties include NCAA Basketball, including the NCAA Men’s and Women’s Tournaments and the Final Four®; NCAA Football; The Masters; US Soccer; and other marquee sporting events. On social media, join the Westwood One Sports community on Facebook at facebook.com/westwoodonesports, Instagram at instagram.com/westwoodonesports, and X at x.com/westwood1sports. For more information, visit www.westwoodonesports.com. About Cumulus Media Cumulus Media (OTCQB: CMLS) is an audio-first media company delivering premium content to a quarter billion people every month - wherever and whenever they want it. Cumulus Media engages listeners with high-quality local programming through 393 owned-and-operated radio stations across 84 markets; delivers nationally-syndicated sports, news, talk, and entertainment programming from iconic brands including the NFL, the NCAA, the Masters, US Soccer, AP News, and the Academy of Country Music Awards, across more than 7,800 affiliated stations through Westwood One, a leading national audio network; and inspires listeners through the Cumulus Podcast Network, an established and influential platform for original podcasts that are smart, entertaining, and thought-provoking. Cumulus Media provides advertisers with personal connections, local impact and national reach through broadcast and on-demand digital, mobile, social, and voice-activated platforms, as well as integrated digital marketing services, powerful influencers, full-service audio solutions, industry-leading research and insights, and live event experiences. For more information visit www.cumulusmedia.com. About the NCAA The National Collegiate Athletic Association provides a world-class athletics and academic experience that fosters lifelong well-being for more than 520,000 student-athletes annually. The NCAA stages 92 championships across three divisions, and its 1,100 member schools provide nearly $4 billion in athletics scholarships every year. Visit ncaa.org and ncaa.com for more. Contact: Lisa Dollinger, Dollinger Strategic Communication, for Cumulus Media | Westwood One, lisa@dollcomm.com, and 512.633.4084. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f5f450f-8a8b-47fc-9639-65fdaed75d6c
2026-03-25 15:19:11

Hanwha Vision Launches Global Brand Campaign "Now You See” Featuring Amanda Seyfried to Showcase the Power of Vision Intelligence
New cinematic campaign highlights the shift from reactive security to proactive insights powered by AI and data TEANECK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Hanwha Vision today announced the launch of "Now You See,” a new global brand campaign featuring Academy Award-nominated actress Amanda Seyfried that introduces Vision Intelligence, a new approach that transforms video technology from a reactive security measure into a proactive tool that drives operational insight. Directed by Michael Gracey, the filmmaker behind The Greatest Showman, the cinematic campaign highlights how video technology is evolving into a strategic tool for improving visibility across organizations as well as day-to-day decision making. By combining high-quality imaging, AI analytics, and intelligent automation, modern vision systems help organizations understand patterns, anticipate risks, and make better decisions across everyday operations. Set on a Hollywood soundstage at Sony Pictures Studios, the campaign follows Seyfried as she participates in a screen test to become the face of Hanwha Vision. As she moves through a series of environments, she encounters real-world applications of Hanwha Vision technology that transform ordinary video footage into actionable intelligence. The campaign’s central message, "Now You See,” reflects Hanwha Vision’s approach to Proactive Vision Intelligence (PVI) - a shift beyond traditional monitoring and recording toward AI-powered insights that help organizations anticipate risks, optimize operations, and make better decisions. "Video technology is evolving from a passive security tool into a platform for understanding how environments actually function,” said CH Ha, President at Hanwha Vision. "‘Now You See’ reflects our belief that technology should not just observe the world but help people understand it more clearly and act with greater confidence.” Throughout the film, Seyfried encounters examples of Vision Intelligence in action: Retail: Heatmaps and people-counting analytics reveal customer traffic patterns that inform store layouts and staffing decisions.Smart City: AI-enabled multi-directional cameras provide 360-degree coverage while classifying vehicles and pedestrians to support faster emergency response.Finance: Intelligent analytics identify unusual behavior around ATMs, helping financial institutions detect suspicious activity earlier.Education: Audio-based analytics detect sounds such as breaking glass or distress signals, enabling faster incident response in privacy-sensitive environments.Manufacturing: AI-driven monitoring identifies safety risks such as worker falls or missing protective equipment, improving workplace safety. The technologies showcased in the campaign are not conceptual demonstrations, but real Hanwha Vision solutions currently deployed across industries worldwide. During production, the same technologies were used on set to monitor equipment safety, manage operations, and demonstrate the capabilities of intelligent video systems in a live environment. About Hanwha Vision America Hanwha Vision America is redefining what’s possible in safety, operations, and business intelligence, going beyond security with its continually expanding ecosystem of surveillance & vision solutions. Built on a foundation of trust, innovation in optical design, image processing, and cybersecurity, Hanwha Vision technologies combine 24/7 protection, Artificial Intelligence and cloud-based platforms with the data-powered analytics customers need to generate actionable market insights. Hanwha Vision America is committed to developing intelligent solutions that keep businesses moving forward, empowering organizations to see more, understand deeper, and respond smarter. Discover more at www.hanwhavisionamerica.com. Media Contact Walker Sands for Hanwha Vision America hanwhapr@walkersands.com
2026-03-25 15:19:08

TCS Toronto Waterfront Marathon Organizers, Canada Running Series, Announce New CEO Ahead Of 2026 Season
Charlotte Brookes & Chris Fagel Chief Executive Officer, Charlotte Brookes alongside Chris Fagel, Chief Financial Officer and Technical Course Director. TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- Canada Running Series (CRS), the organization behind several of Canada’s most iconic road races, today announced the appointment of Charlotte Brookes as its new Chief Executive Officer. Brookes succeeds her father, Alan Brookes, and will lead the organization alongside Chris Fagel, who assumes the role of Chief Financial Officer and Technical Course Director. The announcement comes just ahead of the season’s opening event, the Beneva Spring Run-Off on April 4th, marking not only the start of another exciting year of racing, but the beginning of a new era of leadership for one of Canada’s most respected road racing organizations. CRS, which organizes the internationally acclaimed TCS Toronto Waterfront Marathon, has grown under the Brookes family to become a leader and cornerstone of Canadian road racing, attracting tens of thousands of participants each year. Charlotte brings a deep passion for community-driven sport and a proven track record in event leadership. Her appointment represents a meaningful evolution for CRS, honouring the organization’s rich history while charting a bold path forward. The 2026 season will reflect that renewed vision, with an enhanced women’s program, a strengthened focus on accessibility and inclusion, and continued investment in athlete experience from start line to finish. Under Charlotte’s leadership, CRS is prioritizing initiatives that expand participation, elevate women in sport, and make race experiences more welcoming and accessible to runners of all abilities. "Canada Running Series has always been about more than races, it’s about community, connection, and creating experiences that inspire people to challenge themselves and give back,” said Charlotte Brookes, Chief Executive Officer. "As we begin a new season and step into this next era of leadership, I am honoured to build on the extraordinary legacy my father created while working alongside Chris to bring renewed vision, innovation, and energy to the organization and the sport. We’re building on more than forty years of success while staying true to our founding mission of ‘Building Community Through Running.’ Together, we are committed to strengthening that legacy with an even greater focus on excellence, community, accountability, inclusion, and sustainability.” "Founding and growing Canada Running Series has been one of the great privileges of my life,” said Alan Brookes, now Race Director Emeritus and Vice President. "It’s particularly appropriate for us to take this major step forward now, as 2026 marks the 40th anniversary of my organizing running events in Toronto from when I became Race Director of the Spring Run-Off in April 1986. That was an era before the internet, with no online registration, no chip timing, no AI Race Concierges. From its early days to becoming an internationally-recognized series and home to Canada’s premier marathon we’ve built something truly special. Charlotte has been a vital part of that journey and growth every step of the way, from putting safety pins together for kit stuffing at age 7 to managing race operations today; taking our events from those pioneer days into the modern era. I am proud and delighted to see her take the running experience in Canada to the next level. The future of running events, healthy lifestyles and vibrant communities is both expansive and exciting.” Alan remains engaged with CRS through his involvement with the organization’s flagship event, the TCS Toronto Waterfront Marathon, and special projects as the broader organization transitions into its next chapter. With Charlotte and Chris at the helm, CRS is entering 2026 with both new leadership and generational continuity, reinforcing its position as a cornerstone of the Canadian road racing landscape. The season launches April 4th with the Beneva Spring Run-Off in Toronto, marking Charlotte’s first race as CEO. More information on upcoming events is available at canadarunningseries.com ABOUT CANADA RUNNING SERIES (CRS) Canada Running Series is the nation’s premier running circuit with 6 events, including 4 in Toronto and 2 in Vancouver. It annually attracts over 60,000 participants and raises more than $3 million for more than 200 mostly-local charities. The Series includes the World Athletics Elite Label TCS Toronto Waterfront Marathon, and the Athletics Canada National Marathon Championships. Since 1999, CRS has gained international recognition for innovation and organization. To learn more about CRS, visit https://canadarunningseries.com/. MEDIA CONTACT: Melissa DaCunha, Sutherland Corp media@canadarunningseries.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eee86163-82db-4793-80f4-67849a63f3f7
2026-03-25 15:19:00

Hanwha Vision Introduces Purpose-Built Appliances to Power BLAZE Hybrid AI Video Management System
Pre-configured systems simplify deployment and deliver optimized performance for the BLAZE VMS platform TEANECK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Following the introduction of BLAZE VMS, Hanwha Vision today announced a new lineup of BLAZE appliances, purpose-built systems designed to simplify deployment and operation of the hybrid video management platform. Optimized for BLAZE VMS, the appliances provide organizations with a streamlined way to deploy scalable video surveillance systems while reducing installation complexity and ongoing system management. Purpose-Built Appliances for Simplified Deployment BLAZE appliances are specifically engineered to run the BLAZE VMS platform, delivering tightly integrated hardware and software optimized for video surveillance workloads. By combining recording, video management, and client operations within a single system, the appliances provide a reliable foundation for managing modern video surveillance systems. Each appliance arrives fully pre-installed, pre-licensed, and ready to run out of the box, eliminating the need for operating system installation or manual software configuration. This streamlined approach allows integrators to bring systems online quickly while maintaining consistent configurations across deployments. "BLAZE appliances are designed to remove much of the operational complexity traditionally associated with video management systems,” said Seolhee Heo, Sr. Product Manager at Hanwha Vision. "With a hardened operating system and fully pre-configured platform, customers no longer need to manage operating system maintenance, security patching, or dedicated IT oversight, allowing them to focus on operating their surveillance systems instead of maintaining underlying infrastructure.” Optimized Performance and Reliability BLAZE appliances are engineered specifically for continuous video surveillance workloads, with hardware and software designed to operate together as a unified platform. This tight integration delivers predictable system performance while supporting recording, video management, and client operations within a single appliance. Developed alongside the BLAZE VMS platform, the appliances undergo extensive engineering validation to ensure consistent operation across deployments. This provides a reliable foundation for organizations that require stable system performance and long-term operational dependability. Comprehensive Appliance Lineup Hanwha Vision will offer a comprehensive lineup of 12 purpose-built BLAZE appliance models designed to support a wide range of surveillance environments. Compact models with integrated PoE switch options provide an all-in-one solution ideal for smaller deployments, enabling cameras to be connected and managed from a single, space-saving system.Mid-range appliances are designed for environments with larger camera deployments and extended video retention requirements, offering expanded and redundant storage for flexible system configurations.High-performance AI-enabled appliances include dedicated AI acceleration designed to support advanced capabilities such as Semantic Search within the BLAZE VMS platform. These systems enable organizations to perform on-premises generative AI-powered video investigations, allowing operators to search video using natural language while maintaining full control of their infrastructure and data.End-to-End Hanwha Surveillance Ecosystem When combined with Hanwha Vision devices and the BLAZE VMS platform, the appliances provide a tightly integrated end-to-end surveillance solution. This unified architecture simplifies system design and ensures consistent performance across hardware, software, and connected devices. By delivering hardware and software designed to operate together, Hanwha Vision enables organizations to deploy surveillance systems with greater efficiency while maintaining a seamless operational experience. The result is faster installation, simplified system management, and improved long-term reliability for surveillance deployments. For more information about BLAZE appliances, visit hanwhavisionamerica.com/BLAZE/. About Hanwha Vision America Hanwha Vision America is redefining what’s possible in safety, operations, and business intelligence, going beyond security with its continually expanding ecosystem of surveillance & vision solutions. Built on a foundation of trust, innovation in optical design, image processing, and cybersecurity, Hanwha Vision technologies combine 24/7 protection, Artificial Intelligence and cloud-based platforms with the data-powered analytics customers need to generate actionable market insights. Hanwha Vision America is committed to developing intelligent solutions that keep businesses moving forward, empowering organizations to see more, understand deeper, and respond smarter. Discover more at www.hanwhavisionamerica.com. Media Contact Walker Sands for Hanwha Vision America HanwhaPR@walkersands.com
2026-03-25 15:18:49

Jollibee ​marks first National Day of Joy, bringing smiles across PH
Jollibee, one of the country\'s top fast-food chains, celebrated its first-ever National Day of Joy last March 20, 2026, coinciding with the International Day of Happiness. The day combined community outreach, a mall event, and digital activities to inspire Filipinos to share joy with others. **media[88325]** “Jollibee has always been about serving great-tasting food and sharing the joy of eating with everyone. That’s why International Day of Happiness is so special for us because it reminds us why we do what we do,” said Dorothy Ching, vice president for Marketing of Jollibee Philippines. “National Day of Joy gives us the chance to celebrate those moments and inspire everyone to share happiness. It can be as simple as a family meal, a child’s birthday, or a small act of kindness. Every day, we have the power to brighten someone’s world, and that’s what we want to celebrate together.” **media[88326]** The highlight of the celebration took place at One Ayala, Makati, where the beloved Jollibee mascot welcomed families and friends with hugs and complimentary Crunchy Chicken Sandwiches. Smiles brightened faces as guests posed for photos and shared playful moments with both companions and strangers. Beyond the mall, the festivities reached orphanages and elderly care facilities nationwide. Jollibee brought joy to Missionaries of the Poor in Manila, Little Angels Home Inc. in South Luzon, Children\'s Home of Eucharistic Love and Kindness in North Luzon, Ramon Durano Foundation Home for the Aged in Visayas, and Davao Veil Geriatric Home Care in Mindanao. Children beamed as they received treats, while seniors shared joyful stories and warmly embraced the surprise visits, demonstrating how simple acts can brighten hearts. **media[88327]** The online celebration extended the joy further. Netizens posted their own joyful moments on Facebook, showing family celebrations, playful selfies, and joyful experiences at Jollibee. The trending X Party encouraged fans of Jollibee endorsers and the general public to share stories and videos spreading happiness, creating a virtual chain of smiles and laughter across the country. Meanwhile, the “Choose Your Joy” delivery promo added extra delight to households, offering free delivery on orders over ₱500 placed through the Jollibee App or order.jollibee.com, or a free Peach Mango Pie on orders over ₱300. By making each activity both interactive and meaningful, Jollibee’s National Day of Joy reinforced the brand as a cultural connector, showing how small gestures like hugs, treats, and shared stories can brighten lives nationwide. Craving more Jollibee treats and exclusives? Head to www.jollibee.com.ph for the latest updates, order your favorites at https://order.jollibee.com, and follow us on social media for more Joyful surprises!
2026-03-24 05:07:00

RCBC targets growth with workforce shift as women hit 65% of staff
Rizal Commercial Banking Corp. (RCBC) is pivoting toward a more female-centric workforce as the lender seeks to cement its position among the Philippines’ top private banks. Women now constitute 65 percent of the bank’s total headcount, a figure that significantly outpaces the 35 percent represented by men and underscores a broader shift in the leadership dynamics of the Manila-based institution. The demographic breakdown at RCBC, led by Chairperson Helen Yuchengco Dee, reflects a trend across its operations ranging from retail banking and frontline services to high-level executive management. This concentration of female talent is being framed by the bank not merely as a diversity metric, but as a strategic pillar for its next phase of expansion in a competitive regional market. Rowena F. Subido, RCBC’s head of human resources, said the bank’s current workforce composition is the result of internal systems designed to recognize talent irrespective of gender. According to Subido, the bank is actively investing in mentorship and leadership development programs to ensure that this majority demographic has a clear path to senior decision-making roles. The goal is to create an environment where women can lead the bank’s future initiatives, she said. As the fifth-largest privately owned bank in the Philippines, RCBC is navigating an era of digital transformation and heightening competition from both traditional lenders and fintech startups. The bank, a key unit of the Yuchengco Group of Companies, provides a spectrum of financial services including corporate, retail, and investment banking, as well as wealth management. Its reliance on female leadership comes as the institution looks to scale its nationwide branch network and enhance its digital platforms to reach a broader segment of the Filipino population. The bank’s leadership argues that fostering an inclusive workplace is essential to its long-term stability and performance. Internal initiatives currently focus on building talent pipelines that allow employees to transition from operational roles into strategic positions. These efforts include continuous learning opportunities and professional growth tracks intended to prepare the workforce for the complexities of modern financial services. Subido noted that by investing in systems that support such development, RCBC is empowering its employees to contribute more effectively to the bank\'s strategic priorities. These priorities include expanding customer reach and strengthening digital capabilities to maintain its market standing. For RCBC, the focus remains on maintaining a culture where professional growth is accessible, ensuring the institution remains resilient as it adapts to the evolving economic landscape of the Philippines.
2026-03-21 08:36:00

Belen powers Solar Spikers past Highrisers ahead of play-In clash
Capital1 survived a gritty challenge from Galeries Tower, pulling off a hard-earned 25-20, 22-25, 25-22, 26-24 victory to close out the Premier Volleyball League All-Filipino Conference preliminaries at the FilOil Playtime Centre on Saturday, March 21. Bella Belen bounced back in emphatic fashion after being held below 20 in her previous outing, delivering a triple-double performance to power Capital1’s win. The former three-time UAAP MVP erupted for 23 points, 14 excellent digs and 15 receptions, showcasing her all-around brilliance. She dictated the tempo, steadied the defense and delivered crucial hits when it mattered most. But she didn’t do it alone this time, as Capital1 drew strong support across the board. France Ronquillo led the charge offensively with 20 points to earn Best Player of the Game honors, while Cherry Nunag and Sydney Niegos chipped in 14 and 11 points, respectively. Despite the match carrying no bearing on their already-set Play-In fates, both teams competed with playoff-like intensity, knowing a win would provide a crucial morale boost ahead of their rematch in the next phase. Capital1 (4-5) and Galeries Tower (2-7) finished eighth and ninth, respectively, in the 10-team field, landing in the same Play-In bracket (Group 1) along with the No. 5 team. Group 2 will feature the sixth, seventh, and 10th-ranked squads. The Play-In stage begins Tuesday, with teams set to play a round-robin format. The top performers will advance to knockout matches against the losers of the qualifying round crossover clashes. Meanwhile, the top four teams – still incomplete at press time – will battle for the first two semifinal berths starting Thursday. PLDT and Cignal have already secured spots in the qualifying round, while Akari, Farm Fresh, Creamline, and Nxled remain in contention, with tiebreak points likely to determine the final standings. Initially expected to dominate, Capital1 instead found itself pushed to the limit by a determined Galeries Tower side eager to snap its skid and build momentum heading into the Play-In. The Solar Spikers dominated the attack department, 74-59, overwhelming Galeries Tower’s defense and offsetting the 23 free points they conceded from errors. The victory snapped Capital1’s two-game skid and provided much-needed momentum heading into the Play-In stage. Galeries Tower put up a fight with four players also scoring in double figures, led by Aiza Pontillas with 17 points, alongside Jean Asis (14), and Erika Deloria and Gayle Pascual with 10 each. However, a costly fourth-set meltdown underscored the Highrisers’ struggle with composure – an area they must address if they hope to pull off an upset in the next round. The Solar Spikers took the opening set but saw the Highrisers respond strongly to even the match. Capital1 regained control in the third frame, but Galeries Tower appeared poised to force a decider after racing to a commanding 14-6 lead in the fourth. However, the Highrisers faltered down the stretch as Capital1 unleashed a late surge led by the league’s top scorer. Belen delivered three of the Solar Spikers’ last four points, rescuing the Solar Spikers from a 23-24 deficit with a mix of power and precision. She drew support from Ronquillo and Leila Cruz, while a crucial ace by Nunag helped spark the comeback. From a tense 19-all count, Capital1 leaned on composure and firepower. Though Galeries Tower stayed within striking distance behind Pontillas, Belen took over in the clutch – tying the set, saving a set point with a thunderous kill, and eventually sealing the one-hour, 55-minute win. A costly error by Winnie Bedana gave Capital1 the edge at 25-24, and moments later, Belen put the finishing touches with another decisive hit. In the end, when the pressure peaked, Capital1 – and Belen – delivered.
2026-03-21 08:34:00

Issue of Shares and Cleansing Notice
Settlement of the Placement for A$25m TORONTO and PERTH, Western Australia, March 19, 2026 (GLOBE NEWSWIRE) -- Further to its ASX announcement on 13 March 2026, Cygnus Metals Limited ("Cygnus” or the "Company”) has today issued a total of 156,250,000 fully paid ordinary shares ("Shares”) at an issue price of A$0.16 each under the Placement, raising A$25 million before costs. The Shares were issued pursuant to ASX Listing Rules 7.1 and 7.1A. Cygnus issued the Shares without disclosure under section 708A(5) of the Corporations Act 2001 (Cth) ("Act”). With reference to those Shares issued, in accordance with section 708A(6) of the Act, the Company gives notice under paragraph 708A(5)(e) that: the Shares were issued without disclosure to investors under Part 6D.2 of the Act, andas at the date of this notice:the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company;the Company has complied with sections 674 and 674A of the Act; andthere is no excluded information within the meaning of sections 708A(7) or 708A(8) of the Act, which is required to be disclosed under section 708A(6)(e) of the Act. As previously announced, the Company has ongoing exploration and drill programs at its Chibougamau Copper-Gold Project in Quebec and is awaiting assay results from its current drill program (which remains ongoing). The Company will announce its assay results when it is in a position to complete the collation and interpretation of all data and in accordance with its continuous disclosure obligations, the JORC Code and the ASX Listing Rules. This announcement has been authorised for release by the Board of Directors of Cygnus. David Southam Executive Chairman T: +61 8 6118 1627 E: info@cygnusmetals.com Media: Paul Armstrong Read Corporate +61 8 9388 1474 About Cygnus Metals Cygnus Metals Limited (ASX:CY5, TSXV:CYG, OTCQB:CYGGF) is a diversified critical minerals exploration and development company with projects in Quebec, Canada and Western Australia. The Company is dedicated to advancing its Chibougamau Copper-Gold Project in Quebec with an aggressive exploration program to drive resource growth and develop a hub-and-spoke operation model with its centralised processing facility. In addition, Cygnus has quality lithium assets with significant exploration upside in the world-class James Bay district in Quebec, and REE and base metal projects in Western Australia. The Cygnus team has a proven track record of turning exploration success into production enterprises and creating shareholder value.
2026-03-19 22:48:34

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
David Meeker Quote David Meeker Quote Dr. Shoemaker quote Dr. Shoemaker quote IMCIVREE packaging IMCIVREE packaging with vial IMCIVREE 3D Render IMCIVREE 3D Render -- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction - -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] -- -- Company to host conference call today at 7:00 p.m. ET -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO). Acquired HO is a rare disease characterized by accelerated and sustained weight gain caused by an injury to the hypothalamus or hypothalamic dysfunction. With this label expansion, IMCIVREE is indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired HO. "IMCIVREE is now the first and only FDA-approved therapy for acquired HO, offering a targeted approach that addresses the underlying biology of this disease and meets a critical unmet need for patients who previously had no treatment options,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. "This is a transformative milestone for Rhythm and reinforces our commitment to bringing meaningful therapies to patients living with rare MC4R pathway diseases.” The MC4R pathway is responsible for controlling physiological functions such as energy expenditure, hunger, and weight regulation. Acquired HO most frequently follows tumors and their treatment or other hypothalamic injury or dysfunction. Based on analysis of the literature, tumor registries and claims data, Rhythm estimates there are approximately 10,000 people living with acquired HO in the U.S. "Having a therapy for individuals and families affected by acquired hypothalamic obesity has the potential to be transformational,” said Amy Wood, Executive Director and Founder of the Raymond A. Wood Foundation. "We’ve seen firsthand the devastating impact acquired hypothalamic obesity has on patients’ and families’ lives, including relentless hunger and accelerated and sustained weight gain. IMCIVREE offers hope and a path forward for thousands of patients who have long been without options.” The approval is supported by the positive pivotal Phase 3 TRANSCEND trial of setmelanotide in 142 patients with acquired HO. The global study met its primary endpoint, with a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI). For the primary endpoint of mean BMI change from baseline, study participants on setmelanotide therapy (n=94) achieved a -15.8% reduction compared with a +2.6% increase among patients on placebo (n=48) at 52 weeks (p20% of participants) were skin hyperpigmentation, nausea, vomiting and headache. "Setmelanotide has shown effectiveness in targeting the underlying biology of acquired HO,” said Ashley Shoemaker, M.D., MSCI, Associate Professor of Pediatrics, Pediatric Endocrinology at Vanderbilt Health. "Patients treated with setmelanotide experienced meaningful reductions in BMI and hunger, demonstrating the therapy’s ability to deliver clinically significant outcomes in both children and adult patients. Acquired HO is a severe disease that requires early and proactive management. With the availability of IMCIVREE, physicians can offer a targeted therapy.” IMCIVREE® (setmelanotide) is also approved in the U.S. and Europe in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. Rhythm is committed to supporting access for patients to its medicines and IMCIVREE® (setmelanotide) will be available for patients in the U.S. immediately. Rhythm InTune provides personalized, ongoing educational support for individuals living with certain rare forms of obesity. The program is designed for patients seeking education for themselves and their health care providers, assistance with insurance navigation at treatment initiation, injection support, and guidance on what to expect throughout treatment. For more information, contact patientsupport@rhythmtx.com. Conference Call Information Rhythm will host a live conference call and webcast at 7:00 p.m. ET today to discuss the FDA approval of IMCIVREE for patients with acquired HO. To access the live conference call, participants may register here. A live webcast of the event will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the event and will be available for 30 days following the event. About Acquired Hypothalamic Obesity Acquired hypothalamic obesity is a rare disease characterized by accelerated and sustained weight gain caused by an injury to the hypothalamus. Hypothalamic injury may lead to decreased alpha-melanocyte-stimulating hormone (α-MSH) production and impairment of MC4R pathway signaling. The MC4R pathway is responsible for regulating energy balance and body weight. Acquired hypothalamic obesity most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors. Additional causes of injury may include traumatic brain injury, stroke or inflammation. Due to impairment of the MC4R pathway, patients experience accelerated and sustained weight gain, often accompanied by hyperphagia and/or decreased energy expenditure. Acquired hypothalamic obesity can occur as early as six months following hypothalamic injury. Rhythm estimates there are approximately 10,000 people living with acquired HO in the U.S. About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA. Setmelanotide Indication In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology. Limitations of Use Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benignOther types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.Important Safety Information CONTRAINDICATIONS Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. WARNINGS AND PRECAUTIONS Disturbance in Sexual Arousal: Spontaneous penile erections and increased frequency of penile erections in males have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention. Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE. Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients. IMCIVREE may also cause development of new melanocytic nevi or darkening of pre-existing nevi. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions. Acute Adrenal Insufficiency with Acquired HO: Patients with acquired HO and secondary adrenal insufficiency reported serious adverse reactions related to acute adrenal insufficiency in 5% of IMCIVREE-treated patients and no placebo-treated patients. In patients with secondary adrenal insufficiency, monitor for clinical signs of acute adrenal insufficiency. Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus: Patients with acquired HO and concomitant central diabetes insipidus (DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of IMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia in 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor serum sodium levels with changes in fluid intake and hydration status. Adjust the doses of concomitant therapies for DI/AVP deficiency as needed. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20% in at least 1 indication) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection. USE IN SPECIFIC POPULATIONS Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety Information. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication; the approval and use of IMCIVREE in patients with acquired hypothalamic obesity and its availability for patients; the commercial growth of IMCIVREE; our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates; the estimated market size and addressable population for our drug products, including IMCIVREE for the treatment of hypothalamic obesity in the United States, the European Union and Japan; the future announcement of data from our ongoing clinical trials; the ongoing enrollment in and potential progress or outcomes of our clinical trials; the presentation of the full data from the TRANSCEND study at an upcoming medical meeting; and the content, date and timing of any of the foregoing. Statements using words such as "expect”, "anticipate”, "believe”, "may”, "will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption "Risk Factors” in Rhythm’s Annual Report on Form 10-K for the year ended December 31, 2025 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise. Corporate Contact: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. dconnolly@rhythmtx.com Media Contact: Layne Cosgrove Real Chemistry llitsinger@realchemistry.com Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/e1b973c3-f7ea-411b-b76e-61c421fbc4b2 https://www.globenewswire.com/NewsRoom/AttachmentNg/c7fdc6e3-8dde-4716-ad5a-ee861bbe53a8 https://www.globenewswire.com/NewsRoom/AttachmentNg/a10f49df-12fb-4e4a-84b9-7c3124cdb808 https://www.globenewswire.com/NewsRoom/AttachmentNg/08536ceb-4c66-4372-8b34-f3f7b85e0462
2026-03-19 22:48:06

New Crypto: Pepeto Announces DeFi Tools Innovation While Ethereum Price Prediction Targets $12K and Whale Activity Surges
Dubai, UAE, March 19, 2026 (GLOBE NEWSWIRE) -- Pepeto dropped a DeFi exchange tools innovation and the presale blew past $8.19 million while the rest of the market bled out this week. That kind of capital flowing in during a correction tells you everything about the conviction behind it. Crypto analysts note: "When a project accelerates through a crash, it shows exactly where serious capital sees the biggest returns forming." The Ethereum price found a floor above $2,100 where a heavy buy wall is stacked according to Brave New Coin, and the Ethereum price prediction is setting up the kind of recovery that sends capital rushing back into Ethereum based projects such as Pepeto. The presale kept accelerating, and on chain activity confirms that whale addresses tied to large cap sell offs are the same ones building positions inside this early opportunity. Something about this project's timeline has those wallets moving with urgency. Pepeto DeFi Innovation Arrives as the Ethereum Price Prediction Points to a Recovery Worth Trillions Pepeto's zero fee execution layer and AI driven token screening just advanced to their final build stage. The goal is a live exchange before the bull market so presale wallets benefit from trading volume starting the first hour after the Binance listing. ETH pulled back to $2,130 from $2,317 but the structure underneath is stronger than the price shows. The MVRV ratio sits in the 0.8 to 1.0 zone that preceded every major Ethereum rally in history according to CoinPedia. The top 100 USDC wallets hold $32.7 billion, the highest on record, meaning a wall of capital is waiting for the signal to deploy. The Ethereum price prediction maps $5,000 first with projections reaching $8,500 and $12,000 once the Glamsterdam upgrade lands. That is a 5.6x from here and it takes years to develop. Every crypto fortune was built on that same pattern, and the whale wallets entering Pepeto right now while holding their ETH positions are executing it in real time. They understand what Ethereum delivers over years and they want that exposure. But they are choosing the new crypto Pepeto for the multiples that ETH at a $233 billion valuation is physically too large to produce from here. Pepeto Is the New Crypto Drawing Institutional Attention The ethereum price prediction heading higher directly supports the future of this Ethereum based crypto, because every dollar of volume flowing into the network feeds the demand for projects built on it. Pepeto's composable settlement protocol with embedded AI verification across Ethereum, BNB Chain, and Solana is approaching its final window before full launch, and the innovative utility sitting on the most proven blockchain in crypto is exactly what positions this exchange to capture serious demand the moment it goes live. The team made security a priority from day one, and SolidProof completed a full audit with zero risks flagged, giving serious investors the verification layer they require before committing capital at scale. Pepeto carries the same explosive community energy that pushed Dogecoin to a $90 billion valuation, but this time innovative utility. The Elon Musk whispers circulating through every crypto channel right now are following the identical path that made the earliest DOGE believers millionaires well before any official word dropped. Meme culture fused with genuine DeFi innovation on Ethereum is the combination analysts keep circling when they call Pepeto the standout project of this cycle. Pushing whales to go in heavy. The size of what they are putting in tells you exactly what they expect this project to deliver once the Binance listing arrives. FInal Verdict Pepeto's Binance listing is closing in and the presale advantage disappears the instant it goes live. The ethereum price prediction will eventually reach $12,000 over years of network upgrades and institutional adoption. Pepeto's listing compresses that kind of return potential into a single event. The Musk connections to the project spreading across every crypto community right now follows the exact trajectory that preceded the biggest catalyst in Dogecoin's history, and every investor who rode DOGE to millions from that moment carries one regret: the position they took should have been bigger. Pepeto is handing the market that identical window right now, except with a verified exchange underneath that Dogecoin never had. The new crypto Pepeto official website is still accepting entries at presale pricing, but every round that closes pushes the cost higher and every day that passes brings the listing closer. The wallets moving right now are the ones that will own the returns this cycle is remembered for, and the ones reading this who wait will carry the cost of that decision for the rest of the bull run. CLICK TO VISIT PEPETO OFFICIAL WEBSITE FAQs What is the ethereum price prediction for 2026? The ethereum price prediction targets $5,000 near term with $8,500 and $12,000 projected as the Glamsterdam upgrade and MVRV accumulation signals align. What is the best new crypto to buy now? Analysts name Pepeto the leading new crypto with $8.19 million raised, DeFi tools at final readiness, and whale wallets entering ahead of the Binance listing. CONTACT: MEDIA CONTACT Contact: Dani Bonocci Email: info@pepeto.io Website: https://pepeto.io/ Phone: +971586738991
2026-03-19 22:47:47

晶泰AI赋能管线再迎临床转化:莱芒生物"千分之一"剂量CAR-T疗法获FDA临床批准
深圳 2026年3月18日 /美通社/ -- 近日,晶泰科技孵化企业莱芒生物宣布,其研发的 META 10-19 注射液(代谢增强型 CD19 CAR-T)的 新药临床试验申请( IND )已获得美国食品药品监督管理局( FDA )批准,计划最早于今年第四季度开启临床试验 。本次获批适应症为复发或难治性 CD19 阳性的 B 细胞血液肿瘤,包括 B 细胞急性淋巴细胞白血病(B-ALL)与 B 细胞非霍奇金淋巴瘤(B-NHL)的多种常见亚型。 莱芒生物由晶泰科技孵化,专注于开发新一代 AI 赋能的代谢增强型免疫疗法。其首个管线产品 META 10-19 已完成多项针对血液肿瘤、红斑狼疮等重大疾病的 IIT 研究(研究者发起临床研究),以低至常规 CAR-T 剂量千分之一的极低剂量,帮助数十位患者实现完全缓解(CR), 有望以 " 极低剂量 + 免清淋 " 的创新策略,将单价百万的 CAR-T 疗法推进至平价时代 。此次 META 10-19 注射液在美获批临床, 标志着莱芒生物核心管线正式迈入全球化临床开发阶段, 并再次展现了晶泰科技赋能孵化企业研发极具市场竞争力的创新疗法、并持续实现临床转化的高效率与高成功率,管线加速进入兑现期。 2025 年全球 CAR-T 等细胞疗法市场规模达 61.22 亿美元,同比增长 32.9%。据弗若斯特沙利文预计,到 2030 年,全球 CAR-T 细胞疗法市场将达到 218 亿美元。 在晶泰科技的投资孵化与技术支持下 ,莱芒生物聚焦创新肿瘤免疫治疗药物管线的研发,开发并持续升级了其独有的 META 10 与 META 10-AI 两大 AI+ 代谢重编程技术平台 ,并成功研发 META 10-19 注射液, 仅需常规 CAR-T 治疗 1%-1‰ 的注射量,即可实现高效体内扩增 ,有效解决现有 CAR-T 疗法普遍面临的 T 细胞耗竭这一疗效瓶颈,并展现出优越的临床响应率和安全性,为安全高效、医保可负担的新一代 "平价" CAR-T 疗法早日上市奠定基础。 莱芒生物的 META 10-19 注射液 的安全性与初步有效性已在多项 IIT 临床中获得充分验证,并开创 " 极低剂量 + 免清淋 " 的创新性治疗策略: 在复发或难治性淋巴瘤/白血病等适应症中,META 10-19 以极低给药量,帮助首批入组的 20 余位患者达到100%完全缓解(CR),受试者涵盖中枢神经系统转移患者、无法自主活动的重症患者等极具挑战性的病例;近日,首例采用"极低剂量+免清淋"方案治疗的套细胞淋巴瘤(MCL)患者在接受 META 10-19注射后,达到完全缓解(CR),为晚期血液肿瘤患者开辟了一条更安全、更有效的临床新路径;在中重度系统性红斑狼疮(SLE)适应症中,患者采用"极低剂量+免清淋"的治疗方案,且无需中断原有治疗,单次输注低至常规剂量 1‰的 META 10-19后实现完全停药下的 DORIS 缓解(完全缓解)。 目前,莱芒生物正在中美两地同步推进多项新药临床试验申报, META 10-19 注射液是其首个获 FDA 批准进入临床阶段的项目 ,进一步印证了其核心管线临床价值,为其后续全球研发与注册路径奠定了坚实基础。晶泰科技通过卓有成效的投资孵化,正持续赋能生态圈合作伙伴加速前沿科学进展向管线资产与临床项目的转化,为全球患者带来更多突破性疗法的同时,为投资者创造长期可持续的回报。 关于莱芒生物 深圳莱芒生物科技有限公司(Leman Biotech Co., Ltd)是一家处于临床阶段的免疫代谢创新药物研发公司,由瑞士洛桑联邦理工学院(EPFL)唐力教授团队联合晶泰科技共同创立。基于免疫代谢重编程(META 10)+前沿人工智能(AI)的创新技术,公司专注于研发代谢增强型肿瘤免疫治疗药物。公司核心技术 META 10 展示出治愈实体肿瘤的巨大潜力,相关成果发表于 Nature、Nature Biotechnology、Nature Immunology 和 Lancet Haematology 等国际顶级学术期刊,并申请了多项 PCT 专利和中国发明专利。2022 年以来,公司累计获得超 4 亿元风险投资和项目资助,荣膺 2025 年全国 "颠覆性技术创新" 大赛最高奖项等数十项生物医药领域国家或省市级奖项,并入选国家重点研发计划 "颠覆性技术创新" 重点专项。临床进展获美国基因与细胞治疗协会(ASGCT 2024)和美国癌症协会(AACR 2024)最新突破性(Late-Breaking)进展口头报告(全国唯一)。 关于晶泰科技 晶泰科技("XtalPi Holdings Limited",股份简称:晶泰控股,XTALPI,股票代码:2228.HK)由三位麻省理工学院的物理学家于 2015 年创立,是一个基于量子物理、以人工智能赋能和机器人驱动的创新型研发平台。公司采用基于量子物理的第一性原理计算、人工智能、高性能云计算以及可扩展及标准化的机器人自动化相结合的方式,为制药及材料科学(包括农业技术、能源及新型化学品以及化妆品)等产业的全球和国内公司提供药物及材料科学研发解决方案及服务。
2026-03-18 12:50:00

Orbit International Corp. Reports 2025 Year End Results
2025 Net Loss of $5,025,000 ($1.51 loss per share) vs. Net Loss of $646,000 ($0.19 loss per share) in 2024 2025 EBITDA, As Adjusted, was a loss of $3,971,000 ($1.19 loss per share) vs. earnings of $159,000 ($0.05 per diluted share) in 2024 Fourth Quarter 2025 Net Loss of $708,000 ($0.21 loss per share) vs. Net Loss of $252,000 ($0.08 loss per share) in Prior Year Period Fourth Quarter 2025 EBITDA, As Adjusted, was a loss of $465,000 ($0.14 loss per share) vs. earnings of $383,000 ($0.11 per diluted share) in Prior Year Period Backlog at December 31, 2025 was approximately $12.2 million compared to approximately $12.0 million at December 31, 2024 HAUPPAUGE, N.Y., March 18, 2026 (GLOBE NEWSWIRE) -- Orbit International Corp. (OTCID Basic Market:ORBT) today announced results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025vs. Fourth Quarter 2024 Net sales were $6,726,000, as compared to $8,708,000.Gross margin was 28.6%, as compared to 34.6%.Net loss was $708,000 ($0.21 loss per share), as compared to net loss of $252,000 ($0.08 loss per share).Earnings before interest, taxes, depreciation and amortization, fair value adjustment on contingent liabilities (earn-out) and other non-current liability, contingent liability (legal matter) and stock-based compensation (EBITDA, as adjusted) was a loss of $465,000 ($0.14 loss per share), as compared to earnings of 383,000 ($0.11 per diluted share).Full Year 2025 vs. Full Year 2024Net sales were $22,450,000, as compared to $29,898,000.Gross margin was 25.6%, as compared to 33.3%.Net loss was $5,025,000 ($1.51 loss per share), as compared to a net loss of $646,000 ($0.19 loss per share).Earnings before interest, taxes, depreciation and amortization, fair value adjustment on contingent liabilities (earn-out) and other non-current liability, contingent liability (legal matter) and stock-based compensation (EBITDA, as adjusted) was a loss of $3,971,000 ($1.19 loss per share), as compared to earnings of $159,000 ($0.05 per diluted share).Backlog at December 31, 2025 was $12.2 million compared to $12.0 million at December 31, 2024. Mitchell Binder, President and CEO of Orbit International commented, "Unfortunately, 2025 was a very challenging period for our Company. Lower anticipated bookings in 2024 and the first half of 2025 affected 2025 delivery schedules for our various business units. Delivery schedules were lined up more favorably in the second half of 2025; however, a single supply chain issue undermined significant scheduled shipments to an Orbit Power Group ("OPG”) customer during the third and fourth quarters and approximately $1,400,000, scheduled for delivery in the second half of 2025, was delayed until the first quarter of 2026. Although the units were substantially completed in 2025 and our customer paid approximately 89% of the total order purchase price, we were unable to recognize revenue of approximately $1,400,000. Had we been able to recognize this revenue in 2025, our operating loss for the year would have been reduced by approximately $700,000. Our net loss for the twelve months ended December 31, 2025, was $5,025,000 ($1.51 loss per share) compared to a net loss of $646,000 ($0.19 loss per share) for the prior comparable period. EBITDA, as adjusted, for the twelve months ended December 31, 2025, was a loss of $3,971,000 ($1.19 loss per share) compared to earnings of $159,000 ($0.05 per diluted share) in the prior comparable period. Operating results were also adversely affected by legal fees incurred by our Simulator Product Solutions LLC ("SPS”) subsidiary.” Binder added, "Our current fourth quarter operating results were negatively affected by the aforementioned delayed shipment from our OPG as well as lower sales by SPS. In addition, our fourth quarter was adversely affected by several one-time charges. Despite higher sales from our Orbit Instrument division, higher than expected outside test service costs were incurred in connection with the qualification of newly designed units on three separate programs. Our consolidated net loss for the fourth quarter was approximately $708,000 ($0.21 loss per share) and our EBITDA, as adjusted, loss was $465,000 ($0.14 loss per share). However, exclusive of the incremental outside test service cost incurred, the legal fees incurred in connection with the termination of the former President of SPS, a settlement payment concerning another SPS matter, and an approximately $109,000 loss of profitability due to the previously mentioned single supply chain issue, our EBITDA, as adjusted would have been a loss of approximately $91,000.” Binder noted, "Operating results for SPS for the three months and twelve months ended December 31, 2025, were adversely impacted by lower sales in the current and twelve month periods, a consequence of reduced bookings in the second half of 2024 and lower than expected bookings throughout 2025. Prior period revenues during 2024 were positively impacted by higher bookings during the 2023 fiscal year. 2025 bookings were also negatively affected by ongoing opportunities that were not yet finalized in 2025 and certain lost opportunities, primarily due to lack of funding or our customers losing awards to competitors. However, bookings for SPS in 2025 did slightly improve from bookings in 2024 and proposals for new and follow-on opportunities have significantly increased. In addition, we incurred significant infrastructure costs in 2023 and 2024 in order to support SPS’ sales increase since the Company’s acquisition of the SPS business in 2022. At the time of the SPS acquisition, we anticipated the need to invest in infrastructure and internal controls in order to bring SPS up to the standards of a public company. However, after several quarters of personnel and cost increases, we have taken precautionary measures to trim certain costs as we continue to align our organization to support our growth while striving to improve our operating results.” Mr. Binder added, "Our sales for the twelve months ended December 31, 2025, decreased significantly to $22,450,000 compared to $29,898,000 from the prior year comparable period. This decrease in sales was primarily attributable to significantly lower sales at both our Orbit Electronics Group ("OEG”) and our OPG although the reduction at OPG was directly attributable to the aforementioned supply chain issue. As previously mentioned, the lower sales at our OEG were attributable to lower bookings in the second half of 2024 and throughout 2025 due primarily to contract delays, which are an inherent risk in contracting with the U.S. government and its prime contractors.” Mr. Binder further added, "Our gross margin for the twelve months ended December 31, 2025, decreased to 25.6% compared to 33.3% in the prior year comparable period. The decrease in gross margin during the twelve months ended December 31, 2025, primarily reflected significantly lower SPS and OPG gross margins due to a reduction in sales which resulted in a higher percentage of overhead and other fixed costs relative to sales. The decrease in gross margin at our OPG was due to lower sales as a result of the previously mentioned aforementioned supply chain issue as well as a higher percentage of lower margin commercial sales in the fourth quarter.” Mr. Binder added, "For the twelve months ended December 31, 2025, selling, general and administrative expenses were $10,375,000, compared to $10,439,000 during the prior year comparable period, a decrease of $64,000. The decrease was primarily due to lower expenses at our Orbit Instrument division, our OPG and lower corporate costs, and despite an increase of more than $400,000 in SPS expenses. The increase in selling, general and administrative expenses at SPS was principally due to more than $360,000 of expenses incurred for (i) an outside engineering firm engaged to modify legacy drawings as well as bill of material part identification that was developed prior to the acquisition; (ii) legal fees incurred in connection with the litigation associated with the SPS acquisition and the termination of the former President of SPS and (iii) legal fees in connection with a settlement payment concerning a matter that originated prior to the acquisition in 2022. The engineering firm was needed to conform drawing documentation to the actual manufacturing procedures to build SPS products as well as to comply with internal inventory controls. This was in addition to more than $200,000 in engineering fees that were incurred in the fourth quarter of 2024.” Mr. Binder continued, "Backlog at December 31, 2025, was approximately $12,200,000 compared to approximately $12,000,000 at December 31, 2024, an increase of approximately 1.7%. This increase in backlog is reflective of a general increase in backlog from our OPG and SPS, and despite a decrease in backlog from our Orbit Instrument division and Q-Vio Corp. ("Q-Vio”) subsidiary for the 2025 calendar year. Our Orbit Instrument division faced numerous delays on follow-on contracts from its customers throughout the year. Absent these delays, we would have had approximately $1,400,000 in additional bookings in 2025. We are now expecting these bookings in the first half of 2026. SPS recorded firm bookings at the end of 2025 and since January 1, 2026 have approximately $5,000,000 in proposals to its customers. Contract delays are an inherent part of doing business with the U.S. Government.” David Goldman, Chief Financial Officer, noted, "At December 31, 2025, our cash and cash equivalents aggregated approximately $684,000 and borrowings under our $4,000,000 Line of Credit ("LOC”) were $2,475,000. Our book value per share at December 31, 2025 was $3.83, which compares to $4.04 at September 30, 2025 and $5.34 at December 31, 2024. (Note: book value per share does not include any additional value for our fully reserved deferred tax asset.) To offset future federal and state taxes resulting from profits, we have approximately $10.0 million and $1.0 million in available federal and New York State net operating loss carryforwards, respectively.” Mr. Binder added, "Because our revenues are tied to delivery schedules specified in our contracts, it is often difficult to judge our performance on a quarterly basis. Our operating results for the twelve months ended December 31, 2025, resulted from weak bookings in the second half of 2024 and throughout 2025 that primarily emanated from contract delays. These contract delays have particularly affected our Orbit Instrument division, which has historically been our most profitable business. Although we received some of the contracts at the end of the year, the number of proposals for follow-on business has grown with outstanding proposals from this division totaling approximately $4,750,000 waiting to be awarded. A portion of these awards are expected in the first half of 2026 although timing of the receipt of these awards is an uncertainty. ” Mr. Binder concluded, "Improved bookings from both our OPG and SPS subsidiary have carried over into the 2026 year. In particular, since January 1, 2026, SPS has proposed approximately $5,000,000 in new and follow-on business which does not include proposals made prior to year-end which could also result in new purchase orders. Last, Q-Vio has quoted certain new and follow-on opportunities and continues to work on two new projects with its customers that could result in significant awards. However, these awards would not be expected until sometime during the 2027 calendar year.” Orbit International Corp., through its Electronics Group, is involved in the development and manufacture of custom electronic device and subsystem solutions for military, industrial and commercial applications through its production facilities in Hauppauge, NY and Carson, CA. Orbit’s Power Group, also located in Hauppauge, NY, designs and manufactures a wide array of power products including VPX, COTS (Commercial-off-the-shelf) and commercial power supplies. Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company including statements regarding our expectations of Orbit International Corp.’s operating plans, deliveries under contracts and strategies generally; statements regarding our expectations of the performance of our business; expectations regarding costs and revenues, future operating results, additional orders, future business opportunities and continued growth may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although Orbit International Corp. believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond Orbit International Corp.’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact Orbit International Corp. and the statements contained in this news release can be found in Orbit International Corp.’s reports posted with the OTC Disclosure and News service. For forward-looking statements in this news release, Orbit International Corp. claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Orbit International Corp. assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. CONTACT David Goldman Chief Financial Officer 631-435-8300 (See Accompanying Tables) Orbit International Corp. Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended December 31, (unaudited) Year Ended December 31, (unaudited) (audited) 2025 2024 2025 2024 Net sales $6,726 $8,708 $22,450 $29,898 Cost of sales 4,805 5,695 16,696 19,945 Gross profit 1,921 3,013 5,754 9,953 Selling general and administrative 2,502 2,716 10,375 10,439 expenses Interest expense 53 86 159 119 Other expense (income), net 69 (3) 109 (436) (Loss) income before income taxes (703) 214 (4,889) (169) Income tax provision 5 466 136 477 Net loss $(708) $(252) $(5,025) $(646) Basic loss per share $(0.21) $(0.08) $(1.51) $(0.19) Diluted loss per share $(0.21) $(0.08) $(1.51) $(0.19) Weighted average number of shares outstanding: Basic 3,334 3,339 3,331 3,343 Diluted 3,334 3,339 3,331 3,343 Orbit International Corp.Consolidated Statements of Operations (in thousands, except per share data) (unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 EBITDA (as adjusted) Reconciliation Net loss $(708) $(252) $(5,025
2026-03-18 12:49:53

LiveOne (Nasdaq: LVO) Raises 2026 Cost Savings Target from $5M to $7.5M ($3.5M Completed); Increases Payables Conversion Target from $11M to $13M+ at $7.50 per share ($5M Completed)
Deploys AI (Anthropic Claude, OpenAI) to Slash Costs, Reduce Workforce from 350 to 78 (~19% Reduction this Quarter), Drive All Subsidiaries to Positive Adjusted EBITDA* Additional ~$1.5M CPS savings expected by year-endLaunching two new Fortune 500 B2B partnerships reaching 100M+ monthly subscribers~$5.7M remaining under share repurchase planAcquired 900k+ shares of PodcastOne (Nasdaq: PODC) LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) -- LiveOne, Inc. (Nasdaq: LVO), a creator-first, music, entertainment and technology platform, today announced that it has increased its projected 2026 cost savings target to more than $7.5 million, driven by continued operational efficiencies and workforce optimization initiatives. The Company also expanded its payables conversion initiative to more than $13 million at $7.50 per share, further strengthening its balance sheet. "We continue to exceed our cost reduction targets while strengthening our balance sheet and positioning the Company for scalable, profitable growth,” said Robert Ellin, Chairman and CEO of LiveOne. "Our investments in AI-driven efficiencies, combined with expanding strategic partnerships, are driving meaningful operating leverage across the business.” About LiveOne Headquartered in Los Angeles, CA, LiveOne (Nasdaq: LVO) is an award-winning, creator-first, music, entertainment, and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. LiveOne's subsidiaries include Slacker, PodcastOne (Nasdaq: PODC), PPVOne, Custom Personalization Solutions, LiveXLive, DayOne Music Publishing, Drumify and Splitmind. LiveOne, a dedicated over-the-top application powered by Slacker, is available on iOS, Android, Roku, Apple TV, Spotify, Samsung, Amazon Fire, Android TV, and through STIRR's OTT applications. For more information, visit liveone.com and follow us on Facebook, Instagram, TikTok, YouTube and X at @liveone. For more investor information, please visit ir.liveone.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are "forward-looking statements,” which may often, but not always, be identified by the use of such words as "may,” "might,” "will,” "will likely result,” "would,” "should,” "estimate,” "plan,” "project,” "forecast,” "intend,” "expect,” "anticipate,” "could,” "believe,” "seek,” "continue,” "contemplate,” "predict,” "potential,” "target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: LiveOne’s reliance on its largest OEM customer for a substantial percentage of its revenue; LiveOne’s ability to consummate any proposed financing, acquisition, spin-out, special dividend, merger, distribution or transaction, the timing of the consummation of any such proposed event, including the risks that a condition to the consummation of any such event would not be satisfied within the expected timeframe or at all, or that the consummation of any proposed financing, acquisition, spin-out, merger, special dividend, distribution or transaction will not occur or whether any such event will enhance stockholder value; LiveOne’s ability to continue as a going concern; LiveOne’s ability to attract, maintain and increase the number of its users and paid members; LiveOne identifying, acquiring, securing and developing content; LiveOne’s ability to implement its recently announced digital asset treasury strategy and/or purchase digital assets from time to time pursuant to such strategy, including for the maximum announced amount, and other risks related to such strategy; LiveOne’s intent to repurchase shares of its and/or PodcastOne’s common stock from time to time under LiveOne’s announced stock repurchase program and the timing, price, and quantity of repurchases, if any, under the program; LiveOne’s ability to maintain compliance with certain financial and other debt covenants; LiveOne successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; LiveOne’s ability to repay its indebtedness when due; LiveOne’s ability to satisfy the conditions for closing on its announced additional convertible debentures financing; uncertain and unfavorable outcomes in legal proceedings and/or LiveOne’s ability to pay any amounts due in connection with any such legal proceedings; significant legal, commercial, regulatory and technical uncertainty and risks related to Bitcoin, Ethereum and other digital assets; regulatory developments related to digital assets and digital asset markets; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of LiveOne’s subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in LiveOne’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC”) on July 15, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 14, 2025, and in LiveOne’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof, and LiveOne disclaims any obligation to update these statements, except as may be required by law. LiveOne intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Use of Non-GAAP Financial Measures* To supplement our consolidated financial statements, which are prepared and presented in accordance with the accounting principles generally accepted in the United States of America ("GAAP”), we present Contribution Margin (Loss) and Adjusted Earnings Before Interest Tax Depreciation and Amortization ("Adjusted EBITDA”), which are non-GAAP financial measures, as measures of our performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, or as a substitute for, or superior to, operating loss and or net income (loss) or any other performance measures derived in accordance with GAAP or as an alternative to net cash provided by operating activities or any other measures of our cash flows or liquidity. We use Contribution Margin (Loss) and Adjusted EBITDA to evaluate the performance of our operating segment. We believe that information about these non-GAAP financial measures assists investors by allowing them to evaluate changes in the operating results of our business separate from non-operational factors that affect operating income (loss) and net income (loss), thus providing insights into both operations and the other factors that affect reported results. Adjusted EBITDA is not calculated or presented in accordance with GAAP. A limitation of the use of Adjusted EBITDA as a performance measure is that it does not reflect the periodic costs of certain amortizing assets used in generating revenue in our business. Accordingly, Adjusted EBITDA should be considered in addition to, and not as a substitute for operating income (loss), net income (loss), and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, Adjusted EBITDA as presented herein may not be comparable to similarly titled measures of other companies. Contribution Margin (Loss) is defined as Revenue less Cost of Sales before (a) Cost of Sales share-based compensation expense, (b) depreciation, and (c) amortization of developed technology. Adjusted EBITDA is defined as earnings before interest, other (income) expense, income tax expense, depreciation and amortization and before (a) non-cash GAAP purchase accounting adjustments for certain deferred revenue and costs, (b) legal, accounting and other professional fees directly attributable to acquisition activity, (c) employee severance payments and third party professional fees directly attributable to acquisition or corporate realignment activities, (d) certain non-recurring expenses associated with legal settlements or reserves for legal settlements in the period that pertain to historical matters that existed at acquired companies prior to their purchase date and a one-time minimum guarantee to effectively terminate a live events distribution agreement post COVID-19, and (e) certain stock-based compensation expense. Management does not consider these costs to be indicative of our core operating results. With respect to projected full fiscal year 2026 Adjusted EBITDA, a quantitative reconciliation is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to purchase accounting adjustments, acquisition-related charges and legal settlement reserves excluded from Adjusted EBITDA. We expect that the variability of these items to have a potentially unpredictable, and potentially significant, impact on our future GAAP financial results. For more information on these non-GAAP financial measures, please see the tables entitled "Reconciliation of Non-GAAP Measure to GAAP Measure” included at the end of this release. LiveOne Press Contact: press@liveone.com Follow LiveOne on social media: Facebook, Instagram, TikTok, YouTube, and X at @liveone.
2026-03-18 12:49:48

MACOM’s Microwave and Optical Comprehensive Solutions on Display at SATShow Week 2026
LOWELL, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Inc. ("MACOM”), a leading supplier of semiconductor products, will showcase its latest RF and optoelectronics solutions for satellite communications (SATCOM) at Booth 1637, during SATShow Week, taking place March 24 to 26, 2026 in Washington, D.C. These solutions can enable higher frequency bands, improved power efficiency and more scalable architectures, which are critical to next-generation satellite networks. MACOM will host live demonstrations highlighting advanced semiconductor and optical technologies designed to support the evolving SATCOM needs, including direct-to-device, high frequency RF and optical connectivity solutions. With more than seven decades of experience serving the space industry, MACOM continues to expand its product portfolio and manufacturing capabilities to address growing demand for satellite Broadband, next generation communications services and advanced space missions. Featured Demonstrations and Technology Highlights: High-Power L and S-Band Direct to Device(D2D) Transmit/Receive: This demonstration features our receive-side line up (MAAL-011078 and MAAL-011314) along with our transmit-side line up (driver amplifier MAAM-011395 and power amplifier MAPC-A1109) designed to support satellite communication applications. The transmit lineup features 1 W of output power, >40 dB gain and >40% efficiency, and wide bandwidth utilizing MACOM PURE CARBIDE® GaN technology. The receive lineup features 0.5 dB NF, >40 dB gain, and low power consumption.Ka-Band Power Amplifiers: This demonstration showcases a 25W GaN-on-SiC power amplifier, CMPA2H3B025D, supporting Ka-band SATCOM applications from 27 - 31 GHz. Offered in bare die form as well as in a pure-copper based flange package, the CMPA2H3B025 delivers high power, efficiency and linearity. This is an ideal solution for satellite BUCS and SSPAs.Linearized Q-Band Power Amplifier (PA): MACOM will demonstrate a linearized Q-Band GaN MMIC power amplifier that delivers substantial improvements in linear output power and efficiency through advanced analog linearization techniques. This capability can enable higher data-rate RF transmission with reduced power dissipation, addressing the stringent performance demands for next generation satellite data links.Free Space Optical (FSO) and RF-over-Fiber (RFoF): Showcasing a variety of components supporting both FSO and fiber-based optical links. Highlights include transport architectures for optical SATCOM (ground-to-ground, ground-to-satellite and satellite-to-satellite) featuring static hardware, components and system diagrams.SATCOM RF and Microwave Components: MACOM’s booth will feature a wide range of RF devices to support Ku- and Ka-Band SATCOM applications. Solutions include GaAs and GaN PAs, gain blocks, low noise amplifiers and linearizers, as well as a variety of switches, mixers, attenuators and power shifters based on GaAs, silicon-on-insulator (SOI) and diode technologies. Together, these components can enable high performance scalable architectures for next generation satellite payloads and ground infrastructure.SATShow Week 2026 Information: Venue:Walter E. Washington Convention Center, Washington, D.C.Date/Time:Tuesday, March 24:10:00 am to 5:45 pm Wednesday, March 25:9:00 am to 6:00 pm Thursday, March 26:9:00 am to 1:00 pmFor more information about SATShow Week 2026, visit https://www.satshow.com/ About MACOM MACOM designs and manufactures high-performance semiconductor products for the Industrial and Defense, Data Center and Telecommunications industries. MACOM services over 6,000 customers annually with a broad product portfolio that incorporates RF, Microwave, Analog and Mixed Signal and Optical semiconductor technologies. MACOM has achieved certification to the IATF16949 automotive standard, the AS9100D aerospace standard, the ISO9001 international quality standard and the ISO14001 environmental management standard. MACOM operates facilities across the United States, Europe, Asia and is headquartered in Lowell, Massachusetts. Company Contact: MACOM Technology Solutions Inc. Stephen Ferranti Senior Vice President, Corporate Development and Investor Relations P: 978-656-2977 E: stephen.ferranti@macom.com
2026-03-18 12:49:45

Converge Partners with Vanova Health to Accelerate Healthcare Market Expansion
Performance Marketing and Brand Stewardship for Company Focused on Supporting Independent Physicians NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Converge, a full-service performance marketing agency, announced a new partnership with Vanova Health, a clinically integrated network and practice support solutions provider headquartered in Verona, New Jersey, with ambitious growth plans across the healthcare landscape in New Jersey. Vanova Health is deeply committed to empowering independent physicians and helping them keep their practices independent in an increasingly complex and consolidated healthcare environment. The engagement brings together Converge’s strategic, creative, and performance capabilities to help Vanova Health scale its market presence while remaining a strong steward of the brand equity it has already established. Converge is supporting Vanova Health’s mission through a growth-strategy-led approach that activates the brand in the market by translating early positioning into visible, credible, repeatable engagement, first with healthcare professionals (HCPs), then with consumers so, the brand earns trust, drives consideration, and builds sustained demand. Converge has accelerated momentum in 2026 by growing new clients 50%, after tripling EBITDA in 2025, deepening key enterprise relationships, and strengthening leadership with seven strategic additions. Converge will build on Vanova Health’s brand loyalty and enterprise credibility, elevating its established presence and amplifying influence in a competitive healthcare market. Under the partnership, Converge will deliver an integrated scope of work spanning brand positioning and activation, website redesign and SEO and GEO strategy, content and marketing execution, digital services, and planning and buying analytics. Converge has successfully built and scaled marketing platforms and full funnel campaigns for brands operating in complex, high consideration sectors, including financial services, legal, and nonprofit. "This partnership reflects our belief that in an independent physician empowered landscape, building high performance healthcare brands demands the right mix of proven vertical marketing strategies with the speed, flexibility, and test and learn approach of today’s most advanced digital brands,” said Shoshana Winter, CEO of Converge. "Vanova Health has built meaningful trust with physicians and enterprise partners. Our role is to build on that foundation and steward the brand in an extraordinarily complex and noisy landscape, through relevant positioning, performance driven digital experiences, and thought leadership that maximizes credibility and trust while resonating with the healthcare community broadly. At its core, this is about activating an undiscovered but deeply trusted brand in a competitive and confusing market by leveraging modern, data driven insights to engage HCPs and build awareness.” "As an early-stage healthcare brand in a complex landscape, it was critical for us to find a partner that was more than a marketing agency, but a true growth partner,” said Becky Levy, CEO of Vanova Health. "We were referred to Converge through an existing Converge client. What stood out immediately was their investment in understanding our business and our mission. Converge’s independence, senior-level hands-on guidance, and expert teams that translate brand vision into measurable action made this an easy decision.” Converge will deliver a comprehensive brand playbook, accelerate SEO- and GEO-optimized digital upgrades, and build a thought-leadership engine to drive qualified payer and provider demand "As a health care organization, credibility and trust are everything,” said Levy for Vanova Health. "Converge understands how to honor the relationships we’ve built while helping us ensure that our mission of supporting independent physicians and reducing the cost of healthcare in New Jersey is clear.” The win further strengthens Converge’s healthcare portfolio and underscores growing demand for marketing partners that can seamlessly integrate brand stewardship, performance marketing, and analytics, particularly for high growth healthcare organizations navigating complex, high consideration markets. About Vanova Health At Vanova Health, our mission is to empower independent physicians. We offer tailored services to help New Jersey physicians navigate healthcare challenges and maintain their independence. For payors, we create value by reducing the total cost of care, improving quality, and boosting patient engagement with their physicians and providers. Together, we create a healthier future for New Jersey’s communities. About Converge Converge is a full-service, boutique performance marketing agency focused on driving measurable, accountable growth for clients in high-consideration categories including professional services, financial services, retail, non-profit, healthcare and education. Founded in 2006, with lead acquisition as the primary offering, today Converge offers a variety of direct marketing capabilities including media strategy, buying and planning, advanced data & measurement, audience modeling and predictive analytics, performance UI/UX and creative services. Converge manages integrated multi-channel media and lead acquisition campaigns with a focus on print, display, paid search, paid social, SEO, email, and CTV. Servicing clients across multiple verticals including Home Services, Legal, Insurance, Financial Services, Converge has generated over $2B in client sales and more than 1M leads for its clients. https://convergemarketing.com/ Media Contact: James A. Pearson Chief Communications Officer, Converge james.pearson@convergemarketing.com 646-522-4297
2026-03-18 12:49:30

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM” or the "Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039. The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad and encompass multiple cancer types - including pancreatic cancer. AIM also holds a U.S. patent (expires August 9, 2039) for methods involving the use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands (expires December 19, 2039) for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Imfinzi (durvalumab). AIM CEO Thomas K. Equels stated: "AIM is committed to developing Ampligen for the treatment of late-stage pancreatic cancer, which is an extremely lethal and unmet global health problem. Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy.” AIM also intends to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in the treatment of pancreatic cancer. The Company already holds Orphan Drug designations for pancreatic cancer in the United States and the European Union. While the details of the designations vary by region, the purpose is to incentivize the development of therapies for unmet health needs, by providing various benefits and market exclusivity after a drug receives market approval. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials. Forward-Looking Statements Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. No assurance can be given that intention to seek Orphan Drug Designation will result in the granting of that status, nor that the possession of Orphan Drug Designations or any patents means that a drug will receive market approval. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks. Please review the "Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the Registration Statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
2026-03-18 12:49:26

env zero and CloudQuery Announce Merger to Create the Industry’s First Unified Cloud Intelligence Platform
The combined entity will provide a unified solution for cloud governance and asset management, enabling enterprise platform teams to ensure resiliency across the entire cloud lifecycle BOSTON, March 18, 2026 (GLOBE NEWSWIRE) -- env zero (envzero.com), the leader in Infrastructure as Code (IaC) management and governance, and CloudQuery (cloudquery.io), the leading cloud asset management platform, today announced the successful close of their merger. The combined company will operate under the env zero brand, creating a powerhouse in the cloud operations space. The merger addresses a critical gap in the market: Modern cloud teams struggle with infrastructure that exists outside Infrastructure as Code. Automation platforms can’t see it, and discovery tools can’t safely fix it. By combining CloudQuery’s complete cloud asset inventory with env zero’s infrastructure automation engine, we’re creating a new kind of platform-one that continuously discovers everything running in your cloud and automatically brings it to its desired state. A Unified Vision from Day 0 to Day N IaC manages what teams intend to deploy. Asset tools show what already exists. But cloud teams still lack a system that connects the two. The combination of env zero and CloudQuery will change that, combining infrastructure automation with complete cloud asset intelligence to manage the entire lifecycle of cloud infrastructure, from Day 0 provisioning to Day N operations. "We kept hearing the same thing from customers: visibility without action and action without context both fall short. Customers need visibility, context, and action working together in one place, and that is exactly what we are giving them,” said Steve Corndell, CEO of the new env zero. "By bringing CloudQuery’s data capabilities into env zero, we’re giving platform engineers a complete solution to manage reliable, secure, and cost-effective cloud environments-from the first line of code through the entire lifecycle.” Leadership and Innovation The combined company will be led by Steve Corndell as Chief Executive Officer. Yevgeny Pats, Founder and CEO of CloudQuery, will join the leadership team as Chief Technology Officer (CTO) of the new env zero, overseeing the integration of the two technologies and driving the future product roadmap. "CloudQuery was built to solve the visibility problem inherent in modern cloud infrastructure,” said Yevgeny Pats. "Joining env zero allows us to close the loop between knowing what exists and taking action on it. Together, we are building an autonomous system that doesn't just tell you what you have in the cloud, but ensures it stays reliable and compliant automatically.” The combined company is also proud to welcome industry veteran Oved Lourie as Field CTO, a role purpose-built to keep customer voice at the center of the platform's evolution, ensuring that what gets built is exactly what the market demands. The Evolution of Platform Engineering: Closing the Operational Gap The merger arrives as the industry reaches a critical tipping point. Platform Engineering has rapidly evolved from a niche discipline into the vital intersection of Security, Compliance, FinOps, and Performance Management, and the stakes have never been higher. Enterprises are now leveraging foundational models to accelerate the SDLC by an order of magnitude, collapsing the time between ideation and production. But speed without governance is exposure. Historically siloed security, compliance, FinOps, and performance functions can no longer keep up, creating compounding risk at exactly the moment organizations can least afford it. The new env zero fills this gap, merging the predictive power of IaC governance with the real-time clarity of asset management to give platform teams the control plane that AI-accelerated development demands. "The 'Operational Gap' is the space between what you intended to build and what is actually running in the cloud,” added Steve Corndell. "As foundational models push code to production faster than ever before, that gap becomes a liability. By combining our IaC expertise with CloudQuery's context-rich insights, we are giving Platform Engineering teams a single pane of glass to manage security, compliance, cost and performance simultaneously. We aren't just helping teams deploy; we are helping them run their entire cloud operation autonomously.” The merger officially closed on March 12. Customers of both platforms can expect continued support for existing services with an accelerated roadmap for integrated features. Executives from the new env zero will be available for meetings at KubeCon Europe 2026, in Amsterdam, upon request. About env zero env zero is the leader in cloud governance for Infrastructure-as-Code, helping enterprises deliver infrastructure at the speed and scale required for the AI era. The env zero Cloud Governance Platform unifies automation, governance, and intelligent guardrails into a single control plane, enabling platform teams to codify, standardize, and secure infrastructure across any cloud or IaC framework including Terraform, OpenTofu, Pulumi, CloudFormation, Terragrunt, and Kubernetes. Founded in 2018, the company partners with global innovators such as PayPal, Broadcom, Paramount, and MongoDB to accelerate innovation without sacrificing compliance or control. About CloudQuery CloudQuery is a cloud asset management platform that transforms cloud infrastructure into searchable, actionable data. Founded in 2021, It is used by security and platform teams at Fortune 100 banks, global technology companies, and fast-moving FinTechs to manage complex, multi-cloud footprints at scale. CONTACT: Media Contact: Joe Austin, APR joe@austinprar.com
2026-03-18 12:49:21

Foresight Raises $US25 Million to Close the Execution Gap in the Global Infrastructure Supercycle
Series A led by Macquarie Capital Venture Capital will fund product expansion and global scale as delivery risk becomes the defining constraint on AI infrastructure, energy and industrial investment LONDON and NEW YORK and TEL AVIV, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Foresight, the AI-powered project delivery platform for large-scale infrastructure, today announced it has raised $US25 million in Series A funding led by Macquarie Capital Venture Capital, with participation from, seed investor Creandum, as well as ISAI Build (Bouygues group VC fund managed by ISAI), i2bf Global Ventures and Somersault Ventures. The funding will accelerate Foresight’s product development, team expansion and global go-to-market as demand intensifies across AI infrastructure, power, defense, advanced manufacturing, energy and mobility. The round comes at a time when unprecedented levels of capital are flowing into complex infrastructure programs-from hyperscale data centers and power generation to advanced manufacturing and defense. These programs are growing larger, more power-dense and more interdependent, relying on multi-billion-dollar delivery schedules and global supply chains. In this environment, small execution failures compound quickly into schedule slippage, cost escalation and delayed revenue activation. Independent research indicates that nearly 90 percent of large-scale infrastructure projects are delivered late or over budget. In AI infrastructure specifically, delays directly affect capacity activation, financing costs, customer commitments and competitive positioning. Foresight was built to close this gap. "The scale of capital now committed to infrastructure is historic, but capital alone doesn’t build anything on time,” said Igor Shifrin, Co-Founder and CEO of Foresight. "Foresight replaces fragmented oversight with predictive control-giving owners forward-looking visibility into risk and the ability to intervene before delays materialize. This funding allows us to scale globally and support the next generation of infrastructure delivery.” Gary Munitz, Global Co-Head of Macquarie Capital Venture Capital, said: "Macquarie Capital Venture Capital seeks to partner with high-growth, early-stage software companies that drive innovation within their sectors. We invested in Foresight because of its potential to transform the operating model for how complex projects are delivered. Delivery discipline is crucial in a market where delays directly impact returns, and Foresight provides project owners with the clarity and control to maintain a competitive edge.” "Delays in major projects are not rare events caused by black swans,” said Dr. Atif Ansar, Co-Founder and Executive Chairman of Foresight. "They are systemic, driven by small, compounding execution failures and predictable human biases in planning and decision-making. My research at Oxford has spent years quantifying this problem. Foresight is the first platform that operationalizes these insights, giving every level of the organization, from C-suite to field, the tools to see risk early and act on it.” Platform and Traction Foresight’s Predictive Project Delivery platform operates as a unified AI control system purpose-built for complex infrastructure programs. It establishes a reliable baseline schedule in days rather than months, continuously validates real-world progress against plan, integrates execution signals across stakeholders and forecasts risk early enough for decisive intervention. Customers using Foresight report: 2x more accurate completion forecasts compared to traditional bottom-up schedules30 percent reduction in overruns by identifying delay drivers before escalationPortfolio-level visibility across concurrent builds, enabling owners to manage risk across entire programs rather than project by projectUse of Funds Foresight will use the Series A to deepen its product capabilities, expand its engineering and go-to-market teams and accelerate international growth to meet rising demand across key verticals. The company plans to extend its platform into adjacent infrastructure sectors-including power, defense and advanced manufacturing-where the same execution challenges apply at even greater scale. About Foresight Foresight is a predictive project delivery platform built for high-complexity, capital-intensive infrastructure programs. Designed for environments such as hyperscale data centers and advanced industrial facilities, it replaces static schedules and backward-looking reports with a continuously updated control system aligned to a single source of truth. By validating progress, integrating execution data and forecasting risk early, Foresight enables asset owners and operators to protect capital, accelerate time-to-revenue and deliver infrastructure with greater certainty. The company has raised $25 million in Series A funding led by Macquarie Capital Venture Capital. Founded in 2018, Foresight operates globally from New York, London and Tel Aviv. For more information, visit https://www.foresight.works/ About Macquarie Capital Venture Capital Macquarie Capital is the advisory, capital markets and principal investment arm of Macquarie Group. It encompasses corporate advisory, a full spectrum of capital solutions, including capital raising services from equity, debt and private capital markets and principal investments from Macquarie’s balance sheet. Macquarie Capital Venture Capital (MCVC) is the venture unit within Macquarie Capital. MCVC has over 30 years’ experience providing expertise and capital to early-stage software companies, leveraging the strength of Macquarie’s balance sheet to lead funding rounds across a company’s full lifecycle. The team focuses on companies headquartered in Australia, Israel, the United Kingdom and continental Europe that are driving innovation in cybersecurity, compliance, regulatory technology, and artificial intelligence. Visit Macquarie Capital Venture Capital’s website to learn more. Media Contacts iMiller Public Relations +1.914.315.6424 pr@imillerpr.com Foresight Works pr@foresight.works
2026-03-18 12:49:20

Mayor Isko thanks PBBM for P5K cash aid to Manila tricycle drivers amid oil price surge
**media[86713]**Manila City Mayor Francisco “Isko Moreno” Domagoso, on Tuesday, March 17, thanked President Ferdinand Marcos Jr. as the national government began distributing P5,000 cash assistance to tricycle drivers in Metro Manila to help cushion the impact of rising fuel prices triggered by tensions in the Middle East.Speaking at the ASAC Covered Court, one of several payout sites in the National Capital Region, Domagoso said the assistance would provide immediate relief to transport workers struggling with the sharp increase in oil prices.“Nagpapasalamat tayo kay Presidente. Napakalaking bagay nito para sa ating mga driver, maibsan ang hinaharap nilang suliranin dahil sa presyo ng gas (We thank the President. This is a big help for our drivers as it eases the burden they are facing because of the high price of fuel),” the mayor said.Domagoso also expressed gratitude on behalf of Manila residents and the transport sector, saying the city is thankful for the national government’s support during a period of economic strain.The assistance follows the announcement by Marcos Jr. on Monday, March 16, of government measures aimed at cushioning the effects of global oil price increases linked to geopolitical tensions in the Middle East.Under the program, the Department of Social Welfare and Development will distribute P5,000 in cash assistance to around 139,000 tricycle drivers across 17 local government units in Metro Manila beginning March 17.The President said similar support will also be extended to tricycle drivers outside the National Capital Region, while jeepney drivers and transport network vehicle service (TNVS) drivers are expected to receive the same amount in the coming days.Aside from the cash assistance, the national government is also preparing fuel subsidies for transport workers and additional aid for farmers and fisherfolk affected by rising oil prices.
2026-03-17 02:38:00

金斯瑞生物科技公布2025年业绩:稳健增长蓄势待发,业务增长迎来再加速
新泽西州皮斯卡特维2026年3月16日 /美通社/ -- 全球领先的生命科学研发与制造服务提供商金斯瑞生物科技股份有限公司(HK.1548)今日公布截至2025年12月31日止的全年业绩,公司业务稳健增长,在复杂市场环境中展现出良好的经营韧性与发展潜力。 2025年,金斯瑞持续经营业务收入约959.5百万美元,同比增长61.4%。毛利增长103.3%至553.2百万美元。持续经营业务经调整净利润约230.3百万美元,同比增长285.0%。公司三大业务板块均实现了增长,运营效率持续提升,进一步巩固了长期发展的财务基础。 金斯瑞集团轮值CEO邵炜慧表示:"2025年的业绩体现了公司核心业务的稳健增长与平台能力的持续提升。依托创新驱动和全球化战略,金斯瑞不断强化三大业务板块的协同优势。未来,我们将继续深化技术创新与全球运营能力建设,与全球合作伙伴共同成长,为客户与股东创造长期价值。" 业务板块亮点 金斯瑞生命科学——依托"从基因到蛋白"的一体化飞轮效应,实现第二增长曲线突破 金斯瑞生命科学板块全年收入约522.1百万美元,同比增长14.8%;经调整毛利267.3百万美元,同比增长12.5%。增长主要得益于"基因到蛋白"一体化平台协同效应的持续释放,以及全球化布局带来的收入结构多元化。公司通过品牌升级与精准营销持续拓展客户基础,新客户销售额实现快速增长,同时欧洲和亚太市场份额进一步扩大,巩固其全球市场竞争力。 蓬勃生物——收入增速持续攀升,全球业务稳健扩张 生物药CRDMO平台子公司蓬勃生物持续扩大业务规模。2025年,蓬勃生物收入约388.7百万美元,同比增长309.1%;经调整毛利约258.4百万美元,同比增长1697.5%。公司紧抓市场机遇,凭借平台优势精准匹配市场需求,常规服务业务实现稳健增长,收入的有机增长超过21%。同时依托自有平台和高潜力资产,稳步推进多个项目,以赋能客户成功,加速药物研发进程。 百斯杰——以创新性研发和全球化战略,驱动业务持续增长 工业合成生物学子公司百斯杰持续推进"AI+合成生物学"研发体系,加速创新产品商业化。2025年,百斯杰收入约为58.0百万美元,同比增长7.9%;经调整毛利约为23.0百万美元。同时,公司凭借AI研发平台效力的提升,专利申请达历年最高,研发效率取得历史性突破,为创新产品的全球推广奠定坚实基础。公司的创新甜蛋白产品Mellia®在获得美国FDA GRAS认证后,正积极推进中国市场准入,预计今年年中将正式启动商业化,为业务增长注入新的活力。 全球运营与可持续发展 金斯瑞持续推进自动化、数字化及全球生产网络建设,构建更具效率与韧性的全球化运营平台。同时,2025年公司成功完成品牌焕新,进一步强化了"以客户为中心、与客户一道Scripting Possibilities"的理念。此举驱动我们持续赋能全球科学家与合作伙伴,将"可能"化为现实,加速创新与突破,进一步提升全球品牌影响力与客户体验。 在可持续发展方面,金斯瑞持续推进ESG实践,不断获得多项国际权威认可,包括MSCI AA评级、入选富时社会责任指数系列、获得EcoVadis银牌评级,并成功入选2026年标普全球可持续发展年鉴,跻身全球可持续发展标杆企业之列。 展望 在生命科学创新爆发的拐点,金斯瑞锚定"技术驱动+全球布局"双轮战略:一方面加速AI赋能研发、生物智造升级与前沿疗法落地;另一方面深化生命科学、生物药CRDMO与合成生物学三大引擎的协同效应,构建全球竞争力,确保公司在新周期中持续领跑,为客户创造价值,为股东兑现长期回报。 2025年财务表现* 收入 于2025年,本集团录得收益约959.5百万美元,较2024年的约594.5百万美元增加61.4%。这主要是由于(i)许可收益大幅增加,主要源自礼新所产生的分许可收益;(ii)持续投入商业推广,配合全球品牌焕新提升品牌知名度,尤其在欧美市场成效显著;(iii)业界对AI驱动药物开发及多抗体药物开发需求持续增长,带动基因至蛋白业务快速成长;(iv)成功把握住生物制剂CRDMO需求回升及市场环境复苏的趋势加速增长;及(v)推出创新性工业酶制剂产品,不断拓展市场。 毛利 于2025年,本集团的毛利由2024年的约272.1百万美元,增加103.3%至约553.2百万美元。毛利增加主要是由于收益增加,特别是生物制剂开发服务分部的许可收益增加。经调整毛利较上期增加98.6%。 销售及分销开支 于2025年,本集团的销售及分销开支由2024年的约88.1百万美元,增加12.9%至约99.5百万美元。这主要由于(i)扩充商业团队并加强在当地招聘经验丰富的专业人才,及(ii)持续投资区域运营以支撑全球关键市场的业务发展与客户参与度。经调整销售及分销开支较上期增加14.6%。 行政开支 于2025年,行政开支由2024年的约114.4百万美元,增加12.4%至约128.6百万美元。这主要是由于(i)产能扩建配套及增强行政职能导致开支持续增加,及(ii)新厂筹备阶段所产生的相关费用。经调整行政开支较上期增加14.8%。 研发开支 于2025年,研发开支由2024年的约53.8百万美元,增加32.4%至约71.2百万美元,主要归因于专业人才招募数量增加以及战略研究计划的扩展。经调整研发开支较上期增加32.8%。 持续经营业务经调整净利润 报告期内本集团持续经营业务的经调整净利润约為230.3百万美元,较上期增长285.0%。
2026-03-15 16:39:00

金斯瑞生物科技公佈2025年業績:穩健增長蓄勢待發,業務增長迎來再加速
新澤西州皮斯卡特維2026年3月15日 /美通社/ -- 全球領先的生命科學研發與製造服務提供商金斯瑞生物科技股份有限公司(HK.1548)今日公佈截至2025年12月31日止的全年業績,公司業務穩健增長,在複雜市場環境中展現出良好的經營韌性與發展潛力。 2025年,金斯瑞持續經營業務收入約959.5百萬美元,同比增長61.4%。毛利增長103.3%至553.2百萬美元。持續經營業務經調整淨利潤約230.3百萬美元,同比增長285.0%。公司三大業務板塊均實現了增長,運營效率持續提升,進一步鞏固了長期發展的財務基礎。 金斯瑞集團輪值CEO邵煒慧表示:「2025年的業績體現了公司核心業務的穩健增長與平台能力的持續提升。依托創新驅動和全球化戰略,金斯瑞不斷強化三大業務板塊的協同優勢。未來,我們將繼續深化技術創新與全球運營能力建設,與全球合作夥伴共同成長,為客戶與股東創造長期價值。」 業務板塊亮點 金斯瑞生命科學——依托「從基因到蛋白」的一體化飛輪效應,實現第二增長曲線突破 金斯瑞生命科學板塊全年收入約522.1百萬美元,同比增長14.8%;經調整毛利267.3百萬美元,同比增長12.5%。增長主要得益於「基因到蛋白」一體化平台協同效應的持續釋放,以及全球化佈局帶來的收入結構多元化。公司通過品牌升級與精準營銷持續拓展客戶基礎,新客戶銷售額實現快速增長,同時歐洲和亞太市場份額進一步擴大,鞏固其全球市場競爭力。 蓬勃生物——收入增速持續攀升,全球業務穩健擴張 生物藥CRDMO平檯子公司蓬勃生物持續擴大業務規模。2025年,蓬勃生物收入約388.7百萬美元,同比增長309.1%;經調整毛利約258.4百萬美元,同比增長1697.5%。公司緊抓市場機遇,憑借平台優勢精準匹配市場需求,常規服務業務實現穩健增長,收入的有機增長超過21%。同時依托自有平台和高潛力資產,穩步推進多個項目,以賦能客戶成功,加速藥物研發進程。 百斯傑——以創新性研發和全球化戰略,驅動業務持續增長 工業合成生物學子公司百斯傑持續推進「AI+合成生物學」研發體系,加速創新產品商業化。2025年,百斯傑收入約為58.0百萬美元,同比增長7.9%;經調整毛利約為23.0百萬美元。同時,公司憑借AI研發平台效力的提升,專利申請達歷年最高,研發效率取得歷史性突破,為創新產品的全球推廣奠定堅實基礎。公司的創新甜蛋白產品MelliaR在獲得美國FDA GRAS認證後,正積極推進中國市場准入,預計今年年中將正式啟動商業化,為業務增長注入新的活力。 全球運營與可持續發展 金斯瑞持續推進自動化、數字化及全球生產網絡建設,構建更具效率與韌性的全球化運營平台。同時,2025年公司成功完成品牌煥新,進一步強化了「以客戶為中心、與客戶一道Scripting Possibilities」的理念。此舉驅動我們持續賦能全球科學家與合作夥伴,將「可能」化為現實,加速創新與突破,進一步提升全球品牌影響力與客戶體驗。 在可持續發展方面,金斯瑞持續推進ESG實踐,不斷獲得多項國際權威認可,包括MSCI AA評級、入選富時社會責任指數系列、獲得EcoVadis銀牌評級,並成功入選2026年標普全球可持續發展年鑒,躋身全球可持續發展標桿企業之列。 展望 在生命科學創新爆發的拐點,金斯瑞錨定「技術驅動+全球佈局」雙輪戰略:一方面加速AI賦能研發、生物智造升級與前沿療法落地;另一方面深化生命科學、生物藥CRDMO與合成生物學三大引擎的協同效應,構建全球競爭力,確保公司在新週期中持續領跑,為客戶創造價值,為股東兌現長期回報。 2025年財務表現* 收入 於2025年,本集團錄得收益約959.5百萬美元,較2024年的約594.5百萬美元增加61.4%。這主要是由於(i)許可收益大幅增加,主要源自禮新所產生的分許可收益;(ii)持續投入商業推廣,配合全球品牌煥新提升品牌知名度,尤其在歐美市場成效顯著;(iii)業界對AI驅動藥物開發及多抗體藥物開發需求持續增長,帶動基因至蛋白業務快速成長;(iv)成功把握住生物制劑CRDMO需求回升及市場環境復甦的趨勢加速增長;及(v)推出創新性工業酶制劑產品,不斷拓展市場。 毛利 於2025年,本集團的毛利由2024年的約272.1百萬美元,增加103.3%至約553.2百萬美元。毛利增加主要是由於收益增加,特別是生物制劑開發服務分部的許可收益增加。經調整毛利較上期增加98.6%。 銷售及分銷開支 於2025年,本集團的銷售及分銷開支由2024年的約88.1百萬美元,增加12.9%至約99.5百萬美元。這主要由於(i)擴充商業團隊並加強在當地招聘經驗豐富的專業人才,及(ii)持續投資區域運營以支撐全球關鍵市場的業務發展與客戶參與度。經調整銷售及分銷開支較上期增加14.6%。 行政開支 於2025年,行政開支由2024年的約114.4百萬美元,增加12.4%至約128.6百萬美元。這主要是由於(i)產能擴建配套及增強行政職能導致開支持續增加,及(ii)新廠籌備階段所產生的相關費用。經調整行政開支較上期增加14.8%。 研發開支 於2025年,研發開支由2024年的約53.8百萬美元,增加32.4%至約71.2百萬美元,主要歸因於專業人才招募數量增加以及戰略研究計劃的擴展。經調整研發開支較上期增加32.8%。 持續經營業務經調整淨利潤 報告期內本集團持續經營業務的經調整淨利潤約為230.3百萬美元,較上期增長285.0%。 投資者及媒體聯繫: 投資者關係 郵箱:ir@genscript.com 媒體咨詢 郵箱:media@genscript.com 公司官網: https://www.genscript.com.cn 財務回顧 *為更好地反映本集團現有業務及經營的關鍵表現,經調整淨利潤按不包括以下各項的淨虧損計算:(i)以股權結算的股份薪酬開支;(ii) 收購及優先股公允價值虧損的影響;(iii)外匯遠期和期權合約虧損;(iv)長期資產減值虧損;(v)匯兌損益;(vi)非流動金融資產的公允價值收益或虧損;(vii)股權融資活動的未實現融資成本; (viii) 應占傳奇集團的虧損及解除合併的服務費;及(ix)於傳奇集團投資的減值。本文件旨在提供簡要信息,並非針對公司、其證券或任何相關事項的完整或全面說明。如欲獲取更多詳細信息,敬請參閱金斯瑞集團3月15日發佈於公司官網的正式公告,一切信息應以正式公告為準。
2026-03-15 16:36:00

Brazil revokes visa of US diplomat in Bolsonaro row
RIO DE JANEIRO — Brazil's President Luiz Inacio Lula da Silva on Friday banned a US diplomat who wanted to visit the jailed former far-right leader Jair Bolsonaro amid fears of US meddling ahead of elections this year.Bolsonaro, sentenced for plotting a coup, was hospitalized in intensive care Friday after developing bronchopneumonia.US President Donald Trump has called the case against his Latin American ally a "witch hunt."Lawyers for Bolsonaro earlier this week asked the Supreme Court to allow Darren Beattie, the US State Department's new advisor on Brazil, to visit Bolsonaro in prison on March 18.The Supreme Court initially agreed to the visit but later revoked the authorization after the Brazilian government cautioned against the meeting."I banned him from coming to Brazil," Lula said at an event in Rio de Janeiro on Friday.A Brazilian diplomatic source told AFP that Beattie's visa was revoked Friday due to "lies about the purpose of the visit."Lula said the US diplomat would not be allowed into Brazil until Washington lifted a visa ban on Brazilian Health Minister Alexandre Padilha.Padilha was sanctioned late last year over his role in a program to employ Cuban doctors in Brazil.Bid to steal electionBolsonaro, 70, is serving a 27-year sentence over his failed bid to remain in power after his defeat by Lula in 2022.He was suffering from "high fever, a drop in oxygen saturation, sweating and chills," according to a statement from the DF Star Hospital in Brasilia, and receiving intravenous antibiotics to treat "bilateral bacterial bronchopneumonia."His medical team later told a press conference Friday that his condition was "stable" but gave no indication of when he might be discharged.Bolsonaro's trial last year sparked the ire of the Trump administration, which imposed high tariffs on a range of Brazilian goods as punishment.Washington scaled back the tariffs after a meeting between Lula and Trump in October.But Brazil remains wary of Trump's campaign to sway events in Latin America, after his overthrow of Venezuelan leader Nicolas Maduro and attempts to influence elections from Argentina to Honduras.Trump was embroiled in his own attempt to overturn an election when he refused to accept defeat to Joe Biden in 2020, culminating with a mob of supporters attacking the US Congress building in Washington.'Undue interference'Brazil's foreign ministry said Beattie's visa had been granted exclusively to allow him to attend a forum on critical minerals and to participate in meetings with Brazilian government officials.It added that the visit of a foreign public official to a former president during an election year "could constitute undue interference" in Brazil's internal affairs, according to court documents.Bolsonaro remains a figurehead of the Brazilian right, despite his incarceration and debilitated physical state.He has suffered from recurring health issues since being stabbed in the abdomen during a campaign event in 2018.The Supreme Court has until now denied requests that he be allowed to serve his sentence under house arrest."They are playing with my father's life," his senator son Flavio Bolsonaro, who is running for president in October's elections against Lula, said Friday.
2026-03-14 03:30:11

Ateneo ends slump, sweeps UE to close first round
MANILA, Philippines — Ateneo de Manila University snapped a two-game slump, ending the first round with a 25-14, 25-17, 25-20 sweep of the University of the East in the UAAP Season 88 Collegiate Men’s Volleyball Tournament at the SM Mall of Asia Arena on Saturday.Jian Salarzon, who was limited to just four points in the previous match, bounced back with 15 points on 12 attacks, three blocks, and six receptions to lead the Blue Eagles to their drought-ending win.“Sobrang dami ng tight games namin this first round na kung dapat nadisiplina lang namin ‘yung sarili namin eh nagawan agad namin ng paraan sana makakakuha pa kami ng wins. Magbibase kami sa assessment namin, ipa-polish pa yung kailangan namin,” said Ateneo head coach Vince Mangulabnan.“Sa men’s volleyball ngayon, hindi mo talaga alam kung sinong malakas at sino ang hindi kasi sobrang pantay pantay talaga siya. Malingat ka lang ng konti, tatalunin ka eh.”The victory was much needed for the Blue Eagles, who came off two straight losses against the league’s top teams, the Far Eastern University Tamaraws and the National University Bulldogs.Ateneo finished the first round with a 3-4 record, currently in solo fourth place, though De La Salle University and University of the Philippines, both at 2-4, still have a game left.The Red Warriors threatened to extend the match with a 17-15 lead in the third set, but the Blue Eagles remained resolute. Off-the-bench Julio Yu sparked an 8-0 fightback, allowing Ateneo to seize control and secure the victory in 80 minutes.Pacinio contributed eight points, while Kennedy Batas and Rodge Alejos added five and four points, respectively.Aceron led UE with 14 points, but support was scarce. Mark Lee Budias was the next highest scorer with just four points.The Red Warriors ended the first round on a four-game skid, dropping to 1-6 and sitting in last place. TMT
2026-03-14 03:29:49

Trump turns to Strategic Petroleum Reserve as oil prices soar
NEW YORK — Oil prices have soared since the US and Israel launched their war against Iran, and President Donald Trump is now turning to America’s Strategic Petroleum Reserve as part of a wider agreement from many of the world’s wealthiest countries to tap into emergency stockpiles.Trump previously downplayed the need of using reserve oil after the Iran war broke out, maintaining that US supplies were ample and prices would soon fall. But that changed Wednesday, when the International Energy Agency pledged to release 400 million barrels of oil available from its member nations’ stockpiles, the largest volume of emergency oil pulled in the organization's history.The US is one of the IEA's 32 member countries. And the Trump administration soon confirmed that it would release 172 million barrels from the Strategic Petroleum Reserve starting next week as part of this effort — with deliveries set to roll out over 120 days.The widening war has strained the energy sector globally. And in the U.S., drivers are already facing higher gas prices, a key cost of living. Trump's Republican Party is under pressure over the issue of affordability ahead of November midterm elections. And tapping the reserve is among the few things a president can do on his own to try to make an impact on oil prices — although it's not a permanent fix.Here is a look at what would be involved:What is the Strategic Petroleum Reserve?The Strategic Petroleum Reserve is a collection of underground salt caverns in Texas and Louisiana that can hold more than 700 million barrels of oil, although it is not currently full. The reserve held more than 415 million barrels as of the end of last month, up from about 395 million barrels at this time in 2025, according to the US Energy Department.The reserve was created after the 1970s Arab oil embargo to give the United States a supply that could be used in an emergency. The amount of oil inside peaked more than a decade and a half ago, Energy Department data shows, when the reserve held more than 726.6 million barrels at one point.Will gas prices get cheaper when the reserve is tapped?While pulling from the reserve may provide some short-term relief, it's takes a while for new supply to trickle down to consumers — and many factors go into prices at the pump.In the US, the average price for gasoline has already climbed nationally — sitting at nearly $3.60 per gallon on Thursday, up about 35 cents from a week ago and 65 cents a month ago, per motor club AAA.Refineries buy crude oil in advance, so it’s possible that the pain of higher prices could increase further if the war drags on. And even if more oil were withdrawn from the reserve, refineries could still be working with more expensive supply for a bit.As always, some states also have pricier averages than others, due to factors ranging from nearby refinery supply to local fuel requirements and differing tax rates. On Thursday, California had the highest average of nearly $5.37 per gallon, while Kansas had the lowest of about $3.04 a gallon.Gas prices are regressive — meaning lower-income people are more likely to spend a higher percentage of their money on fuel than affluent Americans. So increases hurt the most price-sensitive consumers.How is the reserve used?Today, the US exports more petroleum than it imports. But the reserve remains and has been tapped for various reasons over time, from offsetting the impact of hurricanes and ship-channel closings to raising money for deficit reduction.Former presidents have turned to the reserve amid supply disruptions spanning from geopolitical conflicts, adding more supply onto the market in the hope of pushing prices lower. President Joe Biden drew significantly from the reserve in 2022 following Russia’s invasion of Ukraine, dropping the stockpile to its lowest level since the 1980s. Back in 1991, President George H.W. Bush also authorized withdrawing nearly 34 million barrels during the Gulf War, although only 17 million barrels were used. And in 2011, President Barack Obama approved the release of 30 million barrels to offset the disruption of supply from Libya.Why is Trump tapping the reserve now?As the Iran war continues to escalate, oil prices have spiked and swung rapidly. That's because the flow of oil tankers through the Strait of Hormuz has all but stopped, cutting off a vital passageway where roughly one-fifth of the world’s oil sails through on a typical day. Major producers in the region like Iraq, Kuwait and the United Arab Emirates have also cut production because they are running out of storage space. And Iran, Israel and the US have all struck oil and gas facilities, worsening supply concerns.The price for a barrel of Brent crude, the international standard, was back over the $100 mark on Wednesday — up from nearly $70 a barrel just late last week. Meanwhile, benchmark US crude was $96.12 as of morning trading.In efforts to alleviate some of the effects of the Iran war on energy markets, the IEA on Wednesday said it will make 400 million barrels of oil available. The Trump administration's plans to pull 172 million barrels from the reserve are part of that effort.Trump frequently criticized the administration of his predecessor, Joe Biden, for tapping the reserve to try and bring down gas prices. US Secretary of Energy Chris Wright reiterated that criticism when announcing the coming release from the reserve on Wednesday — and said that the US had arranged to replace about 200 million barrels of reserve oil within the next year.How do they get the oil out?Oil is lighter than water — that’s why disasters like those caused by the Exxon Valdez tanker and the Deepwater Horizon drilling rig create slicks on the surface. To remove oil from the reserves, water is pumped into the salt caverns, making the crude float to the surface, where it is captured and sent through pipelines to refineries.
2026-03-12 17:39:50

President of the Association of American Physicians and Surgeons (AAPS) Calls for Physician Stewardship
TUSCON, Ariz., March 09, 2026 (GLOBE NEWSWIRE) -- Since the early years of American independence, life expectancy increased from 32 years in 1800 to 68.2 years in 1950. Private indemnity insurance developed to help cover the cost of medical care. Only 9 percent of the U.S. population had such coverage in 1940, but 75 percent did by 1960, writes George L. Smith, III, M.D., in the spring issue of the Journal of American Physicians and Surgeons. Dr. Smith, current president of the Association of American Physicians and Surgeons (AAPS), practices family medicine in Covington, Ga.The federal government has increasingly been involved in the financing of care, starting with the Hill-Burton Act of 1946, which provided grants for hospital construction. Passage of Medicare and Medicare in 1965 has been followed by incremental controls on allowable services and charges, and efforts to end private indemnity coverage and even our entire private medical system, Dr. Smith writes.During a mission trip to Ukraine in 2000, Dr. Smith experienced the reality of socialized medicine. A nurse kept him from discarding a used tongue depressor that he had brought along so that it could be used on another patient. He also notes that in a communist system, there is not just scarcity of material resources but no room for morals or rules to protect the individual."The communist has no security as long as capitalism exists,” Dr. Smith points out. The goals and methods in the 1946 Blueprint for World Conquest are still pertinent in the ongoing all-encompassing class struggle despite the collapse of the Soviet empire.As physician stewards. Dr. Smith states that "we have the responsibility to warn others regarding socialism and communism and help them realize we must solve our own medical coverage problems in a manner that protects the freedoms we hold so dear.”The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.Contact: George L. Smith, III, at gsds74@icloud.com or Jane M. Orient, M.D., (520) 323-3110, janeorientmd@gmail.com
2026-03-09 21:40:58

Building on Taco Tuesday, Taco John's Expands Daily Deals to Deliver Even More Value
Building on Taco Tuesday, Taco John's Expands Daily Deals to Deliver Even More ValueNew weekday deals launching across the brand’s 325+ locationsST. LOUIS PARK, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Taco John’s® fans are in for some big savings with new weekday deals launching across the brand’s 325+ locations. Beginning this week, the expanded lineup gives guests even more reasons to stop by again and again, whether longtime fans or first-time tasters:Taco Tuesday: Enjoy the Crispy Taco for just $1.39 every Tuesday.Wake Up WednesdayTM: Start the day strong with the Meat & Potato Breakfast Burrito for $3.19.Taco Bravo® Thursday: Score the award-winningTaco Bravo for just $2.79. The fan favorite was recently crowned the #1 Fast Food Taco in USA TODAY's 10Best Readers' Choice Awards*. Delivering crave-worthy Taco John’s favorites at prices that make every day feel fiesta-worthy, these specials are designed to give guests more ways than ever to savor the best of West-MexTM. Signature everyday touches continue to set Taco John’s apart, including fresh Pico de Gallo, crispy taco shells and chips fried in-house daily, and bold proprietary seasonings that are featured in hearty meals made with 100% North American beef, all-white meat chicken or hand-cut sirloin steak."Taco John’s has long been known for Taco Tuesday, and we’re thrilled to spotlight other crave-worthy specials throughout the week that deliver on that excitement for guests. We’re proud to be the place our communities come to for tacos and burritos any day of the week, and these new daily deals give our guests even more reasons to stop in and save on the flavors they crave,” said Kevin Flaherty, Taco John’s Chief Marketing Officer.Everyday Value & RewardsBeyond weekday specials, Taco John’s Meal Steals at $5, $7 and $9 are available daily, offering guests hearty West-Mex meals featuring signature menu items. Rewards Members can unlock even more exclusive savings in the Taco John’s app this season, including:Free Delivery during college basketball playoffs (March 17-22): Free delivery on orders of $20 or more when ordering from TacoJohns.com or in the appNational Burrito Day (April 3): Free Bean Burrito with a $3+ purchaseTax Day (April 15): Free Small Potato Olés® with a $3+ purchase For more information or to find a location, visit www.TacoJohns.com or download the Taco John’s app.*https://tacojohns.com/taco-johns-taco-bravo-named-best-fast-food-taco-in-annual-usa-todays-10best-survey/About Taco John’s®Welcome to the Frontier of West-MexTM-a land for wide-open appetites, where classic American comfort meets the bold spice and flavor of Mexican-inspired cuisine. With more than 325 restaurants in 21 states, Taco John’s® has spent more than 55 years crafting made-to-order favorites with quality ingredients, house-made Pico de Gallo, crispy corn shells and tortilla chips fried fresh in-store daily, and originals you won’t find anywhere else-like hot, crispy Potato Olés® and the award-winning Taco Bravo®, recently named the best fast food taco in America. Founded in 1969 in Cheyenne, Wyoming, Taco John’s has earned recognition from Entrepreneur and QSR Magazine as one of the nation’s top chains to watch. Learn more at TacoJohns.com and follow Taco John’s on Facebook, Instagram and TikTok.Media Contact:Joshua LevittPR for Taco John’sjosh@fikacollective.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d52481d7-0283-401d-a836-ebd8c5a15430.
2026-03-09 21:40:49

Novonesis named a Great Employer to Work For in North Carolina
Employee PhotoNovonesis employees gathered at the Franklinton, North Carolina site during Manufacturing Day 2025.Franklinton, North Carolina, March 09, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, has been named a 2026 Great Employer to Work for in North Carolina by Best Companies Group (BCG), marking the company’s first time earning this prestigious recognition. BCG is a trusted leader in workplace culture research and recognition, distinguishing top companies around the United States for more than 20 years. The honor is based entirely on confidential employee feedback and a comprehensive evaluation of workplace practices, culture, and leadership. Novonesis ranked 6th on the list of Great Employers to Work for in North Carolina. With more than 700 employees across North Carolina, Novonesis’ recognition reflects its commitment to building a workplace where people can be themselves, grow their careers, and contribute to meaningful work that improves lives and the planet. "At Novonesis, we believe people are at the heart of everything we do,” said Tue Micheelsen, President of Novonesis North America. "Being named a Great Employer is especially meaningful because it is rooted in direct employee feedback. Our teams in North Carolina are passionate about our purpose - to better our world with biology - and this recognition affirms our commitment to creating a culture where people feel respected, supported, and inspired to make a difference.” Novonesis’ workplace culture is built around the idea of ‘The biological choice’ - offering employees a career that matters. Across its North Carolina operations, employees are empowered to bring their authentic selves to work, collaborate across disciplines, and develop professionally while advancing biosolutions that transform industries ranging from food and agriculture to health, energy, and manufacturing. With major operations in Franklinton, Morrisville, and Durham, Novonesis employs scientists, engineers, manufacturing specialists, and corporate professionals, including teams at North America’s largest multipurpose enzyme manufacturing facility in Franklinton. Together, these teams drive innovation across more than 30 industries, helping customers produce more sustainably, reduce environmental impact, and improve everyday life. "Our culture is rooted in respect, inclusion, and continuous learning,” said Darren Alfano, Head of People & Organization at Novonesis. "We want every colleague to feel they belong, are challenged to grow, and can see the real-world impact of their work. This recognition reinforces that Novonesis is not just a great place to work, it’s a place to build a purpose-driven career.” Novonesis has proudly called North Carolina home for more than four decades and continues to invest in the region through workforce development, advanced manufacturing, STEM education partnerships, and community engagement. The company collaborates closely with state agencies, academic institutions, and industry organizations to strengthen the state’s leadership in biotechnology and biomanufacturing while creating high-quality jobs and expanding career pathways. "We are proud to honor Novonesis with this certification,” said Jaime Raul Zepeda, Executive Vice President of Best Companies Group. "Their commitment to employee well-being, innovation, and excellence truly embodies what it means to be a Great Employer in North Carolina.” See all the 2026 Great Employers to Work for in North Carolina winners here. ### About Novonesis Novonesis is a global company leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes, and lives. In more than 30 industries, our biosolutions are already creating value for millions of consumers and benefitting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology. Learn more on www.novonesis.com MEDIA RELATIONS - NORTH AMERICA Kathy Humphrey Head of Communications, North America Phone: 1 919-494-8764 khp@novonesis.com AttachmentEmployee Photo
2026-03-09 21:40:38

Olimpic Maids Celebrates 145th 5-Star Google Review, Reinforcing Role as Best House Cleaning Service in Jersey City, NJ
Jersey City Cleaning Services by Olimpic Maids LLC provides professional deep home cleaning and maid services for residents in Jersey City, New Jersey. This video highlights the company’s residential cleaning solutions designed to help homeowners maintain a cleaner and healthier living space.Jersey City, NJ, March 09, 2026 (GLOBE NEWSWIRE) -- Olimpic Maids today announced that it has reached its 145th 5-star Google review, marking a significant milestone in customer satisfaction and service quality. The achievement reflects continued trust from local clients and reinforces Olimpic Maids’ role as the best house cleaning service in Jersey City, NJ.Fresh, spotless living space after a professional cleaning.The milestone highlights consistent feedback from homeowners who rely on Olimpic Maids for dependable, stress-free cleaning services. Clients frequently reference the company’s straightforward online booking process with instant pricing, along with clear communication, English-speaking staff, and consistent results as reasons for their positive experiences."We believe booking a cleaning should feel straightforward and stress-free, with clear pricing and no unnecessary back-and-forth,” said a spokesperson for Olimpic Maids.Olimpic Maids provides flat-rate cleaning services that are completed thoroughly rather than by the hour. Many homeowners choose recurring service to ensure their homes remain consistently maintained without the burden of managing cleaning themselves.In addition to residential house cleaning, Olimpic Maids also provides office cleaning and short-term rental cleaning services, including Airbnb turnovers, across Jersey City, Hoboken, and nearby areas.As the company continues to grow, it remains focused on delivering reliable service and a seamless experience for homeowners and businesses alike.For more information about Olimpic Maids or to book a cleaning, visit https://olimpicmaids.com.About Olimpic MaidsOlimpic Maids is a professional cleaning company based in Jersey City, NJ. The company provides residential house cleaning, office cleaning, and short-term rental cleaning services for clients across Jersey City, Hoboken, and nearby areas. Olimpic Maids is recognized for its transparent flat-rate pricing, licensed and insured teams, and commitment to consistent service quality.Olimpic Maids’ online booking page allows Jersey City residents to view flat-rate pricing and schedule a cleaning in seconds.Press InquiriesOlimpic Maidspress [at] olimpicmaids.comhttps://olimpicmaids.comA video accompanying this announcement is available here: https://youtube.com/watch?v=fY2TRB0RA_4
2026-03-09 21:40:29

Itafos to Present at the Sidoti Small Cap Conference
HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) ("Itafos” or "the Company”) announced today that it will be presenting at the Sidoti Small Cap Conference at 3:15 EST on Thursday March 19, 2026. Register here to attend the virtual event: https://sidoti.zoom.us/webinar/register/WN_YCIRIrUhQBuEB2r6HTcp5A.About ItafosItafos is a phosphate and specialty fertilizer company with businesses and projects spanning three continents:Conda - a vertically integrated phosphate fertilizer business located in Idaho, US, with the following production capacity: approximately 550kt per year of MAP, MAP+, SPA, merchant grade phosphoric acid ("MGA”) and APPapproximately 27kt per year of hydrofluorosilicic acid ("HFSA”)Arraias - a vertically integrated phosphate fertilizer business located in Tocantins, Brazil, with the following production targets (following the proposed restart of the beneficiation circuit): approximately 275kt per year of single superphosphate ("SSP”), PAPR and DAPR approximately 170kt per year of SSP, 60kt per year of PAPR and 45kt per year of DAPRapproximately 40kt per year of excess sulfuric acid (220kt per year gross sulfuric acid production capacity)Farim - a high-grade phosphate mine project located in Farim, Guinea-Bissau; andSantana - a vertically integrated high-grade phosphate mine and fertilizer plant project located in Pará, Brazil The Company is a Delaware corporation headquartered in Houston, Texas, with shares trading on the TSX Venture Exchange under the ticker "IFOS”. The Company’s shares also trade in the US on the OTCQX® Best Market ("OTCQX”) under the ticker symbol "ITFS”. The Company’s principal shareholder is CL Fertilizers Holding LLC ("CLF”), an affiliate of global private investment firm Castlelake, L.P.For more information, or to join the Company’s mailing list, please visit www.itafos.com.About Sidoti Events, LLC ("Events”) and Sidoti & Company, LLC ("Sidoti”)In 2023, Sidoti & Company, LLC, Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti’s coverage universe comprises approximately 160 equities, of which 50 percent participate in the firm’s rapidly growing Company Sponsored Research ("CSR”) program. Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti’s small- and microcap-focused nationwide sales force, which has connections with approximately 2,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.Forward-Looking InformationCertain information contained in this news release constitutes forward-looking information. All information other than information of historical fact is forward-looking information. Statements that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future include, but are not limited to, statements regarding estimates and/or assumptions in respect of the Company’s financial and business outlook are forward-looking information. The use of any of the words "intend”, "anticipate”, "plan”, "continue”, "estimate”, "expect”, "may”, "will”, "project”, "should”, "would”, "believe”, "predict” and "potential” and similar expressions are intended to identify forward-looking information.The forward-looking information contained in this news release is based on the opinions, assumptions and estimates of management, some of which are set out herein, which management believes are reasonable as at the date the statements are made. Those opinions, assumptions and estimates are inherently subject to a variety of risks and uncertainties and other known and unknown factors that could cause actual events or results to differ materially from those projected in the forward-looking information.Although the Company has attempted to identify crucial factors that could cause actual actions, events or results to differ materially from those described in the forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Additional risks and uncertainties affecting the forward-looking information contained in this news release are described in greater detail in the Company’s Annual Information Form and current Management’s Discussion and Analysis available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at www.itafos.com. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. The reader is cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates, assumptions or opinions should change, except as required by applicable securities law. The forward-looking information included in this news release is expressly qualified by this cautionary statement and is made as of the date of this news release.NEITHER THE TSX-V NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX-V) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.Contacts:For Investor Relations:Matthew O’NeillExecutive Vice President & Chief Financial Officerinvestor@itafos.com713-242-8446For Media:Alliance Advisors IRFatema BhabrawalaDirector, Media Relationsfbhabrawala@allianceadvisors.com647-620-5002
2026-03-09 21:40:16

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera” or the "Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.Conference Call and Webcast InformationEvent:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference CallDate:Thursday, March 19, 2026Time:10:00 a.m. ETConference Call:1-888-222-5806 (U.S.)1-412-902-6516 (international)Webcast:Webcast - Biofrontera Inc. 4Q25 and Full Year 2025 Results Conference Callhttps://event.choruscall.com/mediaframe/webcast.html?webcastid=XTq1cPRZ About Biofrontera Inc.Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.Forward-Looking StatementsCertain statements in this press release may constitute "forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera’s commercial opportunities and the commercial success of its products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® and/or RhodoLED® XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the "SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.Investor RelationsBen Shamsian646-829-9701shamsian@lythampartners.com1 https://www.skincancer.org/skin-cancer-information/actinic-keratosis/
2026-03-09 21:40:13

CPS to Host Conference Call on Fourth Quarter 2025 Earnings
LAS VEGAS, Nevada, March 09, 2026 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) ("CPS” or the "Company”) today announced that it will hold a conference call on Wednesday, March 11, 2026 at 1:00 p.m. ET to discuss its fourth quarter 2025 operating results.Those wishing to participate can pre-register for the conference call at the following link https://register-conf.media-server.com/register/BI939b54a85b184d6b8c4cb82440102b17. Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the schedule start time. A replay will be available beginning two hours after conclusion of the call for 12 months via the Company’s website at https://ir.consumerportfolio.com/investor-relations.About Consumer Portfolio Services, Inc.Consumer Portfolio Services, Inc. is an independent specialty finance company that provides indirect automobile financing to individuals with past credit problems or limited credit histories. We purchase retail installment sales contracts primarily from franchised automobile dealerships secured by late model used vehicles and, to a lesser extent, new vehicles. We fund these contract purchases on a long-term basis primarily through the securitization markets and service the contracts over their lives.Investor Relations ContactDanny Bharwani, Chief Financial Officer949-753-6811
2026-03-09 21:40:09

Global Times: A target of seeking progress while maintaining stability, being proactive and pragmatic
BEIJING, March 7, 2026 /PRNewswire/ -- GDP growth of 4.5 percent to 5 percent, while striving for better results in practice - this is one of the main development targets for this year outlined in the Government Work Report. Economic growth targets have long attracted close attention. Over the past three years, China set its GDP growth target at around 5 percent, and the actual growth rate met the goal each year. Against this backdrop, this year's target has drawn particular interest. On Thursday, while taking part in a deliberation with his fellow deputies from the delegation of Jiangsu Province at the fourth session of the 14th National People's Congress (NPC), Chinese President Xi Jinping said that to fulfill the development goals of the 15th Five-Year Plan period (2026-2030), China must navigate a more complex environment and resolve more deep-seated contradictions. Xi, also general secretary of the Communist Party of China Central Committee and chairman of the Central Military Commission, urged major provincial economies to redouble efforts to gain experience in analyzing new situations and solving new problems. For the first year of the 15th Five-Year Plan (2026-30) period, why the growth target was set at "4.5 percent to 5 percent"? What such a target implies for effective economic work? Thinking these questions through clearly and thoroughly will help us to fully, deeply, and accurately understand and grasp the strategic arrangements for economic and social development during the 15th Five-Year Plan period, as outlined at the Fourth Plenary Session of the 20th Communist Party of China (CPC) Central Committee, and to unite our efforts and work diligently to achieve a good start to the 15th Five-Year Plan. The growth target of 4.5 percent to 5 percent is a proactive and pragmatic goal that grasps the underlying principles, taking into account both domestic economic operations and changes in the external environment, and balancing needs and possibilities. For the target itself, "4.5 percent to 5 percent" is a range-based target. This leaves room to respond to various uncertainties while allowing different regions to set their own growth targets in light of local conditions. It also helps guide all sectors to focus their efforts on achieving high-quality development. Indeed, this is not the first time China has set a range-based target in recent years. In 2016, China set its growth target at 6.5 percent to 7 percent, and in 2019 at 6 percent to 6.5 percent. Actual growth reached 6.8 percent and 6.1 percent in those two years, respectively. The decision to again adopt a target range this year reflects a coordinated consideration of both international and domestic situations, balancing development needs with possibilities, and embodying a pragmatic, fact-based approach. Meanwhile, the sentence in the growth target - "striving for better results in practice" - underscores a proactive and enterprising goal-oriented approach and policy orientation. As long as favorable conditions are fully utilized, achieving better results remains entirely possible. In terms of the general laws of economic development, it is common for growth to stabilize as an economy expands in size. After surpassing 140 trillion yuan in 2025, China's annual economic increment alone is now comparable to the total output of a medium-sized economy. At the same time, the conditions underpinning China's growth such as factor endowments and allocation efficiency are evolving, while continued development faces increasing constraints from resources and the environment. Today, achieving each additional percentage point of GDP growth requires greater efforts and the ability to confront larger challenges. The growth target of 4.5 percent to 5 percent fully takes into account changes in both domestic and international situations and the evolving development environment. At present, China's development environment is undergoing profound and complex changes. Domestically, the population aging is deepening, resource and environmental constraints are intensifying, and the transition from old to new growth drivers remains a demanding task. Externally, economic globalization is facing headwinds, geopolitical risks are intensifying, and global economic growth remains sluggish. The IMF forecasts global economic growth of 3.3 percent in 2026. The growth target of 4.5 percent to 5 percent reflects a careful consideration of various domestic and international factors, as well as our advantages and potential risks and challenges. It is a realistic goal that fully acknowledges potential difficulties while remaining achievable with sustained effort. The growth target of 4.5 percent to 5 percent balances the needs of both current and long-term development. An important indicator of basically realizing socialist modernization is the "per capita GDP reaching the level of a moderately developed country." Working backward from the long-term development goals through 2035 and taking into account the projected population by that time, China's GDP would need to grow at an average annual rate of 4.17 percent during the 15th and 16th Five-Year Plan (2031-35) periods. Considering factors such as resource supply, technological progress, and institutional innovation, China's potential growth rate over the next decade is fully capable of supporting an average annual expansion of about 4.17 percent. Viewed within the broader framework of Chinese modernization, the growth target of 4.5 percent to 5 percent aligns with medium- and long-term development goals and will help ensure the basic realization of socialist modernization. It represents a proactive yet pragmatic goal - one that aims high while maintaining steady progress - consistent with China's current development stage and the general laws of economic development. For the first year of the 15th Five-Year Plan period, the growth target of 4.5 percent to 5 percent also takes into full account the need to leave policy space for structural adjustment, risk prevention, and reform. It will help stabilize employment, businesses, markets, and expectations, promote both qualitative improvements and reasonable quantitative growth in the economy, maintain social harmony and stability, and secure a solid start to the 15th Five-Year Plan period. The growth target of 4.5 percent to 5 percent reflects an approach that seeks progress while maintaining stability and emphasizes improvement in quality and efficiency, helping drive high-quality and sustainable development. While presiding over a group study session of the Political Bureau of the CPC Central Committee on January 30, General Secretary Xi noted that the extent of scientific and technological breakthroughs largely determines the speed, breadth and depth of the development of future industries. "Developing new quality productive forces is crucial to driving high-quality development and enhancing economic competitiveness." Achieving high-quality development requires continuous improvements in labor, capital, land, resource and environmental efficiency, as well as a greater contribution from technological progress and higher total factor productivity. Estimates show that in order to basically realize socialist modernization by 2035, China needs to maintain an average annual growth of around 2 percent in total factor productivity. Raising total factor productivity hinges on guiding advanced production factors to cluster around the development of new quality productive forces. Adhering to the overall principle of pursuing progress while ensuring stability and focusing on high-quality development, the growth target of 4.5 percent to 5 percent carries richer meaning. It provides scientific guidance for growth in scale while setting higher requirements for improvements in quality and efficiency, reflecting deeper changes in development philosophy, growth models and sources of momentum. In the first week after the Spring Festival holidays, China achieved a series of breakthroughs in key technologies: original advances in core lithium battery technologies, new progress in space-based biological experiments, and the first large-scale use of drones at offshore oilfields. Some foreign media commented that China, now entering an "innovation boom," is reshaping the global technological landscape. At the ongoing "two sessions," lawmakers and political advisers have also brought a number of encouraging new developments. Huang Sanwen, president of the Chinese Academy of Agricultural Sciences and an academician of the of the Chinese Academy of Sciences, said proudly that "China's grain, vegetables and meat are now mainly produced using Chinese-developed seeds." Pan Jianwei, executive vice president of the University of Science and Technology of China, noted that China continues to lead globally in quantum communication while remaining among the world's top tier in quantum computing. Zhong Baoshen, chairman and general manager of Longi Green Energy Technology, said with confidence that China's photovoltaic industry has demonstrated strong growth potential and resilience, achieving a shift from catching up to taking the lead. Economic development is a dynamic process. Today's growth cannot be measured with yesterday's yardsticks, nor can today's development be viewed through the lens of the past. Today, the growth target of 4.5 percent to 5 percent is not merely a speed indicator, nor a simple linear expansion in scale. Achieving it requires fully and faithfully implementing the new development philosophy, balancing improvements in quality with expansion in scale, and continuously generating stronger momentum for Chinese modernization. The growth target of 4.5 percent to 5 percent can be fully achieved with sustained effort, and even better results can be pursued. The key lies in seeking truth from facts and working diligently to deliver concrete results. The 15th Five-Year Plan period is a critical stage. Viewed from the historical timeline, only ten years remain until China aims to basically realize socialist modernization by 2035. It is therefore necessary to consolidate the foundation and advance on all fronts - achieving visible accomplishments while also undertaking long-term, foundational work. The tighter the timeframe and the more complex the situation becomes, the more important it is to maintain strategic resolve, strengthen confidence in development, and carry forward a spirit of hard work, using the certainty of high-quality development to cope with the uncertainties of the international environment. South China's Guangdong Province, a pioneer, trailblazer and testing ground of reform and opening-up, has ranked first in China in terms of regional GDP for 37 consecutive years. How can it continue to stay at the forefront? Comparing oneself to others makes it hard to escape anxiety over growth rates. Comparing to its own past, however, allows Guangdong to better clarify its goals and find the right direction. For instance, in addressing the "largest shortcoming" of unbalanced urban-rural and regional development, Guangdong has launched the "Hundreds, Thousands and Tens of Thousands Project" tailored to its conditions, promoting stronger counties, invigorated towns, and revitalized villages. Baiyun District, the largest central urban district in Guangzhou by both area and population, has long faced constraints from its urban-rural dual structure in pursuing high-quality development. In Qinghe Village of Renhe Town, 1,800 mu (120 hectares) of scattered farmland have been transformed into Renheyuan, a national 3A-level tourist attraction. In Helong Subdistrict, a low-end village-level industrial park has been upgraded into the design capital of Guangzhou, generating annual revenues of over 90 billion yuan. Since the implementation of the "Hundreds, Thousands and Tens of Thousands Project," all four towns in Baiyun District have entered the list of China's top 250 towns in terms of economic strength, while total collective village income across the district has surpassed 10 billion yuan, ranking first in Guangzhou. The principle of "comparing with oneself" provides an important methodological approach for regions across China to carry out economic work in line with their own conditions. Southwest China's Yunnan Province has remained committed to an eco-priority and green development path, building a strong ecological security barrier in Southwest China. Shanghai is working to accelerate the building of a sci-tech innovation hub with global influence. North China's Shanxi Province is striving to make new strides in transforming its resource-based economy. "Comparing with oneself" means focusing on doing one's own work well and addressing the challenges encountered in one's own development process. During the 15th Five-Year Plan period, China's development environment will undergo profound and complex changes, and economic and social development will face many new issues. "We must seize this window of opportunity to consolidate and expand our advantages, remove bottlenecks and constraints, and shore up weaknesses. In the face of intense international competition, we must gain strategic initiative, advance major tasks that bear on the overall progress of Chinese modernization, and ensure decisive progress toward the basic realization of socialist modernization." Chinese modernization is achieved step by step through hard work. By making our utmost efforts and striving for the best possible results - forging ahead step by step, advancing stage by stage, and accumulating small victories into greater ones - our target will definitely be achieved. This was compiled from an article originally published by the People's Daily on March 6, 2026. https://www.globaltimes.cn/page/202603/1356414.shtml
2026-03-07 02:07:00

Reklamo ni Nadia Montenegro laban sa Senate employee, pinanigan ng prosekusyon
Abswelto si Nadia Montenegro sa alegasyong paggamit ng marijuana sa loob ng Senate of the Philippines noong August 12, 2025, ayon sa abodago niyang si Atty. Maggie Abraham-Garduque.Naghain si Montenegro ng reklamo sa Pasay Prosecutor's Office laban sa Senate Sergeant-at-Arms officer na si Victor G. Patelo, kaugnay ng Unjust Vexation at paglabag sa Safe Spaces Act (Republic Act No. 11313) na kilala rin bilang “Bawal Bastos” Law.Ayon sa resolusyon, pinaghinalaang naninigarilyo ng marijuana si Montenegro, na noo'y Political Affairs Officer ni Senator Robin Padilla, dahil umano sa “unusual odor” mula sa palikuran na ginamit ng aktres, na mariing na pinabulaanan niya.Napilitan si Montenegro na ipakita sa security personnel ang laman ng kanyang bag at bulsa na naglalaman ng vape.Binalaan naman ng nagsumite mismo ng incident report na si Patelo na maaaring may "naiinggit" sa aktres. Pero tinuloy pa rin nito ang paghain ng ulat, kung saan pinangalanan niya si Montenegro bilang subject.Dahil dito, sinabi ng kampo ni Montenegro na nagdulot ang insidente ng trauma at matinding pinsala sa kanyang reputasyon.Pahayag ni Atty. Abraham-Garduque, "Congratulations Nadia Montenegro Pla. This is an early gift for you before Women's Day on March 8."The resolution categorically stated that despite the fact that he knew that you were not smoking marijuana in the Senate of the Philippines on August 12, 2025, the respondent made an incident report which became the basis of the widespread false news against you last year not only to your extreme damage and prejudice but to your family as well."This is a testament that albeit you are a woman, you can fight so that YOUR TRUTH can be heard."I know what you have gone through and I am very happy to be your lawyer so that this vindication will be given and finally be given to you.“This revelation of her truth is the start of healing for Nadia." Kasunod ng isyu, nag-resign si Nadia sa kanyang posisyon bilang miyembro ng staff ni Senator Padilla para maprotektahan ang kanyang mental health at kapakanan ng kanyang mga anak.Aniya, "My decision to resign should not be misconstrued as an admission of guilt—it is not. Rather, it is a demonstration of my deep respect for the Senate and Senator Padilla's office, so that this issue does not cause further distraction or harm. To prevent this baseless issue from growing any further, I would rather remove myself from the spotlight and allow the Senate to focus on its important work."Bago ang kanyang pagbibitiw, hiniling kay Montenegro na mag-file ng leave of absence.Samantala, tingnan ang ilang celebrities na nadawit noon sa isyu ng droga:
2026-03-07 02:04:00

GSIS offices to stay open on Fridays
State-run Government Service Insurance System (GSIS) said it will maintain five-day operations at its frontline service counters even as the state pension fund shifts to a four-day on-site workweek to bolster national energy conservation efforts.Beginning March 9, GSIS employees will transition to a temporary special work arrangement where personnel report to offices from Monday to Thursday, with Fridays designated as a mandatory work-from-home day. The adjustment follows a directive from President Ferdinand Marcos Jr. aimed at mitigating the impact of rising global fuel and electricity costs.GSIS President and General Manager Wick Veloso said in a statement that the agency has established specific shifts for frontline staff to ensure the Lobby and Pensioners Lounge remain open to the public for the full workweek. The measure remains in effect until further notice as the government seeks to curb power consumption across state-owned and controlled corporations.The shift toward hybrid work comes amid heightened volatility in global energy markets, largely driven by ongoing conflict in the Middle East. By reducing the physical footprint of its workforce on Fridays, the GSIS expects a significant drop in its operational overhead. Veloso noted that the agency’s existing investment in renewable energy will further insulate it from high utility costs during the transition.“With this setup, our energy consumption on Fridays will be practically free because of our existing solar panels,” Veloso said, adding that the move balances the need for environmental sustainability with the agency’s mandate to serve its members.While the majority of the administrative workforce moves to remote operations once a week, the pension fund emphasized that all offices remain responsible for continuous service delivery. The GSIS currently manages the social security benefits of government employees, including life insurance, retirement, and disability programs.
2026-03-07 02:04:00

PrintKK Partners with Etsy, Giving Sellers Access to Print-on-Demand Fulfillment Across Nearly 200 Countries
Etsy sellers can now connect to PrintKK's global production network, AI design tools, and 48-hour fulfillment-launching custom products with zero inventoryLOS ANGELES, March 5, 2026 /PRNewswire/ -- PrintKK (www.printkk.com), a global print on demand platform, today announced its integration with Etsy, enabling sellers on the marketplace to create, customize, and sell products globally without holding inventory. The integration is now live and connects Etsy sellers to PrintKK's fulfillment network spanning nearly 200 countries.Through the integration, Etsy sellers connect their shops directly to PrintKK's dashboard. When a customer places an order, PrintKK handles production, packaging, and shipping-with most orders dispatched within 48 hours from fulfillment centers located across multiple continents. Sellers pay only when an order is placed, eliminating upfront costs.PrintKK offers over 1,000 customizable product categories tailored to Etsy's creative marketplace, including apparel, accessories, home decor, light fixtures, rugs and mats, and furniture. The platform supports bulk product uploads and includes an AI design tool that generates production-ready artwork in seconds, helping sellers quickly test new product ideas and respond to seasonal trends."Etsy sellers thrive on originality, and that's exactly what print on demand enables," said William Ning, CEO of PrintKK. "With this integration, a seller can go from design concept to live Etsy listing in under an hour-no sourcing, no warehousing, no minimum orders. We've seen early partners expand their catalogs by 3-5x within the first month."The integration automates order routing, production tracking, and shipping updates between Etsy and PrintKK. Sellers manage their entire workflow-from design creation to fulfillment monitoring-through a single dashboard, reducing the operational complexity of running a multi-product Etsy shop.PrintKK also integrates with Shopify, WooCommerce, Wix, Walmart, eBay, BigCommerce, and Square, allowing sellers to manage cross-platform operations from one account.The Etsy integration is available immediately to all PrintKK users at no additional cost. Sellers can get started at printkk.com/integration/etsy.About PrintKKPrintKK is a global print-on-demand platform that enables e-commerce sellers to design, produce, and ship customized products worldwide. The platform offers 1,000+ product categories-spanning apparel, home decor, lighting, rugs, furniture, and accessories-with AI-assisted design tools and a production network that ships most orders within 48 hours. PrintKK integrates with Etsy, Shopify, WooCommerce, and other major marketplaces. For more information, visit www.printkk.com.CONTACT:Eve Smithpress@printkk.com
2026-03-05 15:29:20

ATOTO P10 Pro Debuts on Kickstarter with AI Vision Safety Guard and Dual 1080p Recording
HONG KONG, March 5, 2026 /PRNewswire/ -- ATOTO announced the launch of P10 Pro on Kickstarter. Positioned as an AI-powered driving and parking safety display built on Android system, P10 Pro pairs a large wireless CarPlay/Android Auto screen with ATOTO-developed AI Vision, dual-channel 1080P recording, low-power parking protection, and cloud-based evidence tools. Dispatch is scheduled to begin in April 2026, with deliveries expected to start in May.Click here to view the official campaign page— Lock in Early-Bird Perks"P10 Pro is built for drivers who want more than a screen," said Peter, general manager at ATOTO. "We combined a full Android platform with AI vision safety, true dual-channel recording, and cloud tools that help drivers document what happened and stay connected to their vehicle—on the road, when parked, and when away."P10 Pro, A Cloud-Connected Portable Driving HubAI-powered safety for driving and parkingFor daily driving, P10 Pro supports front and cabin cameras recording simultaneously in 1080P, with front-camera WDR and strong-light suppression, plus IR night vision for the in-cabin view. Collision-triggered emergency recording helps surface and preserve key clips after an impact. For critical moments, Instant Golden Hour Emergency Notification can send key images and location details to preset emergency contacts.For parking, P10 Pro introduces Low-Power Parking Guard, designed to extend monitoring for up to 72 hours. When paired with optional connectivity, drivers can use Remote LiveView to check on the cabin and surroundings from a phone.Parking Monitor & Live ViewATOTO-developed AI Vision and in-car AI assistanceATOTO-developed AI Vision adds practical, on-screen cues designed to reduce overlooked risks: fun object and car-type recognition, road-condition hints, and cabin hints for kids and important items. P10 Pro also supports natural-language Q&A with AI, along with driving reminders such as low-fuel prompts and gas suggestions when connected to OBD data.Cloud Witness: lock and upload evidence when it mattersCloud Witness is built for drivers who want a fast, intentional way to protect their rights. Drivers can lock important footage and upload it to the cloud, creating a ready record that can be reviewed, organized, or shared when needed.Optional LTE connectivity with multi‐path networkingP10 Pro supports multiple network paths—including optional LTE (4G SIM / Cloud SIM), dual‐band Wi-Fi, and tethering—to keep cloud features and remote access available across different routines. This connectivity foundation also supports additional features such as live tracking, geofence alerts, and trip logs with GPS tracks and playback.How P10 Pro differs from typical portable CarPlay screensMany entry-level portable CarPlay screens focus on mirroring and basic inputs on lightweight RTOS/Linux platforms. P10 Pro takes a different approach with a full Android platform and an integrated safety workflow that combines capture, AI awareness, and cloud tools.Full Android platform designed for richer app capability and performance beyond basic mirroring workflows.Native dual-channel 1080P recording (front + cabin) with WDR front camera and IR night vision in-cabin.Unified Bluetooth Audio (UBA) workflow designed to reduce audio routing friction across daily use.Cloud tools including Cloud Witness, Remote LiveView, and Golden Hour emergency notification for evidence and remote awareness.BLE accessory ecosystem and centralized control for supported devices, plus OTA updates.Campaign details and availabilityThe P10 Pro Kickstarter campaign launched on February 25, 2026 and is scheduled to run through April 11, 2026. Limited early-bird tiers start at:9-inch model: $499.99 (MSRP $833.99; save up to 40% )10.25-inch model: $549.99 (MSRP $916.99; save up to 40%)Dispatch is planned for April 2026, with deliveries expected to begin in May. Early‐bird perks are limited—backers are encouraged to visit the campaign page to secure available tiers.Campaign page-Get Early‐Bird PerksAbout ATOTOFounded in 2015, ATOTO is a global automotive electronics brand specializing in intelligent in-car infotainment and safety solutions. With a strong focus on research, design, and vertically integrated manufacturing, ATOTO develops Android-based car systems, AI-enabled driving tools, and connected vehicle technologies for drivers worldwide. The company operates under a direct factory-to-customer model, delivering continuous software updates and long-term after-sales support across international markets.PR Inquiries:pr@atotoglobal.com
2026-03-05 15:29:10

Inside HSBC Premier’s ‘World of Opportunity’ at The Peninsula Manila
Hongkong and Shanghai Banking Corporation (HSBC) Premier turned some of the most recognizable spaces inside The Peninsula Manila into immersive “worlds” for its top clients, transforming the hotel into a series of environments built around the priorities of modern global living.The Consevatory, Salon de Ning, and several of the hotel’s function rooms were reimagined as curated spaces reflecting the pillars of HSBC Premier’s offerings: health, travel, international connectivity, and wealth. The event, held on February 23, 2025, introduced the bank’s “Worlds of Opportunity” concept that frames premium banking not just as financial services, but as support that extends into mobility, healthcare, and long-term financial planning.**carousel[84059,84057]**A world of healthA Tai Chi demonstration beckoned slowly across the Garcia Villa and Balagtas function rooms as a harpist’s melodies filled the space, setting a calm rhythm for the evening’s opening experience.HSBC framed the environment as its “World of Health,” centered on the bank’s partnership with Allianz through the Allianz Well program.Through the program, HSBC Premier clients may access health insurance coverage with an annual plan limit of up to ₱100 million for in-patient hospitalization. Clients also gain access to leading medical facilities in the Philippines and worldwide, with the option to include coverage in the United States.**carousel[84050,84054,84062,84058,84056,84061]**A world of travelAcross the hotel’s glass-roofed Conservatory, an LED cube installation flickered with images of destinations from different countries. At the “World of Travel”, the bank showcased its Premier Travel Card which mirrors that lifestyle. Offering airport lounge access in more than 1,800 cities worldwide up to ten times a year, along with complimentary airport transfers and meet-and-greet services. Travel insurance coverage of up to $100,000 provides additional protection.Cardholders also benefit from special flight and hotel offers, a low 0.99 percent foreign exchange rate on overseas spending, and four times bonus points on international purchases, along with discounts at duty-free stores.**carousel[84065,84051,84055,84053,84060]**A world of internationalAt the Upper Lobby, a digital installation titled “Wall Alive” displayed the mechanics of HSBC’s global banking network.The installation introduced the next stage of the program: “World of International,” highlighting services designed for clients whose financial lives stretch across borders.Through HSBC’s Global View and Global Transfers features, customers can manage HSBC accounts worldwide with a single log-on and move funds between globally linked accounts in real time and free of charge through the HSBC Philippines mobile app.**carousel[84052,84048,84063,84064]**A world of wealthFinally, inside Salon de Ning, an interactive installation drew guests around a table displaying the investment capabilities available through HSBC’s network.The space represented HSBC Premier’s “World of Wealth,” which focuses on helping clients manage assets across markets.Premier clients gain access to multi-currency wealth solutions supported by insights from HSBC’s international research teams.“We understand what success means for our customers, and that includes having the freedom to grow, explore, protect what matters most, and most importantly, the freedom to belong anywhere in the world,” said Pramoth Rajendran, HSBC Philippines head of International Wealth and Premier Banking.
2026-03-05 15:29:00

VEVOR Partners with Houston Rockets, Marks Strategic U.S. Expansion with Houston Flagship Store
HOUSTON, March 5, 2026 /PRNewswire/ -- VEVOR, a global leader in home improvement solutions, recently announced its first-ever partnership in professional sports with the NBA's Houston Rockets. As part of this collaboration, VEVOR will appear at home games and community events, forging deeper connections with Rockets fans and Houston residents. The partnership represents a key pillar of VEVOR's U.S. localization strategy and underscores the brand's long-term commitment to both the city and the broader U.S. market.VEVOR x HOUSTON ROCKETSBuilding Community Through Shared ValuesVEVOR's brand strategy closely aligns with the spirit of the Houston Rockets and the city itself. On the court, the Rockets have long exemplified excellence, resilience, and teamwork, while off the court, Houston embodies a culture of exploration, hard work, and ambition-from its heritage as "Space City" to its vibrant, thriving community.This shared mindset connects seamlessly with VEVOR's mission to empower creators, professionals, and DIY enthusiasts through tools, solutions, and community-driven programs that inspire innovation, problem-solving, and growth. Houston also serves as the launchpad for VEVOR's first global exploration of an omnichannel "online + offline" retail model, reinforcing the city's strategic significance in the brand's global expansion.HOUSTON ROCKETS x VEVOR "We are honored to partner with the Houston Rockets. The Rockets embody a relentless pursuit of excellence-an ethos that shapes how we build our products and support the creators and small businesses we serve. This collaboration goes beyond sponsorship; it reflects our long-term commitment to Houston. By bringing innovative tools and practical solutions to the community, we aim to help Houston's makers and entrepreneurs turn ideas into impact and build a stronger ecosystem of creativity and opportunity." said Gavin Wu, Brand Director at VEVOR.Launching VEVOR's Physical Retail Presence in the U.S.As part of its broader U.S. retail expansion, VEVOR is opening its first global flagship store in Houston, which began soft opening in February and will officially celebrate its grand opening in March.The store features a BOPIS (Buy Online, Pick Up In Store) model, seamlessly integrating online convenience with in-store accessibility. Customers can purchase products online and retrieve them in-store, offering flexibility, efficiency, and a streamlined shopping experience.A Hands-on experience zone invites visitors to explore and test tools and solutions in real-world settings, bridging the gap between online research and tactile engagement. This interactive space caters to a broad audience-DIY enthusiasts, professional builders, and small business owners-helping them make informed decisions while experiencing products firsthand.Beyond retail, the store serves as a hub for learning, discovery, and collaboration, reinforcing VEVOR's mission to empower home creators, problem-solvers, and local innovators, and supporting the growth of Houston's home improvement community.The flagship store will officially open at 10951 Farm to Market 1960 Road W, Houston on March 9, 2026 with special appearances by Houston Rockets representatives. Join us for a day of celebration, exploration, and hands-on experiences!About VEVORVEVOR is a global home improvement brand that empowers home creators, who actively reshape living spaces to express their inner pursuits, finding joy in turning visions into reality with their own hands to upgrade spaces with pro-level gear at fair prices. From backyard makeovers to apartment innovations, VEVOR delivers uncompromised quality through vertical integration - combining precision engineering with the joy of making.Founded in 2007 as an eBay seller, VEVOR began selling on Amazon in 2013 and launched vevor.com in 2020. The brand unveiled its refreshed identity in 2025. Today, VEVOR operates in over 50 countries, with a network of 200+ global warehouses and a catalog of over 15,000 products spanning tools, outdoor equipment, and home improvement solutions.The brand's promise is built on four pillars: professional-grade performance, unexpected value, complete home ecosystem coverage, and uncompromising quality. This commitment is reflected in its 90% customer satisfaction rate, supported by 24/7 assistance and a 30-day hassle-free return policy.For more information, visit www.vevor.com or search "vevor" on Amazon.Media Contact: media@vevor.com
2026-03-05 15:28:51

The world's largest brain research prize awarded for groundbreaking discoveries on how we sense touch and pain
The Brain Prize 2026 is awarded to Professors David Ginty (US) and Patrik Ernfors (Sweden) for their pioneering discoveries on how the nervous system detects and processes touch and pain. Their work has rewritten textbooks and opened new avenues for the development of targeted treatments for conditions such as chronic pain and hypersensitivity to touch.COPENHAGEN, Denmark, March 5, 2026 /PRNewswire/ -- The somatosensory system provides us with the sense of our own body and its physical interactions with the world. Our sense of touch enables us to perceive a passing breeze, feel the shape and texture of objects in our hands or the physical contact of others. It provides crucial sensory feedback that controls how we move our body and respond to the outside world. The somatosensory system also encompasses our ability to feel pain. Pain can be caused by mechanical stimuli, heat and noxious chemicals. While unpleasant, it is essential for our survival, acting as a warning system that protects us from what is harmful. Disruptions in our normal ability to sense touch and pain can lead to severe and debilitating conditions, including hypersensitivity to touch - observed in many developmental disorders - and chronic pain which affects millions of people worldwide.HM The King of Denmark, patron of The Brain Prize, attending the prize ceremony 2025.Although touch and pain have been studied for more than 150 years, Patrik Ernfors (Karolinska Institutet, Sweden) and David Ginty (Harvard Medical School, US) have revolutionised the field by identifying how nerve cells in the skin transform painful, thermal and mechanical stimulation, such as stroking, vibration, or indentation, into neural signals. They have further mapped how these signals are transmitted to and processed within the spinal cord and then sent to the brain where the perception of – and the emotional and behavioral reactions to – our interactions with the physical world are created.Together, their discoveries have rewritten textbook principles of somatosensation and provided the foundation for a new generation of targeted interventions for pain and somatosensory dysfunction based on specific cell types and neural pathways.Professor Andreas Meyer-Lindenberg is Chair of The Brain Prize Selection Committee and explains the reasoning for awarding Professors David Ginty and Patrik Ernfors the Brain Prize 2026:"Somatosensation defines the integrity of the body and the boundary between the body and the world and is thus crucial for our sense of physical self and our interactions with the world around us. The ability to detect and interpret touch, pain, itch, and temperature depends on an extraordinary diversity of peripheral sensory neurons, supporting cells, and precisely organised spinal cord and brainstem circuits. By discovering and categorising distinct sensory neuron types, linking them to specific end organs and pathways, and providing novel widely used genetic and molecular tools, their work has created a blueprint for understanding normal touch and for pinpointing where things go wrong in disorders such as chronic pain, and hyper- and hyposensitivity that may be associated with diseases of the nervous system."On behalf of the Lundbeck Foundation, CEO Lene Skole extends her warmest congratulations to the two prize recipients:"Our ability to feel touch and pain is perhaps the most underappreciated of our senses. It gives us our sense of self and of our interactions with the world. Without it we would feel disembodied. This is hard to imagine and to really appreciate how profound it is, we need only look at what happens when the sense of touch and pain goes wrong. The fundamental new insights into the neuroscience of touch and pain provided by Patrik Ernfors and David Ginty are truly remarkable and carry hope for patients living with disorders such as chronic pain. It is a true pleasure to award these outstanding scientists with The Brain Prize 2026."MORE INFObrainprize.org
2026-03-05 15:28:41

The SBB Research Group Foundation Sponsors World Wildlife Fund
CHICAGO, March 05, 2026 (GLOBE NEWSWIRE) -- World Wildlife Fund collaborated in a volunteer initiative alongside the SBB Research Group Foundation, which partners with local nonprofits through its Champion A Charity Program. The SBB Research Group Foundation supports the World Wildlife Fund (WWF) with a continued partnership dedicated to expanding ongoing conservation efforts for the black-footed ferret, one of North America’s most endangered species. This year’s contribution builds on the SBB Research Group Foundation’s previous support and helps WWF broaden the reach of its disease mitigation strategy across additional prairie dog colonies.In 2024, WWF focused on advancing drone delivery systems for vaccine-laced bait pellets, a critical tool for combating sylvatic plague in prairie dog populations, the primary food source for black-footed ferrets. With the 2025 partnership, WWF is now able to apply these upgraded technologies across a larger habitat range, allowing vaccination efforts to reach new sites that were previously inaccessible. Expanding this work is critical to stabilizing prairie dog numbers and, in turn, improving survival for the black-footed ferret."WWF has proven how targeted vaccine delivery can protect both prairie dogs and the ferrets that rely on them,” said Erin Noonan, a volunteer with the SBB Research Group Foundation. "This year’s support is about helping and strengthening the long-term health of this fragile ecosystem.”The SBB Research Group Foundation values the opportunity to continue supporting WWF’s conservation initiatives.To learn more about WWF and their efforts to save the black-footed ferret, please visit:WWF Black-Footed FerretAbout the SBB Research Group Foundation The SBB Research Group Foundation is a 501(c)(3) nonprofit that furthers the philanthropic mission of SBB Research Group LLC (SBBRG), a Chicago-based investment management firm led by Sam Barnett, Ph.D., and Matt Aven. The Foundation provides grants to support ambitious organizations solving unmet needs with thoughtful, long-term strategies. In addition, the Foundation sponsors the SBBRG STEM Scholarship, which supports students pursuing science, technology, engineering, and mathematics degrees. Contact: Erin Noonan Organization: SBB Research Group FoundationEmail: grants@sbbrg.org Address: 450 Skokie Blvd, Building 600, Northbrook, IL 60062 United States Phone: 1-847-656-1111 Website: https://www.sbbrg.org
2026-03-05 15:26:26

Duke Robotics Announces 25-for-1 Reverse Stock Split
Reverse Split Intended to Increase Per-Share Trading Price; May Support a Potential Exchange UplistingFollowing the Reverse Stock Split, the Company's ticker symbol on the OTCQB is expected to trade under the symbol DUKRD for 20 trading daysFort Lauderdale, FL, March 05, 2026 (GLOBE NEWSWIRE) -- Duke Robotics Corp. (OTCQB: DUKR) ("Duke Robotics” or the "Company”), a leader in advanced robotics and drone-based solutions for civilian and defense markets, today announced that a reverse stock split of the Company’s issued and outstanding common shares, par value $0.0001 per share (the "Common Stock”) at a ratio of 25-for-1 (the "Reverse Stock Split") is expected to be implemented at market open on March 6, 2026. The Company's Common Stock will begin trading on the OTCQB on a post-split basis at the market open on March 6, 2026. Following the Reverse Stock Split, the Company's ticker symbol on the OTCQB is expected to trade under the symbol DUKRD for 20 trading days, in accordance with OTC Marketplace rules.The Reverse Stock Split was approved by the Company’s Board of Directors and by the Company’s stockholders. The primary purpose of the Reverse Stock Split is to increase the per-share market price of the Company’s Common Stock, which is intended to support a potential uplisting to a national securities exchange, subject to the Company meeting applicable listing requirements.The Company will trade under a new CUSIP Number, 903448207. The Reverse Stock Split will become effective upon the filing of a Certificate of Change with the Secretary of State of Nevada.After giving effect to the Reverse Stock Split of the Company’s Common Stock, each twenty-five (25) Common Stock will be combined into one (1) Common Stock, such that the Company’s 56,302,147 Common Stock outstanding will be reduced to approximately 2,252,086 Common Stock outstanding, subject to the treatment of fractional shares. The total number of authorized Common Stock will not be reduced and will remain at 350,000,000 shares following the effectiveness of the Reverse Stock Split. No fractional shares will be issued as a result of the Reverse Stock Split as any fractional stock resulting from the Reverse Stock Split will be rounded up to the nearest whole stock on a per stockholder basis.The Reverse Stock Split is not expected to change any stockholder’s proportional ownership interest, except for minimal effects that may result from the treatment of fractional shares. Registered stockholders holding shares in book-entry form need not take any action, and stockholders holding shares through a broker or nominee should contact their broker or nominee with any questions. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company’s outstanding options, warrants and other equity-based awards, in accordance with their terms.Equiniti Trust Company, LLC, will act as the exchange agent for the Reverse Stock Split. Please contact Equiniti Trust Company, LLC for further information at 919-744-2722.About Duke RoboticsDuke Robotics Corp. (OTCQB: DUKR) develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. The Company’s Insulator Cleaning Drone (IC Drone) is a first-of-its-kind, drone-enabled system for cleaning and monitoring high-voltage electric utility insulators. Leveraging Duke’s technologies, the IC Drone provides a safer, more efficient, and cost-effective alternative method. In defense, through a collaboration agreement with Elbit Systems Land Ltd. ("Elbit”), the Bird of Prey weapons drone system is an agile, fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, marketed by Elbit under the brand name Bird of Prey (formerly known as TIKAD). For additional Company information, please visit https://dukeroboticsys.com and follow us on Twitter (X) and LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements. Words such as "future" and similar expressions, or future or conditional verbs such as "will," are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs, assumptions, and information currently available to us. For example, the Company uses forward-looking statements when discussing the expected timing and effects of the Reverse Stock Split, including when the Company’s Common Stock is expected to begin trading on a split-adjusted basis, the anticipated impact of the Reverse Stock Split on the market price of the Company’s Common Stock, and the Company’s plans regarding a future potential uplisting to a national securities exchange, subject to the Company meeting applicable listing requirements. Our actual results may differ materially from those expressed or implied due to known or unknown risks and uncertainties. These include, but are not limited to, risks related to the successful market adoption of our technologies, the continued development and refinement of our technology, our ability to effectively collaborate with Elbit Systems, fluctuations in foreign currency exchange rates, operational challenges associated with marketing activities in new markets, economic conditions that may affect defense spending and infrastructure investment, geopolitical factors that could impact business operations, regulatory challenges in various regions, and competition from technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and any subsequent filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Company Contact:Duke Robotics Corp.Yossef Balucka, CEOinvest@dukeroboticsys.comCapital Markets & IR:Arx Investor RelationsNorth American Equities Deskduke@arxhq.com
2026-03-05 15:26:22

Precision Assembly Chooses TAB Bank for a $2.5 Million Asset-Based Lending Facility to Accelerate Growth
OGDEN, Utah, March 05, 2026 (GLOBE NEWSWIRE) -- TAB Bank closed a $2.5 million asset-based lending facility, which includes a $1.5 million inventory subline for Precision Assembly, Inc. The capital provided from this credit facility will create opportunities for Precision Assembly to accelerate growth, while advancing their goals of providing quality parts and components for their customers.Based in Utah, Precision Assembly is a contract electronics manufacturing services provider specializing in printed circuit board assembly and related engineering support through design, layout, prototyping, and surface-mount assembly for their customers in the medical, dental, education, transportation, law enforcement, industrial, mining, and farming industries."TAB Bank was wonderful to work with. They were very attentive to our financing needs and provided great solutions for this credit facility. They are very friendly and I would recommend them as a trusted banking partner,” stated Mauro Carlini, CFO of Precision Assembly.TAB Bank offers customized financial solutions for small to mid-sized businesses across various industries. Services include asset-based lending, equipment financing and working capital solutions tailored to help companies scale and thrive.About TAB BankAt TAB Bank, our mission is to unlock dreams with bold financial solutions that empower individuals and businesses nationwide. We are committed to building value in all we do through our innovative banking products. Our dedication drives us to continuously improve, ensuring that we meet the evolving needs of our clients with excellence and agility. For over 27 years, we have remained steadfast in offering tailored, technology-enabled solutions designed to simplify and enhance the banking experience. For more information about how we can help you achieve your financial dreams, visit www.TABBank.com.Contact Information:Trevor MorrisDirector of Marketing801-710-6318trevor.morris@tabbank.com
2026-03-05 15:26:15

Crypto News: Pepeto Announces Major Advancement as Binance Launch Nears As Cardano Target $10
Dubai, UAE, March 02, 2026 (GLOBE NEWSWIRE) -- Pepeto just confirmed a major advancement in platform development as the presale crosses $7.43 million raised with demand accelerating faster than any previous stage. Copycat tokens are launching daily on decentralized exchanges, a pattern that only appears in crypto news when something big is about to go live. What makes this project special is how it combines meme culture and real utility into one ecosystem, giving both casual buyers and institutional investors a reason to invest in the same token. Pepeto is building tools that represent a genuine upgrade over what Cardano delivered, and this article breaks down why while examining whether Cardano can realistically reach $10.Crypto News: Can Cardano Reach $10 and Why Pepeto's Innovation Tells a Different Story for Smart InvestorsCardano earned its reputation as one of the most academically rigorous blockchains in the industry, built on peer reviewed research with a focus on scalability that attracted a loyal following. As CoinCodex reported, their algorithm does not see Cardano reaching $10, with the highest projected price sitting at $1.25 even out to 2049. As Benzinga covered, most analysts project ADA between $0.30 and $0.80 through 2026, and the $10 target would require a 3,500% gain the fundamentals do not support. The vision was strong but execution fell short because adoption stayed limited and the ecosystem never attracted the developer activity needed to compete.That gap is exactly where Pepeto enters with infrastructure that does what Cardano promised but could not deliver at scale. History proves that projects solving fundamental crypto problems at presale prices deliver returns no large cap can match, the same way Ethereum rewarded early believers at $0.30, and the same way Solana turned presale buyers into millionaires before the market caught on. The difference between wealth creation and regret in crypto is not intelligence or luck, it is the vision to act before the crowd validates what you already see.Why Both Meme Coin Communities and Institutional Capital Are Investing in Pepeto at the Same TimePepeto achieved something no other project in this cycle has managed, which is attracting both meme coin communities and serious institutional capital into the same presale at the same time despite those groups having completely different reasons for investing. The meme coin side sees Pepeto's branding as the god of frogs as a cultural evolution of what made Pepe one of the most recognized symbols in all of crypto, and the redemption narrative built into the project's identity has turned heads across every major meme coin community. But what the large wallet investors see is entirely different, because Pepeto is building a complete trading platform where all cryptocurrencies can be exchanged on a single secure system with fees so low they barely register, instant cross chain transfers through a dedicated bridge, and zero tax swaps across Ethereum, BNB Chain, and Solana.The meme appeal will push the price high after launch because viral culture is the fastest discovery engine in crypto, and when the initial excitement settles, the infrastructure underneath keeps demand growing because traders actually need what Pepeto built. That combination has never existed before at a presale entry this early, which is why analysts are calling Pepeto the biggest project of 2026, and saying the biggest project rather than the biggest meme coin is not a mistake, because clearly this is far more than a meme coin. Dual security audits from SolidProof and Coinsult verify the smart contracts, and 211% APY staking rewards compound daily for every holder while the Binance listing draws closer with each milestone the project passes.The Logic Behind Pepeto's Acceleration Makes the Analyst Predictions Impossible to IgnoreNow the picture becomes clear. The innovation behind Pepeto, the way the team wove meme culture into a real trading ecosystem, and the speed of every milestone all reveal a team that knows exactly how to build for maximum impact. Bitcoin bounced from around $65,000 to above $69,000 today showing early signs of recovery, and every day that passes brings the bull run closer while the presale window shrinks. Analysts calling Pepeto the biggest success story of 2026 are following logic anyone can see, because a project with viral energy, real infrastructure, and a Binance listing on the horizon does not stay at presale prices for long. Visit the Pepeto official website and secure your position before this opportunity becomes a headline you read about instead of a return you earned.Click To Visit Pepeto Website To Enter The PresaleFAQsCan Cardano realistically reach $10 in this cycle?It’s hard for cardano to reach $10 as most analysts project Cardano trading between $0.30 and $0.80 in 2026. Early stage projects like Pepeto offer significantly higher return potential from presale entry.What is the latest crypto news about Pepeto and Binance?Pepeto confirmed major tool advancement with $7.43 million raised and a Binance listing approaching. Demand is accelerating with copycat tokens appearing daily, a signal that launch is near.Why are institutional investors buying a meme coin like Pepeto?Institutional investors buying a meme coin like Pepeto because it combines meme culture with a full trading platform, cross chain bridge, and zero tax swaps. Visit the Pepeto official website for ecosystem and staking details.CONTACT: MEDIA CONTACTContact: Dani BonocciEmail: info@pepeto.ioWebsite: https://pepeto.io/Phone: +971586738991
2026-03-02 19:19:48

Stellantis Publishes Agenda for 2026 Annual General Meeting of Shareholders
Stellantis Publishes Agenda for 2026 Annual General Meeting of ShareholdersAMSTERDAM, March 2, 2026 - Stellantis N.V. today announced the publication of the agenda and explanatory notes for its 2026 Annual General Meeting of Shareholders (AGM), which is scheduled for April 14, 2026, in Amsterdam.The terms of office of John Elkann, as executive director, and Robert Peugeot and Henri de Castries, as non-executive directors, will conclude at the end of the AGM. John Elkann and Robert Peugeot are proposed for re-election in the respective roles upon binding nomination by Exor N.V. and Établissements Peugeot Frères S.A. / Peugeot Invest S.A., respectively. In addition, the Stellantis Board of Directors, based on the recommendation of the ESG Committee, has resolved to propose the re-election of Henri de Castries as non-executive director and the appointment of Juergen Esser as an additional non-executive director. If elected, all proposed directors will serve a two-year term.Juergen Esser brings strong experience and clear ambition to deliver industry-leading value creation, supported by digitally enabled business models. He holds a Diploma in Political Economies from the Friedrich-Wilhelms-University in Bonn, Germany, and currently serves as Deputy CEO and Chief Financial, Technology & Data Officer at Danone. The Board believes that his appointment will further enhance its collective expertise and operational effectiveness.The official notice of the AGM, along with explanatory notes and related materials - including biography of the non-executive director proposed to join the Board and the voting instructions - is now available in the Investors section of Stellantis’ corporate website at www.stellantis.com. Shareholders may also request a printed copy of these materials, including Stellantis’ audited financial statements for the year ended December 31, 2025, using the contact information provided below.# # #About StellantisStellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit www.stellantis.com.@StellantisStellantisStellantisStellantis For more information, contact: communications@stellantis.comAttachmentEN-20260302-Stellantis-2026-AGM-Agenda
2026-03-02 19:19:40

Instead Achieves 67% of All Government Tax Filing Approvals, On Track for Complete Nationwide Coverage in Weeks
AI Startup Accomplishes Regulatory Feat "No Company Has Done in Decades"SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Instead has secured 67% of all required government approvals for electronic and print tax filing across federal, state, and municipal jurisdictions, with over 85% of applications submitted and complete nationwide coverage expected within weeks.The AI-powered platform has built the first autonomous AI tax agent capable of true end-to-end preparation and filing across all major entity types (Forms 1040, 1041, 1120, 1120-S, and 1065), positioning the company to disrupt the $15 billion tax preparation industry."No company has accomplished these approvals in decades," said Andrew Argue, CEO and founder of Instead. "Even if another company started today with hundreds of millions of dollars, it would take them years to get through the regulatory approvals our team has achieved."Instead's "zero-touch tax return" represents the industry's first truly autonomous workflow. The AI system takes every document from taxpayers, extracts all data, creates work papers, populates the return, and reviews it for accuracy, with human reviewers signing off in minutesThe comprehensive approval scope creates a direct challenge to established platforms like CCH, GoSystem, UltraTax, Lacerte, and ProConnect. Unlike existing AI tax tools that handle only partial workflows, Instead's unified system provides complete automation while eliminating the need for multiple software licenses."If you're a firm that's tried AI products that only do part of the process, they prepare work papers but don't populate the return, or require you to keep your legacy tax software, we want to talk," Argue said.Instead is actively recruiting beta firms for product rollout later this year, with major partnership announcements expected soon. The company is targeting current users of legacy platforms ahead of the next renewal cycle.For more information, visit www.instead.com.About InsteadInstead (www.instead.com) is an AI-driven tax platform that helps individuals, businesses, and tax professionals discover, implement, and document tax strategies with confidence. The first platform in decades approved by the IRS to e-file across all major entity types, Instead has introduced the zero-touch tax return - an autonomous AI workflow that end-to-end prepares and files returns. The company has secured 67% of all required government approvals, with full nationwide coverage expected shortly.Media Contact:Olivia RodiManager of Marketing, Insteadolivia@instead.com
2026-03-02 19:18:55

Jo Malone London introduces Georgia May and Lizzy Jagger as global brand ambassadors for English Pear
LONDON, March 2, 2026 /PRNewswire/ -- The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger. Hailing from rock and roll roots, Georgia May and Lizzy have unique individual styles and personalities, reflected in their unique choice of scents. English Pear & Freesia and English Pear & Sweet Pea offer two takes on the perfect pear, both featuring this timeless, quintessential Jo Malone London ingredient. The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger. Georgia May Jagger Georgia May began modelling at a young age, featuring in campaigns for a variety of global beauty and fashion brands. She launched her own skincare brand MAY Botanicals in 2023. She co-owns hair dye brand Bleach London and is the Wellbeing Ambassador for the British Beauty Council. Lizzy Jagger Lizzy first appeared on the catwalk in 1998 and has been modelling ever since, representing many designers at fashion weeks and featuring in campaigns for global brands. She is an advocate for women's rights and worked on the award-winning documentary Equal Means Equal with Kamala Lopez, pushing for Women's Equality Day to become Women's Equality Week. The campaign Experience the sunlit orchard. Sister scents, one bond and an English pear in every bottle. English Pear & Freesia: a cult classic Orchards steeped in golden sunshine, warming the russet curves of luscious pears. The sensuous freshness of the just-ripe fruit wrapped in elegant white freesias, enhanced with rose and rooted in patchouli. Top: Williams Pear Heart: Freesia Base: Patchouli 'I love it because it's classic and elegant. I feel I can reach for it every day and wear it anywhere. It's really timeless'—Georgia May Jagger English Pear & Sweet Pea: a new classic Sun-warmed orchards spring to life as tempting green pears fill the branches. The luscious fruits enveloped in softly scented pastel sweet peas, nestled on a base of powdery white musk. Top: Williams Pear Heart: Sweet Pea Base: White Musk 'I can't help but smile when I wear English Pear & Sweet Pea. It's playful, subtle, and instantly makes my day better'—Lizzy Jagger About Jo Malone London: Since 1994 Jo Malone London has created a palette of exquisitely simple, elegant scents and curated a world where every sense is indulged. Acquired by The Estée Lauder Companies Inc. in 1999, today the brand is internationally known for its unexpected fragrances and distinctly British character. Discover these new products alongside the full collection from March 2026, online and in-store. Follow Jo Malone London on TikTok, Instagram, Facebook, X, YouTube, LinkedIn and Pinterest @JoMaloneLondon #EnglishPear
2026-03-02 19:12:00

OVN LLC Begins a New Chapter: AI as a Strategic Partner in Modern Logistics
ELK GROVE VILLAGE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- In today’s logistics landscape, artificial intelligence is no longer a distant concept. It is a practical tool shaping real operations in real time. OVN LLC announces the integration of AI-driven systems into its daily workflow - not as a replacement for people, but as a powerful assistant built on a decade of operational data and experience.OVN has spent years refining processes across dispatch, compliance, routing, and driver management. Now, that accumulated knowledge powers an internal AI agent designed to support the company’s team with greater precision and speed.AI Supporting Real OperationsOVN’s AI agent assists dispatchers and operations staff with:Optimizing routes based on live traffic, weather, and road conditionsSupporting onboarding and verification of new drivers and owner-operatorsReviewing airway bills, bills of lading, and shipment documentationMonitoring shipment data for inconsistencies or risk indicatorsThe system learns from historical shipment patterns and company-specific performance data, allowing it to act as a second layer of review and analytical support.This approach enhances accuracy, reduces processing time, and strengthens compliance - while keeping human oversight at the center of every decision.Technology That Amplifies PeopleOVN makes it clear: this is not an "AI-only” operation.Dispatchers still communicate directly with drivers.Operations managers still make critical decisions.Customer support remains live, 24/7/365.AI operates in the background - checking, verifying, analyzing, and recommending - enabling OVN’s team to work faster and smarter."Artificial intelligence is not replacing our people - it is reinforcing them.”"The future belongs to companies that combine experience with intelligence - both human and artificial.”A Smarter Standard of ServiceBy integrating AI into routing, compliance checks, document validation, and driver onboarding, OVN strengthens its ability to deliver:More precise dispatch executionFaster administrative processingImproved documentation accuracyEnhanced shipment visibilityGreater operational consistencyThe result is a stronger, more resilient service model built on human expertise supported by intelligent systems.The Future Is Operational - TodayAI is no longer a promise. It is infrastructure.OVN’s latest integration reflects a long-term vision: using data responsibly, strengthening internal processes, and continuously improving service quality without compromising the human element that defines the company.The future is here - and OVN is using it to raise the standard.About OVN LLCOVN LLC is an asset-based expedited freight carrier headquartered in Elk Grove Village, Illinois. With a fleet of 1,000+ cargo vans, TWIC/TSA-certified drivers, 24/7/365 live dispatch, and advanced technology infrastructure, OVN delivers fast, secure, and transparent logistics solutions across North America.Media Contact:Oleh HolovatiukCEOOVN LLCPhone: 888-385-9060Website: https://ovn.llc
2026-03-02 18:58:55

Laoag City's Pamulinawen Festival reclaims Tan-ok Festival title after 12 years
LAOAG CITY – Thousands of spectators witnessed pride, unity, and greatness through the 13th Tan-ok ni Ilocano Festival, the mother of all cultural festivals in Ilocos Norte province, at Ferdinand Marcos Stadium here on Saturday night.A total of 22 contingents showcased their culture and talents, with Laoag City’s Pamulinawen Festival performance reclaiming the championship after 12 years.Participated in by 180 young performers from different schools, the city’s winning performance honored Laoag’s heritage through the eyes of the kutsero, the horse-drawn carriage driver whose craft has long defined the city’s identity.The Pamulinawen Festival won three consecutive titles in 2012 to 2014.Last year’s winner, the municipality of Piddig\'s Basi Festival, placed second, followed by Banna’s Abuos Festival, Pinili’s Abel and Bawang Festival, Burgos’ Saniata Festival, Batac’s Empanada Festival, Nueva Era’s Tadek Festival, and Currimao’s Dinaklisan Festival.Beyond the cash prizes awarded by the provincial government, the festival served as a platform for economic and artistic empowerment, generating job opportunities for local dancers, musicians, choreographers and costume designers, while boosting tourism and small businesses.Organizers said close to 6,000 artists and artisans shared their talents and skills, showcasing the thriving creative industry in the province that supports local livelihood.Ilocos Norte Gov. Cecilia Araneta-Marcos underscored the importance of safeguarding the culture, the people, and the community that define the province."This year, Tan-ok carried a beautiful new direction. We are bringing the stories of every town closer together, just as we bring government services closer to every Ilokano family. From amianan (north) to abagatan (south), from the mountains to our coastal communities, each town carries a story shaped by faith, celebration, hard work, and love for home,” she said. (PNA)
2026-03-01 08:50:00

EverForward Trading Implements Exposure-Gating Framework as Brian Ferdinand Strengthens Capital Discipline for 2026
Las Vegas, Nevada , Feb. 27, 2026 (GLOBE NEWSWIRE) -- In 2026, market instability is no longer episodic. It is embedded.Liquidity can thin without warning. Correlation structures can compress and invert intraday. Execution reliability can deteriorate precisely when risk sensitivity increases. In this landscape, the assumption that capital should remain continuously deployed has become structurally dangerous.EverForward Trading has responded by institutionalizing an exposure-gating framework designed to prevent structural overextension. The initiative is being advanced under the direction of Brian Ferdinand, whose mandate for 2026 centers on capital durability, environmental validation, and disciplined authorization before deployment.The governing principle is clear:Capital is deployed by permission, not by default.Environment Before EngagementAt EverForward, markets are no longer treated as automatic deployment venues. They are assessed as conditional systems requiring qualification.Before exposure is activated, the firm evaluates whether the current environment demonstrates structural alignment across multiple dimensions:Depth and resilience of executable liquidityStability of volatility transmissionContainment of loss expansion under stressIntegrity of cross-asset behavior These variables are analyzed collectively, not independently. A failure in any one dimension can invalidate deployment.Within this architecture, inactivity is not hesitation. It is structural compliance.As Ferdinand has noted internally:"Strategies rarely collapse because their logic disappears. They collapse because their assumptions are forced into distorted environments.”Separation of Signal and RiskA defining feature of the 2026 framework is the firm’s strict separation between research insight and capital allocation.Analytical edge does not automatically convert into exposure.Each strategy must pass through a structured authorization layer that evaluates how it behaves under adverse structural shifts, including:Liquidity contraction and its effect on transaction cost expansionVolatility acceleration and its impact on drawdown geometryCascading failure probabilities across correlated instruments The objective is not to optimize historical return curves. It is to confirm that structural damage remains bounded when assumptions degrade.By prioritizing survivability over backtest symmetry, EverForward reduces reliance on historical smoothness and increases forward resilience.System-Enforced ConstraintThe firm’s governance model also removes discretionary escalation during instability.Exposure ceilings are predefined. Execution permissions are system-controlled. Risk tolerances are codified before stress emerges.When volatility expands or correlations destabilize, no additional authority is granted to urgency.Speed does not override structure.This deliberate constraint introduces friction into the deployment process - a stabilizing mechanism designed to prevent narrative-driven overreach during high-noise regimes.Adaptation Through ValidationWithin EverForward’s operating philosophy, adaptation is not synonymous with frequent modification.Changes to strategy parameters or allocation logic are introduced only after diagnostic confirmation that structural conditions have shifted materially. Performance divergence alone does not trigger alteration.System evolution is treated as engineering calibration, not tactical improvisation.This distinction preserves continuity of logic while maintaining flexibility when regime transitions are objectively confirmed.Strategic Positioning for 2026As structural fragmentation becomes a persistent feature of global markets, EverForward’s posture remains intentionally selective:Validate the environmentAuthorize exposure conditionallyPreserve capital as strategic inventory In a market culture that often equates activity with competence, the firm’s direction reflects a disciplined conclusion:Participation is discretionary. Preservation is mandatory.Performance, within this framework, is not pursued at the expense of structural integrity. It is built upon it.About Brian FerdinandBrian Ferdinand serves as Portfolio Manager and Trader at EverForward Trading, overseeing portfolio construction, capital allocation, and execution governance across liquid global markets. His approach emphasizes controlled exposure scaling, execution realism, and structural risk containment across varying market regimes.He is also a member of the Forbes Business Council, an invitation-only organization of senior executives and industry leaders.About EverForward TradingEverForward Trading is a trading firm focused on portfolio construction, active execution, and scalable risk management across global liquid markets. The firm prioritizes disciplined exposure governance, structural durability, and performance consistency built on systematic capital control.CONTACT: Shazir Mucklaiinfo@everforwardtrading.com
2026-02-27 22:49:29

EverForward Trading Introduces Regime-Validation Model as Brian Ferdinand Reframes Risk for 2026
London, United Kingdom, Feb. 27, 2026 (GLOBE NEWSWIRE) -- In 2026, the most significant threat to trading performance is not volatility - it is structural misinterpretation.Markets no longer transition cleanly between regimes. Liquidity can appear abundant while depth quietly erodes. Correlations can remain stable statistically while execution realities shift underneath. Signals can remain intact while their transmission mechanism degrades.In response to this environment, EverForward Trading has implemented a regime-validation model designed to prevent structural overextension. The initiative is being led by Brian Ferdinand, whose 2026 mandate centers on capital durability, execution realism, and systemic exposure control.The operating thesis is simple but uncompromising:Not all market conditions deserve capital.From Continuous Deployment to Conditional ActivationTraditional trading cultures often equate engagement with competitiveness. If markets are open, exposure is active.EverForward has deliberately rejected that premise.Instead of default participation, the firm now operates under a regime-qualification protocol. Exposure is activated only after the environment demonstrates structural integrity across key dimensions:Order book continuity under stressPredictability of volatility transmissionContainment of drawdown accelerationStability of cross-asset relationships If any one of these elements deteriorates, exposure scales down automatically - or is suspended entirely.Standing aside is not interpreted as missed opportunity. It is interpreted as adherence to structural logic.Engineering Around Structural DriftA central insight behind the 2026 framework is the concept of structural drift - the gradual deviation between modeled assumptions and live-market behavior.This drift does not announce itself. It compounds quietly.Under Ferdinand’s direction, EverForward has embedded diagnostic overlays that monitor:Liquidity degradation velocityExecution slippage expansionIntra-regime correlation compressionVolatility clustering persistence These diagnostics function as early-warning mechanisms. When structural drift exceeds tolerance thresholds, risk authority contracts before losses escalate.The objective is not faster reaction.It is earlier detection.Risk as Infrastructure, Not EmotionAnother defining characteristic of EverForward’s current doctrine is the removal of discretionary escalation during instability.Exposure ceilings are not debated intraday. Execution permissions are not expanded under narrative pressure. Risk tolerances do not widen in response to recent losses. All constraints are predefined and system-enforced. This architecture eliminates a common institutional failure mode: granting urgency temporary authority over process. In Ferdinand’s view, resilience is not built through aggression. It is built through constraint.Performance Through PreservationMany firms attempt to engineer performance first and manage risk around it. EverForward has inverted that sequence. The 2026 architecture treats preservation as the enabling condition for performance. If capital remains structurally intact across adverse regimes, opportunity remains accessible when clarity returns. This inversion reframes trading from a return-maximization exercise to a survivability-first discipline.In practical terms, it means:Smaller exposure during structural ambiguity Larger exposure only after environmental validationNo compulsion to "make back” lossesNo structural dependence on constant engagementStrategic OutlookAs structural noise becomes embedded in global markets, EverForward’s posture remains intentionally conservative in design and selective in deployment. The firm’s directional bias for 2026 is not toward speed. It is toward durability. In an environment where many participants confuse activity with edge, EverForward’s operating conclusion is clear:Capital is strategic inventory. It must be preserved before it is deployed.Endurance is not a philosophical preference.It is a competitive advantage.About Brian FerdinandBrian Ferdinand is a Portfolio Manager and Trader at EverForward Trading, responsible for portfolio construction, execution strategy, and capital allocation oversight. His approach emphasizes structural validation, controlled exposure scaling, and forward resilience across shifting market regimes.He is also a member of the Forbes Business Council, an invitation-only network of senior executives and industry leaders.About EverForward TradingEverForward Trading is a trading firm specializing in portfolio construction and active execution across liquid global markets. The firm operates with a discipline-first mandate, prioritizing structural integrity, systematic exposure governance, and long-term capital durability.CONTACT: Shazir Mucklaiinfo@everforwardtrading.com
2026-02-27 22:49:23

YZi Labs Uncovers Disturbing Filing Evidence Suggesting Undisclosed 10X Ownership in CEA Industries; Demands Immediate SEC Disclosures to Bring Potential Shadow "Group” into the Light
Company Filings Reveal Massive, Undisclosed Warrant Exercises that Appear to Have Placed 10X’s Total Ownership of the Company Above the 5% SEC Reporting Threshold by Late 2025YZi Labs Highlights the Concerning Lack of Transparency and Disclosure from 10X Capital, Which Is Controlled by BNC Board Member Hans Thomas, Regarding its Ownership of the Company in Apparent Violation of SEC RequirementsUnanimous Board Entrenchment Actions, Combined with Overlapping Insider Affiliations, Raise Questions as to the Existence of an Undisclosed "Group” of Significant Ownership that May Require Disclosure Under Section 13(d)(3)ROAD TOWN, British Virgin Islands, Feb. 27, 2026 (GLOBE NEWSWIRE) -- YZILabs Management Ltd. ("YZi Labs” or "YZi”), a significant stockholder of CEA Industries Inc. (NASDAQ: BNC) ("BNC” or the "Company”), today released additional filing evidence that suggests 10X Capital Asset Management LLC ("10X”), and its affiliates, and certain related individuals (together, "10X Capital”) collectively beneficially own more than 5% of the Company’s outstanding shares of common stock.This additional information substantiates YZi Labs’ previously articulated concerns about the lack of disclosure by 10X Capital and Hans Thomas - a member of the Company’s Board of Directors (the "Board”) and the majority owner and controller of 10X Capital Partners LLC, the Company’s asset manager - regarding their beneficial ownership of the Company. More than a week has passed since YZi Labs publicly called on 10X and Mr. Thomas to clarify their ownership level or file a Schedule 13D, which is required by the U.S. Securities and Exchange Commission (the "SEC”) when a person or group’s ownership exceeds 5% of a public issuer’s outstanding stock.10X and Mr. Thomas’ continued silence on this issue - particularly after YZi Labs called attention to it - introduces new concerns that they may have deliberately evaded mandatory SEC reporting requirements and have prevented stockholders from having full transparency regarding any coordinated "group” of insiders who may be in control of the Company's governance."It has been more than a week since YZi Labs pointed out these glaring discrepancies, yet 10X has offered nothing but silence,” said Alex Odagiu, Investment Partner at YZi Labs. "The math in the Company’s own SEC filings leaves little room for ambiguity. 10X appears to have crossed the 5% ownership threshold months ago - but instead of complying with basic federal securities laws, they chose to hide in the shadows while choreographing a Board effort to entrench themselves. This seems to be a textbook example of a potential undisclosed ‘group’ operating to disenfranchise public stockholders. The market demands transparency, not a trail of breadcrumbs designed to obscure a silent intrigue.”The Buried 5.39% Warrant ExercisesThe Company’s own filings point to an obvious conclusion. Based on the Company’s public disclosures, the only publicly identified holders of the Strategic Advisor Warrants appear to be 10X BNB Cayman Sponsor and YZi Labs, while the Asset Manager Warrants are only held by 10X Capital Partners LLC.In its Form 10-Q for the quarter ended October 31, 20251, the Company reported that 2,376,236 warrants were exercised in the combined Strategic Advisor Warrants / Asset Manager Warrants activity table over the previous six months. Separately, the Company’s Form S-3 filed on September 19, 20252, disclosed that 10X BNB Cayman Sponsor held 2,376,239 shares underlying its Strategic Advisor Warrants3, 10X Capital Partners LLC held 640,099 shares of Common Stock underlying its Asset Manager Warrants4, and YZILabs Management Ltd. held 3,564,359 shares of Common Stock underlying the Strategic Advisor Warrants5. This equals a total of 6,930,697 shares of Common Stock underlying the Strategic Advisor Warrants / Asset Manager Warrants.YZi Labs definitively confirms it has not exercised its Strategic Advisor Warrants, completely eliminating the only other publicly identified holder of the Strategic Advisor Warrants and Asset Manager Warrants. The Company’s disclosure that 2,376,236 warrants were exercised is nearly identical to the 2,376,239 shares underlying 10X BNB Cayman Sponsor’s Strategic Advisor Warrants, as disclosed in the Company’s Form S-3, strongly supporting the inference that the exercised block was attributable primarily to 10X BNB Cayman Sponsor or 10X Capital Partners LLC (or some combination of the two) - both of which are affiliated with 10X Capital Asset Management LLC.Based on the Company’s disclosed 44,062,938 shares outstanding as of December 12, 2025, these exercises alone equate to approximately 5.39% of outstanding common stock. This math strongly suggests that 10X may have crossed the 5% ownership threshold by late 2025.Any attempt by 10X to hide behind generic beneficial ownership blocker language only raises more severe questions: did the Company waive the beneficial ownership blocker for the 10X entities? Is 10X actively selling its BNC shares? If 10X believes no Schedule 13D was required, it must explain, clearly and publicly, who exercised that near-identical warrant block, on what basis, and why the market was left to piece together the truth from arithmetic buried in the Company’s filings.Mr. Thomas has still not filed a Form 3 with the SEC as required by Section 16 as a current director - despite being appointed more than six months ago. As the Founder and CEO of 10X Capital Partners, he almost certainly has beneficial ownership of the shares held by 10X and its related entities. Stockholders deserve to know his and 10X’s ownership in the Company and whether he and 10X are selling their shares - information YZi Labs believes would be clear if Mr. Thomas complied with his filing obligations.The Undisclosed "Group”The disclosure analysis extends far beyond 10X BNB Cayman Sponsor. The Company’s public filings show that additional insiders and directors held BNC common stock during the relevant period, including CEO David Namdar (864,428 shares6), President and Chairman of the Board Anthony K. McDonald (15,025 shares7), Director Nicholas J. Etten (9,347 shares8), Director Carly E. Howard (1,330 shares9), and former Director Russell Read (1,330 shares, while serving as a director10), based on Forms 3 and 4 filed with the SEC. This block of insider-held stock represents approximately 2.02% of the Company's outstanding shares. When combined with the estimated 5.39% held by 10X BNB Cayman Sponsor, these publicly disclosed ownership positions would control approximately 7.41% of the Company, raising further questions as to whether coordinated action may exist that would require disclosure under Section 13(d).These directors are not passive bystanders. The Board acted unanimously to adopt extreme governance measures, publicly announcing in an SEC-filed press release (Exhibit 99.1 to its December 29, 2025 Form 8-K) that it had adopted a stockholder rights plan (a "poison pill”) and amended and restated its bylaws on December 26, 2025. This demonstrates highly coordinated action at the absolute highest level of the Company’s governance.In this context, the market is entitled to rigorously scrutinize whether 10X-linked entities, the Company’s CEO (a former Partner at 10X), and directors holding Company stock were acting together with respect to the acquisition, holding, and voting of BNC securities within the exact meaning of Section 13(d)(3).If 10X Capital and these inside participants contend no such "group” existed, they must explain to stockholders how unanimous Board action, deeply overlapping affiliations, and aligned ownership positions used to deploy hostile entrenchment tactics do not constitute concerted action requiring full and immediate SEC disclosure.YZi Labs will continue to take all necessary steps to ensure that BNC stockholders are informed and that the Company's Board and its true controllers are held strictly accountable to federal securities laws.About YZi LabsYZILabs Management Ltd. is an investment firm focused on strategic, transparent, and high-governance participation in the digital asset and blockchain sectors. YZi Labs is committed to advancing best-in-class oversight, operational integrity, and shareholder alignment in all investment partnerships.Media Contactmedia@yzilabs.comCERTAIN INFORMATION CONCERNING THE PARTICIPANTSYZILabs Management Ltd. ("YZi Labs Management”), together with the other participants named herein (collectively, "YZi Labs”), has filed a preliminary consent statement and an accompanying WHITE consent card with the Securities and Exchange Commission ("SEC”) to be used to solicit stockholder written consents to, among other things, expand the size of the Board of Directors (the "Board”) of CEA Industries Inc., a Nevada corporation (the "Company”) and elect certain persons nominated for election to the Board.YZI LABS STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE CONSENT STATEMENT AND OTHER CONSENT MATERIALS, INCLUDING A WHITE CONSENT CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH CONSENT MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS CONSENT SOLICITATION WILL PROVIDE COPIES OF THE CONSENT STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.The participants in the consent solicitation are expected to be YZi Labs Management, Changpeng Zhao, Max Baucus Sieben, David James Chapman, Marie Teresa Goody Guillén, Jiajin He, Alex Odagiu, Matthew Roszak and Ling Zhang (collectively, the "Participants”).As of the date hereof, YZi Labs Management directly beneficially owns 2,150,481 shares of common stock, par value $0.00001 per share (the "Common Stock”). As of the date hereof, YZi Labs Management holds (i) 7,750,510 shares of Common Stock underlying certain Pre-Funded Warrants (the "Pre-Funded Warrants”), (ii) 9,900,991 shares of Common Stock underlying certain Stapled Warrants (the "Stapled Warrants”) and (iii) 3,564,359 shares of Common Stock underlying certain Strategic Advisor Warrants (the "Strategic Advisor Warrants”). Each of the Pre-Funded Warrants, the Stapled Warrants and the Strategic Advisor Warrants either provide that, or the holder has elected that, the holder shall not have the right to exercise any portion of any such warrants to the extent that after giving effect to such issuance after exercise, such holder and certain of its affiliates would be deemed to beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 4.99% of the Company’s then outstanding shares of Common Stock (the "Beneficial Ownership Limitations”). As of the date hereof, none of YZi Labs Management’s Pre-Funded Warrants, Stapled Warrants or Strategic Advisor Warrants are currently exercisable, and are not expected within 60 days to be exercisable due to the Beneficial Ownership Limitations. Mr. Zhao, as the sole director of YZi Labs Management, may be deemed the beneficial owner of the 2,150,481 shares of Common Stock directly owned by YZi Labs. As of the date hereof, Ms. He may be deemed to beneficially own 2,099,644 shares of Common Stock, including 1,188,120 shares of Common Stock underlying certain Stapled Warrants, and Mr. Odagiu may be deemed to beneficially own 4,918 shares of Common Stock. As of the date hereof, each of Messrs. Baucus, Chapman and Roszak, and Msses. Goody Guillen and Zhang do not beneficially own any shares of Common Stock.1 Please refer to Note 14 of Form 10-Q filed by the Company on December 12, 2025: https://www.sec.gov/ix?doc=/Archives/edgar/data/0001482541/000149315225027782/form10-q.htm#fact-identifier-12352 See Form S-3 filing dated September 19, 2025: https://www.sec.gov/Archives/edgar/data/1482541/000149315225014357/forms-3asr.htm3 See Note 110 of the "Selling Stockholders” table from the Form S-3 filing.4 See Note 110 of the "Selling Stockholders” table from the Form S-3 filing.5 See Note 120 of the "Selling Stockholders” table from the Form S-3 filing.6 See Form 3 filed by Mr. Namdar on December 19, 2025: https://www.sec.gov/Archives/edgar/data/1482541/000149315225028565/xslF345X02/ownership.xml7 See Form 4 filed by Mr. McDonald on October 7, 2025: https://www.sec.gov/Archives/edgar/data/1454332/000149315225017199/xslF345X05/ownership.xml8 See Form 4 filed by Mr. Etten on July 29, 2025: https://www.sec.gov/Archives/edgar/data/1482541/000164117225021470/xslF345X05/ownership.xml9 See Form 4 filed by Ms. Howard on December 23, 2025: https://www.sec.gov/Archives/edgar/data/1482541/000149315225029140/xslF345X05/ownership.xml10 See Form 4 filed by Mr. Read on December 23, 2025: https://www.sec.gov/Archives/edgar/data/1482541/000149315225029150/xslF345X05/ownership.xml
2026-02-27 22:49:22

Securitize’s Explosive Growth and the $SLINK Narrative Play Positioning Retail Early in the RWA Revolution
$SLINK launches on Solana as a fair‐launched narrative token aligned with the Securitize tokenization ecosystem.New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tokenization is no longer a future concept. It is the infrastructure upgrade that is reshaping global finance today.Trillions in real-world assets - real estate, private credit, funds, equities and more - are moving on-chain. Leading this shift is Securitize, the institutional-grade tokenization platform powering BlackRock’s BUIDL fund, partnering with major banks and asset managers, and executing landmark deals such as tokenized luxury resorts.In the first nine months of 2025 alone, Securitize reported $55.6 million in revenue, an 841% increase year-over-year. Full-year 2024 revenue reached $18.8 million (129% growth), with $4B+ in assets under management as of November 2025. The company has now filed its S-4 registration statement with the SEC for a SPAC merger with Cantor Equity Partners II (Nasdaq: CEPT), targeting a Nasdaq listing under ticker SECZ in the first half of 2026 at a pre-money valuation of approximately $1.25 billion.While institutions secure early allocations but face long lockup periods, retail investors have historically waited on the sidelines.$SLINK was created to change that dynamic.A Clean, Fair-Launched Narrative Token$SLINK is a pure fair launch on Solana via Pumpfun. Launched with full transparency, it gives the community a straightforward way to follow the Securitize infrastructure story from the earliest stages.Key conviction signals include:• 20 million tokens (2% of original supply) permanently burnt via creator-fee buyback from the open market• Founder @psxagent007 (a Securitize seed investor since 2018) has locked 50% of total supply (500 million $SLINK) for 6 months on-chainThese actions reflect genuine long-term alignment rather than short-term hype.$SLINK is currently a narrative token only. The founder has publicly outlined the intention to pursue full regulatory registration as a compliant asset-backed token in the future, subject to regulatory approval. Until that process is complete, $SLINK carries no ownership rights, no economic exposure, no yields, and no affiliation with Securitize.Why This Narrative Matters NowThe RWA sector is experiencing explosive growth. Tokenized market cap has surged dramatically year-over-year, driven by real institutional demand for compliant, liquid, programmable versions of traditional assets.Securitize is at the center of this shift. Its technology enables fractional ownership, 24/7 trading, and enforceable rights while meeting the strict regulatory standards institutions require. As more assets move on-chain, the platforms with proven infrastructure and blue-chip partnerships are positioned to capture the largest share of value creation.$SLINK offers the community a transparent, clean micro-cap vehicle to align with this infrastructure leader early - before the broader market fully prices in the coming catalysts.How to Get $SLINKWebsite: https://sharelink.companyX: https://x.com/SLINKsolLive Chart: https://dexscreener.com/solana/7okHmAi1re834jSp2kAdduML9a1RfZ5fQJfQ878k8y7gImportant Disclaimer$SLINK is a narrative/community token only. Future plans to register as an asset-backed token are subject to regulatory approval and may change. The token currently provides no ownership rights, no economic exposure, no yields, and no affiliation with Securitize. Not a security or investment product. NFA - DYOR. Crypto investments carry high risk; only invest what you can afford to lose.The infrastructure is winning.The narrative is just getting started.Welcome to the next chapter of finance.Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. Investing involves risk, including the potential loss of capital. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release.CONTACT: Viola WilliamsPublic RelationsInfo(at)sharelink.company
2026-02-27 22:49:15

Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules
$3.25 Million Upfront With up to Approximately $6.5 Million of Potential Aggregate Proceeds Upon the Exercise in Full of WarrantsFREEHOLD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon” or the "Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 6,372,550 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to an aggregate of 6,372,550 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 6,372,550 shares of common stock, at a purchase price of $0.51 per share (or pre-funded warrant in lieu thereof) and associated warrants. The warrants have an exercise price of $0.51 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval and the Series A-2 warrants will expire eighteen months from the date of stockholder approval.H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Roth Capital Partners acted as financial advisor to the Company.The aggregate gross proceeds to the Company from the offering were approximately $3.25 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be approximately $6.5 million. No assurance can be given that any of such warrants will become exercisable or will be exercised. The Company intends to use the net proceeds from the offering for the repayment of certain outstanding debt and for working capital and general corporate purposes.The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Avalon GloboCare Corp.Avalon GloboCare Corp. (NASDAQ: ALBT) is a technology-focused company developing and acquiring innovative artificial intelligence platforms. Through its AI-driven subsidiary, Avalon Quantum AI LLC, the Company is advancing next-generation AI systems, including automated video generation, enterprise documentation, and workflow automation solutions. Avalon is also expanding its intellectual property portfolio in cellular therapy and generative AI publishing and software. In addition, Avalon is marketing the KetoAirTM breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to pursue additional diagnostic applications for the technology.For more information about Avalon, please visit www.avalon-globocare.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.Forward-Looking StatementsCertain statements contained in this press release are "forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as "will”, "anticipate”, "estimate”, "expect”, "should”, "may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the use of proceeds from the offering, the receipt of stockholder approval for the warrants and the exercise of the warrants prior to their expiration. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.Contact Information:Avalon GloboCare Corp.4400 Route 9 South, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.comInvestor Relations:Crescendo Communications, LLCTel: (212) 671-1020 Ext. 304albt@crescendo-ir.com
2026-02-27 22:49:05

OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company’s business to the digital investment banking and financial technology sectors. The name "CapForce” represents the "Force of Capital,” symbolizing the Company’s conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their weight to enter the mid-cap or even large-cap universe. In connection with the name change, the Company expects to change its ticker symbol to "CFOR.”About CapForce Inc.CapForce Inc. (Clarksburg, Md., U.S.A.), along with its subsidiaries CapForce International Holdings Ltd. and iCapX Sdn. Bhd., provides fintech-enabled digital investment banking services for global high-growth mid-sized private companies seeking public market listings and other capital markets advisory services, of listing market capitalization value in the range of $1 billion to $10 billion, with its key focus on small-cap and mid-cap listing stocks underserved by bulge bracket investment banks. In furtherance of such core strategy, CapForce Inc. is pursuing fintech-enabled and AI-powered asset and wealth management services for its core investment banking clients across the world with the development of a digital investment banking platform designed to facilitate cross-border securities activities, AI-powered robo-advisory services, and technology-driven capitalization table management solutions. The timing and implementation of these initiatives are subject to market conditions, regulatory approvals, and other relevant factors. CapForce Inc.’s controlling shareholder, AEI Capital Group, is an Asia-based alternative asset management group with groupwide AUM exceeding $7 billion, focused on global growth equity (private and public markets) as its core strategies, along with other satellite strategies in furtherance of its core strategies including private credit, hedge funds, funds-of-funds and real estate, having its footprints in Hong Kong, Kuala Lumpur, Singapore, London and Washington D.C.For more information, please visit https://capforce.opgen.com/.Forward-Looking StatementsThis press release contains "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are intended to qualify for the safe harbor from liability established thereunder. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond the Company’s control, and which may cause results to differ materially from expectations, including risks regarding the implementation and execution of operational, legal, and administrative changes associated with the name change, the effectiveness of the Company’s rebranding efforts, potential confusion among customers, partners, or investors, and costs associated with the rebranding process. For further discussion of factors that could materially affect the outcome of the Company’s forward-looking statements and its future results and financial condition, see "Risk Factors” in Part I, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other reports filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.CapForce Inc.:Christian-Laurent Benoit BonteChief Executive OfficerInvestorRelations@opgen.com
2026-02-27 22:49:02

Pulsar Helium Announces Closing of Fundraise
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.CASCAIS, Portugal, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) ("Pulsar” or the "Company”), a primary helium company, is pleased to announce that further to its announcements on February 19 and 20, 2026, it has conditionally closed its placing (the "Placing”) of 9,191,175 common shares of the Company (each, a "Placing Share” and each common share of the Company, a "Common Share”) at a price of £0.80 (approximately CAD$1.47) per Placing Share for total gross proceeds of £7,352,940 (approximately US$10.0 million / CAD$13.7 million). Closing of the Placing remains subject to receipt of final approval from the TSX Venture Exchange.Net proceeds received pursuant to the Placing will be used to advance Pulsar’s flagship Topaz helium project in Minnesota, USA (the "Topaz Project”), to progress the Falcon project in Michigan (the "Falcon Project”), and for general working capital and corporate purposes. At the Topaz Project, the Company intends to undertake extended well testing and reservoir evaluation; conduct an additional seismic survey to enhance structural interpretation and reservoir modelling; consolidate and expand its mineral and leasehold interests; update the independent resource estimate; and complete a pre-feasibility study for integrated helium and CO2 production. The Company also intends to place deposits on certain long-lead processing equipment for the contemplated helium recovery and CO2 capture facility. In addition, a portion of the proceeds is expected to support geophysical, geochemical and related exploration activities at the Falcon Project.In connection with the Placing, OAK Securities (a trading name of Merlin Partners LLP) ("OAK”) was paid an advisory fee of £20,000 (approximately CAD$37,000) and a cash fee in an amount of £441,176 (approximately CAD$812,000). The Company also issued 551,470 non-transferable Common Share purchase warrants ("Broker Warrants”) to OAK, with the Broker Warrants being exercisable for 12 months from the date of issue at a price of £0.80 (approximately CAD$1.47).Additional InformationThe Placing was conducted pursuant to Pulsar’s Canadian base shelf prospectus dated February 11, 2026 (the "Base Shelf Prospectus”) as supplemented by the Company’s prospectus supplement dated February 19, 2026 relating to the Placing (the "Prospectus Supplement”), copies of which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca. As the Prospectus Supplement and the Base Shelf Prospectus qualify the distribution of the Placing Shares sold pursuant to the Placing, the Placing Shares are not subject to any resale restrictions in Canada. Such documents are not prospectuses for the purposes of the FCA’s Prospectus Rules: Admission to Trading on a Regulated Market sourcebook.Access to the Prospectus Supplement and the Base Shelf Prospectus is provided in accordance with Canadian securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment thereto. An electronic or paper copy of the Prospectus Supplement, the corresponding Base Shelf Prospectus and any amendment thereto may be obtained, without charge, from the Company at connect@pulsarhelium.com, by providing the contact with an email address or mailing address, as applicable.On behalf of Pulsar Helium Inc."Thomas Abraham-James”President, CEO and DirectorFurther Information: Pulsar Helium Inc.connect@pulsarhelium.com+ 1 (218) 203-5301 (USA/Canada)+44 (0) 2033 55 9889 (United Kingdom)https://pulsarhelium.comhttps://ca.linkedin.com/company/pulsar-helium-inc.OAK Securities*(Broker and exclusive bookrunner and placement agent in connection with the Placing)Jerry Keen / Calvin Man+44 7432 270007 / +44 7733 117328+44 20 3973 3678jerry.keen@oak-securities.com / calvin.man@oak-securities.com*OAK Securities is the trading name of Merlin Partners LLP, a firm incorporated in the United Kingdom and regulated by the UK Financial Conduct Authority.Strand Hanson Limited (Nominated & Financial Adviser, and Broker)Ritchie Balmer / Rob Patrick+44 (0) 207 409 3494Yellow Jersey PR Limited(Financial PR)Charles Goodwin / Annabelle Wills+44 777 5194 357pulsarhelium@yellowjerseypr.comAbout Pulsar Helium Inc. Pulsar Helium Inc. is a publicly traded company quoted on the AIM market of the London Stock Exchange (United Kingdom) and listed on the TSX Venture Exchange with the ticker PLSR (Canada), as well as on the OTCQB with the ticker PSRHF (United States of America). Pulsar's portfolio consists of its flagship Topaz helium project in Minnesota, the Falcon project in Michigan (both in the USA), and the Tunu helium project in Greenland. Pulsar is the first mover in both locations with primary helium occurrences not associated with the production of hydrocarbons identified at each.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Important NoticesTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES AND IS DIRECTED ONLY AT PERSONS WHOSE ORDINARY ACTIVITIES INVOLVE THEM IN ACQUIRING, HOLDING, MANAGING AND DISPOSING OF INVESTMENTS (AS PRINCIPAL OR AGENT) FOR THE PURPOSES OF THEIR BUSINESS AND WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND ARE: (1) IF IN THE UNITED KINGDOM, "QUALIFIED INVESTORS", BEING PERSONS FALLING WITHIN THE MEANING OF PARAGRAPH 15 OF SCHEDULE 1 OF THE PUBLIC OFFERS AND ADMISSIONS TO TRADING REGULATIONS 2024, WHO (A) FALL WITHIN ARTICLE 19(5) (INVESTMENT PROFESSIONALS) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") OR (B) FALL WITHIN ARTICLE 49(2)(A) TO (D) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE ORDER; (2) IF IN MEMBER STATES OF THE EEA, "QUALIFIED INVESTORS", BEING PERSONS FALLING WITHIN THE MEANING OF ARTICLE 2(E) OF THE PROSPECTUS REGULATION; OR (3) PERSONS TO WHOM THEY MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").THIS ANNOUNCEMENT AND THE INFORMATION IN IT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. PERSONS DISTRIBUTING THIS ANNOUNCEMENT MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN PULSAR HELIUM INC.THE PLACING SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT”) OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD, RESOLD OR DELIVERED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. THE PLACING WAS MADE SOLELY OUTSIDE THE UNITED STATES TO PERSONS IN OFFSHORE TRANSACTIONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT ("REGULATION S")) MEETING THE REQUIREMENTS OF REGULATION S. PERSONS RECEIVING THIS ANNOUNCEMENT (INCLUDING CUSTODIANS, NOMINEES AND TRUSTEES) MUST NOT FORWARD, DISTRIBUTE, MAIL OR OTHERWISE TRANSMIT IT IN OR INTO THE UNITED STATES OR USE THE UNITED STATES MAILS, DIRECTLY OR INDIRECTLY, IN CONNECTION WITH THE PLACING.The distribution or transmission of this Announcement and/or the Placing and/or issue of the Placing Shares in certain jurisdictions may be restricted or prohibited by law or regulation. Persons distributing this Announcement must satisfy themselves that it is lawful to do so. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken by the Company, Strand Hanson or OAK or any of their respective affiliates, agents, directors, officers or employees that would permit an offer of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company, Strand Hanson and OAK to inform themselves about and to observe any such restrictions.This Announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States (including its territories and possessions, any state of the United States and the District of Columbia), Australia, the Republic of South Africa or Japan or any other jurisdiction in which the same would be unlawful. No public offering of the Placing Shares is being made in any such jurisdiction.In the United Kingdom, in relation to the Placing Shares this Announcement is being directed solely at persons in circumstances in which section 21(1) of the Financial Services and Markets Act 2000 (as amended) does not apply.Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into Australia, the Republic of South Africa or Japan or any other jurisdiction outside the United Kingdom.Persons (including, without limitation, nominees and trustees) who have a contractual right or other legal obligations to forward a copy of this Announcement should seek appropriate advice before taking any action.OAK, which is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom and is acting as bookrunner to the Company and no one else in connection with the Placing, and OAK will not be responsible to anyone (including any purchasers of the Placing Shares) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.Strand Hanson Limited ("Strand Hanson"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting as nominated adviser to the Company in connection with the Placing. The responsibilities of Strand Hanson as the Company's Nominated Adviser under the AIM Rules for Companies and the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company or to any director or shareholder of the Company or any other person. Strand Hanson will not be responsible to any person other than the Company for providing the protections afforded to clients of Strand Hanson or for providing advice to any other person in connection with the Placing or any acquisition of shares in the Company.No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Strand Hanson or OAK or by any of Strand Hanson or OAK's affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.Any indication in this Announcement of the price at which the existing ordinary shares in the capital of the Company have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser.No statement in this Announcement is intended to be a profit forecast, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.Neither the content of the Company's website (or any other website) nor any website accessible by hyperlinks on the Company's website (or any other website) is incorporated in, or forms part of, this Announcement.Information to DistributorsUK Product Governance RequirementsSolely for the purposes of the Product Governance requirements contained within Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all distribution channels as are permitted by UK Product Governance Requirements (the "UK Target Market Assessment"). Notwithstanding the UK Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.The UK Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the UK Target Market Assessment, OAK will only procure investors who meet the criteria of professional clients and eligible counterparties.For the avoidance of doubt, the UK Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A, respectively, of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to, the Placing Shares.Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.EU Product Governance RequirementsSolely for the purposes of the product governance requirements contained within (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"), (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II and (c) local implementing measures (together the "EU Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the EU Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by EU Product Governance Requirements (the "EU Target Market Assessment"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the EU Target Market Assessment, OAK will only procure investors who meet the criteria of professional clients and eligible counterparties.For the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares.Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.Forward-Looking StatementsThis news release contains forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to the Company's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forward-looking statements. Forward-looking statements herein include, but are not limited to, statements relating to the final approval of the TSX Venture Exchange and the expected use of net proceeds of the Placing. Forward-looking statements may involve estimates and are based upon assumptions made by management of the Company, including, but not limited to, the Company's capital cost estimates, management's expectations regarding the availability of capital to fund the Company's future capital and operating requirements and the ability to obtain all requisite regulatory approvals.No reserves have been assigned in connection with the Company's property interests to date, given their early stage of development. The future value of the Company is therefore dependent on the success or otherwise of its activities, which are principally directed toward the future exploration, appraisal and development of its assets, and potential acquisition of property interests in the future. No un-risked Contingent and Prospective Helium Volumes have been defined at the Tunu Project. However, estimating helium volumes is subject to significant uncertainties associated with technical data and the interpretation of that data, future commodity prices, and development and operating costs. There can be no guarantee that the Company will successfully convert its helium volume to reserves and produce that estimated volume. Estimates may alter significantly or become more uncertain when new information becomes available due to for example, additional drilling or production tests over the life of field. As estimates change, development and production plans may also vary. Downward revision of helium volume estimates may adversely affect the Company's operational or financial performance.Helium volume estimates are expressions of judgement based on knowledge, experience and industry practice. These estimates are imprecise and depend to some extent on interpretations, which may ultimately prove to be inaccurate and require adjustment or, even if valid when originally calculated, may alter significantly when new information or techniques become available. As further information becomes available through additional drilling and analysis the estimates are likely to change. Any adjustments to volume could affect the Company's exploration and development plans which may, in turn, affect the Company's performance. The process of estimating helium resources is complex and requires significant decisions and assumptions to be made in evaluating the reliability of available geological, geophysical, engineering, and economic data for each property. Different engineers may make different estimates of resources, cash flows, or other variables based on the same available data.Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward- looking statements. Such risks and uncertainties include, but are not limited to, that Pulsar may be unsuccessful in drilling commercially productive wells; the uncertainty of resource estimation; operational risks in conducting exploration, including that drill costs may be higher than estimates; commodity prices; health, safety and environmental factors; and other factors set forth above as well as risk factors included in the Company’s Annual Information Form dated February 3, 2026 for the year ended September 30, 2025 found under Company’s profile on www.sedarplus.ca.Forward-looking statements contained in this news release are as of the date of this news release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. No assurance can be given that the forward-looking statements herein will prove to be correct and, accordingly, investors should not place undue reliance on forward-looking statements. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
2026-02-27 22:48:58

PH cities join Marcos, DepEd push to speed up classroom construction
CITY governments across the country have joined the Department of Education (DepEd) and the administration of President Ferdinand Marcos Jr. in a unified effort to speed up the construction of classrooms, marking the first time cities nationwide formally committed to a single coordinated plan to address the country’s classroom shortage. City mayors from across Luzon, Visayas and Mindanao signed an agreement with the DepEd at Malacañan Palace, pledging to help fast-track permits, identify priority schools, and support the construction of safe and modern classrooms in their communities. President Marcos thanked the city local government units for answering the call to help solve the classroom gap. “Tiyakin nating hindi maaantala ang mga proyekto. Tiyakin nating de-kalidad ang mga silid-aralan. Tiyakin natin na ang bawat sentimo na pinaghirapan ng ating mga kababayan ay gagamitin sa tama (Let us ensure that the projects will not be delayed. Let us ensure that the classrooms are of high quality. Let us ensure that every cent earned through the hard work of our fellow citizens is used properly),” President Marcos said.The agreement builds on an earlier partnership with provincial governments and forms part of a broader national strategy to close the country’s 165,000 classroom gap. Education Secretary Sonny Angara, who pushed for the flexibility provision of classroom construction in the 2026 General Appropriations Act, said the partnership will help deliver classrooms faster by working closely with local governments that understand the needs of their schools. “Malaking hakbang ito upang mas mapabilis ang pagpapatayo ng mga silid-aralan. Alam ng ating mga lungsod kung saan pinaka kailangan ang mga classroom, at sa pagtutulungan natin, mas mabibigyan natin ng ligtas at maayos na lugar ang ating mga mag-aaral at guro (This is a big step toward speeding up the construction of classrooms. Our cities know where classrooms are most needed, and through our cooperation, we can better provide our students and teachers with safe and suitable places to learn and work),” Angara said.President Marcos has identified education as a top priority with a total of P85 billion allocated in 2026 for basic education facilities construction and rehabilitation. DepEd is also exploring new approaches, such as public-private partnerships and leasing, to speed up delivery and improve learning conditions. LGUs are also encouraged to set up Learning Continuity Spaces or LCS to ensure uninterrupted learning during classroom construction and in times of emergencies or disasters. Angara said the nationwide partnership empowers cities to take direct action in helping build classrooms, reduce overcrowding, and ensure learners and teachers have better spaces for teaching and learning. The signing was witnessed by teachers and learners, who will directly benefit from the faster construction of classrooms and better learning spaces.
2026-02-26 12:48:55

Ruby Central Aligns Brand with Evolving Community and Future-Focused Mission
LOAS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ruby Central has completed a brand update to better reflect its mission and the evolving needs of the Ruby community.Ruby Central’s role remains consistent: stewarding RubyGems.org, supporting governance, strengthening supply chain security, and growing the Ruby community in strength and participation. Over time, however, the visual identity became inconsistent and fragmented.Ruby Central partnered with Flagrant for guidance throughout the process. As outlined in the public case study, the organization’s brand assets had been assembled over many years without a unified system. Flagrant conducted a structured review of existing materials, evaluated whether a full redesign was warranted, and worked with Ruby Central to determine that a disciplined refresh would best serve the community.Core visual references remain intact, while updates were made to improve legibility, accessibility, and consistency across technical documentation, governance materials, and event platforms.The goal was not to redefine Ruby Central, but to ensure its presentation matches the substance of its work. The updated brand system is designed to provide a stable visual foundation for long-term community growth.Ruby Central extends its appreciation to Flagrant for their thoughtful guidance and disciplined design work.The first opportunity to see the updated brand fully realized will be at RubyConf 2026, taking place July 14-16 at Red Rock Casino Resort & Spa in Las Vegas. Attendees will experience the refreshed brand across conference materials, signage, stage design, and digital touchpoints. The intent is practical: a stronger alignment between Ruby Central’s mission and its flagship programs.The case study linked to this update details the process, tradeoffs, and reasoning behind the refresh, offering transparency into how Ruby Central approaches long-term investments on behalf of the community.To read the full case study on the brand update, visit: https://www.beflagrant.com/work/ruby-central-rebrandAbout Ruby CentralRuby Central is a 501(c)(3) nonprofit organization that supports the Ruby programming language and its global community. Ruby Central stewards RubyGems.org and produces RubyConf, while developing programs that strengthen participation, sustainability, and leadership across the Ruby ecosystem.Media Contact:Cindi SuteraCommunications, Ruby CentralCindi@RubyCentral.org610-613-2773
2026-02-26 12:48:17

Cronos Group Reports 2025 Fourth Quarter and Full-Year Results
Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 millionAchieved record net revenue in Q4 2025 and FY 2025Eighth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the number one cannabis brand1Industry leading balance sheet with $832 million in cash and cash equivalents and short-term investments TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos” or the "Company”), today announced its 2025 fourth quarter and full-year business results."Cronos delivered record net revenue, gross profit and Adjusted EBITDA in 2025, reflecting the continued strength of our core business and the progress we are making towards our strategic priorities. We achieved record net revenue for both the fourth quarter and the full year, driven by strong consumer demand for our leading brands, the completion of the expansion at Cronos GrowCo, and the increasing contribution from our international markets,” said Mike Gorenstein, Chairman, President and CEO of Cronos."Looking ahead, we are excited about the opportunities in front of us as we enter 2026,” continued Gorenstein. "Once completed, our pending acquisition of CanAdelaar will establish a strategic footprint in Europe and enable us to leverage our borderless product strategy in the Netherlands’ legal adult-use cannabis market. Outside the Netherlands, with the scale benefits expected from Cronos GrowCo’s expansion, continued growth in our proprietary products, and the strength of our international presence, we believe Cronos is well-positioned to deliver sustainable net revenue and Adjusted EBITDA growth and to create long-term shareholder value.”Consolidated Financial ResultsOn June 20, 2024 the Company made an additional investment (the "Cronos GrowCo Transaction”) in Cronos Growing Company Inc. ("Cronos GrowCo”) to fund the expansion of cultivation operations. Cronos also obtained majority control of the board of directors of Cronos GrowCo and began consolidating Cronos GrowCo's results from July 1, 2024. Prior to this date, the Company's investment in Cronos GrowCo consisted of an investment accounted for under the equity method and loans receivable from Cronos GrowCo.The tables below set forth our condensed consolidated results of continuing operations, expressed in thousands of United States ("U.S.”) dollars for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods.(in thousands of USD) Three Months Ended December 31, Change Year ended December 31, Change 2025 2024 $ % 2025 2024 $ %Cronos net revenue, excluding Cronos GrowCo net revenue(i) $41,231 $28,195 $13,036 46% $136,289 $111,241 $25,048 23%Cronos GrowCo net revenue(ii) 3,300 2,106 1,194 57% 10,298 6,374 3,924 62%Net Revenue $44,531 $30,301 $14,230 47% $146,587 $117,615 $28,972 25% Cost of sales 28,280 19,494 8,786 45% 83,174 91,710 (8,536) (9)%Inventory write-down 62 - 62 N/A 654 707 (53) (7)%Gross profit $16,189 $10,807 $5,382 50% $62,759 $25,198 $37,561 149%Gross margin(iii) 36% 36% N/A -pp 43% 21% N/A 22pp Inventory step-up recorded to cost of sales - (1,832) 1,832 N/A 517 5,284 (4,767) N/AAdjusted Gross Profit(iv) $16,189 $8,975 $7,214 80% $63,276 $30,482 $32,794 108%Adjusted Gross Margin(v) 36% 30% N/A 6pp 43% 26% N/A 1pp Net income (loss) $(491) $43,941 $(44,432) (101)% $(2,929) $40,022 $(42,951) N/M Adjusted EBITDA(iv) $456 $(7,203) $7,659 N/M $10,110 $(34,942) $45,052 N/M Other Data Cash and cash equivalents(vi) $791,794 $858,805 $(67,011) (8)% Short-term investments(vi) 40,000 - 40,000 N/M Capital expenditures(vii) 2,274 3,708 (1,434) (39) % 26,056 13,154 12,902 98%(i) Cronos net revenue, excluding Cronos GrowCo net revenue is net revenue less Cronos GrowCo net revenue and is after intercompany eliminations. (ii) Cronos GrowCo net revenue is Cronos GrowCo's net revenue after intercompany eliminations.(iii) Gross margin is defined as gross profit divided by net revenue.(iv) See "Non-GAAP Measures" for more information, including a reconciliation of adjusted earnings (loss) before interest, taxes, depreciation and amortization ("Adjusted EBITDA”) to net income (loss) and a reconciliation of Adjusted Gross Profit to gross profit.(v) Adjusted Gross Margin is defined as Adjusted Gross Profit divided by net revenue. See "Non-GAAP Measures” for more information.(vi) Dollar amounts are as of the last day of the period indicated.(vii) Capital expenditures represent component information of investing activities and is defined as the sum of purchase of property, plant and equipment, and purchase of intangible assets.Fourth Quarter2025Net revenue of $44.5 million in Q4 2025 increased by $14.2 million from Q4 2024. The increase was primarily due to higher cannabis flower sales in Israel and other countries, which carry no excise taxes, and higher cannabis flower and extract sales in the Canadian market.Gross profit of $16.2 million in Q4 2025 increased by $5.4 million from Q4 2024. The increase was primarily due to higher average sales prices driven primarily by a mix shift to Israel and other countries and higher sales volumes. Gross profit was positively impacted by $1.8 million in the fourth quarter of 2024 in connection with the finalization of the purchase accounting for the Cronos GrowCo Transaction. No such benefit was recognized in the fourth quarter of 2025.Adjusted Gross Profit of $16.2 million in Q4 2025 improved by $7.2 million from Q4 2024. The improvement was primarily driven by higher average sales prices driven primarily by a mix shift to Israel and other countries and higher sales volumes.Net loss of $0.5 million in Q4 2025, compared to net income of $43.9 million from Q4 2024. The change was primarily driven by foreign currency transaction losses in the current period compared with gains in the prior-year period, partially offset by higher gross profit.Adjusted EBITDA of $0.5 million in Q4 2025 improved by $7.7 million from Q4 2024. The improvement was primarily driven by higher Adjusted Gross Profit.Full-Year 2025Net revenue of $146.6 million in full-year 2025 increased by $29.0 million from full-year 2024. The increase was primarily due to higher cannabis flower sales in Israel and other countries, which carry no excise taxes, the inclusion of a full year of Cronos GrowCo sales in the current period, and higher cannabis extract sales in the Canadian market, partially offset by a decrease in cannabis flower sales in the Canadian market due to supply constraints. Cronos GrowCo contributed $10.3 million of cannabis flower sales in the year ended December 31, 2025, an increase of $6.4 million from 2024.Gross profit of $62.8 million in full-year 2025 increased by $37.6 million from full-year 2024. The increase was primarily due to lower amounts of inventory step-up from the Cronos GrowCo Transaction recognized into cost of sales, the consolidation of Cronos GrowCo, higher average sales prices driven primarily by a mix shift to Israel and other countries, higher sales volumes, and production efficiencies. For 2025 and 2024, gross profit was reduced $0.5 million and $5.3 million, respectively, as a result of the impact of the inventory step-up from the Cronos GrowCo Transaction that was recorded into cost of sales.Adjusted Gross Profit of $63.3 million in full-year 2025 increased by $32.8 million from full-year 2024. The increase year-over-year was primarily due to the consolidation of Cronos GrowCo, higher average sales prices driven primarily by a mix shift to Israel and other countries, higher sales volumes, and production efficiencies.Net loss of $2.9 million in full-year 2025, compared to net income of $40.0 million from full-year 2024. The change was primarily driven by foreign currency transaction losses in the current period compared with gains in the prior-year period, partially offset by higher gross profit and lower operating expenses.Adjusted EBITDA of $10.1 million in full-year 2025 improved by $45.1 million from full-year 2024. The improvement was primarily driven by higher Adjusted Gross Profit and lower operating expenses due to a decline in general and administrative costs.Business UpdatesBrand and Product PortfolioSpinach®2Spinach® maintained its position as one of Canada’s leading cannabis brands throughout 2025, consistently ranking #2 overall despite flower supply constraints that limited growth. In Q4 2025, Spinach® remained the #4 flower brand in Canada, with market share expanding modestly to 5.1%.SOURZ by Spinach® edibles continued to lead the edibles category, holding the #1 national market position each quarter. Achieving market share of 21.7% for the fourth quarter and over 20% for the full year, the brand continued to innovate, highlighted by the launch of SOURZ by Spinach® Fully Blasted formulations and various multipack launches. In Q4 2025, four SOURZ by Spinach® gummies products ranked among the top 10 edibles nationally, including the top-selling edibles SKU in Canada, the Fully Blasted Blue Raspberry Watermelon 10 Pack.Throughout 2025, the Spinach
2026-02-26 12:48:12

Anterix Deepens Collaboration with Qualcomm to Accelerate Utility Grid Connectivity
Collaboration Advances a Scalable Path to 5G for Anterix-Enabled Private Wireless NetworksWOODLAND PARK, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX), the market leader in mission-critical private wireless broadband spectrum for the utility sector, today announced an expanded collaboration with Qualcomm Technologies Inc. to accelerate adoption of next-generation connectivity for utilities and critical infrastructure operators nationwide.The collaboration underscores Anterix’s role in moving the utility industry beyond spectrum access to a complete private wireless connectivity platform - one that enables utilities to deploy, operate, and evolve private wireless broadband networks that support safer operations, greater resilience, and long-term grid modernization."Utilities and other critical infrastructure industries are essential to the nation’s security and economic vitality,” said Vivek Khanna, Vice President of Product Management at Qualcomm. "By collaborating with Anterix, the market leader in private broadband connectivity for utilities, Qualcomm is reinforcing our commitment to the utility market and giving utilities access to the chipset innovation needed to build a more secure, resilient, and connected energy future.”A key outcome of the collaboration between Anterix and Qualcomm is the development of new industrial-grade IoT chipsets optimized specifically for utility use cases at scale. Qualcomm’s Snapdragon SDX35-3 and SDX32-3 IoT Modems will deliver 4G and 5G cellular connectivity on Anterix’s 900 MHz broadband platform, enabling greater distributed intelligence, operational visibility, and resilient communications at the grid edge. To date, eight utilities have selected Anterix-enabled private wireless as the foundation for next-generation grid connectivity."By joining forces with Qualcomm, we are giving utilities a clear, scalable roadmap to 5G - one that delivers immediate operational value while supporting long-term network evolution,” said Carlos L’ Abbate, Chief Technology & Engineering Officer at Anterix. "Building on the FCC's decision to expand the 900 MHz band to 10 MHz, this collaboration further future-proofs the adoption of private wireless, with Anterix-enabled networks serving as a foundation for smarter operations, stronger resilience, and a future-ready energy system.”The Snapdragon SDX35-3 IoT Cellular Modem already is being incorporated by members of the Anterix Active Ecosystem, including Easymetering, whose AMI 2.0 and grid-edge solutions demonstrate how utility-owned private wireless can support electrification, distributed energy resources, and enhanced customer engagement-while maintaining the reliability and security utilities require.Shareholder Contact Natasha Vecchiarelli Vice President, Investor Relations & Corporate Communications Anterix 973-531-4397 nvecchiarelli@anterix.com Media ContactPaul GaigeSenior Vice PresidentBurson504-957-1434Paul.Gaige@bursonglobal.comAbout AnterixAnterix is transforming how critical infrastructure stays connected. As the market leader in mission-critical private wireless broadband spectrum, Anterix delivers more secure, private 900 MHz licensed spectrum and advanced intelligent infrastructure solutions that enhance efficiency, strengthen resilience, and accelerate digital transformation. Backed by a growing ecosystem of industry-leading partners, Anterix provides the connectivity foundation that powers a more resourceful and resilient future. Learn more at www.anterix.com.Forward-Looking StatementsCertain statements contained in this press release may constitute forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties. Forward-looking statements include statements that may predict, forecast, indicate or imply future events or achievements such as statements in this press release related to Anterix’s business, plans and opportunities. Any such forward-looking statements are based on the current expectations of Anterix's management and are subject to a number of risks and uncertainties that could cause Anterix's actual future results to differ materially from those implied by the forward-looking statements. These risks and uncertainties are identified and described in more detail in Anterix's most recent filings on Forms 10-K and 10-Q and in other filings that it makes with the SEC from time to time. These documents are available on Anterix's website at www.anterix.com under the Investor Relations section and on the SEC's website at www.sec.gov. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, Anterix undertakes no obligation to update publicly or revise any forward-looking statements contained herein.
2026-02-26 12:48:08

North American Niobium Adds Sabot to Technical Review Pipeline
Rare earth element and niobium anomalies found in sediments and surrounding rocksVancouver, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Initial prospecting results and geological observations suggest that the broader area encompassing North American Niobium and Critical Minerals Corp.’s (CSE: NIOB) (OTCQB:NIOMF)(FSE: KS82.F) Bardy, Blanchette and Sabot projects in Québec may be comparable in style to the large rare-earth element (REE) deposits found in Greenland. As such, the Company has begun a technical review aimed at assessing Sabot’s potential to be incorporated into near-term exploration planning alongside the priority Bardy and Blanchette projects.HighlightsSabot added to near-term technical review pipeline based on recent prospecting results and geological context; Sabot is adjacent to the Company’s priority Bardy and Blanchette properties, supporting operational and logistical efficienciesProspecting grab sample (G170073) returned 0.155% total rare earth oxides (TREO) and 313.12 parts per million of magnet rare earth oxides (MREO), including 76.72 parts per million praseodymium (Pr) and 228.61 parts per million neodymium (Nd)Geological setting at Sabot includes an alkaline intrusion in contact with metasediments; textures observed in the intrusion suggest interaction between the alkaline magma and the metasedimentary host rocks - conditions that may have been ideal for the formation of a rare earth element (REE) and/or other critical element depositConceptual exploration targets include potential silica-rich roof/contact zones and/or upper portions of an alkaline system that may be associated with REE mineralization and other elements such as Niobium; additional surface work is required to refine and prioritize targets North American Niobium’s 100% owned Sabot Project is approximately 45 kilometres northwest of the La Tuque Municipality in Québec. Although the Company’s exploration strategy in the province has consistently focused on its Bardy, Blanchette, and Seigneurie projects, Sabot is close to Bardy and Blanchette. It benefits from existing regional access and the Company’s established stakeholder engagement efforts in the area. Sabot’s location supports a coordinated approach to target development and potential drill planning, subject to review and approvals.Sabot prospecting grab sample returns elevated rare earth element valuesA prospecting grab sample collected during Q4 2025 returned elevated rare earth element values. Results are summarized below.Table 1: Sabot Prospecting Grab Sample (Selected Result). MREO in this release refers to the combined content of Nd + Pr + Dy + Tb (reported in ppm) whereas TREO refers to total rare earth oxides.Sample IDProjectRock TypeTREO (%)MREO (ppm)*Pr (ppm)Nd (ppm) G170073 Sabot Granite 0.155 313.12 76.72 228.61 Grab samples are selective by nature and may not be representative of mineralization hosted on the Project.Geologic rationale and conceptual targetingThe Company has identified a syenitic intrusion in contact with silica-rich metasediments (the Wabamask metasedimentary complex is associated with quartzites) near the Sabot Prospect area. The intrusion is interpreted as part of a regional alkaline syenitic complex (~1019-1025 Ma) and is younger than the niobium-rare earth element pegmatite occurrences observed at Bardy and Blanchette (~1060-1070 Ma), suggesting that at least two temporally distinct Nb-REE mineralizing events are present within NIOB’s area of interest in the Grenville Proterozoic belt. Uranium-lead (U-Pb) age dating was completed in 2018 by the late Jean David (report MB201817).Government geologists in the field observed the presence of sedimentary xenoliths within the syenitic intrusions, which indicates interaction between the alkaline magma and the silica-rich country host rocks. This geological setting has proven to be associated with major deposits, such as the Motzfeldt Project in Greenland.Alkaline intrusion-related REE systems like the Motzfeldt Project can be large-tonnage in some cases. Motzfeldt has reported a large, inferred resource at the Aries deposit (JORC-compliant), cited in public disclosure as 340 million tonnes grading 0.26% TREO, 0.185% Nb205 and 0.46% ZrO2. The Company emphasizes that mineralization, resources, or deposits on other properties are not necessarily indicative of mineralization on Sabot, and such comparisons are provided for geological context only.On Sabot, the southern contact at the centre of the property of the Syenite intrusion (Rheaume Intrusive Suite) is associated with bottom-lake sediment anomalies (approx. 90th percentile) in La-Nb-Y (as compiled by the Government of Québec, report PRO 2009-03). These three elements can be indicative of REE-bearing syenitic intrusions. Finally, the syenite and the metasediments are associated with REE anomalies. This observation is conceptual and requires follow-up work, including additional geochemical coverage and geological validation.At this stage, the Company’s working interpretation is equally conceptual: Sabot may represent an upper portion of an alkaline system and/or a silica-rich roof/contact zone, either of which can be prospective environments for REE mineralization, and other critical elements such as Niobium, in certain geological settings. The Company cautions that additional geochemical and geological work is required to refine these conceptual targets and to assess the extent, style, and continuity of any potential mineralization.Figure 1: Sabot is located in the vicinity of the Blanchette and Bardy properties, immediately north of the Blanchette project, approximately 45 km northwest of La Tuque; across the area shown, multiple rare earth element (REE) prospects are present, some of which are associated with elevated niobium values and occur in spatial association with several alkaline intrusive suites.Please click to view image"While Sabot was not initially an immediate priority for the Company, results from our recent prospecting program, together with the geological setting, appear to warrant additional work,” said Murray Nye, Chief Executive Officer of North American Niobium. "Over the coming weeks, our technical team will review Sabot alongside our Québec portfolio to determine the most effective next steps ahead of any drilling decisions.”ABOUT NORTH AMERICAN NIOBIUM AND CRITICAL MINERALS CORP.North American Niobium and Critical Minerals Corp. is a North American mineral exploration company focused on the acquisition and development of precious, base, and critical mineral assets. Its portfolio includes the Silver Lake property in British Columbia’s Omineca Mining Division and a recently acquired land package in Québec’s Grenville Province. The Québec properties add exposure to rare earth elements (REE), niobium (Nb), and nickel-copper (Ni-Cu) occurrences, expanding the Company’s footprint into critical minerals that are strategically important for energy and defense applications.ON BEHALF OF THE BOARD OF DIRECTORS:Murray NyeChief Executive Officer1055 West Georgia Street, Suite 1500Vancouver, BC V6E 0B6CanadaFor further information, please contact:Murray Nye, CEOEmail: info@northamericanniobium.comPhone: +1 (647) 984-4204CSE:NIOBOTCQB: NIOMFFSE:KS82.FFORWARD LOOKING STATEMENTSThis news release contains "forward-looking statements” within the meaning of applicable Canadian securities legislation. All statements in this release, other than statements of historical fact, that address events, results, outcomes or developments that the Company expects, anticipates or intends to occur in the future, or that otherwise reflect management’s expectations or beliefs about future events, are forward-looking statements. Forward-looking statements are generally, but not always, identified by the use of words and phrases such as "expects,” "plans,” "anticipates,” "believes,” "intends,” "estimates,” "projects,” "potential,” "opportunity,” "strategy,” "target,” "forecast” and similar expressions, or statements that events, conditions or results "will,” "would,” "may,” "could,” or "should” occur or be achieved.Forward-looking statements in this release include, but are not limited to: (i) statements regarding the Properties and their mineral prospectivity; (ii) the Company’s planned exploration, development and evaluation activities on the Properties; and (iii) the potential for the Grenville Province to host significant rare earth element, niobium, nickel-copper or other critical mineral deposits. Such forward-looking statements are based on the Company’s current plans, intentions, expectations and beliefs and are subject to certain assumptions, including, without limitation, assumptions that exploration results will continue to support the prospectivity of the Properties.Although the Company believes the expectations expressed in such forward-looking statements are reasonable, such statements are not guarantees of future performance or outcomes and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated include, but are not limited to: the timing and receipt of required regulatory approvals; changes in commodity prices and market conditions; the availability of capital and financing on acceptable terms; general economic, business and political conditions; risks inherent in mineral exploration and development, including operational risks, geological uncertainties, environmental risks and accidents; changes in government regulation or policy; and the speculative nature of mineral exploration and development. Additional information regarding risks and uncertainties faced by the Company is available in the Company’s public disclosure record on SEDAR+ (www.sedarplus.ca).Readers are cautioned that forward-looking statements are not guarantees of future performance, and undue reliance should not be placed on them. The forward-looking statements contained in this release are made as of the date hereof and are based on information currently available and management’s beliefs, estimates, expectations and opinions at that time. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Qualified PersonThe scientific and technical information contained in this news release has been prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101”). Clyde McMillan, P.Geo., a consultant to the Company and a Qualified Person as defined under NI 43-101, has reviewed and approved the technical information contained herein.The Company also wishes to acknowledge and pay tribute to the late Jean David for his important contributions to Québec geoscience, including the U-Pb geochronological work referenced herein.The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release
2026-02-26 12:48:00

'Too much division' in NUP over VP Duterte impeachment, says Puno
National Unity Party (NUP) Chairman Antipolo City 1st district Rep. Ronaldo "Ronnie" Puno admits that there\'s "too much division" in the party when it comes to the impeachment proceedings against Vice President Sara Duterte.“I doubt that there will be a uniform party stand here because there is just too much division among our members," Puno told House reporters in an interview Thursday, Feb. 26."So the tendency now or the direction now is that we probably will have para kaya conscience vote na (something like a conscience vote) that everybody will be allowed to vote the way he wants to vote,” said the House deputy speaker.The Committee on Justice is scheduled to begin tackling Vice President Duterte\'s four impeachment complaints on Monday, March 2.Rather out of the blue, the NUP--the second biggest political party in the House of Representatives in terms of membership--came out with a supoosed party stand on Wednesday night, Feb. 25.In the statement that was attributed to NUP Secretary General Reginald Velasco, the party said that if would only vote in favor of Duterte\'s impeachment only if it sees "compelling new evidence".This was a surprise to some, especially since the NUP--along with Lakas-Christian Muslim Democrats (Lakas-CMD)--were viewed as the main drivers of the impeachment proceedings against the same official last year under the previous 19th Congress.One of the endorsers of the fourth complaint filed against Duterte--Manila 6th district Rep. Bienvenido "Benny" Abante--is even an NUP stalwart.While he echoed some of the points in the statement, Puno clarified that it was merely a "consensus" of the people from NUP that he spoke with.There are just over 40 NUP members in the 316-strong House of Representatives. “No, this is not the party stand. This is just the consensus of the ones that I have talked to.We will have another formal meeting,” the Antipolo lawmaker said.Puno further said of the impeachment proceedings: "There\'s no clear bias or leaning towards either side at this point. So we are very divided right now. So we ended up with let\'s see what the evidence will show.”Last Feb. 18, Vice President Duterte announced her plan to run for the Palace seat in 2028.
2026-02-26 12:48:00

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for ataciceptwith Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025."In 2025, Vera Therapeutics delivered on several key milestones as we advanced atacicept toward potential FDA approval and commercialization,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "The BLA has been granted priority review and we expect to be commercially prepared to successfully launch atacicept in IgAN in mid-2026 if approved. Our commercial team brings decades of experience launching innovative therapies and is eager to bring this potentially disease-modifying therapy to patients with IgAN and other autoimmune kidney diseases.”"Vera Therapeutics has established a leadership position within the IgAN space based on the compelling profile of atacicept. Data from the ORIGIN clinical program have shown that blocking BAFF and APRIL with atacicept results in clinically meaningful reductions to proteinuria, Gd-IgA1, and hematuria (Phase 2 and 3) and a stabilization of eGFR (Phase 2),” said Robert M. Brenner, M.D., Chief Medical Officer of Vera Therapeutics. "Vera is confident in the strength of the atacicept data package to support approval and deliver a potential new therapy to the IgAN patients and caregivers whom we serve.”Key Full Year 2025 and Recent Business HighlightsPositive primary endpoint results from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgAN were presented in a featured late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2025 and published in the New England Journal of MedicineFDA granted priority review to the atacicept BLA for the treatment of IgAN in adults, and assigned a PDUFA target action date of July 7, 2026; Vera Therapeutics plans for a potential commercial launch in mid-2026Matt Skelton, Chief Commercial Officer, advancing preparations for U.S. commercial launchAppointed James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience, to Board of DirectorsSuccessfully completed an equity financing and entered into a debt agreement resulting in combined potential gross proceeds of $800 million, strengthening Vera Therapeutics’ balance sheet to fund operations beyond the potential approval and U.S. commercial launch of ataciceptAnticipated Upcoming MilestonesPotential FDA approval of atacicept in IgAN - PDUFA date of July 7, 2026Planned U.S. commercial launch of atacicept, pending FDA approval - mid-2026Initial results from PIONEER - a Phase 2 basket trial evaluating atacicept in expanded IgAN populations, and other autoimmune kidney diseases - expected in 1H 2026Pivotal ORIGIN 3 study completion with two-year eGFR data - expected in 2027Financial Results for the Year Ended December 31, 2025For the year ended December 31, 2025, Vera Therapeutics reported a net loss of $299.6 million, or a net loss per diluted share of $4.66, compared to a net loss of $152.1 million, or a net loss per diluted share of $2.75, for the year ended December 31, 2024.During the year ended December 31, 2025, net cash used in operating activities was $241.1 million, compared to $134.7 million for the year ended December 31, 2024.Vera Therapeutics reported $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which combined with availability under its debt facility, Vera Therapeutics believes to be sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond.About Atacicept Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with IgAN, lupus nephritis, and other autoimmune kidney diseases.About the Atacicept Clinical Program The ORIGIN Phase 2b clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further improvements in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN.The ORIGIN Phase 3 trial met the primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria at week 36, in the prespecified interim analysis. Across the ORIGIN program in IgAN, the safety profile of atacicept appears favorable, and comparable to placebo. The trial continues in a placebo-controlled blinded manner to evaluate the change in kidney function over two years as measured by eGFR, with results expected in 2027. For more information about ORIGIN 3, please visit http://www.clinicaltrials.gov.Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA’s determination that, based on an assessment of data from the ORIGIN Phase 2b clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera Therapeutics believes atacicept is positioned for best-in-class potential, targeting B cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical trials across different disease areas.The ORIGIN Extend study provides ORIGIN study participants with extended access to atacicept until its potential commercial availability in their region and captures longer-term safety and efficacy data. Atacicept is also being evaluated in expanded IgAN populations, anti-PLA2R positive primary membranous nephropathy, and anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) patients in the PIONEER trial.About Vera TherapeuticsVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.Forward-looking StatementsStatements contained in this press release regarding matters, events or results that may occur in the future are "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, approval of atacicept by the FDA, including expected timing; the timing, preparedness and success of the commercial launch of atacicept in the U.S.; the ability of atacicept to be a disease-modifying therapy for patients with IgAN and other autoimmune kidney diseases; Vera Therapeutics' confidence in the strength of the atacicept data package to support FDA approval; Vera Therapeutics' ability to fund operations beyond anticipated approval and U.S. commercial launch of atacicept; timing of initial results from PIONEER and completion of ORIGIN 3; atacicept’s positioning for best-in-class potential; and the plans, commitments, aspirations and goals under the caption "About Vera Therapeutics”. Words such as "anticipate,” "believe,” "expect,” "may,” "plan,” "potential,” "will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.For more information, please contact:Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@lifesciadvisors.comMedia Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@veratx.comVERA THERAPEUTICS, INC.Condensed Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) For the Year Ended December 31, 2025 2024 Operating expenses: Research and development $215,256 $126,172 General and administrative 100,217 40,998 Total operating expenses 315,473 167,170 Loss from operations (315,473) (167,170)Other income, net 15,859 15,023 Provision for income taxes (1) (1)Net loss $(299,615) $(152,148)Change in fair value on marketable securities 393 142 Comprehensive loss $(299,222) $(152,006)Net loss per share attributable to common stockholders, basic and diluted $(4.66) $(2.75)Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 64,233,814 55,326,680 VERA THERAPEUTICS, INC.Condensed Balance Sheets(in thousands)(Unaudited) December 31, 2025 2024 Assets Current assets: Cash, cash equivalents and marketable securities$714,589 $640,852 Prepaid expenses and other current assets 14,294 10,366 Total current assets 728,883 651,218 Operating lease right-of-use assets 1,923 3,372 Other noncurrent assets 3,927 1,091 Total assets$734,733 $655,681 Liabilities and stockholders' equity Current liabilities: Accounts payable$21,898 $7,665 Operating lease liabilities 549 1,483 Accrued expenses and other liabilities, current 31,008 16,223 Total current liabilities 53,455 25,371 Long-term debt 74,838 50,687 Operating lease liabilities, noncurrent 1,919 2,468 Total liabilities 130,212 78,526 Stockholders' equity Common stock 71 64 Additional paid-in-capital 1,364,529 1,037,948 Accumulated other comprehensive income 786 393 Accumulated deficit (760,865) (461,250)Total stockholders' equity 604,521 577,155 Total liabilities and stockholders' equity$734,733 $655,681
2026-02-26 12:47:55

Consolidated Lithium Metals Announces $17.07 Million Private Placement Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36 | OTCQB: JORFF) ("CLM” or the "Company”) announces today that it intends to complete a non-brokered private placement offering (the "Offering”) of securities of the Company for aggregate gross proceeds to the Company of up to $17,070,000, in a combination of:a) up to 31,250,000 units of the Company that will be issued pursuant to the Listed Issuer Financing Exemption (as defined herein) and other available exemptions from Canadian prospectus requirements as further described herein (each, a "LIFE Unit”) at a price of $0.08 per LIFE Unit for up to $2,500,000 in gross proceeds. Each LIFE Unit will consist of one common share of the Company (each, a "Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant”);b) up to 50,000,000 flow-through shares of the Company (each, a "Critical FT Share”) at a price of $0.10 per Critical FT Share for up to $5,000,000 in gross proceeds. Each Critical FT Share will consist of one Common Share that will qualify as a "flow-through share” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the "Tax Act”); andc) up to 79,750,000 flow-through units of the Company that will be issued as part of a charity arrangement (each, a "Charity FT Unit” and collectively, with the LIFE Units and Critical FT Shares, the "Offered Securities”) at price of $0.12 per Charity FT Unit, and will be issued pursuant to the Listed Issuer Financing Exemption and other available exemptions from Canadian prospectus requirements as further described herein, for up to $9,570,000 in gross proceeds. Each Charity FT Unit will consist of one Common Share and one-half of one Warrant that will each qualify as a "flow-through share” within the meaning of subsection 66(15) of the Tax Act.Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.12 for a period of 36 months from the closing date of the Offering. Warrants sold pursuant to the Listed Issuer Financing Exemption will not be exercisable until 60 days from the closing date of the Offering.The LIFE Units and the Charity FT Units will be offered for sale to purchasers in all provinces of Canada pursuant to the listed issuer financing exemption (the "Listed Issuer Financing Exemption”) under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106”) and the Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The LIFE Units, the Critical FT Shares and the Charity FT Units will also be offered for sale to purchasers in all provinces of Canada pursuant to other exemptions from the prospectus requirements, including those available under NI 45-106. The Company will ensure that the total number of LIFE Units and Charity FT Units issued pursuant to the Listed Issuer Financing Exemption, together with all issuances of common shares and warrants issued pursuant to the Listed Issuer Financing Exemption in the preceding 12 month period, will not exceed 50% of its outstanding listed equity securities as of the date immediately preceding the Company’s first issuance of securities pursuant to such prospectus exemption during the preceding 12 month period.Offered Securities that will be issued under the Listed Issuer Financing Exemption will not be subject to a hold period pursuant to applicable Canadian securities laws and all Offered Securities issued under other exemptions under NI 45-106 will be subject to a statutory four-month hold period pursuant to applicable Canadian securities laws.Finder’s fees may be paid to eligible finders in accordance with the policies of the TSX Venture Exchange (the "TSXV”) consisting of a cash commission equal to up to 8% of the gross proceeds raised under the Offering and finder warrants ("Finder Warrants”) in an amount equal to up to 8% of the number of Offered Securities sold pursuant to the Offering at an exercise price equal to the $0.08 per Finder Warrant for Finder Warrants issued due to sales of LIFE Units, $0.10 per Finder Warrant for Finder Warrants issued due to sales of Critical FT Shares, and $0.12 per Finder Warrant for Finder Warrants issued due to sales of Charity FT Units. Each Finder Warrant shall consist of one Common Share and one-half of one Warrant.The Company intends to use the gross proceeds from the Offering for exploration expenses and critical mineral mining expenditures on the Kwyjibo Rare Earth Project (the "Project”), as detailed in the Company’s press release dated November 18, 2025, and its lithium properties and for working capital and general corporate purposes. The Company will use an amount equal to the gross proceeds received by the Company from the sale of the Critical FT Shares and Charity FT Units, pursuant to the provisions in the Tax Act, to incur eligible "Canadian exploration expenses” that qualify as "flow-through critical mineral mining expenditures” as both terms are defined in the Tax Act (the "Qualifying Expenditures”) related to the Project and its lithium properties in Quebec, Canada on or before December 31, 2027, and to renounce all the Qualifying Expenditures in favour of the purchasers of the Critical FT Shares and Charity FT Units effective December 31, 2026. In the event that the Company is unable to renounce or incur 100% of the Qualifying Expenditures, the Company will indemnify each purchaser of Critical FT Shares and/or Charity FT Units, as applicable, for the additional taxes payable to such purchaser as a result of the Company’s failure to renounce the Qualifying Expenditures as agreed.Completion of the Offering is subject to regulatory approvals, including the TSXV.There is an offering document related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and at the Company’s website at www.consolidatedlithium.com. Prospective investors should read this offering document before making an investment decision.U.S. Offering and No U.S. Registration The Company may also offer the Offered Securities for sale pursuant to exemptions from the prospectus requirement under Ontario Securities Commission Rule 72-503 - Distributions Outside of Canada in the United States ("U.S.”) pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended, and in certain other jurisdictions outside of Canada and the U.S. provided it is understood that no prospectus filing or comparable obligation, ongoing reporting requirement or requisite regulatory or governmental approval arises in such other jurisdictions.The securities described herein have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the U.S. or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any U.S. state in which such offer, solicitation or sale would be unlawful.About Consolidated Lithium MetalsCLM is a Canadian junior mining exploration company trading under the symbol "CLM” on the TSX Venture Exchange, "Z36” on the Frankfurt Stock Exchange and "JORFF” on the OTCQB® Venture Market. The Company is focused on the exploration and development of critical mineral projects in stable jurisdictions. The Company is committed to supporting the energy transition through the responsible development of critical mineral supply chains.Additional information on CLM can be found on its website at: www.consolidatedlithium.com and by reviewing its profile on SEDAR+ at www.sedarplus.ca.For Further Information, Contact:Rene BhartiVice President Corp. Dev.Email: info@consolidatedlithium.comPhone: +1 (647) 965 2173Website: www.consolidatedlithium.comAdvisors: Wildeboer Dellelce LLP is acting as legal counsel for CLM in respect of the Offering. CLM has engaged Integrity Capital Group Inc., BT Global Growth Inc., Independent Trading Group (ITG), Inc. and Kernaghan & Partners Ltd. to support its efforts. For further information, contact Jeremy Rogers at jrogers@integritycapitalgrp.com or 647-998-4212.Cautionary Statement on Forward-Looking InformationThis news release contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies, including the Offering, regulatory and TSXV approvals of the Offering and the use of proceeds of the Offering, including Qualifying Expenditures. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CLM to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including risks related to:regulatory approvals, such as approval of the TSXV of the Offering; general business, economic, competitive, political, social, and market conditions; accidents, labour disputes and shortages; and other risks of the mining industry. Forward-looking statements contained herein are made as of the date of this press release and CLM disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
2026-02-26 12:47:43

FTI Consulting Reports Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter 2025 Record Revenues of $990.7 Million, Up 11% Compared to $894.9 Million in Prior Year QuarterFourth Quarter 2025 EPS and Adjusted EPS of $1.78, Up 29% and 14%, Compared to EPS of $1.38 and Adjusted EPS of $1.56 in Prior Year Quarter Full Year 2025 Record Revenues of $3.789 Billion, Up 2% Compared to $3.699 Billion in Prior YearFull Year 2025 Record EPS of $8.24 and Adjusted EPS of $8.83, Up 6% and 11%, Compared to EPS of $7.81 and Adjusted EPS of $7.99 in Prior YearIntroduces 2026 Guidance WASHINGTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today released financial results for the full year and fourth quarter ended December 31, 2025.For the full year 2025, revenues of $3.789 billion increased $90.2 million, or 2.4%, compared to revenues of $3.699 billion in the prior year. The increase was driven by revenue growth in the Corporate Finance, Forensic and Litigation Consulting and Strategic Communications segments, which was partially offset by revenue declines in the Economic Consulting and Technology segments. Net income of $270.9 million compared to $280.1 million in the prior year. The decrease in net income was primarily due to higher direct costs, which included an increase in variable compensation and forgivable loan amortization, as well as an increase in income taxes, special charges and interest expense, which more than offset the increase in revenues and the decrease in selling, general and administrative ("SG&A”) expenses. Adjusted EBITDA of $463.6 million, or 12.2% of revenues, compared to $403.7 million, or 10.9% of revenues, in the prior year.Full year 2025 earnings per diluted share ("EPS”) of $8.24 compared to $7.81 in the prior year. Full year 2025 EPS included a $25.3 million special charge related to severance and other employee-related costs, which reduced EPS by $0.59. Full year 2024 EPS included an $8.2 million special charge related to severance and other employee-related costs, which reduced EPS by $0.18. Full year 2025 Adjusted EPS of $8.83 compared to Adjusted EPS of $7.99 in the prior year.Steven H. Gunby, CEO and Chairman of FTI Consulting, commented, "We delivered our eleventh year in a row of Adjusted EPS growth and our eighth year in a row of record revenues. We delivered those record results notwithstanding the major headwinds that we were facing in a couple of our businesses during the year, which underscores, once again, the power and resilience of a business committed to investing in great talent and helping clients with their most significant challenges and opportunities.”Cash Position and Capital AllocationNet cash provided by operating activities of $152.1 million for the year ended December 31, 2025 compared to $395.1 million for the year ended December 31, 2024. The year-over-year decrease in net cash provided by operating activities was primarily due to higher forgivable loan issuances, compensation and income tax payments, which was partially offset by an increase in cash collections.Cash and cash equivalents of $265.1 million at December 31, 2025 compared to $660.5 million at December 31, 2024 and $146.0 million at September 30, 2025. Total debt, net of cash, of $99.9 million at December 31, 2025 compared to $(660.5) million at December 31, 2024 and $364.0 million at September 30, 2025. The sequential decrease in total debt, net of cash, was primarily due to net cash provided by operating activities.During the quarter ended December 31, 2025, the Company repurchased 519,944 shares of its common stock at an average price per share of $160.58 for a total cost of $83.5 million. In full year 2025, the Company repurchased 5,264,916 shares of its common stock at an average price per share of $163.07 for a total cost of $858.6 million. As of December 31, 2025, approximately $491.8 million remained available for common stock repurchases under the Company’s stock repurchase program.Fourth Quarter 2025 ResultsFourth quarter 2025 revenues of $990.7 million increased $95.8 million, or 10.7%, compared to revenues of $894.9 million in the prior year quarter. Excluding the estimated positive impact of FX, revenues increased $81.5 million, or 9.1%, compared to the prior year quarter. The increase was driven by revenue growth in the Corporate Finance, Forensic and Litigation Consulting, Strategic Communications and Technology segments, which was partially offset by revenue declines in the Economic Consulting segment. Net income of $54.5 million compared to $49.7 million in the prior year quarter. The increase in net income was primarily due to higher revenues, which was partially offset by an increase in direct costs, which includes higher variable compensation and forgivable loan amortization, as well as an increase in income taxes, interest expense and SG&A expenses compared to the prior year quarter. The increase in income taxes was primarily driven by $11.8 million of valuation allowance expenses against certain prior year foreign deferred tax assets. Adjusted EBITDA of $106.2 million, or 10.7% of revenues, compared to $73.7 million, or 8.2% of revenues, in the prior year quarter.Fourth quarter 2025 EPS of $1.78 compared to $1.38 in the prior year quarter. Fourth quarter 2025 EPS included the aforementioned valuation allowance on certain prior year foreign deferred tax assets, which reduced EPS by $0.38. Fourth quarter 2024 EPS included the aforementioned $8.2 million special charge, which reduced EPS by $0.18. Fourth quarter 2025 Adjusted EPS of $1.78 compared to $1.56 in the prior year quarter.Fourth Quarter 2025 Segment ResultsCorporate FinanceRevenues in the Corporate Finance segment increased $87.5 million, or 26.1%, to $423.2 million in the quarter compared to $335.7 million in the prior year quarter. Excluding the estimated positive impact of FX, revenues increased $82.8 million, or 24.7%. The increase in revenues was primarily due to increased demand and higher realized bill rates for turnaround & restructuring, transactions and transformation services, as well as an increase in success fees. Segment operating income of $76.7 million compared to $36.1 million in the prior year quarter. Adjusted Segment EBITDA of $80.1 million, or 18.9% of segment revenues, compared to $44.7 million, or 13.3% of segment revenues, in the prior year quarter. The increase in Adjusted Segment EBITDA was primarily due to higher revenues, which was partially offset by an increase in compensation, largely related to variable compensation, higher SG&A expenses and an increase in pass-through expenses.Forensic and Litigation ConsultingRevenues in the Forensic and Litigation Consulting segment increased $17.0 million, or 9.7%, to $192.9 million in the quarter compared to $175.9 million in the prior year quarter. Excluding the estimated positive impact of FX, revenues increased $15.1 million, or 8.6%.The increase in revenues was primarily due to higher realized bill rates for risk & investigations services. Segment operating income of $21.6 million compared to $14.3 million in the prior year quarter. Adjusted Segment EBITDA of $23.8 million, or 12.3% of segment revenues, compared to $18.0 million, or 10.2% of segment revenues, in the prior year quarter. The increase in Adjusted Segment EBITDA was primarily due to higher revenues, which was partially offset by an increase in variable compensation.Economic ConsultingRevenues in the Economic Consulting segment decreased $29.9 million, or 14.5%, to $176.2 million in the quarter compared to $206.1 million in the prior year quarter. Excluding the estimated positive impact of FX, revenues decreased $34.1 million, or 16.6%. The decrease in revenues was primarily due to lower demand for non-merger and acquisition ("M&A”)-related antitrust and M&A-related antitrust services, which was partially offset by increased demand for financial economics services and higher realized bill rates for international arbitration services. Segment operating loss of $0.3 million compared to segment operating income of $14.4 million in the prior year quarter. Adjusted Segment EBITDA of $1.0 million, or 0.6% of segment revenues, compared to $15.8 million, or 7.7% of segment revenues, in the prior year quarter. The decrease in Adjusted Segment EBITDA was primarily due to lower revenues and an increase in forgivable loan amortization, which was partially offset by lower compensation, which includes lower variable compensation and the impact of an 8.6% decline in billable headcount, and lower bad debt.TechnologyRevenues in the Technology segment increased $8.4 million, or 9.3%, to $99.0 million in the quarter compared to $90.6 million in the prior year quarter. Excluding the estimated positive impact of FX, revenues increased $7.2 million, or 7.9%. The increase in revenues was primarily due to higher demand for litigation and M&A-related "second request” services. Segment operating income of $10.7 million compared to $1.3 million in the prior year quarter. Adjusted Segment EBITDA of $14.8 million, or 14.9% of segment revenues, compared to $6.6 million, or 7.2% of segment revenues, in the prior year quarter. The increase in Adjusted Segment EBITDA was primarily due to higher revenues.Strategic CommunicationsRevenues in the Strategic Communications segment increased $12.8 million, or 14.8%, to $99.4 million in the quarter compared to $86.6 million in the prior year quarter. Excluding the estimated positive impact of FX, revenues increased $10.4 million, or 12.1%. The increase in revenues was primarily due to higher demand for corporate reputation services and a $5.3 million increase in pass-through revenues. Segment operating income of $18.0 million compared to $12.5 million in the prior year quarter. Adjusted Segment EBITDA of $19.0 million, or 19.2% of segment revenues, compared to $13.8 million, or 15.9% of segment revenues, in the prior year quarter. The increase in Adjusted Segment EBITDA was primarily due to higher revenues, which was partially offset by increases in pass-through expenses and variable compensation.2026 GuidanceThe Company estimates that revenues for full year 2026 will range between $3.940 billion and $4.100 billion. The Company estimates that EPS for full year 2026 will range between $8.90 and $9.60. The Company does not expect Adjusted EPS to differ from EPS.Fourth Quarter and Full Year 2025 Conference CallFTI Consulting will host a conference call for analysts and investors to discuss fourth quarter and full year 2025 financial results at 9:00 a.m. Eastern Time on Thursday, February 26, 2026. The call can be accessed live and will be available for replay over the internet for 90 days by logging onto the Company’s investor relations website here.About FTI ConsultingFTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of December 31, 2025. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.80 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.Non-GAAP Financial MeasuresIn the accompanying analysis of financial information, we sometimes use information derived from consolidated and segment financial information that may not be presented in our financial statements or prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Certain of these financial measures are considered not in conformity with GAAP ("non-GAAP financial measures")under the United States Securities and Exchange Commission ("SEC") rules. Specifically, we have referred to the following non-GAAP financial measures:Adjusted Segment EBITDAAdjusted EBITDAAdjusted EBITDA MarginAdjusted Net IncomeAdjusted Earnings per Diluted ShareWe have included the definition of Segment Operating Income (Loss), which is a GAAP financial measure, below in order to more fully define the components of certain non-GAAP financial measures in the accompanying analysis of financial information. We define Segment Operating Income (Loss) as a segment’s share of consolidated operating income. We use Segment Operating Income (Loss) for the purpose of calculating Adjusted Segment EBITDA, which is a non-GAAP financial measure. We define Adjusted Segment EBITDA as Segment Operating Income (Loss) before depreciation, amortization of intangible assets, remeasurement of acquisition-related contingent consideration, special charges and goodwill impairment charges. We use Adjusted Segment EBITDA as a basis to internally evaluate the financial performance of our segments because we believe it reflects core operating performance and provides an indicator of the segment’s ability to generate cash.We define Adjusted EBITDA, which is a non-GAAP financial measure, as consolidated net income before income tax provision, other non-operating income (expense), depreciation, amortization of intangible assets, remeasurement of acquisition-related contingent consideration, special charges, goodwill impairment charges, gain or loss on sale of a business and losses on early extinguishment of debt. We define Adjusted EBITDA Margin, which is a non-GAAP financial measure, as Adjusted EBITDA as a percentage of total revenues. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with a more complete understanding of our operating results, including underlying trends. In addition, EBITDA is a common alternative measure of operating performance used by many of our competitors. It is used by investors, financial analysts, rating agencies and others to value and compare the financial performance of companies in our industry. Therefore, we also believe that these non-GAAP financial measures, considered along with corresponding GAAP financial measures, provide management and investors with useful supplemental information.We define Adjusted Net Income and Adjusted Earnings per Diluted Share ("Adjusted EPS"), which are non-GAAP financial measures, as net income and EPS, respectively, excluding the impact of remeasurement of acquisition-related contingent consideration, special charges, goodwill impairment charges, the gain or loss on sale of a business and losses on early extinguishment of debt. We use Adjusted Net Income for the purpose of calculating Adjusted EPS. Management uses Adjusted EPS to assess total Company operating performance on a consistent basis. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with useful supplemental information on our business operating results, including underlying trends.Non-GAAP financial measures are not defined in the same manner by all companies and may not be comparable with other similarly titled measures of other companies. Non-GAAP financial measures should be considered in addition to, but not as a substitute for or superior to, the information contained in our Consolidated Statements of Comprehensive Income. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this press release.Safe Harbor StatementThis press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact, including among other things, statements about future events, anticipated growth, industry prospects, our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements often contain words such as "may,” "might,” "will,” "should,” "could,” "would,” "estimates,” "expects,” "anticipates,” "projects,” "plans,” "intends,” "believes,” "commits,” "aspires,” "forecasts,” "future,” "goal,” "seeks” and variations of such words or similar expressions. There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements contained in, or implied by, this press release. Although we believe that the expectations and assumptions reflected in these forward-looking statements are reasonable, we can provide no assurance that these expectations and assumptions will prove to be correct. These forward-looking statements relate to future events, results and outcomes, are inherently uncertain and involve known and unknown risks, uncertainties and other factors that may cause our actual results and outcomes, and the timing of our results and outcomes, to differ materially from those expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results or outcomes to differ materially from those contained in any forward-looking statements. Important factors that could cause our actual results or outcomes to differ materially from the forward-looking statements we make in this press release include those set forth under the heading "Risk Factors” in Part I, Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 26, 2026 as well as in other information that we file with the SEC from time to time. All forward-looking statements are presented as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included herein. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statement for any reason.FINANCIAL TABLES FOLLOWFTI CONSULTING, INC.CONSOLIDATED BALANCE SHEETS(in thousands, except per share amounts) December 31, December 31, 2025 2024 Assets Current assets Cash and cash equivalents$265,091 $660,493 Accounts receivable, net 1,037,678 1,020,174 Current portion of notes receivable 87,861 44,894 Prepaid expenses and other current assets 126,997 93,953 Total current assets 1,517,627 1,819,514 Property and equipment, net 169,333 150,295 Operating lease assets 201,492 198,318 Goodwill 1,242,777 1,226,556 Intangible assets, net 13,547 16,770 Notes receivable, net 250,667 109,119 Other assets 95,085 76,258 Total assets$3,490,528 $3,596,830 Liabilities and Stockholders’ Equity Current liabilities Accounts payable, accrued expenses and other$206,247 $224,394 Accrued compensation 712,335 639,745 Billings in excess of services provided 56,607 67,620 Total current liabilities 975,189 931,759 Long-term debt 365,000 - Noncurrent operating lease liabilities 224,510 208,036 Deferred income taxes 99,611 111,825 Other liabilities 92,487 86,920 Total liabilities 1,756,797 1,338,540 Stockholders’ equity Preferred stock, $0.01 par value; shares authorized - 5,000; noneoutstanding - - Common stock, $0.01 par value; shares authorized - 75,000; sharesissued and outstanding - 30,864 (2025) and 35,913 (2024) 309 359 Additional paid-in capital 354 39,650 Retained earnings 1,862,672 2,394,853 Accumulated other comprehensive loss (129,604) (176,572)Total stockholders’ equity 1,733,731 2,258,290 Total liabilities and stockholders’ equity$3,490,528 $3,596,830 FTI CONSULTING, INC.CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(in thousands, except per share data) Three Months EndedDecember 31, 2025 2024 (Unaudited)Revenues$990,746 $894,924 Operating expenses Direct cost of revenues 683,080 624,864 Selling, general and administrative expenses 213,601 208,051 Special charges - 8,230 Amortization of intangible assets 629 1,034 897,310 842,179 Operating income 93,436 52,745 Other income (expense) Interest income and other 864 7,779 Interest expense (7,537) (716) (6,673) 7,063 Income before income tax provision 86,763 59,808
2026-02-26 12:47:40

US House rejects bill requiring aircraft locators to prevent midair collisions
The House failed to approve a bill Tuesday that was crafted after last year’s tragic midair collision near Washington, D.C., to require all aircraft flying around busy airports to have key locator systems to prevent such crashes. The collision of an airliner and an Army helicopter killed 67 people in January 2025.The National Transportation Safety Board has been recommending such Automatic Dependent Surveillance-Broadcast systems to be installed since 2008. The bill that already passed the Senate would have required aircraft to be equipped with a system that can receive data about the locations of other aircraft. The complementary ADS-B Out system that broadcasts an aircraft’s location is already required.The families of the victims who died when an American Airlines jet collided with an Army Black Hawk helicopter strongly supported the measure, and a number of them watched the vote from the House gallery. But the Airlines for American trade group, the military and the major general aviation groups that represent business jets and small plane owners backed a competing and more comprehensive House bill that was just introduced last week.Tim Lilley, whose son Sam was the first officer on the airliner, said he’s really disappointed, but he and the other families will continue to press for meaningful reforms. And he hopes that will happen before the next tragedy.“We’re going to end up back here having the same conversation because of another midair (collision) is what’s going to happen. Hopefully — fingers crossed — that doesn’t,” Lilley said.Under the special process that was used to fast-track the bill, the ROTOR Act needed to receive more than two-thirds support to pass the House. It received 264 votes, but 133 other representatives voted against it. ROTOR stands for “Rotorcraft Operations Transparency and Oversight Reform.”House Speaker Mike Johnson told The Associated Press that the Senate and the House will work together to get an aviation safety bill done. “We're committed to it,” he said.And House Transportation & Infrastructure Committee Chairman Sam Graves said the House bill could be marked up in committee as soon as next week. That bill is designed to address all 50 of the recommendations the NTSB made, not just the locator technology, but NTSB Chairwoman Jennifer Homendy has said the House bill falls short of accomplishing that.But Lilley said the bill Graves helped write needs to be strengthened.“They’ve had 18 years to get it right. He’s talking about getting it right and he’s not even close on the collision avoidance piece,” he said.The cost of the ADS-B In mandate has been a concern. It’s not clear exactly how much it would cost partly because the systems haven’t yet been designed and certified for every aircraft, but Homendy testified in Congress that American Airlines was able to equip more than 300 of its Airbus a321s for $50,000 apiece, and general aviation pilots have the option of using a portable receiver that costs about $400 and works with an iPad.One of the key researchers who helped develop these locator systems, Fabrice Kunzi, said a plane’s dashboard shouldn’t have to be overhauled to add a new display because the system is designed to give pilots an audible warning about nearby traffic with details of their locations if there is a risk of a collision.House and Senate bills took a different approachThe key difference between the bills is that the House version would not require both kinds of the proven Automatic Dependent Surveillance-Broadcast systems to be installed. Instead, the House bill would require the Federal Aviation Administration to investigate what technology might be best as part of a lengthy rulemaking process before requiring a solution. The House bill also covers many more aspects of the systemic failures the NTSB identified as causing the crash on the evening of Jan. 29, 2025.The bipartisan group of Senate leaders behind the ROTOR Act — led by Republican Ted Cruz and Democrat Maria Cantwell — had argued their bill would be a good first step before drafting additional legislation.Cruz pledged to keep working to pass his bill, which earned bipartisan support Tuesday, because it would require all aircraft to play by the same set of rules. “We will succeed, and ROTOR Act will become the law of the land," he said. "The families and the flying public deserve nothing less.”The main Families of Flight 5342 group had said that while the House bill includes a number of good reforms that should be considered, they can’t support it as written because it doesn’t clearly require ADS-B In equipment. Everyone aboard the helicopter and the American Airlines jet flying from Wichita, Kansas, including the parents of Olympic figure skater Maxim Naumov and 26 other members of the figure skating community, died when the aircraft collided and plummeted into the icy Potomac River.Sara Nelson, who is the president of the Association of Flight Attendants, said her union will keep pushing for changes because bill that failed “was the clearest and most direct way to avoid midair collisions.”Doug Lane said that as he learned more about the crash that killed his wife and 16-year-old figure-skating son, he couldn’t understand why airplanes aren’t already equipped with technology that was first recommended before his son was born, and he's angry the bill failed Tuesday. He said the House bill is a poor substitute because too many of its provisions just call for a study or rulemaking without requiring actual change and there are loopholes.Lane said the House bill is “a clear effort to just punt ADS-B In into a place where it can just go and die. It was not a good-faith effort to come up with a better way to do collision avoidance technology.”Improving the collision warning systemAny plane flying around a major airport is already required to have an ADS-B Out system that continually broadcasts an aircraft’s location and speed installed. ADS-B In systems that can receive those signals and be used to create a display showing pilots where all air traffic is located around them are not standard on airliners, though many general aviation pilots already use a portable receiver to display that information on an iPad.The NTSB investigation showed that system would have provided significantly more warning to the pilots involved in the crash and would have allowed them to avoid the collision. A plane equipped with ADS-B In can give the pilot a detailed description of where other aircraft are, whereas the current technology can only warn that traffic is in the area.Cantwell, the Washington Democrat, said most House Republicans "voted to protect loopholes that helped cause the DCA (Reagan Airport) midair collision rather than acting with urgency to prevent crashes like this from happening again. The families deserve better.”Rep. Nick Langworthy, R-N.Y., who is chairman of an aviation safety caucus, voted for the bill. He said he was puzzled by the Pentagon’s last-minute shift on the bill. He also noted there were many absences among House members due to weather, which also affected the outcome.He said he is sure that the families of the crash victims are disappointed after the vote.“But I don’t think they should be completely dejected. I do think there are avenues to bring it back,” Langworthy said. “There’s will to solve this problem.”
2026-02-25 02:16:41

WeShipCars Expands Its Reach: Now Offering Car Shipping To and From Hawaii
Leading auto transport company broadens nationwide coverage with seamless vehicle shipping solutions connecting the mainland U.S. and the Hawaiian IslandsNorthbrook, Illinois, United States, February 25, 2026 /MarketersMEDIA/ -- WeShipCars, a trusted name in nationwide auto transport, proudly announces the expansion of its services to include professional car shipping to and from Hawaii. This strategic growth marks a major milestone for the company, reinforcing its commitment to delivering reliable, transparent, and customer-focused vehicle transport solutions across the United States - including destinations that require specialized ocean freight coordination.With more than 30 years of combined industry experience, the team behind WeShipCars has built its reputation on simplifying the auto transport process. By adding Hawaii to its service network, the company now bridges the logistical gap between the mainland and the Pacific islands, providing customers with a streamlined, end-to-end solution for one of the most complex transport routes in the country.Expanding Beyond the MainlandShipping a vehicle to or from Hawaii requires far more coordination than standard interstate transport. It involves a combination of overland trucking, port handling, and ocean freight logistics. Recognizing these unique challenges, WeShipCars developed a comprehensive Hawaii car shipping program designed to eliminate confusion and deliver a stress-free experience for customers.Whether relocating for work, coordinating a military move, purchasing a vehicle remotely, or planning a long-term stay in the islands, customers now have access to flexible car shipping estimates and services that fit their timeline and budget. WeShipCars offers door-to-port, port-to-door, and port-to-port services, giving vehicle owners full control over how their shipment is managed.“Our mission has always been to make auto transport simple, transparent, and reliable,” said Dilyan Ivanov, co-owner of WeShipCars. “Expanding into Hawaii allows us to support customers who need dependable vehicle shipping across the Pacific, while maintaining the same personalized service we’re known for nationwide.”Customer-First Service at Every StepFrom its founding, WeShipCars has distinguished itself through a customer-centric philosophy. Rather than treating shipments as transactions, the company emphasizes communication, education, and individualized planning. Every customer works with experienced transport specialists who guide them from quote to delivery.The Hawaii expansion continues this commitment. WeShipCars coordinates mainland pickup, manages port scheduling, oversees ocean carrier logistics, and arranges delivery upon arrival in Hawaii-or back to the continental U.S. This full-service approach removes the burden from customers, ensuring all documentation, timing, and compliance requirements are handled efficiently.Key features of WeShipCars’ Hawaii auto transport service include:Transparent pricing with no hidden feesZero upfront paymentFree cancellationFully insured and vetted network of carriersCustomizable services & dedicated experts24/7 customer supportThese policies reflect the company’s dedication to building long-term trust with its growing customer base.Comprehensive Coverage Across the IslandsWeShipCars facilitates vehicle shipping to and from major Hawaiian ports, including Honolulu (O‘ahu), Kahului (Maui), Nawiliwili (Kauai), and Hilo (Big Island). The company’s experienced logistics partners ensure smooth coordination between mainland departure points and island arrival terminals.Customers shipping from Hawaii back to the mainland receive the same level of oversight and support. Vehicles can be transported from port to residential or commercial destinations across the continental United States, making the service ideal for families relocating, students returning home, and military personnel completing assignments.Flexible Transport Options for Every VehicleUnderstanding that not all vehicles are created equal, WeShipCars offers both open and enclosed transport options as part of its Hawaii program.Open transport remains the most cost-effective and widely used solution, ideal for everyday vehicles such as sedans, SUVs, and pickup trucks. For high-value vehicles-including luxury, classic, exotic, or specialty cars-enclosed transport provides added protection from the elements and road debris during the mainland trucking portion of the journey.Each transport plan is customized based on vehicle type, origin and destination, scheduling preferences, and budget considerations. By tailoring every shipment, WeShipCars ensures that customers receive a solution aligned with their specific needs rather than a one-size-fits-all approach.Strengthening a National FootprintThe addition of Hawaii services positions WeShipCars as a truly nationwide auto transport provider. While many companies limit operations to the 48 contiguous states, WeShipCars has invested in the infrastructure and partnerships necessary to extend its reach across the Pacific.This expansion reflects broader growth within the company, driven by increasing demand for reliable, transparent vehicle shipping services. As remote work, interstate relocation, and online vehicle purchases continue to rise, consumers require dependable transport partners capable of navigating complex routes with professionalism and efficiency.“We see this as more than just geographic expansion,” added Dilyan Ivanov. “It’s about meeting our customers where they are-no matter how far that may be.”About WeShipCarsWeShipCars is a nationwide auto transport company built on transparency, reliability, and personalized service. With over three decades of combined industry expertise, the company specializes in safe and efficient vehicle shipping solutions tailored to individual customer needs. By partnering with fully licensed and insured carriers, WeShipCars ensures that every shipment is handled with care and professionalism. The company’s mission is simple: to make auto transport straightforward, stress-free, and accessible to customers across the United States.For more information about Hawaii car shipping services or to request an instant free car shipping quote, visit https://www.weshipcars.com/.Contact Info:Name: Dilyan IvanovEmail: Send EmailOrganization: WeShipCarsAddress: 964 Enfield Dr.Phone: (708) 300-0063Website: https://www.weshipcars.com/Release ID: 89184275Should you identify any discrepancies, concerns, or inaccuracies in the content provided in this press release or require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team is committed to addressing your concerns within 8 hours by taking necessary actions to resolve identified issues diligently or guiding you through the necessary steps for removal. Our dedication lies in providing accurate and reliable information.
2026-02-25 02:16:08

Stage1Auto Expands Legal Window Tint Installation Services in Edison, NJ
Local auto shop Stage1Auto expands professional window tint installation services in Edison, NJ, responding to rising demand for legal, heat-reducing vehicle tint that complies with New Jersey visibility regulations.Edison, New Jersey, United States, February 25, 2026 -- Edison, NJ – February 24, 2026 – As temperatures rise and UV exposure continues to affect daily commuters across Middlesex County, demand for professional window tint installation in Edison, NJ has increased. Stage1Auto, an Edison-based automotive customization and installation shop located on US-1, has expanded its legal window tint services to meet growing demand for compliant, heat-reducing installations.Drivers throughout Edison and surrounding communities are increasingly seeking window tint solutions that reduce interior heat and glare without violating New Jersey visibility regulations. Improper film installation or non-compliant tint percentages can result in inspection complications or traffic citations, making professional installation an important consideration for vehicle owners.“Customers are asking more detailed questions about legal window tint options,” said a representative from Stage1Auto. “They want to improve comfort and reduce sun exposure, but they also want to make sure their vehicle remains compliant with New Jersey standards.”Modern window tint technology is designed not only to enhance vehicle appearance, but also to reduce infrared heat buildup and block harmful UV rays that can accelerate dashboard fading, upholstery wear, and interior deterioration. For drivers commuting daily along Route 1 and nearby highways, glare reduction has also become a practical safety concern.Stage1Auto provides professional window tint installation tailored to each vehicle type, ensuring proper film selection and application aligned with state guidelines. The shop serves drivers throughout Edison and neighboring communities including Metuchen, Fords, Iselin, and Highland Park.Drivers seeking more information about window tint installation in Edison, NJ can visit:https://www.stageoneauto.com/window-tinting-edison-nj/About the company: Stage1Auto is an automotive customization and installation shop located in Edison, NJ, specializing in professional window tint installation and vehicle appearance upgrades. The company serves drivers throughout Middlesex County and surrounding communities with installation-focused automotive services.Contact Info:Name: Roman DriftwoodEmail: Send EmailOrganization: Stage1AutoAddress: 1217 US-1, Edison, NJ 08837Phone: (908) 718-5977Website: https://www.stageoneauto.com/Release ID: 89184265In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.
2026-02-25 02:16:01

Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement optionsNew York, NY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- DISCLAIMER: This press release is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The statements made about Pulmo Balance have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before starting any new dietary supplement, especially if you have existing health concerns or take medications. This article may contain affiliate links, meaning a commission may be earned at no additional cost to you if you purchase through the links provided. Pricing and availability are subject to change - visit the official website for current pricing.This release is an informational overview of publicly available disclosures for Pulmo Balance and broader consumer research behavior within the respiratory support supplement options category. Nothing in this content should be interpreted as medical advice, a product endorsement, or a performance claim.As respiratory support supplement options remain an active area of consumer research in 2026, Pulmo Balance product disclosures are available through the company's website, including ingredient listings and published policy information. With more people researching what's out there, detailed product information is accessible for anyone trying to better understand their supplement options.This article provides informational context about the respiratory wellness category and summarizes what Pulmo Balance Research has disclosed about its product. Readers seeking primary-source detail can View the current Pulmo Balance offer (official Pulmo Balance page) to review the company's complete product disclosures directly. This article does not assess product effectiveness or outcomes and focuses solely on publicly available disclosures.Why Consumers Are Researching Respiratory Support Supplement OptionsRespiratory wellness supplements are a category that continues to draw consumer attention as more people look into natural options that complement their existing health routines. Whether it's seasonal changes, environmental factors, or a general interest in day-to-day respiratory comfort, people are paying closer attention to what products are available and what factors might be worth considering before making a purchase.For many people, this research starts with a straightforward question - what's actually in these products, and how transparent is the company behind them? That's a reasonable instinct, and it's exactly the kind of thinking that may help consumers compare disclosures more effectively. The respiratory support supplement category includes a wide range of products with different ingredient profiles, pricing structures, and company disclosures, which can make comparison shopping feel overwhelming without organized information.Ingredient transparency, manufacturing practices, and refund policies are among the factors consumers commonly research alongside ingredient lists - a pattern that reflects broader awareness around supplement label literacy in general.What Respiratory Support Supplements Typically Refer ToThe term "respiratory support supplement" generally refers to dietary supplement products that contain ingredients traditionally associated with lung and airway wellness. These are not medications. They are not FDA-approved treatments for any disease or condition. They fall under the Dietary Supplement Health and Education Act (DSHEA), which means companies can market them with structure/function claims but cannot claim to diagnose, treat, cure, or prevent any specific disease.Products in this category commonly feature botanical extracts, enzymes, antioxidant compounds, and mushroom-derived ingredients. Some brands provide detailed Supplement Facts panels with individual ingredient amounts, while others group ingredients into proprietary blends. Understanding what category a product falls into - and what regulatory framework governs it - is an important first step for anyone doing their homework before purchasing.What Botanical Extracts and Enzyme Compounds AreBotanical extracts are concentrated preparations derived from plants - leaves, bark, roots, or flowers - that have histories of traditional use in various herbal wellness practices. Common botanical extracts found in the respiratory support category include mullein leaf, pine bark, and stinging nettle. These ingredients are widely available individually and are also commonly included in combination formulas. The presence of a botanical ingredient in a supplement does not constitute a claim about what that ingredient does.Enzyme compounds, such as bromelain (derived from pineapple), are proteins that facilitate biological processes. Enzymes appear in many supplement categories and are sometimes included alongside botanical ingredients. As with botanicals, the inclusion of an enzyme in a supplement formula does not constitute an efficacy claim for the finished product.How Consumers Evaluate Respiratory Support SupplementsIf you're comparing respiratory support supplements - and the fact that you're reading this suggests you might be - there are a few non-performance factors worth looking at before you focus on any single product. These won't tell you whether a product "works," but they will tell you a lot about the company behind it.Ingredient disclosure completeness is one of the first things to check. Does the company list every ingredient with its individual amount, or does the label use a proprietary blend that groups ingredients together without showing how much of each one you're actually getting? Full disclosure gives you the ability to cross-reference with independent research if you choose to.Dosage transparency matters because research on individual ingredients is typically conducted at specific dosage levels. If a company doesn't disclose how much of each ingredient is in the formula, there's no way for a consumer to compare what's in the bottle to what's been studied independently.Refund and return policy clarity is another indicator worth examining. Some companies advertise generous return windows but include specific procedural requirements. Reading the full refund policy - not just the marketing headline - before purchasing is a smart move.Manufacturing and sourcing disclosures vary significantly across brands. Some companies identify where products are manufactured, whether facilities are FDA-registered, and what quality control measures are in place. Others provide minimal detail.None of these factors tell you whether a supplement will meet your expectations. But they give you a clearer picture of how a company operates - and that's useful information regardless of which product you're evaluating.Ingredient Transparency in the Respiratory Support Supplement CategoryIngredient transparency is a factor many consumers consider when researching supplements. Companies vary in how much detail they provide about formulation, sourcing, and manufacturing processes. Some brands publish complete Supplement Facts panels with individual ingredient amounts, while others use proprietary blends that group ingredients together.According to publicly available company disclosures, Pulmo Balance lists Mullein Extract, Bromelain Powder, Maritime Pine Bark, Stinging Nettle Extract, Tiger Milk Mushroom, Quercetin Dihydrate Extract, and BioPerine as its primary ingredients. The company's published materials describe these as a blend selected for their traditional and research-associated roles in respiratory wellness contexts. Readers interested in specific dosage information can review the company's product page and any available labeling disclosures for the most current formulation details, as individual ingredient amounts are not disclosed in publicly available marketing materials. This overview is informational only and does not evaluate product outcomes or make performance claims.Important context about ingredient research: Some independent research exists related to individual ingredients listed in the Pulmo Balance formula. Studies cited by the company examine individual botanical ingredients in respiratory-related research contexts. However, these studies evaluate individual ingredients at specific dosages - they do not assess the Pulmo Balance formulation itself. Because the specific dosages in the Pulmo Balance formula are not publicly disclosed, direct comparisons to research dosages are not possible. Research on individual ingredients does not automatically translate to efficacy claims for a proprietary blend. The company explicitly states it is not endorsed by, sponsored by, or affiliated with any of the organizations that published the referenced research.Understanding Supplement Labels in the Respiratory CategoryIf you're new to researching supplements, a quick primer on how to read labels can save you a lot of confusion. The Supplement Facts panel is the most important section on any product - it's where you'll find serving size, servings per container, and (ideally) individual ingredient amounts.Products that list ingredients inside a "proprietary blend" are required to show the total combined weight of all ingredients in the blend, but they are not required to disclose how much of each individual ingredient is included. This is legal under current FDA labeling rules, but it does limit your ability to evaluate what you're actually taking on a per-ingredient basis.For respiratory support products specifically, you may also want to look at whether the label includes common allergen disclosures, whether the product is described as non-GMO or third-party tested, and whether the company provides customer service contact information directly on the product page. These are transparency signals - not guarantees of quality - but they help you build a more complete picture before making a decision.What Pulmo Balance Research Discloses About Its ProductPulmo Balance is a dietary supplement manufactured by Pulmo Balance Research, a United States-based company, according to the company's website. The product is marketed as a natural lung support formula containing seven ingredients and is positioned for adults seeking to incorporate respiratory wellness support into their daily routines.The company's published materials reference a blend of ingredients commonly listed within the respiratory support category. According to the company's website, Paul Whitmore is identified as the creator of Pulmo Balance. The company describes the formula as designed for respiratory wellness support and recommends consistent use as part of a broader wellness routine.The company describes the product as non-GMO, non-habit forming, and assembled in the United States. The recommended usage is two capsules daily with a meal, according to the company's website. The product is not recommended for individuals under 18 or for pregnant or nursing mothers.The company recommends a usage period of four months or longer, describing this as its suggested timeline for incorporating the supplement into a daily wellness regimen. As with any dietary supplement, individual experiences vary, and the company notes this in its publicly available materials.Important context: Pulmo Balance is a dietary supplement, not a medication. It has not undergone FDA evaluation and is not intended to diagnose, treat, cure, or prevent any disease. Anyone with existing health concerns or who takes medications should consult a healthcare provider before starting any new supplement.Readers who want to review the company's full ingredient list, product disclosures, and current availability can View the current Pulmo Balance offer (official Pulmo Balance page) to access complete product information directly from the company.Pulmo Balance Pricing Structure and Purchase OptionsPulmo Balance is offered in multiple package configurations through the company's direct-to-consumer website. According to the company, multi-bottle packages may include bundled digital materials - described as "The 7-Day Lung Reset Protocol" and "The Inflammation-Free Breathing Blueprint" (digital downloads, not physical books) - along with shipping incentives on certain package tiers.The company offers single-bottle, three-bottle, and six-bottle configurations. Specific pricing, availability, and promotional details may change over time and can be reviewed on the official product page.According to the company, orders are shipped within 24 working hours using premium carriers, and customers receive tracking numbers via email. Domestic orders typically arrive within 5 to 10 days, according to the company's website.Refund Policies and Customer Support DisclosuresAccording to the company's published policies, Pulmo Balance Research describes a 90-day refund policy and provides customer service contact methods on its website. The company's published return policy includes specific requirements for obtaining a refund, including return authorization procedures and product return conditions. Readers should review the full terms directly on the official page before making a purchase decision.Who May Want to Consult a Healthcare ProfessionalWhile respiratory support supplements are widely available, certain individuals may want to discuss supplementation with a qualified healthcare professional before use. This commonly includes people with existing respiratory conditions or chronic health concerns, anyone currently taking prescription medications or managing ongoing health conditions, women who are pregnant or nursing, individuals with known allergies to any listed ingredient, and anyone under the age of 18.Many people choose to consult qualified healthcare professionals for personalized guidance on whether any supplement fits their individual health circumstances. This is particularly relevant for anyone with existing health conditions or those taking medications. A healthcare provider can evaluate whether a supplement is appropriate alongside your current health plan - and that conversation is always worth having.Frequently Asked Questions About Pulmo BalanceWhat is Pulmo Balance?According to the company's website, Pulmo Balance is a dietary supplement containing seven primary ingredients. It is manufactured by Pulmo Balance Research, a United States-based company, and is marketed as a natural respiratory support formula for adults.How is Pulmo Balance taken?According to the company, the recommended usage is two capsules daily with a meal. The company recommends consistent use for four months or longer as part of a wellness routine.Are individual ingredient amounts disclosed?Specific dosages of each ingredient in the Pulmo Balance formula are not disclosed in publicly available company materials. Readers can review the company's product page and any available labeling disclosures for the most current formulation details.Where is Pulmo Balance manufactured?According to the company's website, Pulmo Balance is assembled in the United States.What is the refund policy?According to the company, Pulmo Balance purchases are covered by a 90-day return policy with specific terms and conditions. Readers should review the complete refund policy on the company's website before ordering.Can Pulmo Balance be taken with medications?Anyone currently taking prescription medications or managing ongoing health conditions should consult their healthcare provider before starting Pulmo Balance or any new dietary supplement.Where to Review Complete Product InformationAccording to the company's website, Pulmo Balance is available exclusively through its direct-to-consumer platform. To review current pricing, package options, the full ingredient list, available labeling disclosures, and the company's complete terms and conditions, View the current Pulmo Balance offer (official Pulmo Balance page).For customer service inquiries, the company provides contact information on the official website, including email support at support@pulmobalance.com and phone support at +1-888-834-4386 (Mon-Sun, 10 AM-1 AM EST).About This PublicationThis press release is published for informational and educational purposes only. It is not medical advice and does not constitute an endorsement or recommendation of any product. Readers should conduct their own research and consult qualified healthcare professionals before making health-related decisions. This publication may contain affiliate links, meaning a commission may be earned at no additional cost to you if you purchase through the links provided.Final Disclaimer: The statements made about Pulmo Balance have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Pricing and availability are subject to change. Always verify current product information, pricing, and terms directly with the manufacturer before making a purchase decision.CONTACT: support@pulmobalance.com+1-888-834-4386 (Mon-Sun, 10 AM-1 AM EST)
2026-02-25 02:14:54

Digital Realty Expands Innovation Lab Network to Singapore and Japan to Accelerate AI and Hybrid Cloud Implementation
Asia Pacific will provide real-world environments for customers and partners to test and optimize next generation infrastructureSINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced the expansion of its Digital Realty Innovation Lab (DRIL) into Singapore and Japan. This marks the first expansion of the company’s global DRIL network into Asia Pacific, following the successful launch of the inaugural DRIL facility in Northern Virginia in September 2025, which received over 120 visits from our enterprise customers.The new DRIL locations will offer our ecosystem of partners and customers fully supported, real-world testing environments where they can bring their own workloads or use pre-configured infrastructure to validate AI and hybrid cloud deployments before scaling live. This is especially important as AI adoption increases and infrastructure readiness has emerged as a critical barrier to moving from experimentation to production at scale.The launch represents Digital Realty’s commitment to support Singapore and Japan’s continued leadership in AI innovation. In Singapore, AI adoption is driving continued growth in the nation’s digital economy, which now accounts for 18.6% of total GDP. At the same time, Japan plans to invest 10 trillion yen or more in the semiconductor and AI sectors by 2030. Both are expected to be available for use by customers and partners this year.Enabling next-generation AI infrastructureThe Singapore DRIL is designed to serve as a digital innovation hub, bringing together local customers, partners, and research institutions with global technology providers and industry participants seeking to develop, test and deploy AI and hybrid cloud solutions in Singapore.In Japan, the DRIL will be located at the company’s NRT12 data center in the Greater Tokyo area. Designed to support advanced AI and high-performance computing use cases, it will feature 20 racks with direct liquid cooling (DLC) capabilities, enabling support for high-power-density workloads."Sustaining rapidly expanding digital economies requires innovation ecosystems built on infrastructure that is not only AI-ready, but also efficient, resilient, and trusted,” said Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty."Since launching the DRIL in the US, we've seen strong demand from customers and partners across Asia Pacific seeking dedicated environments to validate AI and hybrid cloud architectures before deploying at scale. Bringing this capability to Singapore and Japan reflects the digital maturity of these markets and their critical role in shaping the region's long-term digital competitiveness. By creating spaces where enterprises can test, optimize, and de-risk their AI infrastructure, we're accelerating responsible deployment and strengthening Asia Pacific’s position as a hub for trusted digital innovation.”Purpose-built infrastructure for AI and hybrid cloud validationThe new DRIL locations will enable businesses in Singapore and Japan to test performance, optimize configurations, and seamlessly connect to cloud and network providers via ServiceFabric®, Digital Realty’s global interconnection and orchestration platform.By leveraging Digital Realty’s global experience in deploying AI-ready infrastructure and its proven Pervasive Datacenter Architecture (PDx®) methodology, the Singapore DRIL enables customers to test, optimize, and validate AI deployments in real-world conditions, reducing complexity and significantly accelerating the journey from pilot to production.Consistent with the global network of DRILs, key features will include:High-density AI and HPC testing - Support for AI and high-performance computing workloads with high-density colocation, accommodating deployments of up to 150kW per cabinet.Energy and cooling-aware testing - Enables enterprises to evaluate AI performance, power density, and efficiency trade-offs before full-scale deployment.AI infrastructure optimization - Enables businesses to explore AI-specific power, cooling, and GPU resource requirements in an environment optimized for AI workloads.Hybrid cloud validation - Direct cloud connectivity allows enterprises to refine hybrid strategies and seamlessly onboard through ServiceFabric®, Digital Realty’s interconnection and orchestration platform.AI workload orchestration - Customers can orchestrate AI workloads across Digital Realty’s Private AI Exchange (AIPx) to enable secure, low-latency integration across distributed environments.Latency testing across locations - Enterprises can test latency scenarios ensuring seamless performance across multiple locations as well as cloud destinations. The global DRIL network already supports a growing ecosystem of customers and partners, including AMD, Cisco, and Lenovo, focused on scaling AI and hybrid cloud architectures._________________About Digital RealtyDigital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.For Additional InformationMedia ContactsJoyce NgDigital Realtyjong@digitalrealty.comInvestor RelationsJordan Sadler / Jim HusebyDigital Realty+1 (214) 231-1350InvestorRelations@digitalrealty.comSafe Harbor StatementThis press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the company's partnerships and expected benefits, expected completion dates, emerging technologies, artificial intelligence, ServiceFabric®, customer demand and the company's strategy. For a list and description of risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
2026-02-25 02:14:43

Christian pastor asks for compassion amid controversy vs Alvin Aragon
The pastor of Victory Church, which Alvin Aragon attends, gave a statement on Fast Talk With Boy Abunda.In the February 24 episode of the program, veteran host Boy Abunda read the statement from Pastor Nixon Ng. This was in connection with the criticism currently being faced by StarStruck alumnus Alvin.According to Boy, “Humingi kami ng statement galing kay Pastor Nixon Ng of Victory Church sa Pasay. Bahagi ng kanyang statement ay sinasabi niyang, he has that belief of Alvin about the LGBT Community and the role of the father and the husband in the family is not different from the belief of other Christians.”“But he believes Christians should share their conviction with compassion. Conviction and compassion must always come together.'The pastor also believes that the public should be “gracious” toward Alvin amid the controversy he is facing.Boy said while reading the statement, “Naniniwala din siya that the public should be gracious towards Alvin.“He noted that most Christians, 'Especially in the early stages of their faith can be overly passionate and excited about sharing their beliefs.' Pero eventually daw, 'They grow as Christians.'”Watch Fast Talk with Boy Abunda: Sofia Trazona comments about Alvin Aragon's controversies (Episode 798) Alvin recently made showbiz headlines due to his heated statements about his relationship with SexBomb Girls member Izzy Trazona and his trans woman child, Sofia Trazona.In one interview, Alvin objected to being compared to Bulacan vice governor Alex Castro, the husband of another SexBomb Girls member, Sunshine Garcia.He said, “Sinasabi nila, 'Buti pa yung asawa ni Sunshine, vice governor, pinayagan sila mag-concert.“Dapat nga hindi, e. Dapat nga, yung asawa mo, ingatan mo. Hindi mo hahayaang magsuot ng mga damit na para pagnasaan ng mga lalaki."In a separate interview, Alvin also criticized Izzy's former husband, Michael Navarro, for supporting their child Sofia's identity as a trans woman. He also mentioned several celebrities whose children are part of the LGBTQIA+ community, such as K Brosas.Alvin said, “God will throw you to hell if you continue to do homosexuality. Mamuhay ka, and you don't want to believe in Jesus? I assure you that God will throw you to hell if you don't stop, repent, and believe in the gospel."Meanwhile, get to know more about Alvin Aragon in this gallery:
2026-02-25 02:13:00

Foreign debt service burden drops to $12B
THE country’s external debt service burden fell by 22.8 percent to $12.01 billion as of end-November from $15.57 billion a year earlier, preliminary Bangko Sentral ng Pilipinas (BSP) data showed.Principal payments declined to $4.77 billion from $8.21 billion while interest payments also dropped to $7.25 billion from $7.37 billion.Outstanding external debt stood at $149.09 billion as of end-September, up 6.7 percent from $139.64 billion in the previous quarter.As a share of gross domestic product, external debt slightly rose to 30.9 percent, slightly higher from 30.6 percent three months earlier.Public sector external debt totaled $96.29 billion, up from $86.88 billion as of end-June, while private sector debt also increased to $52.79 billion from $52.76 billion.The central bank said external debt “remained manageable, supported by solid economic conditions and prudent policies.”The debt service burden — a measure of the country’s ability to pay its debt — covers principal and interest payments on medium- to long-term credits such as those from the International Monetary Fund, loans under Paris Club agreements and debt restructuring by commercial banks, along with new money facilities.It also includes interest payments on banks’ and nonbanks’ fixed and revolving short-term liabilities but excludes prepayments for future foreign loan maturities and principal payments on short-term obligations.Sought for comment, Rizal Commercial Banking Corp. chief economist Michael Ricafort said the decline was due to a lower share of foreign borrowings in the government’s total borrowing mix to better manage the risk of foreign exchange losses.The government, which has prioritized local borrowings, has set a mix of 77 percent domestic borrowings and 23 percent foreign for 2026.It is planning to borrow P2.68 trillion this year to finance its programs and projects, slightly up from the P2.6 trillion last year.Most will come from the domestic debt market at P2.05 trillion, lower than the P2.11 trillion programmed for 2025.The remaining P627.1 billion will come from external sources, up from 2025’s P488.17 billion. This comprises program loans (P263.3 billion), project loans (P61.7 billion), and bonds and other inflows (P302.1 billion).
2026-02-23 16:19:00

Tariff ruling tagged as stocks, peso gain
THE stock market rose for a fourth straight trading day and the peso also hit a five-month high on Monday, a result an analyst said was partly due to last Friday’s US Supreme Court ruling striking down President Donald Trump’s tariffs.The benchmark Philippine Stock Exchange index (PSEi) added 23.39 points, or 0.36 percent, to 6,488.51 and the broader All Shares also rose, by 20.93 points or 0.59 percent, to 3,591.61.The peso ended at P57.575:$1, strengthening by 60 and a half centavos to its strongest close since Sept. 24, 2025’s P57.461:$1. It opened at P57.95 and traded between P57.53 and P57.999. Volume reached P1.716 billion, up from Friday’s P1.367 billion.Rizal Commercial Banking Corp. chief economist Michael Ricafort said the peso strengthened after the US Supreme Court ruled against former President Donald Trump’s global tariffs, a decision that triggered immediate gains in emerging market stock markets and currencies.He said the PSEi’s advance, which followed a brief profit-taking period ahead of the Lunar New Year holidays and marked near two-week highs, was also supported by the Supreme Court’s tariff ruling.Ricafort said the ruling was expected to speed up global trade, support economic growth and ease inflationary pressures, benefiting Philippine exporters exposed to US tariffs.Meanwhile, Regina Capital Development Corp. managing director Luis Limlingan said investor appetite for stocks was supported by corporate earnings and continued confidence despite cautious trading volume amid global uncertainties.He said the local market resilience was also being underpinned by government reforms and plans for catch-up infrastructure spending in the first quarter, which will boost investor confidence.Market breadth favored advancers on Monday with 123 gainers, 69 decliners, and 72 unchanged, while total turnover reached P5.49 billion, net of extraordinary block sales.
2026-02-23 16:18:00

ICC prosecutors outline charges vs Duterte
THE International Criminal Court (ICC) opened hearings Monday to decide whether former president Rodrigo Duterte should stand trial for crimes against humanity linked to his deadly anti-drug crackdown.The “confirmation of charges” sessions, taking place over four days, will determine whether there is enough evidence against Duterte to proceed to a trial.The 80-year-old was not present in court in The Hague after it granted a defense request to waive his right to appear, despite judges ruling he was fit to take part.Following the hearings, the judges will have 60 days to issue a written decision on whether he should face a full trial.As Monday’s hearing began, prosecutors outlined allegations that Duterte personally orchestrated and endorsed extrajudicial killings (EJKs) during his tenure as mayor of Davao City and later as president of the Philippines.ICC Deputy Prosecutor Mandiaye Niang presented the framework of the case, detailing evidence suggesting that Duterte played a central role in a campaign of widespread and systematic killings targeting individuals perceived to be involved in illegal drugs and other crimes.The charges cover the period from Nov. 1, 2011 to March 16, 2019, and involve 49 incidents resulting in 78 deaths, including children.“Today marks an important day for international justice, for the people of the Philippines, for the victims, and for this court,” Niang said. “The commencement of the confirmation hearing against Mr. Rodrigo Roa Duterte is a reminder that no individual, regardless of office, is above the law.”The chargesThe prosecution charged Duterte with multiple counts of murder and attempted murder as crimes against humanity, structured into three counts: Count One: Murder of 19 victims — including three children — alleged to be criminals in or around Davao City between 2013 and 2016, carried out by members of the Davao Death Squad (DDS) while Duterte was mayor.Count Two: Murder of 14 high-value targets across the Philippines between July 2016 and July 2017, executed by state actors and others in a so-called National Network during Duterte’s presidency.Count Three: Murder and attempted murder of 45 victims — including 43 killings and two attempted killings — during barangay clearance operations nationwide between July 2016 and September 2018, also by members of the National Network.The prosecution said Duterte is individually criminally responsible as an indirect co-perpetrator, as well as in the alternative, for ordering, inducing, or aiding and abetting the crimes. The charges allege that Duterte:– Designed and promoted the policy of “neutralizing” alleged criminals through violent acts, including murder.– Established, supervised, and authorized the DDS and later the national anti-drug campaign “Double Barrel.”– Provided weapons, logistical support, financial incentives, and promotions to perpetrators.– Personally identified targets and publicly named individuals deemed high-value targets.– Made repeated statements encouraging killings and assuring immunity for law enforcement participants.Niang emphasized that Duterte’s influence over both local and national perpetrators was absolute, citing instances where he temporarily suspended operations in response to public outcry, demonstrating that his instructions were obeyed without exception.Evidence overviewThe prosecution highlighted evidence including witness testimonies, official documents, audiovisual material, and financial records, illustrating that Duterte’s so-called war on drugs resulted in thousands of civilian deaths.Victims were often abducted, mistreated, and denied due process, with some children among the dead. Niang also noted Duterte’s public mocking of victims, pointing to a 2016 speech in which he derided a widely circulated photograph of an extrajudicial killing victim.“His intent and knowledge are shown by multiple statements throughout his mayoral and presidential tenure, promoting the common plan and urging police and even members of the public to kill alleged criminals,” Niang said.Victims’ plea for justiceFilipino human rights lawyer Joel Butuyan, representing 497 victims, expressed deep disappointment over Duterte’s absence in The Hague, describing the hearing as the victims’ “last boat” for justice.“The very deep disappointment of the victims stems from the decision allowing Rodrigo Duterte not to be present at this stage,” Butuyan said. “The sight of Mr. Duterte being confronted with the grave and horrible charges against him would have constituted a vital component of justice for the victims.” Butuyan said domestic avenues for accountability in the Philippines are effectively closed. Citing statements from former Justice secretary and current Ombudsman Jesus Crispin Remulla, he said critical evidence had been erased, leaving victims with no recourse but the ICC.He warned that failure to confirm the charges could embolden Duterte to return to the Philippines as a “conquering hero” and further entrench a culture of impunity. Victims, he said, continue to live in fear due to the pervasive influence of Duterte allies and family members in positions of power, both in the Philippines and among expatriate communities abroad.Next stepsFollowing the opening statements, the prosecution team will present further evidence detailing Duterte’s role in creating and supervising the DDS and exercising authority over national law enforcement. Subsequent sessions will examine the full scope of the evidence, including witness testimonies, official orders, and audiovisual material documenting the killings.The confirmation of charges stage will determine whether there is sufficient evidence for the ICC to formally confirm the allegations against Duterte, potentially setting the stage for trial.Rival demonstratorsRival groups of demonstrators camped outside the court. Patricia Enriquez said it was “a historic moment” for victims of Duterte’s alleged crimes.“It is emotional. It is hopeful. It is also very painful,” the 36-year-old researcher said.“I’m hoping that all the Filipinos and everybody in the world will stand with us, stand with truth, stand with justice and stand with accountability,” she said.Aldo Villarta, a 35-year-old chef, said it was a “slap in the face” for the Philippines that an international court was trying the country’s former leader.“We’ve already suffered so long from colonization,” said Villarta, who also argued that Duterte’s human rights were being infringed by imprisonment.Former presidential chief legal counsel Salvador Panelo said on Monday that he traveled to The Hague primarily as a friend of the former president, offering moral support ahead of the confirmation of charges hearing, and not as a member of the official defense team.In a radio interview, Panelo clarified that he has no formal role in crafting Duterte’s defense, noting that the former president’s legal team had only recently been organized.“For now, I am here as a friend,” Panelo said, explaining that his initial purpose in attending the proceedings was to witness the hearings and, if possible, see Duterte.Duterte’s legal team urged his supporters to remain vigilant and discerning ahead of his ICC confirmation of charges hearing, warning against taking government-aligned media reports at face value.Nicholas Kaufman, Duterte’s lead counsel, said the former president’s Filipino and international legal teams are fully engaged in preparing for the proceedings in The Hague.“Be strong. Watch carefully and don’t believe everything the government’s media tells (sic) you,” Kaufman told Duterte’s supporters in a statement.He described the confirmation stage as a critical point where the ICC assesses whether there is sufficient evidence to proceed to trial — a procedure unique to international criminal tribunals.Kaufman stressed that the defense’s role is not to prove Duterte’s innocence, but to challenge the prosecution’s evidence and argue that there are no substantial grounds to believe the alleged crimes were committed.Duterte’s health and cognitive state remain central to the case. Kaufman said the former president suffers from severe short-term memory loss but retains long-term recollections, and that counsel visits have been regular to guide him through legal strategy.Police on alertThe Philippine National Police (PNP) has placed all of its units under heightened alert in anticipation of possible mass gatherings as the confirmation of charges hearings began.PNP chief Gen. Jose Melencio Nartatez Jr. said the entire police force is monitoring the situation on the ground to ensure the peaceful and orderly conduct of all mass gatherings relating to the former president’s ICC battle.“Our security measures are in place and it is intended to ensure the peaceful conduct of any activity in public places. Regardless of the affiliation of the groups, our personnel will be there to protect their rights and maintain peace and order,” Nartatez said.Nartatez directed regional units to pre-position Civil Disturbance Management teams and ensure medical emergency responders are on standby for possible rallies.The PNP chief also appealed for restraint from both critics and supporters of Duterte. WITH AFP
2026-02-23 16:17:00

Tax compliance drive seen lifting revenues
THE Bureau of Internal Revenue (BIR) is optimistic about revenue collections this year amid intensified efforts to improve tax compliance and expand enforcement, its top official said.“If our taxpayers are compliant and registered, then they will be part of the tax base and we will capture their sales,” BIR Commissioner Charlito Martin Mendoza told reporters on Monday, adding that this would “translate to higher revenues for the government.”He said the year was off to a good start as the BIR collected roughly P358 billion as of end-January, higher than the P355.1 billion recorded a year earlier.Mendoza did not provide an estimate of how much additional revenues could be raised from the tax compliance campaign, but stressed that “the important thing is that the process should be correct.”“Not only the revenues that will be collected, but also our negotiators should be compliant,” he said.The BIR chief claimed that they were making tax compliance “easier for honest taxpayers and harder for violators — combining service excellence, digital coordination, and accountable enforcement to protect every peso of revenue for the Filipino people.”He added that the campaign was part of continuing engagement with taxpayers and ongoing taxpayer education efforts, noting that many had failed to comply simply because they lacked the proper guidance and did not clearly understand the BIR’s regulations.“Even though many of the transactions in the BIR are online, we see the value of occasional face-to-face interaction with our taxpayers,” Mendoza said.The BIR collected a total of P3.105 trillion last year, which he said exceeded the P3.101-trillion emerging collection target — an operational aim separate from the official goal of P3.232 trillion.The result — still an improvement from 2024’s P2.83 trillion — was blamed on the suspension of audit operations late last year in the wake of extortion allegations.The bureau has been tasked to collect P3.579 trillion this year and Mendoza said that anticipated economic growth would boost revenues from income, value-added and excise taxes.Digitalization and monitoring initiatives to prevent leakages are also expected to help boost revenues.“Hopefully, this year, the infrastructure projects of the government will accelerate and that will help to increase the revenue that BIR collects,” Mendoza added.NIÑA MYKA PAULINE ARCEO
2026-02-23 16:17:00

EU rejects higher US tariffs; China wants duties scrapped
BRUSSELS/BEIJING/HONG KONG/SEOUL — The European Commission demanded on Sunday that the United States stick to the terms of an EU-US trade deal reached last year, after the US Supreme Court struck down Donald Trump’s global tariffs and he responded with new levies across the board.The Commission, which negotiates trade policy on behalf of the 27 EU member states, said Washington must provide “full clarity” on the steps it intends to take following the court ruling.After the court struck down Trump’s global tariffs on Friday, the US president announced temporary, across-the-board tariffs of 10 percent, which he then hiked to 15 percent a day later.“The current situation is not conducive to delivering ‘fair, balanced, and mutually beneficial’ transatlantic trade and investment, as agreed to by both sides” in the joint statement setting out the terms of last year’s trade agreement, the commission said. “A deal is a deal.”The comments were far more strongly worded than the commission’s initial response on Friday, which had said only that it was studying the outcome of the Supreme Court decision and keeping in contact with the US administration.Last year’s trade deal set a 15-percent US tariff rate for most EU goods, apart from those covered by other sectoral tariffs such as on steel. It also allowed zero tariffs on some products such as aircraft and spare parts. The EU agreed to remove import duties on many US goods and withdrew a threat to retaliate with higher levies.It is not clear whether Trump’s new 15-percent tariffs supersede the EU-US deal. If they do, the EU’s zero tariff exemptions could disappear. The new tariffs could also be placed on top of pre-existing “most-favored-nation” US duties, which is not the case under the EU-US deal.‘Fighting is harmful’Meanwhile, China on Monday said it was making a “full assessment” of the US Supreme Court’s tariff ruling and has urged Washington to lift “unilateral tariff measures” on its trading partners, warning that fighting between the two countries is “harmful.”“US unilateral tariffs ... violate international trade rules and US domestic law, and are not in the interests of any party,” the Chinese ministry said.“Cooperation between China and the United States is beneficial to both sides, but fighting is harmful,” it added.Trade and tariffs are expected to dominate the agenda for both China and the US ahead of a highly anticipated visit by Trump to China in late March and early April — when he will meet his Chinese counterpart, Xi Jinping.Trump’s planned new levies are grounded in a separate but untested law, known as Section 122, that allows tariffs up to 15 percent but requires congressional approval to extend them after 150 days. No president has previously invoked Section 122, and its use could lead to further legal challenges.“China will continue to pay close attention to this and firmly safeguard its interests,” the Commerce Ministry said.The US court’s ruling invalidated a number of tariffs that the Trump administration had imposed on Asian export powerhouses from China and South Korea to Japan and Taiwan, the world’s largest chipmaker and a key player in tech supply chains.South Korea said it would continue to consult with the US to maintain a “balance of interests” between the two countries, while its industry minister said there was concern among officials across industries, including cars, batteries and chips.“The public and private sector need to work together to secure Korean companies’ export competitiveness and diversify their markets,” Industry Minister Kim Jung-kwan said on Monday.India said it had delayed plans to send a trade delegation to Washington this week to finalize an interim trade deal, chiefly because of fresh tariff uncertainty out of the US, according to a source in its trade ministry.US tariffs on Indian goods were set to be cut to 18 percent, while India agreed to buy US items worth $500 billion over five years, ranging from energy supplies to aircraft and parts, precious metals and technology products.
2026-02-23 16:16:00

Lawmakers say Philippines should rejoin ICC
(UPDATE) SEVEN lawmakers on Monday filed resolutions urging the Philippine government to rejoin the International Criminal Court (ICC).House Resolution (HR) 809 was filed by the Makabayan bloc composed of ACT Teachers Rep. Antonio Tinio, Gabriela Women’s Party Rep. Sarah Elago, and Kabataan Rep. Renee Co.“The House of Representatives, as the duly elected, constitutional voice of the Filipino people, is duty-bound to champion justice, truth, and transparency, and to advance the national interest by aligning the country with international norms of human rights protection,” the resolution read.“Now, therefore, be it resolved, as it is hereby resolved, that the House of Representatives, through this resolution, formally expresses its sense urging for the government of the Republic of the Philippines to take necessary steps toward the re-accession of the Philippines to the Rome Statute, thereby rejoining the International Criminal Court [...],” the resolution said.HR 811, meanwhile, was filed by Akbayan Reps. Perci Cendaña, Chel Diokno, and Dadah Kiram Ismula with Dinagat Islands Rep. Kaka Bag-ao.They want the House, through the resolution, to express “strong support” for the country’s re-accession to the Rome Statute and to urge the country’s president “to initiate the necessary constitutional processes for re-accession, subject to Senate concurrence pursuant to Article VII, Section 21 of the Constitution.” The Rome Statute is the treaty that founded the ICC. Under the 1987 Constitution, no treaty shall be valid and take effect unless two-thirds of the whole Senate concurs.HR 811 said “rejoining the ICC will strengthen the country’s commitment to international justice, reinforce its democratic institutions, and enhance its standing in the international community.”Mamamayang Liberal Rep. Leila de Lima supported rejoining the ICC.“I’m all for it,” de Lima said when asked by Co what she thought of rejoining the Rome Statute. Co asked de Lima after the latter delivered a privilege speech.“I’ve been calling for the Philippine government, the current administration, to consider rejoining the ICC because it’s the only international mechanism of accountability that can be relied upon or depended upon if domestic mechanisms of accountability fail or if the state refuses, or [is] unwilling, or [is] unable to genuinely investigate matters under ICC jurisdiction,” de Lima, a former secretary of the Department of Justice and a former senator, said. The Philippines withdrew from the ICC in 2019.De Lima, explaining the process to rejoin the treaty, said that “the [decision] has to be with the executive. ... The executive has to make a decision whether or not to rejoin and then the decision of the president or the executive will be submitted to the Senate for ratification.”
2026-02-23 16:16:00

P39.8B in disaster-response funds available in 2026 budget, says Libanan
House Minority Leader 4Ps Party-list Rep. Marcelino “Nonoy” Libanan highlighted on Sunday, Feb. 22 the availability of P39.8 billion in fresh funding for the country’s disaster-response and rehabilitation efforts.“Congress allocated P39.8 billion for this year’s Calamity Fund—a 90 percent increase from the P21 billion set aside in 2025,” Libanan said in a statement. He made this revelation even as three of the country’s volcanoes – Mayon, Taal, and Kanlaon – were all exhibiting unrest or ongoing eruptions.Libanan broke down the P39.8-billion Calamity Fund under the 2026 General Appropriations Act (GAA) as follows:•P15.3 billion for the Disaster Rehabilitation and Reconstruction Assistance Program for Local Government Units (LGUs);•P12.5 billion in capital outlays for repair and reconstruction of permanent structures, including pre-disaster operations, rehabilitation, and related activities;•P11 billion in aid, relief, and rehabilitation services to communities affected by calamities, including personnel training and other pre-disaster measures; and•P1 billion in adaptation projects and activities for local governments and community organizations under the People’s Survival Fund.“The disaster-response funds cover natural and human-induced calamities, epidemics as declared by the Department of Health (DOH), crises from armed conflicts, insurgency, terrorism, and other catastrophes,” said the minority leader.Libanan’s announcement coincides with reports from the Region 11 Disaster Risk Reduction and Management Council (DRRMC), which on Feb. 21 confirmed that at least seven people were killed in Mati City, Davao Oriental, and Monkayo, Davao de Oro due to flooding and landslides triggered by heavy rains.A total of 84,208 individuals across 65 barangays in the Davao region were affected by prolonged rainfall caused by a shear line, a boundary in the atmosphere where winds moving in different directions converge, often leading to unsettled weather.Earlier this month, tropical storm Basyang caused flash floods and landslides, killing at least 12 people and affecting 232,550 residents across 517 barangays in Mindanao and the Visayas.The 2025 World Risk Report ranked the Philippines No. 1 out of 193 countries for the fourth consecutive year, due largely to its exposure to natural hazards such as typhoons, flooding, sea-level rise, droughts, earthquakes, tsunamis, and volcanic eruptions.The Philippines sits along the western Pacific typhoon corridor where nearly one-third of the world’s most powerful tropical cyclones develop.The country also straddles the Pacific Ring of Fire, known for frequent earthquakes and volcanic activity.
2026-02-22 06:18:00

UTCPI names Lisza Buscaino-Redulla as president
THE United Transportation Coalition Philippines Inc. (UTCPI) has appointed Lisza Buscaino-Redulla as president, tasking the veteran advocate with unifying the nation’s fragmented transport interests amid a period of rapid modernization.Buscaino-Redulla assumes leadership of a coalition that spans the full spectrum of Philippine transit, from traditional jeepneys and buses to transport network vehicle services or TNVS and emerging mobility cooperatives.In her first address as president, she pledged to prioritize a “cohesive and representative voice” for workers in national policy-making.“Our strength lies in unity, and our progress depends on working hand in hand,” Buscaino-Redulla said.“I carry an unshakeable optimism that together we will build a more empowered, inclusive, and forward-looking transportation community for the Philippines,” she added.The appointment comes at a critical juncture for the sector.As the Department of Transportation or DOTr) pushes for sustainable modernization, Buscaino-Redulla emphasized her readiness to collaborate with the agency under Secretary Giovanni Lopez.UTCPI describes the secretary as a “capable and experienced” partner in accelerating reforms.Joining Buscaino-Redulla is a reconstituted board of directors, including Issei John Manila Goto, Bryant Rhey Manabat and Bon Andaya.Lawyer John Paul Nabua will serve as corporate secretary, providing the legal and governance oversight necessary for the coalition’s institutional initiatives.The new leadership team enters office with a mandate to bridge the gap between traditional operators and modern stakeholders.Under Buscaino-Redulla, UTCPI aims to expand partnerships with civil society and government to ensure that modernization does not come at the cost of driver welfare.
2026-02-22 06:12:09

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia” or the "Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffusphereTM technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the "Common Shares"), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the "Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.000001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$63.2 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering."We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia. "We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.”Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum also acted as co-managers for the Offering.As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 7, 2024, and the Company's existing Canadian short form base shelf prospectus, (the "Base Prospectus") dated February 5, 2024. A preliminary prospectus supplement and a final prospectus supplement (the "Supplement”) relating to and describing the terms of the Offering were filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, from LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com, or from Bloom Burton Securities Inc. at ecm@bloomburton.com, or from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Suite 300, Minneapolis, MN 55401, or by telephone at (612) 334-6300, or by email at prospectus@chlm.com.This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.About Eupraxia Pharmaceuticals Inc.Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffusphereTM, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs.Notice Regarding Forward-looking Statements and InformationThis news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the anticipated use of proceeds from the Offering; expectations around the expansion of the Company’s pipeline, additional development milestones with EP-104GI for eosinophilic esophagitis, and meaningful progress towards commercial readiness; expected capitalization into the first quarter of 2028; and the potential for the Company’s technology to impact the drug delivery process. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.For investor and media inquiries, please contact:James Meikle, Eupraxia Pharmaceuticals Inc.236.330.7084jmeikle@eupraxiapharma.comorKevin Gardner, on behalf of:Eupraxia Pharmaceuticals Inc.617.283.2856kgardner@lifesciadvisors.comSOURCE Eupraxia Pharmaceuticals Inc.
2026-02-20 20:21:04

Inscope Raises $14.5M Series A to Replace Manual Financial Statement Preparation for Accounting Firms and Enterprises
SAN FRANCISCO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Inscope, the AI-powered financial reporting platform built for accounting firms and enterprises, today announced it has raised $14.5 million in Series A funding. The round was led by Norwest, with participation from Storm Ventures, existing investors Better Tomorrow Ventures and Lightspeed Venture Partners, and strategic operators across finance and enterprise software.Over the past 12 months, the company has grown its customer base by more than 5× and increased annual recurring revenue by over 30×, driven by adoption among accounting firms and finance teams handling complex, high-volume reporting.In the past year, Inscope has focused on making its platform enterprise-ready, with investments in security, scalability, and auditability. The company is now onboarding several Top 100 accounting firms that support thousands of client engagements on Inscope, reflecting growing demand for standardized, firm-wide reporting infrastructure.The Last Manual Workflow in Finance Despite decades of investment in financial software, financial statement preparation and review remain largely manual. Accounting teams still rely on disconnected Excel files, static documents, email-driven review cycles, and last-minute changes - leading to rework, version confusion, and avoidable audit risk."Accurate and transparent financial reporting is what allows U.S. capital markets to function,” said Mary Antony, Co-Founder and CEO of Inscope. "But with increasing regulatory scrutiny and a shortage of accounting talent, relying on manual, fragmented workflows puts that trust at risk. Inscope provides the infrastructure teams need to produce high-quality, auditable financial statements at scale.”"Financial reporting breaks down when systems aren’t designed for collaboration and change,” said Kelsey Gootnick, Co-Founder and COO of Inscope. "Inscope replaces brittle, manual handoffs with a system that supports real-world review cycles and last-minute changes without breaking.”Inscope embeds intelligence directly into the financial reporting workflow, helping teams draft, roll forward, review, and validate financial statements while maintaining full audit trails and change control.Built for Both Sides of the AuditUnlike traditional reporting tools designed for a single user group, Inscope serves both enterprises preparing financial statements and the accounting firms that audit them. This shared infrastructure reduces handoffs, improves consistency, and lowers the risk of misstatements.Accounting firms using Inscope report 60% faster preparation cycles, improved consistency, and fewer review iterations late in the process."As an accounting advisory partner, consistency and trust are everything,” said Aric Johnstone, Partner at Williams Marston. "Inscope enables our teams to deliver higher-quality financial statements for our clients faster, with less rework during review.”What's NextSince its seed round, Inscope has expanded its technical leadership with the addition of Jared Tibshraeny as Co-Founder and CTO. AI engineering is led by Ankit Arya, who focuses on building systems that understand the structure and logic of financial statements."Most AI tools in finance operate at the surface level,” said Arya. "We’re building systems that understand how financial statements actually work - how tables roll forward, how disclosures connect, and where inconsistencies hide - while preserving auditability end to end.”With the Series A funding, Inscope plans to continue investing in its engineering and go-to-market teams while expanding support for complex reporting requirements across large organizations."Inscope is tackling a problem every CFO and accounting partner recognizes,” said Sean Jacobsohn, Partner at Norwest. "They’ve built AI that finance professionals trust - which is rare, and hard to earn.”The company has raised $18.8 million in total funding to date, including a $4.3 million seed round led by Lightspeed Venture Partners in 2023.About InscopeInscope is the AI-powered financial reporting platform that helps companies and accounting firms prepare, review, and deliver financial statements with greater accuracy and speed. By automating manual workflows and embedding intelligence directly into the reporting process, Inscope reduces risk, improves consistency, and shortens reporting cycles. Founded in 2023 by Mary Antony and Kelsey Gootnick, Inscope is backed by Norwest Venture Partners, Storm Ventures, Lightspeed Venture Partners, and BTV.CONTACT: Media ContactInscopeMary Antony, CEO and co-foundermary@inscopehq.com
2026-02-20 20:21:00

HUMAIN在xAI与SpaceX历史性合并前注资30亿美元E轮融资
在xAI被SpaceX收购前不久,HUMAIN向其E轮融资注资30亿美元,从而在平台规模扩张与整合的关键节点上占据了有利位置 交易完成后,HUMAIN成为重要少数股东,其持有的xAI股份随后转换为SpaceX股份 这项投资建立在HUMAIN与xAI在沙特阿拉伯500兆瓦人工智能基础设施合作项目基础之上,巩固了HUMAIN作为战略发展合作伙伴以及全球领先的前沿人工智能技术投资者的双重角色 沙特阿拉伯利雅得2026年2月19日 /美通社/ -- 作为一家在全球范围内提供全栈人工智能能力的PIF公司,HUMAIN今日宣布对xAI进行30亿美元的战略投资,参与其E轮融资。 此项交易代表了HUMAIN一次重要的端到端资本部署,反映了其专注于定义行业品类的技术平台的长期投资战略持续取得进展。 HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger 此次投资正值xAI一个极具吸引力的转折点,其后该公司于二月初被SpaceX收购。 xAI先进的人工智能能力与SpaceX的规模、基础设施和以使命为导向的工程能力相结合,打造了一个定位独特的平台,有望实现加速增长、深度技术整合和长期价值创造。 通过此次E轮融资交易,HUMAIN成为xAI的重要少数股东,其持股随后转换为SpaceX的股份。 此次交易为HUMAIN获取长期股权增值收益奠定了坚实基础,体现了其在合并前参与xAI最后一轮融资的战略布局。 HUMAIN首席执行官Tareq Amin表示:“此项投资反映了HUMAIN对变革性人工智能的坚定信念,以及我们将大量资本投入到那些集长期愿景、卓越技术与强大执行力于一身的非凡机遇中的能力。 xAI的发展轨迹,在被SpaceX收购(史上规模最大的科技并购案之一)后更显强劲,这正是我们寻求以雄厚资本支持的那种高影响力平台。” HUMAIN参与E轮融资,巩固了其作为规模化的长期战略投资者的角色,能够支持公司跨越多个发展阶段,同时在四大核心领域提供全栈人工智能能力:下一代数据中心;高性能基础设施与云平台;先进人工智能模型;以及变革性人工智能解决方案。 此次投资基于2025年11月在美国-沙特投资论坛(U.S.-Saudi Investment Forum)上宣布的大规模合作协议。根据该协议,HUMAIN与xAI承诺共同开发超过500兆瓦的下一代人工智能数据中心和计算基础设施,并在沙特阿拉伯部署xAI的Grok模型。 这些举措共同深化了长期合作关系,并将HUMAIN的角色从xAI的战略合作伙伴扩展为其全球领先股东。 展望未来,HUMAIN战略包括寻求在人工智能、前沿技术及重要基础架构领域开展更多的投资。
2026-02-19 10:36:00

Winter Wonders: Agoda's Search Insights Unveil South Korea's Winter Appeal among Inbound Travelers
SEOUL, South Korea, Feb. 18, 2026 /PRNewswire/ -- Despite the ongoing cold winter season, South Korea continues to attract interest from inbound travelers, fueled by a variety of seasonal events and activities available during the winter months. Reflecting this trend, digital travel platform Agoda has revealed the most searched destinations and preferred winter activities among international travelers visiting South Korea. According to Agoda's accommodation search data, Seoul ranked as the top destination among inbound travelers, followed by Jeju, Busan, Incheon, and Sokcho, completing the top five.Seoul's appeal was driven in part by the "Seoul Winter Festa," which features a range of seasonal attractions, such as the "Seoul Light Gwanghwamun," the "Seoul Plaza Ice Skating Rink," "Gwanghwamun Market," and "Seoul Light DDP." According to the Seoul Metropolitan Government, the festival recorded an all-time high of nearly 11 million visitors, including both domestic and inbound travelers, reinforcing Seoul's popularity as a winter destination.Interest from international travelers is also expanding beyond major metropolitan areas. Sokcho, known for its local markets, fresh seafood, sweet and sour chicken, and other culinary delicacies, recorded a 37% year-on-year increase in accommodation searches according to Agoda. This may indicate a growing interest in secondary destinations among inbound travelers beyond the primary travel hubs.When it comes to source markets, Japanese travelers emerged as the top market expressing travel interest to South Korea in the winter season, according to accommodation searches made on Agoda. Taiwan ranked second, followed by China, Hong Kong, and Thailand. Thailand newly entered the top five this year, while China recorded the highest year-on-year growth in travel interest among the top five source markets at 56%, potentially influenced by the visa-free entry policy for Chinese group travelers.When looking at the winter activity preferences, Agoda's activities booking data shows that tickets to major theme parks and tourist attractions in Seoul and Busan ranked highest, such as Lotte World and N Seoul Tower Observatory. In addition, foreigner-exclusive tour passes, such as the Visit Busan Pass, and traditional wellness offerings such as SPA LAND Centum City and Aquafield Jimjilbang Spa & Sauna ranked among the top activities. These findings could point to an increasing preference for convenient all-in-one sightseeing options, alongside opportunities for rest and recovery during winter vacations.Jay Lee, Regional Director, North Asia at Agoda, said, "South Korea offers an array of winter experiences, ranging from scenic snowscapes and delicious winter snacks to traditional jjimjilbangs that provide warmth during the colder months. Agoda's data reflects a growing demand for experiences that integrate entertainment, convenience, and relaxation. In response, Agoda remains committed to providing competitive deals and a broad selection of accommodations, flights, and activities for both inbound and domestic travelers this winter season and beyond."Travelers planning trips within South Korea are encouraged to check out Agoda's great value deals on over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities and experiences that are available on the platform. The latest deals are available in the Agoda app or on agoda.com/deals.
2026-02-18 00:37:08

Substandard government projects to become a crime under Sandro Marcos bill
If House Majority Leader Ilocos Norte 1st district Rep. Sandro Marcos would have his way, he would make substandard government projects a punishable crime.This is provided for under Rep. Marcos\' HB No.2811, also known as the proposed "Criminalizing Negligent Contractors Act"."Any contractor, subcontractor, or person acting on their behalf who, through gross negligence, causes the quality of work on a government project to fall below the standards prescribed in the contract, applicable laws, or technical specifications, shall be held criminally liable," read the presidential son\'s bill.In what could be viewed as a response to President Marcos\' State of the Nation Addess (SONA) last July 28, 2025, wherein he blasted anomalous flood control projects, Rep. Marcos filed the bill just three days later."The State shall promote the integrity of government projects by ensuring the optimum quality with which they are undertaken. As such, it shall outlaw the negligence of contractors and subcontractors of government projects," it read."Govemnment infrastructure projects must be implemented with strict adherence to standards of safety and quality, as prescribed by law and by competent authorities. These standards are not mere formalities, they are essential safeguards of public welfare, fiscal responsibility, and the long-term utility of state investments," HB No.2811 further stated.Section 4 of the bill reads: "Any person, including contractors, subcontractors, corporate officers, government employees, or juridical entity found guilty of gross negligence under this Act, whether as principal, accomplice, or accessory, shall suffer the penalty of imprisonment of not less than six (6) years but not more than twelve (12) years; or a fine of not less than Ten Million Pesos (P10,000,000.00); or both at the discretion of the court."The court shall also automatically impose, alongside the principal penalty, the accessory penalty of perpetual disqualification from holding public office and from participating, directly or indirectly, in any government procurement or project."Gross negligence" under HB No.2811 includes, but is not limited to, acts or omissions that result in material deviation from contract specifications or approved plans, compromise of structural integrity or public safety, or use of substandard materials.In filing the measure, Rep. Marcos argued that the Constitution "demands accountability not only for acts of corruption but also for gross negligence, which can result in wasteful spending, substandard outputs, and threats to public safety"."Further, this bill strengthens the accountability framework across the procurement and project implementation, and protects the Filipino people from the grave consequences of negligent execution of government-funded projects," added the second-term congressman.
2026-02-18 00:25:00

CECO Environmental to Release Fourth Quarter Earnings and Host Conference Call on February 24
ADDISON, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that it will report its fourth quarter 2025 financial results on February 24, 2026, premarket. The Company will also host its earnings call starting at 8:30 a.m. Eastern Time (7:30 a.m. CT). The Company’s financial results and presentation will be posted on its website at www.cecoenviro.com.The details for the webcast are:When: Tuesday, February 24 at 8:30 a.m. Eastern TimeWhere: https://edge.media-server.com/mmc/p/esi9fzv8How: Live over the internet - Simply log on to the web at the address aboveRegister to receive the dial-in info and a unique pin: https://register-conf.media-server.com/register/BIef187ad40fff4b6eaf15a109421408aeA replay of the conference call will be available on the Company's website shortly after the live webcast has concluded.ABOUT CECO ENVIRONMENTALCECO Environmental is a leading environmentally focused, diversified industrial company, serving a broad landscape of industrial air, industrial water, and energy transition markets globally through its key business segments: Engineered Systems and Industrial Process Solutions. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean, and more efficient solutions that help protect people, the environment and industrial equipment. In regions around the world, CECO works to improve air quality, optimize the energy value chain, and provide custom solutions for applications in power generation, petrochemical processing, refining, midstream gas transport and treatment, electric vehicle and battery production, metals and mineral processing, polysilicon production, battery recycling, beverage can production, and produced and oily water/wastewater treatment along with a wide range of other industrial applications. CECO is listed on Nasdaq under the ticker symbol "CECO." Incorporated in 1966, CECO’s global headquarters is in Addison, Texas. For more information, please visit www.cecoenviro.com.CECO Environmental Investor Contact:Marcio PintoVice President - Financial Planning & Investor Relations888-990-6670Investor.Relations@OneCECO.com Steven Hooser and Jean Marie YoungThree Part Advisors214-872-2710Investor.Relations@OneCECO.comCECO Environmental Media and Communication Contact:Rachael Gallodoro214-350-2992ceco-communications@OneCECO.com
2026-02-18 00:23:27

Aquino pushes for more consultation on DepEd’s proposed trimestral system
Senator Paolo “Bam” Aquino IV on Sunday, February 15 called for a comprehensive discussion on the Department of Education’s (DepEd) proposed transition to a trimester system.**media[79464]**This after DepEd Secretary Sonny Angara announced plans to pursue the proposal which is aimed at allowing longer and more flexible instructional periods, reducing teacher workload and promoting higher-quality instruction by improving organization of academic year.But Aquino, who heads the Senate Committee on Basic Education, urged the agency to implement dialogues to check the feasibility of the proposal.“Before the DepEd implements the trimester system, it is important that it undergo extensive consultation,” Aquino said in a statement.“We will ensure that there is a Senate Hearing on this reform, to review and discuss it,” he further said.Aquino said the panel supports proposals and reforms that would address the learning gap and help teachers, who are currently overloaded with non-teaching tasks. “While we recognize the need for extensive reform, let us ensure that it is not done hastily and that it goes through proper consultation,” he said. Earlier, Angara said the proposed trimestral system would help create longer, uninterrupted periods of learning, better pacing of lessons and lower administrative burden for teachers, citing the findings from the Second Congressional Commission on Education or EDCOM 2.“In this way, we are safeguarding the quality of education,” Angara said.
2026-02-15 04:53:00

Beko Announces CEO Transition; Strategic Continuity and Sustainability to Remain Core Priorities
ISTANBUL, Feb. 14, 2026 /PRNewswire/ -- Beko (Arçelik A.Ş.) (Bloomberg: ARCLK TI) today announced that Hakan Bulgurlu will step down as Chief Executive Officer as of the company's next General Assembly, concluding an 11-year tenure during which he led the company through a period of significant international expansion and sustainability transformation. He will be succeeded by Can Dinçer, currently General Manager of Arçelik Türkiye and Chief Commercial Officer for South Asia and Türkiye.Hakan Bulgurlu Bulgurlu, who has spent 32 years within the Koç Group, will remain on the Board of Beko B.V. through June 2026 to ensure a seamless transition. He will also complete his term as President of APPLiA, the European home appliance association.This leadership transition follows a structured succession plan designed to ensure strategic continuity and build on Beko's position as a global appliance manufacturer.New Leadership with Deep Operational ExperienceCan Dinçer has held multiple leadership roles across Beko's international operations over a 33-year career spanning Türkiye, Europe, the Americas and Asia-Pacific. Throughout his tenure, Dinçer has played a pivotal role in strengthening the company's market position in Türkiye and delivering consistent commercial performance growth. He has also been instrumental in sustaining stable performance across the South Asia region, reinforcing execution discipline and customer-focused strategies in diverse and competitive markets.A Legacy of International Expansion and Sustainability LeadershipDuring Bulgurlu's tenure, Beko expanded its global footprint and strengthened its competitive position in Europe and beyond through acquisitions, strategic partnerships and integrations across multiple regions, including Singer in Bangladesh, Dawlance in Pakistan, Voltas Beko in India and Arçelik-Hitachi in Asia-Pacific. The creation of Beko Europe and the integration of Whirlpool's MENA operations further reinforced the company's scale and market presence.During this period, sustainability also became more closely integrated into the company's long-term strategy, with climate targets aligned to international standards and operational improvements across its manufacturing footprint. Bulgurlu championed the view that climate responsibility and commercial performance are mutually reinforcing.
2026-02-13 18:39:19

CIB Marine Bancshares, Inc. Announces Expansion of Board of Directors and Appointment of New Director
Annual Meeting of Shareholders Set for April 30, 2026BROOKFIELD, Wis., Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CIB Marine Bancshares, Inc. (the "Company” or "CIB Marine”) (OTCQX: CIBH), the parent company of CIBM Bank, has approved an expansion of the Board from nine to ten members. The newly created seat has been filled with the appointment of Mr. Dennis Pollack, effective February 16, 2026. Mr. Pollack will also join the Board of Directors of the Company’s wholly owned subsidiary, CIBM Bank.Mr. Pollack will serve in the director class scheduled to stand for re‐election at the Company’s 2028 Annual Meeting of Shareholders.The Company also announced that its 2026 Annual Meeting of Shareholders will be held virtually on April 30, 2026. Standing for election at the 2026 Annual Meeting will be Directors Gina M. Cocking, Mark A. Elste, and Steven C. Palmitier."We are very pleased to welcome Mr. Pollack to our Boards,” said Mark Elste, Chairman of CIB Marine. "He brings extensive leadership experience within financial institutions and a deep understanding of the banking industry. His banking expertise, knowledge of the broader markets, and skills in strategic planning and implementation will further strengthen our commitment to creating value for our shareholders and we look forward to his contributions.”Mr. Pollack brings significant board and executive management experience to CIB Marine. His background includes executive roles at Sony Corporation of America, the Connecticut Bank of Commerce, the Savings Bank of Rockland County, and Paulson & Company. He has served on the boards of several depository institutions, including TF Financial Corp., SI Financial Group, Prudential Bancorp, and Provident Bancorp. CIB Marine Bancshares, Inc. is the holding company for CIBM Bank, which operates nine banking offices and has mortgage loan officers and/or offices in six states. More information on the Company is available at www.cibmarine.com, including recent shareholder letters, links to regulatory financial reports, and audited financial statements.FORWARD-LOOKING STATEMENTSCIB Marine has made statements in this release that may constitute "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. CIB Marine intends these forward-looking statements to be subject to the safe harbor created thereby and is including this statement to avail itself of the safe harbor. Forward-looking statements are identified generally by statements containing words and phrases such as "may,” "project,” "are confident,” "should be,” "intend,” "predict,” "believe,” "plan,” "expect,” "estimate,” "anticipate” and similar expressions. These forward-looking statements reflect CIB Marine’s current views with respect to future events and financial performance that are subject to many uncertainties and factors relating to CIB Marine’s operations and the business environment, which could change at any time.There are inherent difficulties in predicting factors that may affect the accuracy of forward-looking statements. Stockholders should note that many factors, some of which are discussed elsewhere in this release and in the documents that are incorporated by reference, could affect the future financial results of CIB Marine and could cause those results to differ materially from those expressed in forward-looking statements contained or incorporated by reference in this document. These factors, many of which are beyond CIB Marine’s control, include but are not limited to:operating, legal, execution, credit, market, security (including cyber), and regulatory risks;economic, political, and competitive forces affecting CIB Marine’s banking business;the impact on net interest income and securities values from changes in monetary policy and general economic and political conditions; andthe risk that CIB Marine’s analyses of these risks and forces could be incorrect and/or that the strategies developed to address them could be unsuccessful.These factors should be considered in evaluating the forward-looking statements, and undue reliance should not be placed on such statements. Forward-looking statements speak only as of the date they are made. CIB Marine undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are subject to significant risks and uncertainties and CIB Marine’s actual results may differ materially from the results discussed in forward-looking statements.FOR INFORMATION CONTACT:J. Brian Chaffin, President & CEO(217) 355-0900brian.chaffin@cibmbank.com
2026-02-13 18:36:41

Proem Acquisition Corp I Announces Closing of $130 Million Initial Public Offering
Dallas, Texas, United States, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Proem Acquisition Corp I (the "Company”) announced the closing of its initial public offering of 13,000,000 units at a price of $10.00 per unit on February 13, 2026. Total gross proceeds from the offering were $130,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company.The units began trading on the Nasdaq Global Market ("NASDAQ”) under the ticker symbol "PAACU” on February 12, 2026. Each unit consists of one ordinary share of the Company and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the ordinary shares and the warrants are expected to be traded on NASDAQ under the symbols "PAAC” and "PAACW,” respectively.The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company may pursue an initial business combination in any business or industry.Clear Street LLC acted as lead book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 1,950,000 additional units at the initial public offering price to cover over-allotments, if any.A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the "SEC”) on February 11, 2026. The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Clear Street LLC, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, by email at ecm@clearstreet.io.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Proem Acquisition Corp IProem Acquisition Corp I is a blank check company newly incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. The Company’s management team is led by Imran Khan, the Chief Executive Officer and Chairman of the Board, and Greg Pearson, the Chief Financial Officer. In addition, the Board includes John Wu, David Eckstein, Amarnath Thombre, and Andrey Kazakov.Forward-Looking StatementsThis press release contains statements that constitute "forward-looking statements,” including with respect to the Company’s initial public offering ("IPO”) including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Proem Acquisition Corp I, including those set forth in the Risk Factors section of Proem Acquisition Corp I’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Proem Acquisition Corp I undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.Contacts:Greg PearsonChief Financial Officer(214) 706-9344
2026-02-13 18:36:40

Chemed Corporation Board of Directors Authorizes an Additional $300 Million for Stock Repurchase and Declares Quarterly Dividend of 60 Cents
CINCINNATI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed’s existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.The Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company’s capital stock, payable on March 13, 2026, to shareholders of record as of February 23, 2026. This is equal to the dividend paid in December 2025. This represents the 219th consecutive quarterly dividend paid by Chemed in its 54 years as a public company.Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.CONTACT: Michael D. Witzeman(513) 762-6714
2026-02-13 18:36:37

Regent Hong Kong Awarded Coveted Forbes Travel Guide Five-star Rating For 2026
HONG KONG, Feb. 12, 2026 /PRNewswire/ -- Regent Hong Kong is honoured to be recognized as a Forbes Travel Guide Five Star Hotel in the newly unveiled 2026 Star Rating list. This prestigious distinction reaffirms our place among the world's most exceptional luxury destinations and celebrates our unwavering dedication to quietly attentive, bespoke, and intuitive service, as well as extraordinary culinary excellence across our acclaimed Dining Destination. Perched at the edge of Victoria Harbour, Regent Hong Kong is a sanctuary of timeless elegance and contemporary refinement. "We are deeply honoured to be recognized by Forbes Travel Guide with a Five-Star award, which marks an important milestone for Regent Hong Kong," said Michel Chertouh, Managing Director of Regent Hong Kong. "This recognition is both a celebration of our dedicated team and a vote of confidence in Hong Kong as a world-class tourism and hospitality destination." Perched at the edge of Victoria Harbour, Regent Hong Kong is a sanctuary of timeless elegance and contemporary refinement. Reimagined by renowned designer Chi Wing Lo, the hotel's interiors reveal an artful interplay of understated luxury and meticulous craftsmanship, balancing sweeping cinematic views of Victoria Harbour and the iconic Hong Kong skyline with intimate, thoughtfully detailed spaces that invite calm, reflection, and connection. At the heart of the experience, Regent Experience Agents curate highly personalized journeys that unfold with effortless grace – from epicurean explorations and bespoke city excursions to quietly exquisite moments framed by the harbour's shimmering waters. Throughout the hotel, guests discover Personal Havens: tranquil settings conceived for rest, restoration, and meaningful connection, whether reclining on a windowfront daybed with a cup of tea or immersing in an Oasis Bathroom bathtub overlooking the harbour, every detail is shaped by tranquility, privacy, and a deep sense of care. "Forbes Travel Guide's Star Award winners exemplify excellence in hospitality," said Amanda Frasier, President of Standards & Ratings for Forbes Travel Guide. "This year's list reflects the changing landscape of luxury with properties setting the standard for authentic experiences while offering unparalleled amenities, enhanced well-being and delivering unforgettable moments. We are thrilled to recognize their dedication to creating truly world-class travel options for today's discerning guest." Room reservations are available via our hotel's website https://hongkong.regenthotels.com/ or via the IHG One Rewards App and WeChat Mini-programme. For more information or to make reservations, please contact us at +852 2313 2333 or email reservations.regenthk@ihg.com. A variety of high-resolution images: https://flic.kr/s/aHBqjAqESF
2026-02-12 09:00:00

Weibo Corporation to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 18, 2026
BEIJING, Feb. 12, 2026 /PRNewswire/ -- Weibo Corporation (Nasdaq: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the fourth quarter and fiscal year 2025 before the U.S. market opens on Wednesday, March 18, 2026. Following the announcement, Weibo's management team will host a conference call from 7 AM – 8 AM Eastern Time on March 18, 2026 (or 7 PM – 8 PM Beijing Time on March 18, 2026) to present an overview of the Company's financial performance and business operations. Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering. Participants Registration Link: https://register-conf.media-server.com/register/BI9a9688ac375946edb8d4042347b0d850 Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com. About Weibo Corporation Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream. Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a "mobile first" philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness Contact:Investor RelationsWeibo CorporationPhone: +86 10 5898-3336Email: ir@staff.weibo.com
2026-02-12 09:00:00

IFS Asset Management recognised as Singapore's Fund Launch of the Year in Asia Asset Management Best of the Best Awards 2026
SINGAPORE, Feb. 12, 2026 /PRNewswire/ -- IFS Asset Management ("IFSAM"), a licensed fund management company that is a subsidiary of IFS Capital Limited and part of the PhillipCapital Group, has been awarded Singapore's Fund Launch of the Year at the Asia Asset Management Best of the Best Awards 2026 ("AAM Awards"), recognising the successful launch and market impact of the IFSAM Private Credit Income Fund ("IPCIF").The AAM Awards celebrate exceptional innovation, performance, and leadership across the Asia-Pacific financial sector. The Singapore's Fund Launch of the Year award recognises the most successful fund launch in Singapore, based on execution quality, innovation, and measurable market impact. IFSAM was selected for its disciplined and differentiated approach to launching a scalable private credit solution aligned with evolving investor needs.The IFSAM Private Credit Income Fund was introduced through a coordinated launch strategy encompassing product design, investor education, distribution readiness, and operational scalability. The fund achieved strong early adoption, reflecting investor demand for income-oriented strategies. A key differentiator behind the award was the fund's innovative structure, which addressed a longstanding gap in Singapore's private credit market.The fund is among the first semi-liquid, open-ended private credit funds in Singapore designed for wealth distribution channels, bridging the gap between illiquid close-ended private credit funds and daily-liquidity fixed income products. This investor-centric design broadened investor access to private credit while maintaining a focus on senior secured, asset-backed lending and prudent risk management.IFSAM's strategy is centred on the opportunity in Asia's underpenetrated private credit market, focusing on senior secured, real estate-backed lending to address the funding gap for creditworthy SMEs. By embedding liquidity design, governance, and scalability from inception, the strategy sets a new benchmark for how private credit funds can be structured for resilience within Singapore's private markets landscape.Backed by IFS Capital's nearly four decades of credit experience, IFSAM combines institutional-grade risk management with deep local market expertise. The recognition reflects the firm's ability to design and deliver private credit strategies that are resilient, well structured, and relevant across market cycles."This accolade affirms not only the strength of IFSAM's flagship private credit strategy, but also our broader commitment to building high-quality, income-oriented private credit solutions designed to perform across market cycles," said Randy Sim, Group CEO IFS Capital."From the outset, the strategy was designed with structure, discipline, and scalability at its core," said Charis Liau, Chief Investment Officer of IFS Asset Management. "This recognition reflects our focus on building private credit solutions that are thoughtfully structured, resilient across market cycles, and aligned with the evolving needs of investors."About IFS Capital LimitedIFS Capital Limited is a specialist financial institution providing private credit origination, insurance, and asset management services to SMEs, consumers, and investors across Asia. We operate through offices in Singapore, Thailand, Malaysia, Indonesia, and Hong Kong (SAR). Incorporated in Singapore in 1987 and listed on the Mainboard of the Singapore Exchange since 1993, IFS Capital is part of the PhillipCapital Group.For more information, visit: www.ifscapital.com.sgAbout IFS Asset ManagementIFS Asset Management (IFSAM) is a Singapore-based fund management company licensed and regulated by the Monetary Authority of Singapore. IFSAM, a subsidiary of IFS Capital Limited, specialises in private credit investments with a focus on asset-backed lending to SMEs in Singapore. With a commitment to disciplined investing and long-term partnerships, the firm combines deep local knowledge with institutional expertise to generate resilient risk-adjusted returns for its investors. IFSAM serves only Accredited Investors and Institutional Investors.For more information, visit www.ifsam.com.sg, or contact info@ifsam.com.sgMedia Contact: IFSCapital@cognitomedia.com
2026-02-12 08:50:24

BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution. SUZHOU, China, Feb. 9, 2026 /PRNewswire/ -- BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group ("Kanghong Pharmaceutical"), recognizing BioDlink's critical contribution to the successful clinical approval of KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia's Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025. As Kanghong Pharmaceutical's CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation, and formulation research. Efficient Execution of a Complex First-in-Class Program KH815 required advanced process design and analytical control, including precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization. Leveraging its expertise in complex ADC development, BioDlink delivered a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines. Despite the complexity of conjugation process development and analytical characterization, BioDlink applied strong technical expertise to define and lock robust process and analytical strategies, enabling successful scale-up and batch release. Through continuous process optimization, development, manufacturing, and regulatory submission activities were completed 1.5 months ahead of plan, exceeding client expectations and demonstrating strong execution capability, which earned high recognition from Kanghong Pharmaceutical for BioDlink's technical expertise and service excellence. Advancing Innovation in ADC Development The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink remains committed to providing end-to-end CDMO services to global partners, accelerating the development of complex biologics from early development through commercialization. About Kanghong PharmaceuticalKanghong is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, neuropsychiatric and others. Kanghong is devoted to the lives of patients through high quality, innovation and responsibility. Since its establishment, the company keeps researching, producing, and commercializing safer and more efficient drugs for pressing unmet medical needs. The company's purpose is to fundamentally improve patients' physical ability and social medical efficacy by using innovative science and breakthrough treatments to achieve progress in human health. About BioDlinkBioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing. With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs. The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivian. Guided by the philosophy of "Quality First, Innovation Driven, Success Together", BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: https://biodlink.com/
2026-02-09 13:00:00

DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway
HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ -- Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as a Class 1.2 innovative vaccine from China's National Medical Products Administration (NMPA). As the first domestically self-developed nasal spray influenza vaccine in China to advance into clinical trial, DIFF-flu leverages a pioneering M2 gene–modified attenuation technology, protected by multiple international invention patents. This achievement underscores DIFF Biotech's leading capabilities in respiratory infectious disease prevention and establishes an important foundation for future industrialization. Dr. Jiasheng Song, Chief Executive Officer of DIFF Biotech, commented: "DIFF-flu's clinical approval marks a major milestone for DIFF Biotech and a meaningful achievement for independent innovation in respiratory infectious disease prevention. As a next-generation attenuation platform, DIFF-flu is designed to achieve an optimal balance between immunogenicity and safety—an advance that holds significant potential for improving influenza protection. We believe this progress will help expand access to safer, more effective influenza prevention, particularly for older adults and other vulnerable populations. DIFF Biotech will continue to drive next-generation vaccine innovation to strengthen public health and contribute to global biomedical progress." A New Attenuation Strategy: Replication Restriction for Enhanced Safety DIFF-flu is developed using an innovative M2 gene–modification strategy that produces a replication-restricted vaccine strain. This approach achieves a deliberate balance between robust attenuation and strong immunogenicity—generating a potent immune response while maintaining an exceptional safety profile. In essence, the technology places a "safety harness" on the virus to prevent uncontrolled replication. Existing nasal spray influenza vaccines on the market rely on cold-adapted attenuation, allowing the vaccine virus to replicate efficiently only at lower temperatures such as those in the nasal cavity but limiting replication in the warmer lower respiratory system and lungs. Because these strains can still replicate in nasal mucosa and cause mild viral shedding, they are generally not recommended for older adults or immunocompromised individuals. Preclinical data indicate that DIFF-flu offers a differentiated safety profile, with negligible viral shedding, and significantly reduced viral loads in respiratory tissues, suggesting the potential to extend nasal spray vaccine eligibility to older adults and other underserved groups. Notably, preclinical data show that DIFF-flu confers 100% protection against epidemic strains circulating more than 50 years ago, while also eliciting strong immunity against contemporary variants. Market Landscape: At-Home Use Policies Unlock Global Opportunities The global influenza vaccine market is undergoing a period of structural evolution. While injectable vaccines remain the predominant format, they continue to face long-standing challenges such as suboptimal uptake and limited ability to curb viral transmission. Nasal spray vaccines—which induce mucosal immunity directly at the site of viral entry—represent an increasingly important direction for influenza prevention. In September 2024, the U.S. FDA granted authorization for at-home administration of a related nasal spray influenza vaccine, paving the way for direct-to-consumer (DTC) distribution models. This regulatory milestone significantly improves convenience and accessibility for the public and creates favorable conditions for DIFF-flu's future global introduction. Global Influenza Burden Underscores the Need to Strengthen Herd Immunity According to the World Health Organization (WHO), seasonal influenza infects up to 1 billion people each year, causing 3–5 million severe cases and 290,000–650,000 respiratory deaths globally. Older adults account for the majority of influenza-related deaths and face heightened risks of complications such as pneumonia, myocarditis, encephalitis, and acute cardiorespiratory failure. Studies show that influenza vaccination can reduce hospitalization risk by 40–60%, making improved vaccine coverage especially critical for aging and medically vulnerable populations. Despite this, vaccination rates remain low in many parts of the world. In China, influenza vaccination coverage is approximately 3.8%, far below mature markets such as the United States (around 49.3%). Increasing vaccination uptake is essential to protect high-risk groups and strengthen community-level immunity. About DIFF Biotech Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biotechnology company specializing in its proprietary Viraltech Architect Platform. Leveraging this platform, the company has built an integrated, end-to-end capability for the development of differentiated biologics. DIFF Biotech has filed over 70 domestic and international invention patents, including more than 10 PCT applications, and has received multiple honors such as the 23rd China Excellent Patent Award, "High-tech Enterprise" and "Quasi-Unicorn" enterprise. The company's R&D efforts span mucosal vaccines, antiviral drugs, oncolytic viruses, and gene therapy products. Its vaccine pipeline—powered by proprietary attenuation technologies—effectively establishes the body's first line of defense at the mucosal barrier, offering clear competitive differentiation. In the oncolytic virus and gene therapy domains, DIFF Biotech has built distinctive capabilities in vector targeting, controllable replication, and high-efficiency gene delivery, enabling the development of advanced, next-generation biologics. For more information, please visit https://en.diff-biotech.com/. E-mail: BD@diff-biotech.com
2026-02-09 13:00:00

'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinary life of its founder, Desh Bandhu Gupta. Together, the three journeys illuminate how a country once completely dependent on imported medicines became the world's pharmacy. The book shares how an individual's life, shaped early by adversity, growing up without privilege or patronage, unpredictably nurtured hunger and drive, to navigate an unforgiving state, blend national health priorities and global standards, to build a multibillion-dollar enterprise whose medicines reach patients in over 120 countries.(L to R) - Dilip Shanghvi, Sun Pharma; Dr. Yusuf Hamied, Cipla; G.V. Prasad, Dr. Reddy’s; Prof. M. M. Sharma, Ex-(UDCT) ICT; Vinita Gupta, Lupin; Moderator, Manish Sabharwal.Made in India shows the distance travelled by a village boy from Rajasthan, who went on to become a teacher, professor and pharmaceutical employee, before founding a company worth $10 billion. It is the story of how an unlikely entrepreneur, given his role models, fought the system and left teaching and pharma jobs, going on to build a successful company, giving wings to a world-class industry and became a business icon for a nation.Written with candor by TeamLease Services co-founder Manish Sabharwal and journalist Sundeep Khanna, the book confronts failures, financial crises, and the personal toll of leadership, alongside achievement and success, in the building of one of the world's biggest generics firms. This is a riveting portrait of entrepreneurship without mythmaking - of how institutions are built slowly, tested severely and rebuilt with resolve. Made in India weaves vivid anecdotes tracing Desh Bandhu Gupta's transformation from a humble professor to a pharma titan, finding his true calling in tending to the unmet needs of people. It issues a powerful call to future leaders, showcasing his journey of visionary entrepreneurship: rising from setbacks with raw grit and unshakeable conviction. Made in India also spotlights Desh Bandhu Gupta's wife Manju Gupta's pivotal role amid the trials and triumphs of building Lupin. Together, the couple also built community service and rural support programs, even as Lupin and India became a reliable global supplier of pharmaceuticals.India has today become the world's pharmacy: Nearly half of the 400 billion pills Americans consume every year are made in India, as are 60 per cent of the world's vaccines. Of the 700 US Food and Drug Administration-approved factories that sell medicines in the US, a third are located in India. The co-creators of Indian pharma - Dr. Yusuf Hamied (Cipla), Anji Reddy (Dr. Reddy's), Parvinder Singh (Ranbaxy), Dilip Shanghvi (Sun), Ramanbhai Patel (Zydus-Cadila), Habil Khorakiwala (Wockhardt) and DBG (Lupin) - matter more to India than their companies' revenues, exports or profits because they saw something no one else did. Together, they raised India's soft and hard power, demolished the myth that multinationals possess unfair advantages over Indian companies, and ended pessimism about India's ability to export goods, making pharma India's biggest manufacturing success. Together, they showed the world that a developing nation can dominate a complex industry when brilliant entrepreneurs meet smart policy. Together, they made India 'Pharmacy to the world'.Made in India came alive during the launch as the authors, and the publisher shared their journeys, followed by a rich and engaging panel discussion on 'Past and Future of Indian Pharma' with pharma leaders Dilip Shanghvi, Sun Pharma, Dr. Yusuf Hamied, Cipla, G.V. Prasad, Dr. Reddy's, Vinita Gupta, Lupin, and Prof. M. M. Sharma, Ex-(UDCT) ICT. The panel discussed insights on leadership, nation-building, and the Indian pharma industry's crucial role in making healthcare affordable and accessible globally. Praise for the book:Dilip Sanghvi of Sun Pharma said, "DBG was a visionary whose heart beat for India and for Indian patients. His relentless focus on excellence defined his personality. He was a remarkable role model for all of us and one of the true architects who helped shape India's journey to becoming the pharmacy to the world".Yusuf Hamied of Cipla said, "DBG built Lupin from extremely modest beginnings, guided by determination and a deep commitment to serving patients. DBG's life story is not only inspiring, but also a reminder of how one individuals purpose can make healthcare accessible and affordable across the world".Made in India is a book for everyone thinking about India's place in the world, seeking role models of a world leading industry from India, entrepreneurs and business people looking for inspiration about building a valuable company, and finally, India's young and their parents, aiming to build ambition, exploration and determination. About LupinLupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Lupin Human Welfare and Research Foundation has impacted more than 2.02 million beneficiaries across 5400 villages in 26 districts, spread across eight states in India.To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin (L to R) - Author Sundeep Khanna; Chiki Sarkar, Juggernaut Books;Manju D Gupta, Lupin;Dilip Shanghvi, Sun Pharma; Vinita Gupta, Lupin; Dr. Yusuf Hamied, Cipla; Prof. M. M. Sharma, Ex-(UDCT) ICT; G.V. Prasad, Dr. Reddy’s;Nilesh Gupta, Lupin; Author Manish Sabharwal.
2026-02-09 12:53:59

The consumer-friendly Energy Star program survived Trump. What about other efficiency efforts?
Energy Star, the program that helps guide consumers to more energy-efficient appliances and electronics, has survived the Trump administration\'s plans to cut it.The program received sufficient support in Congress that it was included in budget legislation signed this week by President Donald Trump.Environmentalists and advocates called it good news for consumers and the planet, but raised concerns over how the program will be administered under a shrunken Environmental Protection Agency.But Energy Star is not the only energy efficiency program targeted by Trump.Here\'s what to know about the outlook for that program and others.What\'s Trump got against energy efficiency?Trump has regularly said efficiency standards for household items and appliances — many strengthened under predecessor Joe Biden\'s administration — rob consumers of choice and add unnecessary costs.His first executive order upon returning to office last year outlined a vision to "unleash American energy." In it, he emphasized safeguarding "the American people\'s freedom to choose" everything from light bulbs to gas stoves to water heaters and shower heads.At the same time Trump has targeted efficiency, he\'s also sought to block renewable energy development such as wind and solar and boosted fossil fuels that contribute to warming, including gas, oil and coal.What happened with Energy Star?Energy Star is a voluntary, decades-old EPA-run program that informs consumers about how efficient home appliances and electronics are, including dishwashers, washing machines and more. The idea is to simultaneously reduce emissions and save consumers money on their energy bills.The Department of Energy develops product testing procedures for Energy Star, while the EPA sets performance levels and ensures the certification label is reliable for consumers. It also applies to new homes, commercial buildings and plants.EPA says the program has saved 4 billion metric tonnes (4.41 billion tons) of planet-warming greenhouse gas emissions since launching in 1992, and can save households an average of $450 annually.Last May, EPA drafted plans to eliminate Energy Star as part of a broader agency reorganization that targeted air pollution regulation efforts and other critical environmental functions. The agency said the reorganization would deliver "organizational improvements to the personnel structure" to benefit the American people.Many groups advocated against the potential closure of the program, citing its benefits to consumers.The legislation Trump signed this week allocated $33 million for the program, slightly more than 2024\'s $32.1 million, according to the Congressional Research Service, but it continues the general trend of declining funding for the program over the past decade. The Association of Home Appliance Manufacturers, among many industry groups to advocate for keeping the program in letters sent to Congress, said it was "very pleased" to see the funding continue.Some concerns remainExperts say uncertainty around the program likely didn\'t impact consumers much over the past year. They note that manufacturers can\'t change their product lines overnight.Amanda Smith, a senior scientist at climate research organization Project Drawdown, said the uncertainty may have had a bigger effect on EPA\'s ability to administer the program. She was among experts wondering how staffing cuts may affect EPA\'s work.EPA spokesperson Brigit Hirsch didn\'t address a question about that, saying in a statement only that EPA Administrator Lee Zeldin "will follow the law as enacted by Congress."What other energy efficiency rules are still in limbo?The Department of Energy has proposed rolling back, weakening or revoking 17 other minimum efficiency standards for energy and water conservation as part of 47 broader deregulatory actions. Those are standards that must be met for the products to be sold legally.That includes air cleaners, ovens, dehumidifiers, portable air conditioners, washers, dishwashers, faucets and many more items that have been in place and updated over the years."These are standards that are quietly saving people money on their utility bills year after year in a way that most consumers never notice," said Andrew deLaski, executive director of the Appliance Standards Awareness Project. "The striking thing is that consumers have a huge array of choices in appliances in the market today. Repealing these standards would simply increase cost. It just doesn\'t make sense."Changing efficiency measures also drives up energy demand at a time when utilities are already challenged to meet the growing needs of data centers, electrification and more.While Congress has supported Energy Star and these separate appliance standards, it also has advanced legislation that would give the president new powers to roll back rules.Manufacturers are likely to continue making efficient consumer appliances, but weakened rules could negatively impact the U.S. marketplace."The problem for U.S. manufacturers is that overseas competitors making inefficient products elsewhere could now flood the U.S. market," deLaski said, noting that would undercut American manufacturers. (AP)
2026-02-08 02:34:00

PH, US ink critical minerals agreement
THE Philippines and the United States have signed a memorandum of understanding (MOU) to develop the domestic critical minerals and rare earths sector, a development the Department of Environment and Natural Resources (DENR) said could make the county a global processing hub.The MOU was signed by Environment Secretary Raphael Lotilla and US Undersecretary of State for Economic Affairs Jacob Helberg on Wednesday at the sidelines of the 2026 Critical Minerals Ministerial hosted by the US State Department, which brought together ministers and senior officials from 54 countries and the European Commission.Critical minerals and rare earths are important inputs in the production of electric vehicles, renewable energy technologies, electronics and advanced manufacturing, and the US has been looking to form a trading bloc to counter China’s dominance of the sector.“[T]he MOU aims to advance Philippine economic policy away from the export of raw mineral ores toward increased domestic processing and value addition, supporting the country’s integration into global supply chains,” the DENR said in a statement on Friday.Lotilla was quoted as saying that via the partnership, “we are building a Filipino-led industry that processes our own resources, creates high-skilled jobs and strengthens our position in the global high-tech supply chain.”“We will be able to keep more of the economic benefits of mining within the country,” he added.With the signing of the MOU, the Philippines joined other countries including Australia, Canada, Japan, South Korea, the United Kingdom, and Asean neighbors Malaysia and Thailand as partners of the US in securing reliable and diversified mineral supply chains.“By advancing critical minerals processing at home, the Philippines takes a significant step toward building a resilient, innovation-driven economy and securing its place in the future of global industry,” Lotilla said.“More importantly, this step forms part of our overall commitment to responsible mining by upholding environmental standards and protecting the well-being of local communities,” he added.During the ministerial meeting, US Vice President JD Vance unveiled plans to marshal allies into a preferential trade bloc for critical minerals, proposing coordinated price floors as Washington escalates efforts to loosen China’s grip on materials crucial to advanced manufacturing.China has wielded its chokehold on the processing of many minerals as geo-economic leverage, at times curbing exports, suppressing prices and undercutting other countries’ ability to diversify sources of the materials used to make semiconductors, electric vehicles and advanced weapons.“We want to eliminate that problem of people flooding into our markets with cheap critical minerals to undercut our domestic manufacturers,” Vance told a gathering of visiting ministers in Washington without mentioning China.“We will establish reference prices for critical minerals at each stage of production ... and for members of the preferential zone, these reference prices will operate as a floor maintained through adjustable tariffs to uphold pricing integrity,” Vance said.Earlier this week, US President Donald Trump launched a US strategic stockpile of critical minerals, called Project Vault, backed by $10 billion in seed funding from the US Export-Import Bank and $2 billion in private funding.China’s expanded export controls on rare earths last year caused production delays and shutdowns for auto manufacturers in Europe and the US, and a China-generated glut of lithium has stalled plans to expand production in the US.Such dependencies have unnerved Washington and its partners, which have struggled for years to implement policies to stand up durable domestic mining and processing alternatives for lithium, nickel, rare earths and other critical minerals.
2026-02-06 16:20:00

Manufacturing output rebounds in December
FACTORY output turned positive in December in both value and volume terms, the Philippine Statistics Authority (PSA) reported on Friday.The value of production index (VaPI) rose by 1.9 percent, rebounding from a 1.0-percent contraction in November and up from 0.3 percent growth a year ago.The volume of production index (VoPI) also bounced back from a 1.1-percent drop a month earlier to growth of 1.0 percent. IT was also better than the year-earlier growth of 0.5 percent.Year to date, VaPI remained positive at 0.4 percent, a turnabout from the 0.02-percent dip seen in 2024 but markedly slower than 2023’s 6.3 percent.VoPI, on the other hand, fell by 0.02 percent for the whole of 2025, reversing from the prior year’s 0.7 percent and the 4.9 percent in 2023.December’s VaPI gain was attributed to a faster increase in the manufacture of other nonmetallic mineral products, which grew by 29.5 percent from just 4.4 percent in the previous month.This sector contributed 23.2 percent to the month’s growth, the PSA said.Other major contributors to the VaPI increase were the manufacture of transport equipment (6.7 percent from 0.2 percent) and the manufacture of machinery and equipment except electrical (9.7 percent from -11.1 percent).Twelve other industry divisions saw expansions while declines were observed in seven.The VoPI, meanwhile, was also primarily driven by the manufacture of other nonmetallic mineral products (31.4 percent from 6.0 percent) along with the manufacture of food products (10.4 percent from 7.6 percent) and the manufacture of machinery and equipment except electrical (10.1 percent from -10.7 percent).Of the remaining industry divisions, 12 gained while seven posted declines.Average capacity utilization was 77.5 percent, slightly higher than November’s 77.4 percent and 76.1 percent a year ago.Of the 651 establishments that participated in the PSA’s Monthly Integrated Survey of Selected Industries, 228 — 35.0 percent — reported operating at full capacity (90-100 percent).Two hundred seventy-three, or 42.0 percent, operated at 70- to 89-percent capacity while the rest — 150 — operated below 70 percent.The Philippine Chamber of Commerce and Industry (PCCI) on Friday welcomed the rebound in manufacturing output, which President Perry Ferrer said “highlights the resilience of Philippine industries.”The business group also recognized the support provided by the Bangko Sentral ng Pilipinas via lower borrowing costs in December.“This move made it easier for manufacturers to access financing, expand production, and operate in a more favorable environment for manufacturing activity,” Ferrer said.The PCCI said it was optimistic about the sector this year as “continued government infrastructure projects, strong domestic consumption, and supportive monetary policy are expected to help sustain growth.”However, it said that “challenges such as rising global prices, supply chain constraints, and energy costs will need to be addressed.”
2026-02-06 16:19:00

ADB, GCash lending arm partner to fund MSMEs
THE Asian Development Bank (ADB) has extended a P1.75-billion loan facility to the lending arm of GCash, Fuse Financing Inc., to provide wider credit access to micro, small and medium enterprises (MSMEs), particularly women-led businesses and those operating in high-poverty areas.The partnership, sealed on Friday, was said to be the base of ADB’s first fintech-focused financing deal of its kind in the Asean region.The ADB financing will allow Fuse Financing to expand its lending portfolio and scale up digital credit access for underserved segments.The loan facility will be complemented by catalytic funding from the Mastercard Impact Fund, supported by the Mastercard Center for Inclusive Growth, to help ensure that financing reaches priority MSMEs and women entrepreneurs more effectively.MSMEs accounted for about 40 percent of gross domestic product and roughly 63 percent of total employment. Data from the Department of Trade and Industry show that out of 1.24 million registered business establishments in 2024, more than 99 percent were classified as micro, small or medium enterprises.Despite their economic importance, the ADB said that access to credit remained one of the biggest challenges faced by small businesses, second only to access to markets.ADB Director General Isabel Chatterton said the partnership would blend development financing with digital innovation to build a more inclusive financial ecosystem.“By combining Fuse’s digital reach with ADB’s development financing, we are building an inclusive digital financial ecosystem that expands access to finance for women-led and rural enterprises across the country,” she said.Beyond the loan facility, ADB will also provide up to $125,000 in technical assistance to support the development of tailored financial products, and to deliver financial and digital literacy training for women, particularly those with limited formal education.This aims to help borrowers better manage their finances, use digital tools and borrow responsibly, reinforcing the sustainability of the lending program.Fuse Financing President and CEO Tony Isidro said the funding would accelerate the company’s mission to deliver fair and accessible loans to Filipinos who need them most.“This investment enables us to accelerate our support for women entrepreneurs and small businesses in underserved areas, sectors with immense potential to drive the country’s long-term growth,” he added.Mastercard Center Senior Vice President Subhashini Chandran, meanwhile, said extending credit to underserved entrepreneurs would help ensure that the benefits of digitalization were more widely shared.
2026-02-06 16:18:00

PPC.co Publishes New SEM Case Study Showing 790% ROAS and 82% Reduction in CPA for Nutrition & Health Brand
A newly released PPC.co case study details how strategic SEM optimization reduced acquisition costs by 82% and increased return on ad spend to 790% for a nutrition and health ecommerce brand.Seattle, Washington, United States, February 6, 2026 -- PPC.co, a leading paid search and performance marketing agency, today announced the publication of a new SEM case study detailing significant performance gains achieved for a nutrition and health product company through targeted campaign optimization and data-driven bidding strategies.The newly released report documents a dramatic month-over-month improvement in campaign performance, including:Cost per acquisition (CPA) reduced from £48.39 to £8.92, an 82% decreaseReturn on ad spend (ROAS) increased from 122% to 790%, a 668% improvementConversion rate increased from 1.36% to 8.77%, representing a 6.5× increaseThese results were achieved through systematic keyword refinement, audience segmentation, bid optimization, and strategic scaling of high-intent search traffic. According to the report, January performance reflected a meaningful transition from campaign learning phases into efficient, scalable acquisition, with every £1 spent returning approximately £7.90 in revenue. Campaign Optimization Drove Consistent Gains Across ChannelsThe case study also details improvements across multiple campaign types, including remarketing and Performance Max campaigns, all of which experienced meaningful ROAS increases month over month. Several campaigns saw triple-digit or higher percentage increases in profitability as targeting, bidding, and geographic refinements were applied. The report highlights that high-intent, brand-adjacent search queries were a major driver of efficiency, enabling scalable conversion growth at significantly reduced acquisition costs. Executive Commentary“Many PPC campaigns plateau because optimization stops at surface-level adjustments,” said Samuel Edwards, Chief Marketing Officer of PPC.co. “This case study demonstrates what happens when campaigns are managed at the query, audience, and bid-strategy level simultaneously. The compounding effect can be dramatic when execution is disciplined.”Timothy Carter, Chief Revenue Officer of PPC.co, added: “Businesses often assume performance marketing improvements happen gradually. In reality, when the underlying data is analyzed correctly and campaigns are structured for intent rather than just traffic, results can accelerate quickly. This case study is a clear example of that shift.”Why Case Studies Matter for Performance Marketing BuyersPPC.co publishes detailed case studies to provide transparency into how paid media campaigns are optimized and how results are measured. The company notes that marketers and operators increasingly demand verifiable performance data rather than generic claims of ROI.The full case study includes detailed breakdowns of:Campaign-level performanceKeyword performance and intent analysisGeographic and device segmentationAudience demographic insightsDay-of-week performance trendsThese insights provide a practical framework for businesses seeking to improve paid search profitability at scale. About PPC.coPPC.co is a performance-driven paid search marketing agency specializing in Google Ads, paid social, remarketing, and conversion optimization. The firm works with startups, ecommerce companies, and enterprise organizations to improve acquisition efficiency, increase conversion rates, and scale profitable growth through data-driven campaign management.PPC.co is part of the Digital.Marketing family of companies, which provides integrated digital marketing, SEO, and development services to businesses worldwide.Contact Info:Name: Samuel EdwardsEmail: Send EmailOrganization: PR DigitalWebsite: https://pr.digitalRelease ID: 89182859Should you detect any errors, issues, or discrepancies with the content contained within this press release, or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond and take necessary steps within the next 8 hours to resolve any identified issues or guide you through the removal process. We value the trust placed in us by our readers and remain dedicated to providing accurate and reliable information.
2026-02-06 16:17:04

Nicolas Torre and his bicycle
NICOLAS Torre III was appointed general manager of the Metropolitan Manila Development Authority (MMDA) in the latter half of December 2025. From the day he took office, Torre has been concerned about the worsening travel experience of Metro Manilans. Some of his proposals have been shot down, but I admire his tenacity and his willingness to break away from conventional but ineffective car-centric approaches.Torre gets it — the need for efficient, safe and sustainable travel options that do not require a private car or motorcycle. His positive messages about bicycles and improving our cycling environment are on point. I would argue that Torre has already done more to raise public understanding of the viability of bicycles as daily transport than any other Filipino public official. In his capacity as spokesman for the MMDA, his pro-cycling advocacy is a welcome and refreshing change.Torre knows cycling from personal experience. In 2011, he regularly biked 27 kilometers (km) each way daily from Sto. Domingo in Quezon City to Camp Bagong Diwa in Bicutan. In those days, he experienced more predictable and shorter travel times on a bicycle, compared with using a car. He also appreciated, I’m sure, the cost savings and health benefits. He also must have observed the many thousands of Filipinos moving around quietly and efficiently by bicycle, without generating heat or harmful emissions. He understands the risks they face as vulnerable road users.The potential benefits from more people on bicycles are huge. In 2021, the policy advocacy organization, AltMobility PH, released a report quantifying the social and economic benefits from cycling (Bikenomics: Assessing the Value of Cycling in the Philippines by Zaxx Abraham, Sarah Arrojado, Cola Cobarrubias, Ira Cruz, Patrick Jalasco, Chinee Leobrera, Keisha Mayuga and Regina Mora. Friedrich Naumann Foundation and AltMobility PH, 2021).This is what they found: Using a bicycle instead of a car can save a household about P281,462 per year; this leaves a family with more money for food, health care, education and savings. If only 5 percent of trips within Metro Manila are made on bicycles, society gains P738 billion in health cost savings annually.When it comes to fighting climate change, bicycles are also one of the best weapons available. In terms of reducing carbon in our atmosphere, attracting more people to cycle instead of using a motor vehicle is like planting trees. Converting 5 percent of car trips in Metro Manila into bicycle trips can save 57,000 tons of CO2 emissions annually, equivalent to planting 2.31 million trees.Torre knows that bike lanes and road-sharing are not a popular topic in certain circles. Many local officials (and many car and motorcycle users) hold the view that bike lanes are often empty, create traffic and should be removed (or converted into motorcycle lanes). Because there has been visible opposition to bicycle lanes (including from within MMDA), Torre deserves our commendation for his willingness to challenge such misplaced views and to push for road sharing, the safety of vulnerable road users and the greater good.Torre is passionate about his advocacy for cycling. On Jan. 29, 2026, he rode his bicycle to inspect bike lanes on his route to the office at MMDA. In the media interview that followed his bike lane audit, he delivered several important messages: that roads should provide space for all road users and that journeys of 15-20 km are very much feasible on a bicycle, requiring less than an hour of travel.On Feb. 1, 2026, Torre joined a bike ride of the Tiklop Society of the Philippines (an organization of users of folding bikes) to campaign for protected bike lanes and more road space for vulnerable road users. In response to media questions, Torre cited the need to reduce car-dependency by making cycling a safe and attractive travel mode. He mentioned the many economic and health gains for the individual as well as the benefits to society of having less road congestion and pollution. He recommended that bike lanes be established on many more major roads in Metro Manila (in addition to EDSA), noting that Metro Manila with its compact area was easily bikeable, distance-wise.On Feb. 3, 2026, Torre engaged the public on his Facebook page, inviting suggestions for making cycling to work more attractive. He started with his own suggestion: lockers and showers at work places so that cyclists can freshen up after a bike ride. His online invitation for suggestions has since attracted a huge number of responses, with protected bike lanes garnering a very high number of mentions.If Torre can get the MMDA to support his cycling advocacy, it may be the first time that all three major transportation-related agencies in the metropolis — the Department of Transportation, Department of Public Works and Highways, and the MMDA — agree that protected bike lanes deserve a larger and fairer share of existing road space. We could be on our way to creating a metropolis-wide network of high-quality protected bike lanes and achieving Torre’s dream of a bicycle-friendly Metro Manila. That would be welcome news indeed.Robert Y. Siy is a development economist, city and regional planner, and public transport advocate. He is a co-convenor of the Move As One Coalition. He can be reached at mobilitymatters.ph@yahoo.com or followed on X @RobertRsiy.
2026-02-06 16:16:00

CGTN: Vision 2030: China's tech blueprint reshaping global innovation
BEIJING, CHINA - Media OutReach Newswire - 5 February 2026 - In 2025, China achieved unprecedented milestones in technological innovation, from breakthroughs in artificial intelligence to advances in deep-space exploration. CGTN presents a feature article examining how these advances reflect not only industrial growth but also China's evolving role in global innovation governance, highlighting the country's commitment to shape international standards, foster collaboration, and address shared challenges like climate change and public health.The World Intellectual Property Organization's Global Innovation Index 2025 places China 10th globally for the first time, first among upper‐middle‐income economies and fifth in innovation output.China leads the world in multiple intellectual property measures, hosts the most top‐100 innovation clusters - including the Shenzhen‐Hong Kong‐Guangzhou cluster now ranked first - and has the world's second‐largest brand value at $1.81 trillion. Building on this momentum, China is advancing industrial leadership under its 15th Five‐Year Plan period (2026-2030).Chinese artificial intelligence (AI) companies have developed more than 200 domestic large models and expanded AI deployment across industries. China's "AI+" initiative integrates digital technologies with manufacturing and smart systems, and in 2025 China's core AI industry exceeded 1 trillion yuan (about $142 billion) in scale, underscoring rapid expansion.Alongside AI developments, China is also expanding its commercial space capabilities: Long March series rockets have launched clusters of satellites from south China's Hainan Province, and the country has applied for frequency and orbital rights for 203,000 satellites to the International Telecommunication Union, planning a mega‐constellation by 2030 that could support a 1.2 trillion yuan industrial chain.Complementing these industry advances, in 2023, Chinese President Xi Jinping proposed the Global Artificial Intelligence Governance Initiative, which outlines China's constructive approach to global AI development and governance and has since informed subsequent international cooperation discussions and frameworks. In July 2025, China released the Global AI Governance Action Plan, a concrete follow‐up to the 2023 initiative that provides guidance for multilateral cooperation on secure, inclusive and human‐centered AI governance among participating countries and organizations.China Media Group also outlined the top 10 AI trends for 2026, including globalization of AI governance, scaling computing power, widespread AI agents and multi‐modal interaction technologies.Supporting these innovations, China strengthens R&D and institutional investment. In 2025, central state‐owned enterprises invested 1.1 trillion yuan in research and development for the fourth consecutive year and 2.5 trillion yuan in strategic emerging industries, while tax and fee reforms totaling about 10.5 trillion yuan during the 14th Five‐Year Plan period (2021-2025) boosted enterprise innovation.Major fundamental science missions, such as Tianwen‐2 asteroid sampling and the Chang'e‐7 lunar water exploration mission, demonstrate growing long‐term research capabilities.Looking ahead, China's next five years of scientific and technological innovation will not be an isolated process. From satellite constellations to AI chips, each breakthrough contributes to addressing global challenges like climate change and disease control.An innovative China, moving with openness and efficiency, is becoming a key engine for shared global progress.For more information, please click:https://news.cgtn.com/news/2026-02-04/Vision-2030-China-s-tech-blueprint-reshaping-global-innovation-1KujBKYBQHK/p.htmlHashtag: #CGTNThe issuer is solely responsible for the content of this announcement.
2026-02-05 06:29:12

‘Triggerman’ Allan Caidic returns to UE as consultant
One of the pillars of University of the East basketball during its glory days in the 1980s, Allan Caidic returns to his roots as he was named consultant for the men\'s team, the school announced recently.The 62-year-old Caidic, a three-time UAAP champion with UE, was tapped to help the Red Warriors’ campaign during the offseason and heading into UAAP Season 89.A contract signing was held last Tuesday, Feb. 3, with school\'s top officials also gracing the event led by UE president and chief academic officer Dr. Zosimo M. Battad, SVP Florence O. Siy, PE director Leo Robert Viajar, assistant PE dir. Lovelyn Yee, sports coordinator Melvin Reyes and legal counsel Atty. Sarah Jane C. Macahilas.“I’m so grateful for the opportunity given by the UE management for making me a part of the UE basketball program,” said Caidic in his interview with the school\'s student publication, UE Dawn.“As a former player, I want to give UE the respect they deserve, so many years na nagdaan... parang nawala na ‘yong glory days before... it’s more of the respect first and syempre we have to do a lot of adjustments.”Caidic, who holds the PBA record for most points by a local (79) and most three-points in a single game (17), will work with head coach Chris Gavina, and assistant coaches Paulo Hubalde and KG Canaleta.They will spearhead UE’s rebuilding phase with Wello Lingolingo leading the way after they finished dead last and without a victory in Season 88.
2026-02-05 06:29:00

Balancing Excellence: An NLCS (Singapore) Student Representing Singapore on the International Cricket Stage
SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- Grade 11 student Aahan Vuthandam represents Singapore in international cricket while maintaining academic excellence at NLCS (Singapore), reflecting the school's ethos of academic rigour, pastoral care, and enrichment. ACC Men’s U19 Premier Cup 2025 | Singapore versus Iran: Aahan Vuthandam received 'Player of the Match' for his extraordinary knock of 188 off 121 balls and 2 wickets with the ball. [Photo used with permission from Singapore Cricket Association] When most Grade 11 students are focused solely on IB Diploma preparations, Aahan Vuthandam is balancing academics with representing Singapore on the international cricket stage and excelling at both. The talented all-rounder has made headlines in Singapore cricket, including a remarkable 188-run knock that earned him Player of the Match honours and recognition as the leading run scorer in the Asian Cricket Council (ACC) Under-19 qualifiers, as well as Player of the Series at the UAE Under-19 tournament, competing against teams from 14 countries. The Challenge of Balancing Passion and Academics For student-athletes like Aahan, the demands are significant. Grade 11 marks a crucial year in the IB Diploma Programme, with rigorous coursework, extended essays, and preparation for final examinations. Add international cricket tournaments, training sessions, and travel commitments, and the challenge becomes formidable. "We knew NLCS had a reputation for academic rigour, which might seem counterintuitive (as a choice for school) when your child dedicates significant time to sport," Aahan's father reflected. "But we believed a more demanding environment would encourage him to develop stronger time management skills and take ownership of his choices." Aahan has been playing cricket since the age of five, and over the years, the sport has built not just his skills on the field, but his resilience, discipline, and sense of responsibility off it. Since joining NLCS (Singapore), he has found an environment that nurtures both his passion and his academic journey. "When you're passionate about something, there's a natural sense of responsibility that comes with it," his father observed. "The encouragement from his teachers and the support from his teammates have motivated him to put in the extra hours needed to keep up with both commitments." How NLCS (Singapore) Supports Student-Athletes NLCS (Singapore)'s approach to supporting student-athletes goes beyond flexible scheduling, reflecting the school's commitment to a holistic education. Tutors' Commitment to Support: Teachers and class mentors actively monitor student-athletes' academic progress and maintain open dialogue with families to understand the structured nature of athletic commitments. When Aahan recently missed around 10 days for an under-19 tournament in Dubai, his teachers offered reassurance. "Before he left, a couple of teachers told him, 'Don't worry, we've got you.' That gave us tremendous confidence," his father shared. Upon his return, he was supported in prioritising key areas of learning, particularly in demanding subjects such as Computer Science HL. This partnership ensures student-athletes receive the guidance and encouragement they need to develop effective time management strategies and balance their dual pursuits. Holistic Development: The school recognizes that elite-level sports cultivate essential life skills, discipline, resilience, teamwork, and the ability to perform under pressure, that complement academic learning. "Through cricket, he has navigated success and setbacks, learned about leadership and collaboration. These are lessons that extend far beyond the classroom," Aahan's father noted. A Community That Inspires Aahan's journey has been shaped not just by his own dedication, but by the community around him. Within Singapore's cricket circles, he has watched older players progress to prestigious universities like Imperial College London, University College London, and the University of Melbourne. Their achievements have served as both inspiration and proof that excelling in sport doesn't mean sacrificing academic aspirations. International Recognition Aahan's recent achievements on the cricket field demonstrate the calibre of talent at NLCS (Singapore). His performances for Singapore's youth teams have drawn attention from cricket circles across Asia, with the Singapore Cricket Association celebrating his contributions to national squads. A Model for Aspiring Student-Athletes Aahan's journey offers encouragement to students passionate about pursuing sports alongside academic excellence. At NLCS (Singapore), the philosophy is clear: the school provides floors, not ceilings. Students are supported to excel academically while being encouraged to pursue their passions without limits. The key lies in finding the right support system. For Aahan, success has come from the combination of parental guidance, dedicated teachers, and inspiring peers. "We've learned that when children have something they're truly passionate about, it becomes a source of energy and motivation that positively impacts every other area of their life," his father reflected. Aahan himself reflected that, "Cricket's challenges have taught me to stay grounded and composed. Sport is a powerful leveller that positively influences other areas of life, including studies and friendships." The school's commitment to nurturing well-rounded individuals means recognising that excellence takes many forms, whether it's achieving top grades, representing your country in sport, excelling in the arts, or contributing to the community. With the right environment and support, students can pursue their passions while building the skills and resilience that will serve them throughout their lives. About North London Collegiate School (Singapore) Founded in August 2020, North London Collegiate School (Singapore) is a British International School offering the academically ambitious NLCS curriculum, followed by the International Baccalaureate (IB) Middle Years Programme and culminating in the IB Diploma Programme. Drawing on 175 years of educational heritage from its founding school in the UK, NLCS (Singapore) nurtures individuals to be intellectually curious, socially confident, and grounded in compassion through a rigorous academic framework, rich co-curricular opportunities, and exceptional pastoral care. Situated on Depot Road, the School is part of a global family of schools committed to educational excellence and developing global citizens. To learn more about NLCS (Singapore), please visit our website (https://nlcssingapore.sg/) and follow us on Instagram, Facebook, YouTube, and LinkedIn. For media enquiries, please contact the NLCS (Singapore) Marketing TeamEmail: marketing@nlcssingapore.sg
2026-02-05 06:28:00

4 provinces in Visayas under Signal No. 2 as ‘Basyang’ accelerates
MANILA, Philippines—At least four provinces in Visayas - Siquijor, the southeastern portion of Negros Oriental, the southern portion of Cebu, and the southern portion of Bohol – were placed under Signal No. 2 as Tropical Storm Basyang further accelerated while moving closer to Eastern Mindanao, the Philippine Atmospheric, Geophysical and Astronomical Services Administration (Pagasa) said on Thursday.Also under the same storm signal are some areas in Mindanao – Surigao del Norte including Siargao, Bucas Grande Islands, Surigao del Sur, the extreme northern portion of Davao Oriental, Agusan del Norte, Agusan del Sur, Misamis Oriental, the northern portion of Bukidnon, the northeastern portion of Lanao del Norte, the northeastern portion of Misamis Occidental and Camiguin.In its 11 a.m. bulletin, Pagasa said Cagayancillo and Cuyo Islands in Luzon and the southern portion of Eastern Samar, the southern portion of Samar, Biliran, Leyte, Southern Leyte, the rest of Bohol, the rest of Cebu, the rest of Negros Oriental, Negros Occidental, Guimaras, Iloilo, Capiz, Aklan, and Antique in the Visayas were under Signal No. 1.Also under the same wind signal were areas in Mindanao - Dinagat Islands, the northern and central portions of Davao Oriental, Davao de Oro, Davao del Norte, the northern portion of Davao del Sur, the rest of Bukidnon, the northern portion of Cotabato, Lanao del Sur, the northern portion of Maguindanao del Norte, the rest of Lanao del Norte, the rest of Misamis Occidental, the eastern and central portions of Zamboanga del Norte, the northern and central portions of Zamboanga del Sur, and the northern portion of Zamboanga Sibugay.Packing maximum sustained winds of 65 kilometers per hour (kph) with gustiness of up to 80 kph, “Basyang” was estimated to be 295 kilometers east of Hinatuan, Surigao del Sur moving westward at 25kph.Pagasa administrator Nathaniel Servando told The Manila Times that the tropical storm will make its initial landfall over Surigao del Sur tonight.“After crossing Mindanao, it is likely to emerge over Bohol Sea tomorrow morning, and may pass close or make another landfall over Siquijor and the southern portion of Negros Oriental by Friday afternoon,” Servando said.It will then slightly weaken as it interacts with the landmass.
2026-02-05 06:27:47

LTO to issue Show Cause Order to BOSS Ironman Challenge organizers
The Land Transportation Office (LTO) announced it will issue a Show Cause Order (SCO) to the BMW Owners’ Society of Safe Riders (BOSS), organizer of the BOSS Ironman Challenge Mindanao Cup 2026 flagging off from General Santos City with a route around Mindanao on January 31 to February 1, 2026. The action follows widespread circulation of disturbing footage and accounts of accidents on social media platforms, which caught the immediate attention of the LTO Chief and enforcement teams.Viral videos**media[76558]**The agency has reviewed viral videos and images shared widely across social media platforms and noted specific traffic violations committed by the event’s participants during the event, in violation of Republic Act No. 4136 (Land Transportation and Traffic Code). These include over speeding, use of unauthorized vehicle accessories and modifications, illegal blinkers, failure to stop at red lights and disregard for road signs, including mandatory stop signs and lane markers.LTO says these alleged violations contributed to serious incidents during the challenge. Multiple collisions were reported, involving both event participants and civilian vehicles. Most tragically, one of these collisions resulted in the death of a seven-year-old child. A separate fatal collision involving another event participant occurred in Kibawe, Bukidnon on February 1, 2026, and is currently under investigation by local authorities.Following initial assessment of the social media content, LTO’s Intelligence and Investigation Division (IID) launched preliminary investigations to verify the allegations and gather additional evidence. Once concluded, the Show Cause Order will be formally issued to the organizers.“The heartbreaking footage we saw circulating online is a stark reminder that road safety is non-negotiable – every life on our roads matters, especially the most vulnerable among us like children,” said LTO Chief, Assistant Secretary Markus V. Lacanilao “Private motor vehicle events must never come at the cost of innocent lives. Under Republic Act No. 4136, organizers have a legal and moral obligation to ensure compliance with traffic laws and prioritize safety for all. We will hold accountable those responsible, and this case sends a clear message: compliance is mandatory, and safety must be at the core of all event planning and execution.”Statement from the organizers**media[76555]**In response, the BMW Owners’ Society of Safe Riders (BOSS), the organizers of the event have released a statement."We share the sentiments of the public we do not want accidents to happen [sic]. Safety has always been our highest priority. Thorough preparations were made in close coordination with Local Government Units, the Philippine National Police, the Land Transportation Office, the Bureau of Fire Protection, and other government agencies to ensure the safety of riders and spectators and the orderly conduct of the event.BOSS shared that the event underwent changes to its format for the 2026 staging."To reduce risk and rider fatigue, the event was conducted over two days with a mandatory overnight rest-stop, unlike earlier formats requiring completion within24 hours. Group riding of five to ten riders was made mandatory to prevent racing and promote discipline, teamwork, and camaraderie..."The organizers also shared that participants were tracked by GPS, provided insurance coverage, as well as briefed prior to the event on the importance of complying with all national and local road safety regulations."Despite these measures, we acknowledge with humility that risks can never be completely eliminated in events involving motorcycles and travelling over a substantial distance. In this regard, we commit to a comprehensive review of our protocols to further enhance safety and cooperate with the appropriate government agency in this regard.Event’s history**media[76557]**The BMW Owners’ Society of Safe Riders (BOSS) Ironman Motorcycle Challenge is a motorcycle and automobile endurance event. Participants are challenged to drive a route spanning of at least 1,200 kilometers in under 24 hours to be named a “Finisher.” It can be done in any brand of motorcycle (400cc and up) or car. Riders are given a number sticker on their motorcycle or car and a card that must be stamped or punched at checkpoints to ensure they are following the prescribed route. All the while, the route is open to vehicular traffic because participants are advised to follow road rules.It traces its origins back to the American Ironbutt challenge where American riders were tasked with completing a 1,000 mile route within a similar time period.Since its inception over 2 decades ago, the organizers have continued to stress that this is not a race, rather, an endurance event. However, the inevitable bragging rights over completing it in the least amount of time has endured over the years, regarded by some participants as unofficial “records” and seen by some as a challenge and time to be beaten. The event doesn’t announce winners, just finishers, however some motorcycle clubs and participants that join actively keep track of the finishing time of their members and hail those with the shortest time as heroes.Reckless riding aside, completing the event is still a noteworthy achievement for any rider. Traveling 1,200-km in one go is not a joke, even when following the speed limit. Varying road conditions, weather conditions, and fatigue are the key challenges to overcome. Not surprisingly, many keep the participation sticker on their motorcycle and the patch that’s awarded after on their jacket as a source of pride.
2026-02-03 20:27:00

Kean University President Lamont O. Repollet and Distinguished Professor Robin Landa Explore Values-Based Leadership in New Book
Leadership by Design: Winning Hearts, Building Your Brand, and Achieving SuccessKean University President Lamont O. Repollet, Ed.D., and Distinguished Professor Robin Landa, co-authors of Leadership by Design: Winning Hearts, Building Your Brand, and Achieving Success.UNION, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kean University President Lamont O. Repollet, Ed.D., has released Leadership by Design: Winning Hearts, Building Your Brand, and Achieving Success, a new book he co-authored with Kean University Distinguished Professor Robin Landa. The book offers a values-driven framework for leaders navigating today’s complex professional and civic landscapes. Blending scholarship, lived experience and practical insight, Leadership by Design presents a three-part framework to leadership centered on winning hearts, building a personal brand and achieving success. The authors emphasize that effective leadership requires forging genuine trust and emotional connection, shaping how leadership is perceived through intentional choices and delivering results measured by meaning, values and legacy. "Leadership by Design reflects a belief I’ve carried throughout my career. Leadership is about more than strategy; it’s about purpose and creating a legacy that empowers others,” Repollet said. "This book represents an opportunity to share that perspective and challenge readers to be intentional architects of the future, designing leadership that is built to last.” WATCH: Leadership by Design: Winning Hearts, Building Your Brand, and Achieving SuccessPublished by Routledge, the 192-page book is written for educators and emerging leaders seeking a practical approach to aligning values with action, and educational leaders are already turning to the book as a resource. A central theme of the book is Repollet’s "crystal ball effect,” a leadership concept that emphasizes making credible, intentional, values-based commitments that inspire trust and shared belief. When leaders articulate plausible and principled goals, individuals and organizations are more likely to work collectively toward long-term success. "As a superintendent, I am always looking for ways to take my district from good to great. Leadership by Design is more than just a guide; it’s a transformative blueprint for educational leaders,” said Charles R. Ford Jr., Ed.D., superintendent of the Monmouth County Vocational School District. "This powerful resource equips educators to lead with authenticity, build a strong and purposeful brand, and ultimately drive meaningful success for students and communities alike.” The collaboration between Repollet and Landa began several years ago at a Kean Human Rights Conference and grew through continued conversations around ethics, leadership and design thinking. Landa, who has authored 27 books, said the partnership was rooted in shared values and a commitment to purposeful leadership. "Dr. Repollet is a rare leader who is ethical, visionary and deeply humanistic,” Landa said. "I knew immediately this project would be different and high level.” For Repollet, the collaboration reflects the leadership philosophy advanced in the book itself. "Collaborating with Robin was a meaningful experience,” Repollet said. "Her expertise helped shape the structure of this book, and together we created a leadership framework rooted in values and intention.” Leadership by Design: Winning Hearts, Building Your Brand, and Achieving Success debuted Tuesday, February 3, and is available through Amazon and major booksellers. Proceeds will benefit the Kean University Foundation "Anyone reading this book should walk away understanding they are the chief architect of the future,” Landa said. "Leadership doesn’t emerge by chance, it must be designed with vision and purpose.” ABOUT KEAN UNIVERSITY Kean University, New Jersey’s urban research university, is a national institution of higher education recognized for its diversity, innovation and the social mobility of its graduates. Designated an R2 research university by the Carnegie Classification of Institutions of Higher Education, Kean ranks among the top eight percent of U.S. universities for research and doctorate production. Founded in 1855 as a teachers college, Kean has evolved into a thriving research university that supports students as they persist to graduation, give back to their communities and launch successful careers. Kean’s six colleges offer more than 50 undergraduate programs, seven doctoral degree programs and more than 70 options leading to master’s degrees, professional diplomas or certifications, across a full range of academic subjects. With campuses in Union, Toms River and Manahawkin, New Jersey, and Wenzhou, China, as well as Kean Online, the University provides students of all backgrounds an affordable and accessible world-class education. Learn more at www.kean.edu. AttachmentLeadership by Design: Winning Hearts, Building Your Brand, and Achieving SuccessCONTACT: Nicole FranciscoKean University(908) 737-0583nifranci@kean.edu
2026-02-03 20:26:32

Park City Communities Housing Authority Earns HUD High Performer Designation
Housing authority exceeds federal performance standards for Housing Choice Voucher program administrationSAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Nan McKay and Associates (NMA) and Park City Communities Housing Authority (PCC) announced today Park City Communities has been designated a High Performer under the U.S. Department of Housing and Urban Development’s Section Eight Management Assessment Program, commonly known as SEMAP, following HUD’s most recent evaluation of the agency’s Housing Choice Voucher (HCV) program. PCC rating is 94%, scoring 133 of a possible 145 points for the fiscal year ending September 31, 2025.Public Housing Agencies receive a SEMAP High Performer rating when they achieve a score of at least 90 percent across 14 federally defined performance indicators. These indicators measure core aspects of voucher program administration, including rent reasonableness determinations, housing quality inspections, waiting list management, and timely use of federal funds. The designation reflects Park City Communities’ compliance with HUD requirements and its performance in administering federal rental assistance to Bridgeport residents who rely on the Housing Choice Voucher program to access stable housing in the private market."SEMAP is designed to assess whether housing authorities are administering the voucher program in a way that meets federal standards and serves residents effectively,” said Jillian Baldwin, CEO of Park City Communities. "This designation reflects the work of our staff to meet HUD requirements and maintain consistent program operations for families and property owners participating in the Housing Choice Voucher program.”HUD uses SEMAP scores to evaluate program management nationwide. Agencies that receive a High Performer rating may be eligible for national recognition from the Department and may receive a competitive advantage when applying for certain HUD funding opportunities."We are proud to see Park City Communities receive this SEMAP High Performer designation,” said John McKay, CEO of Nan McKay and Associates. "This recognition reflects the consistent, high-quality work being done by PCC staff, in partnership with our team, to administer the HCV program in a way that meets HUD standards and serves the Bridgeport community effectively.”Park City Communities administers approximately 3,200 Housing Choice Vouchers in Bridgeport, alongside nearly 2,500 public housing units. The Housing Choice Voucher program provides rental assistance that allows eligible households to lease housing in the private market while ensuring units meet HUD quality and affordability requirements.Nan McKay and Associates provides Housing Choice Voucher program administration services to Park City Communities. The firm supports day-to-day program operations, compliance functions, and reporting requirements in coordination with PCC staff and HUD oversight.SEMAP evaluations are conducted annually and are intended to ensure accountability, protect federal housing funds, and promote consistent program delivery across local housing authorities. For Bridgeport residents participating in the program, the designation indicates that the agency is meeting HUD’s operational benchmarks for managing rental assistance and working with landlords and families to maintain program stability.About Nan McKay and Associates(NMA)For four decades, Nan McKay & Associates has been the leader in providing innovative solutions for neighborhoods across the country. With offices in California, Connecticut, Florida, Illinois, and Kentucky, our San Diego-based, woman-owned company is recognized as one of the most effective, strategic, and compliance-focused organizations serving communities nationwide. The NMA team has real-life professional experience in the field and understands operational best practices and the complexities of state and federal regulations. We're committed to ensuring that housing authorities, property management companies, and municipalities have the resources they need to help the families they serve. www.nanmckay.comMedia ContactJaycob BytelParagon Communicationsjaycob@paragoncomms.com(916) 538-0781
2026-02-03 20:26:29

Overnight Offering Announced
TORONTO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Canadian Life Companies Split Corp. ("the Company”) is pleased to announce it will undertake an offering of Preferred Shares (TSX: LFE.PR.B) and Class A Shares (TSX: LFE) of the Company. The offering will be led by National Bank Financial Inc.The sales period of this overnight offering will end at 8:30 a.m. EST on February 4, 2026. The offering is expected to close on or about February 11, 2026 and is subject to certain closing conditions including approval by the TSX.The Preferred Shares will be offered at a price of $10.45 per Preferred Share and the Class A Shares will be offered at a price of $7.65 per Class A Share.The closing price on the TSX of each of the Preferred Shares and Class A Shares on February 2, 2026 was $10.53 and $7.83, respectively.Since inception of the Company, the aggregate dividends declared on the Preferred Shares have been $12.85 per share and the aggregate dividends declared on the Class A Shares have been $9.85 per share, for a combined total of $22.70 per unit. All distributions paid to date have been made in tax advantage eligible Canadian dividends or capital gains dividends.The net proceeds of the offering will be used by the Company to invest in an actively managed portfolio primarily consisting of four publicly traded Canadian life insurance companies as follows: Great‐West Lifeco Inc., iA Financial Corporation Inc., Manulife Financial Corporation and Sun Life Financial Inc.The Company’s investment objectives are:Preferred Shares:to provide holders of the Preferred Shares with fixed, cumulative preferential monthly cash dividends at a rate equal to the greater of: 7.00% OR Prime Rate plus 2% (max of 9%) annually based on the $10.00 original issue price, and;on or about December 1, 2030 (subject to further 6 year extensions), to pay the holders of the Preferred Shares the original $10 issue price of those shares.Class A Shares:to provide holders of the Class A Shares with regular monthly cash dividends as the directors of the Company may from time to time determine; andon or about December 1, 2030 (subject to further 6 year extensions), to pay the holders of Class A Shares such amounts as remain after paying the holders of the Preferred Shares the amounts owing to them.A prospectus supplement to the Company’s short form base shelf prospectus dated May 1, 2024, as amended October 2, 2025, containing important detailed information about the Preferred Shares and the Class A Shares being offered will be filed with securities commissions or similar authorities in all provinces of Canada. Copies of the prospectus supplement and the short form base shelf prospectus may be obtained from your registered financial advisor using the contact information for such advisor. There will not be any sale or any acceptance of an offer to buy the securities being offered until the prospectus supplement has been filed with the Securities Commissions or similar authorities in each of the provinces of Canada.Investor Relations: 1-877-478-2372Local: 416-304-4443www.lifesplit.cominfo@quadravest.com
2026-02-03 20:26:19

The Bookish Goods Expands Its Collection of Book-Inspired Accessories and Gifts
Columbus-Based Bookish Shop Highlights Kindle Cases, Apparel, and Subscription Offerings for ReadersCOLUMBUS, Ohio , Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Bookish Goods, an online bookish shop known for literary-inspired accessories and apparel, is expanding its curated selection of products designed for readers who enjoy expressing their love of books beyond the page. The brand continues to grow its offerings across Kindle Case(s), apparel, accessories, and giftable items that appeal to avid readers and literary enthusiasts.Among the most popular items offered by The Bookish Goods are its Kindle Case(s), including designs created specifically as a Kindle Paperwhite case. These Kindle cover(s) are designed to combine everyday functionality with book-themed artwork, allowing readers to personalize their reading experience while protecting their devices. The collection reflects the brand’s focus on practical items that align with book-centered lifestyles.In addition to digital reading accessories, The Bookish Goods offers a wide range of bookish gifts intended for personal use or gifting. The product lineup includes book blanket designs for cozy reading sessions, a book tote bag suitable for carrying novels or everyday essentials, and themed accessories that reflect literary humor and culture. These items have positioned the brand as a destination for thoughtfully designed bookish merch.Apparel also plays a central role in the company’s catalog. The Bookish Goods features a variety of bookish tee options as well as a bookish sweatshirt collection, allowing customers to showcase their love for reading through casual wear. The apparel line is complemented by seasonal releases and limited designs that resonate with readers of all genres.The company further supports its community through its subscription offering, which delivers curated bookish goods directly to subscribers. This program allows readers to discover new bookish merch regularly while supporting an independent bookish shop focused on literary creativity.The Bookish Goods operates with a clear mission to create products that resonate with readers who view books as part of their identity and daily life. By offering a range of accessories, apparel, and gifts, the brand continues to serve readers looking for meaningful and practical bookish goods.For more information about The Bookish Goods and its collections, visit https://thebookishgoods.com/CONTACT: Michael LeGrangeThe Bookish Goodshello@thebookishgoods.comhttps://thebookishgoods.com/
2026-02-03 20:26:12

Rep. Paolo Duterte: Probe photo of public official allegedly using illegal drugs
Davao City first district Rep. Paolo Duterte has called for an independent and transparent forensic examination of a photo circulating online that allegedly shows a top public official using illegal drugs.In a statement posted on his official Facebook page, Duterte said the issue of the public official raises serious concerns that should not be dismissed outright.Duterte acknowledged that many Filipinos are understandably alarmed by the image, stressing that public concerns should be addressed directly to prevent further speculation and erosion of trust.“If the photo is fake, it would be better to subject it to an independent, transparent forensic examination so speculation can stop,” Duterte said. “If it is real, the people have the right to hear the truth.”The lawmaker emphasized that no one should be judged solely based on an image, but noted that holders of public office – especially the President – are expected to meet a higher standard of accountability.Duterte warned that silence, avoidance, or downplaying the issue would only deepen public distrust. He said leadership requires transparency and the ability to maintain the people’s complete confidence.He pointed out repeated allegations of drug use that date back to before the 2022 elections, as well as the continued refusal to undergo a hair follicle drug test, saying these factors further contribute to declining public and investor confidence.Duterte also raised concerns about alleged corruption linked to trillions of pesos allocated to flood control projects, funds he said came from taxpayers and remain unaccounted for.He added that the public continues to await resolution of these issues. “If the law is strict on ordinary Filipinos, it should be even stricter on those in positions of power.”Duterte emphasized that accountability should apply equally to all. “The people are watching. In a democracy, asking questions is not an attack – it is an obligation of leadership to respond,” he said.
2026-02-02 10:30:00

Minglanilla mayor, vice mayor, councilors suspended one year
CEBU CITY – Days after he refused the disposal of garbage from Cebu City, the mayor of Minglanilla town, Cebu province was suspended for one year.A suspension order from the Office of the Ombudsman was served on Monday, Feb. 2, against Minglanilla Mayor Rajiv Enad, Vice Mayor Lani Peña, and members of the municipal council from the previous term.Their suspension stemmed from an administrative case involving the alleged non-issuance of a permit.The serving of the suspension went smooth as all the town officials received the written order in person at the municipal session hall.When asked if the suspension had any connection to his public refusal to allow the use of a landfill in Minglanilla for Cebu City’s garbage, Enad clarified that the administrative case is separate and distinct from the recent discussions on solid waste management.He explained that the case relates to municipal actions taken in response to safety concerns affecting residents of Sitio Napo in Barangay Guindarohan, where ground cracks were observed and assessed to pose potential landslide risks.“Public service is not about convenience or self-preservation,” Enad said. “It is about making difficult decisions guided by what is right. Even when the consequences are personal, my responsibility is to stand by what protects the people I serve and to face these challenges through the proper legal process.”The suspension stemmed from a complaint filed several years ago by private entities associated with the operator of the Minglanilla landfill. Local officials noted that multiple similar cases filed by the same group in the past had already been dismissed, with this case being the only remaining unresolved.Enad declined to discuss the merits of the case in detail, stating that the issues involved are now properly addressed through legal channels.He emphasized, however, that the municipal actions cited in the complaint were undertaken in the exercise of regulatory authority and with the primary objective of protecting public safety and the general welfare.Enad was suspended days after he attended an emergency meeting on Jan. 22 at the Capitol convened by Gov. Pam Baricuatro, where officials from the Department of Environment and Natural Resources (DENR), including Secretary Raphael Lotilla, as well as representatives from the Environmental Management Bureau (EMB), Mines and Geosciences Bureau (MGB), DENR-7, and Cebu City officials discussed Cebu City’s solid waste situation.During the meeting, Minglanilla was identified as one of several areas being considered as a possible temporary option for waste disposal, a proposal the mayor publicly declined.Municipal officials also noted that, during the presentation, reference was made to the existence of a pending administrative case involving the mayor, although it was unrelated to the subject matter of the meeting. Enad did not comment further on this point.Enad reiterated that his refusal to host waste from outside the municipality was not intended to offend any party but was grounded on the municipality’s duty to protect its environment, water sources, and the welfare of its residents.He underscored that he will respect the legal process and exhaust all remedies available under the law to address the suspension, while ensuring that municipal services remain uninterrupted for the people of Minglanilla.While serving the suspension, Enad\'s wife, Councilor Lheslen will be acting mayor, with Councilor Mulot Laput stepping in as vice mayor."I respect the Office of the Ombudsman and the processes of our institutions," Enad stressed.
2026-02-02 10:21:00

Que fais-tu?

0.94167804718018


Nouvelles
Nouvelles
Philippines
Dernières nouvelles et titres
Philippines
Nouvelles